"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our fourth quarter and full year 2015 financial results conference call. [Operator Instructions] As a reminder, this conference call is recorded. A replay",310,"Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our fourth quarter and full year 2015 financial results conference call. [Operator Instructions] As a reminder, this conference call is recorded. A replay will be available following the conclusion of tonight's call. Dr. Jeff Leiden, Chairman and CEO; and Ian Smith, Chief Financial Officer, will provide prepared remarks this evening; Stuart Arbuckle, Chief Commercial Officer; and Dr. Jeff Chodakewitz, Chief Medical Officer, will join us for the Q&A portion of the conference call. 
We recently presented at the annual JP Morgan Healthcare Conference, where we provided a conference of update on our business and had opportunity to meet with many investors and analysts. As such, our remarks tonight will be brief. We expect to conclude the call by 5:45 PM.
On tonight's call, Jeff will review key priorities for our business in 2016. Ian will review our fourth quarter and full year 2015 financial results and discuss our 2016 financial guidance, which we provided also earlier this month. As always, you can access the webcast live on our website. 
I will remind you that we will make forward-looking statements on this conference call. The difference are subject to risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the Securities and Exchange Commission. These statements, including without limitation those regarding the ongoing development and potential commercialization of our drug candidates, Vertex's other cystic fibrosis programs and Vertex's future financial performance, are based on management's current assumptions. Actual outcomes and events could differ materially. Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in today's financial results press release. Please also see Slide 4 of tonight's webcast. 
I will now turn the call over to Dr. Jeff Leiden."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. Earlier this month, I met with many of our investors and analysts at the annual J.P. Morgan Healthcare Conference and talked about the important transition that Vertex has made in the last few years. As we enter 20",1597,"Thanks, Michael. Good evening, everyone. Earlier this month, I met with many of our investors and analysts at the annual J.P. Morgan Healthcare Conference and talked about the important transition that Vertex has made in the last few years. As we enter 2016, Vertex is on a path towards sustained earnings and revenue growth-driven by an increasing number of people being treated with our 2 approved medicines for cystic fibrosis, KALYDECO and ORKAMBI. We have a broad and deep pipeline of investigational medicines for CF that we believe may allow us to reach our goal of treating all people with CF in the future. Additionally, our pipeline of medicines for other serious diseases, including cancer, pain and other neurologic diseases, continues to progress at her early stage clinical development. In short, we are a very different company than we were just 4 years ago. 
This evening, I will briefly review our key priorities for 2016 and provide some insight into the upcoming milestones in CF and other parts of our business. Our #1 priority has been and continues to be to increase the number of people eligible for and treated with KALYDECO and ORKAMBI and to develop potential new medicines that they provide even greater benefit for all people with CF in the years ahead. At this time last year, just over 3,000 people were eligible for treatment with KALYDECO. Today, approximately 25,000 people are eligible for KALYDECO or ORKAMBI and we expect the vast majority of these people will begin treatment of these medicines to treat the cost of their CFs. We also expect to increase the number of people eligible for these medicines in 2016 to a later expansion efforts that could include younger patients or patients with other mutations in the CFTR gene. 
Our second key priority for 2016 is to continue building a financial profile of sustained revenues and earnings growth and a strong balance sheet. In 2015, a continued expansion of the KALYDECO label and the approval of ORKAMBI resulted in a significant increase in the number of patients being treated with our medicines, which led to a significant increase in revenues. Our progress in 2015 has positioned us for continued growth and we believe we are on the right path to achieve our goal of building a financial profile consistent with that of other global biotech companies. 
And finally, our third key priority is to invest in our business to create future medicines for other serious diseases. Continued investment in our pipeline is essential for creating additional breakthrough medicines for patients. I'll spend just a few minutes reviewing our recent progress and upcoming milestones that reflect these 3 priorities. 
Our first CF medicine, KALYDECO, was approved by the FDA in January 2012, and since then, our goal has been to bring this medicine to as many people as possible who may benefit. KALYDECO addresses the underlying cause of CF and is a significant medical advance for people with certain mutations in the CFTR gene. Today, approximately 4,000 people are eligible for treatment of KALYDECO in North America, Europe and Australia. We're committed to bringing this medicine to even more patients, who we believe we benefit in years ahead. We are awaiting decision from the U.S. FDA on our application for approval of KALYDECO in people ages 2 and older with CF who have certain residual functional mutations. We are approximately 1,500 people ages 2 and older in the U.S. who have the residual functional mutations represented in the supplemental new drug application for KALYDECO. While our submission for approval in these mutations is primarily based on preclinical data and on a Phase IIa critical study in only 24 patients, we believe that KALYDECO will be beneficial to these patients, given the underlying science behind these precision medicine approach of using genetic markers and predictive assays to identify patients who will likely benefit. Importantly, we chose to seek this approval, knowing that these patients would otherwise have to potentially wait years before potential approval based on Phase III data. With more than 4 years of safety data, we believe that this path towards potential approval is in the best interest of people with CF. However, we also recognize that the application is based upon limited available clinical data and its rare mutations. The PDUFA date for the decision from the FDA is February 7. 
With ORKAMBI, we are working to bring this medicine to more patients, who we believe will benefit, specifically children with 2 copies of the F delta 508 down mutations, similar to approach in KALYDECO. With approval of the European Union at the end of last year, [ph] approximately 20,500 people ages 12 and older are now eligible for treatment with ORKAMBI in the U.S. and Europe. Today, we announced the Phase II study of ORKAMBI in children ages 6 to 11 met its primary safety endpoint and supports our planned submission of a supplemental new drug application in the second quarter of this year in the U.S. If approved, an additional 2,400 people in the U.S. with CF will be eligible for treatment of ORKAMBI. 
While this is primarily a safety study, we also saw encouraging improvements in secondary and exploratory efficacy endpoints, including a statistically significant change in the exploratory endpoint of lung clearance index or LCI. Changes in LCI are also the primary endpoint of an ongoing Phase III [ph] study to support approval of ORKAMBI in this age group in Europe. There are approximately 3,400 children ages 6 to 11 who have 2 copies of the F508 del mutation in the European Union. Additional information on this data was provided in today's press release. 
Today, KALYDECO and ORKAMBI are approved to treat approximately 25,000 people in North America, Europe and Australia. We believe that there are many more people who may benefit from these medicines and we have trials ongoing or planned that could expand the number of people eligible for treatment to approximately 44,000 in years ahead. 
Beyond our approved medicines, we have a pipeline of investigational CF medicines and early-stage research programs, such as gene editing of CRISPR to late-stage developing programs evaluating combinations of our CFTR modulators. This pipeline were present hope for the CF community and our goal is to 1 day treat all people with CF. We have a broad Phase III program underway evaluating the corrector VX-661 in combination with ivacaftor, and we're also advancing the development of 2 next-generation correctors that will be combined with VX-661 and ivacaftor as part of a Phase III study of triple combinations planned for later this year. Both approaches are asking the same fundamental questions: First, can we enhance the benefit for patients already receiving KALYDECO or ORKAMBI? And second, can you provide benefits to new groups of people with CF not currently helped to buy KALYDECO or ORKAMBI, including a very large group of patients with 1 F508 del mutation and the second mutation known to result in minimal CFTR function? The VX-661 program includes 4 Phase III studies in different groups of people with CF, who have at least 1 copy of the F508 del mutation. We will begin to see the first results from the VX-661 program by early 2017, and importantly, this program is also meant to provide a significant amount of safety data to support evaluation of the next-generation corrector with VX-661 and ivacaftor as part of an investigational triple-combination regimen. 
At the end of 2015, we initiated cyclical development of 2 next-generation correctors, VX-152 and VX-440. Phase I study of each compound are ongoing in healthy volunteers and are evaluating single and multiple doses of VX-152 and VX-440 0 as well as well as triple combinations with VX-661 and ivacaftor. Together with a 50 data within the VX-661 program, the studies are designed to support the planned initiation of Phase II studies to evaluate triple combination regimens in patients in the second half of 2016. 
Our business model is unique. The success we've achieved in CF allows us to reinvest into the discovery and development of new transformative medicines. In parallel with CF, we are advancing a number of additional development programs for cancer, pain and other serious diseases. We have significant flexibility in how we may advance these programs it independently for those diseases that we believe are aligned with the focus of our business specifically specialty diseases with G&A expenses are lower your or help collaboration with other companies which we believe will be best suited to rapidly bring these potential medicines to patients. We believe our pipeline represents both potentially trends, to future medicines for patients and significant value for our business. We've begun to provide some additional insight and data for our pipeline programs and I look forward to providing updates and our progress throughout the coming year. 
I mentioned at the start of my remarks that Vertex's undergoing an important transition in recent years. We are now a global biotech company that has independently brought forwards 2 breakthrough medicines to people with CF worldwide and is on the path to delivering significant earnings and cash flow. Our financial performance in 2015 and guidance for 2016 our metrics of the kind of company that we want to become, a company that consistently create transformative new medicines for patients, generate significant value for shareholders and reinvest reinvesting strategic opportunities to create future medicines. This is our business model, and I'm pleased with our success to date and with our outlook for the coming years. 
With that, I'll turn the call over to Ian."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff. For my remarks today, I will review our fourth quarter and full year 2015 financial results and discuss our 2016 financial guidance for total KALYDECO net revenues and non-GAAP operating expenses, excluding cost of revenues. I'll also discus",1301,"Thanks, Jeff. For my remarks today, I will review our fourth quarter and full year 2015 financial results and discuss our 2016 financial guidance for total KALYDECO net revenues and non-GAAP operating expenses, excluding cost of revenues. I'll also discuss our expectation for providing ORKAMBI guidance in 2016. 
Financial results first. Our 2015 net CF product revenues were approximately $983 million. This includes KALYDECO net revenues of $632 million and ORKAMBI net revenues of $351 million. Total CF product revenues increased by more than 110% compared to 2014. In the fourth quarter of 2015, we reported total net CF product revenues of approximately $401 million, including KALYDECO net revenues of $181 million and ORKAMBI net revenues up $220 million. Fourth quarter KALYDECO sales of $181 million were up 45% versus the fourth quarter of last year and up 9% versus the third quarter of 2015. This included approximately $6 million and in Mentor restocking that occurred at the end of the fourth quarter. Growth in KALYDECO was driven by both label expansion efforts, which increase the number of eligible patients to approximately 4,000 and by the completion of the reimbursement discussions in Europe. With ORKAMBI, more than 1,500 patients start in the fourth quarter resulting in sales of $220 million, up 68% versus third quarter of 2015. As expected, we saw a very rapid uptake for ORKAMBI in the period immediately following FDA approval with more than 3,000 people starting treatment in the third quarter. Demand for patients and physicians has been strong. But as expected, fewer patients started treatment in the fourth quarter compared to the third quarter in line with our prior statements regarding expectations for the rate of uptake for ORKAMBI. We expect this trend to continue through the end of 2016, by which time, we expect the vast majority of the 8.5 thousand eligible patients in U.S. to have initiated treatment with ORKAMBI. 
Gross-to-net adjustments were largely unchanged from the third quarter and were in and the high cycle digits due primarily to a greater proportion of patients with commercial plans initiating treatment in the first 6 months following approval of ORKAMBI as compared to government-paid plans. Each of the 50 state Medicaid programs has now paid a claim for ORKAMBI, thus, we expect gross-to-net adjustments will increase to the mid-teens by the end of 2016 to reflect an increase in patients treated being covered by Medicaid. 
As we enter 2016, we are pleased with the launch of ORKAMBI today and remain focused on working to ensure those who need the medicine have access to it, educating health care providers and supporting appearance to ORKAMBI. Now to operating expenses. Our fourth quarter non-GAAP operating expenses were $282 million, including R&D expenses of $204 million and SG&A expenses of $78 million. The increased R&D expense in the fourth quarter of 2015 compared to 2014 were primarily the result of increased costs related to be pivotal Phase III program of VX-661 and in combination with ivacaftor. The increased SG&A expenses were primarily the result of an increased investment in global commercial support for the launch of ORKAMBI. And tonight, I'm pleased to report that for the fourth quarter of 2015, we recorded a non-GAAP net profit of $43 [ph] million or $0.17 per diluted share compared to non-GAAP net loss of $132 million or $0.55 per share for the fourth quarter of 2014. Our 2015 non-GAAP net loss was $268 million or $1.11 per share compared to non-GAAP net loss of $511 million or $2.17 per share for the full year 2014. From a balance sheet perspective, we started 2016 with a strong cash position of $1.04 billion. Vertex also has $300 million outstanding from a credit agreement that provides for a secured loan of up to $500 million. 
Now let's turn to be 2016 financial guidance, which we first provide it on January 10. We expect 2016 KALYDECO net revenues of $670 million to $690 million. Our guidance for KALYDECO revenues reflect the continued use of KALYDECO as was seen in the fourth quarter of 2015, which results in revenues of $181 million and the expectation for up to approximately 200 patients with a gating mutation to enroll in the Phase III clinical study of VX-661 in combination with ivacaftor, who would otherwise have received KALYDECO, which will thus reduce 2016 KALYDECO revenues. There is also an approximately $6 million inventory stocking that occurred at the end of the fourth quarter 2015 that is not expected to take your future quarters and is best accounted for in our guidance. Importantly, our current guidance excludes any potential revenues from the approval of KALYDECO for people with residual function mutations. We will update our KALYDECO guidance should we received FDA approval for residual functional mutations. 
With ORKAMBI, more than 4,500 people have begun treatment in the U.S. by the end of 2015. There are 4 primary pieces of information regarding the launch that will inform our decision regarding ORKAMBI guidance. First, since all patients are initiating treatment with ORKAMBI in 2015 have been on treatment for approximately 6 months or less, we are waiting additional information on compliance rate for patients taking ORKAMBI. While we continue to expect that the vast majority of eligible patients in the U.S. will begin treatment with ORKAMBI by the end of 2016, we are waiting additional information with a specific weight of update and on specific proportion of the 8,500 eligible patients who will begin treatment with ORKAMBI in 2016. 
And finally, additional information on the [indiscernible] defined as how many patients remain on treatment will also be taken into account. These 4 factors, the compliance rate, the length of these patients begin treatment, the total number of patients who initiate treatment and the persistence rate, all are important when we consider our guidance for ORKAMBI. 
In 2016, we expect the recognize revenues from sales of ORKAMBI in the U.S. and Germany. In Germany, there are approximately 2,500 people with CF ages 12 and older, with 2 copies of F508del mutation. In Europe, country-by-country reimbursement discussions are underway. However, we do not anticipate any significant ORKAMBI revenue from countries other than the U.S. and Germany in 2016. 
The vital component of our financial guidance's non-GAAP operating expenses, which are comprised of R&D and SG&A expenses and exclude cost of revenues. We expect our total 2016 non-GAAP operating expenses of $1.18 billion to $1.23 billion. As a reminder, our guidance for 2015 operating expenses was for $1.05 billion to $1.1 billion, and we reported 2015 operating expenses at the low end of this range of $1.06 billion, largely as a result of cost related to VX-661 that will now occur in 2016 as opposed to 2015. The increase in expense expected operating expenses for 2016 as compared to 2015 is primarily a result of expanded development efforts related to the pivotal Phase III development program for VX-661 in combination with ivacaftor and for multiple Phase I and II studies of Vertex's early stage in mid-stage pipeline of potential CF medicines and anticipated SG&A costs to support the launch of ORKAMBI in new global markets. The components of Vertex is non-GAAP operating expenses include non-GAAP R&D expenses, which we expect to be in the range of $850 million to $890 [ph] million and non-GAAP SG&A expenses, which we expect will be in the range of $330 million to $350 million. Vertex's expected non-GAAP R&D and SG&A expense excludes stock-based compensation expense and certain other expenses. 
In summary, we are in a strong financial position as we enter in 2016. We remain committed to delivering a financial profile that is similar to many of our large cap biotech peers, which includes sustainable revenue and earnings growth, high operating margins and most importantly, continued investment create future medicines."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question comes from the line of Jeff mentioned of Barclays.",14,"[Operator Instructions] Our first question comes from the line of Jeff mentioned of Barclays."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I got a commercial and clinical question for you. I guess we'll start with commercial. I want to know if you can go in a little bit more detail about persistence rates over time with KALYDECO? And then what are the real benchmark for ORKAMBI? I'm just cur",62,"I got a commercial and clinical question for you. I guess we'll start with commercial. I want to know if you can go in a little bit more detail about persistence rates over time with KALYDECO? And then what are the real benchmark for ORKAMBI? I'm just curious if you guys attract people who have discontinued and later come back to therapy?"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So, Jeff, maybe Stuart will take that question [indiscernible]  Fourth quarter. Stuart will take the question. You might also want to comment on some of the other features that are affecting how we're thinking about the launch as well.",39,"So, Jeff, maybe Stuart will take that question [indiscernible]  Fourth quarter. Stuart will take the question. You might also want to comment on some of the other features that are affecting how we're thinking about the launch as well."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, jeff, it's Stuart here. So let me just reiterate a couple of things that Ian said about ORKAMBI and the factors we are taking into account when thinking about the launch and we're tracking very closely. One is obviously the peak penetration, so the n",508,"Yes, jeff, it's Stuart here. So let me just reiterate a couple of things that Ian said about ORKAMBI and the factors we are taking into account when thinking about the launch and we're tracking very closely. One is obviously the peak penetration, so the number of eligible patients in total we get initiated on therapy over time and we continue to expect the vast majority of 8,500 patients well. That is the rate of update. How quickly we get to that peak penetration. As you know, at the end of December, we had about 4,500 patients on therapy. That's about 55% of the total and we expect it will get to peak penetration during the course of 2016. And then as you said, one of the other key component is persistence, the number of patients who stay on therapy. And obviously, it's pretty early days, because whilst we've already been on the market for 6 months, we really don't have long-term experience with very many patients yet. In the Phase III study for ORKAMBI, at about 24 weeks in traffic and transport, about 5% of patients would discontinue. At 48 weeks in the open label expansion with ORKAMBI, we were -- 15% of patients have discontinued. So that's in the ORKAMBI chronicle trials, and time will tell whether we see a higher or lower number but probably a higher number who are discontinuing in the real world. With KALYDECO, in the studies we've done, it was about 5% of patients again discontinued in the KALYDECO clinical trials. It was actually slightly higher than that in the real world. It got closer to 10%, so in the real world over time and largely, that was over a longer period of time, we did see a slightly higher number, a higher percentage of patients of KALYDECO discontinued versus the clinical trials. The last thing we're going to be thinking about that is obviously compliance, not the percentage of patients, who actually take the pills that are being described by their physician. As you know, KALYDECO is very, very high at 85%, certainly the highest I've ever seen personally for a chronic medication of the CF medicines or roundabout the 60% [ph] range, I would anticipate ORKAMBI is going to be in that range probably toward the higher part of that range, but somewhere in that range. And the other question, we'll have to look at very closely and again, we just don't have data on it, we don't have data on it in the clinical program, Jeff, and we'll have to see how it plays out in the real world, is whether physicians and patients choose to reinitiate therapy if they discontinued for some reason. We just have no information from the clinical trials because they just weren't set up to look at that. If the patient discontinued, they would just kind of exclude it from further therapy, so we just don't have data on that right now, Jeff. Hopefully, that gives you some perspective on what we're thinking."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","That's helpful. And just real quick on the clinical side, when you look at the 1 5 2 and 4 4 0 study in healthy, has there been any evidence of drug-drug interactions with KALYDECO [indiscernible] 6 6 1? And I guess, I'm trying to figure out whether you g",89,"That's helpful. And just real quick on the clinical side, when you look at the 1 5 2 and 4 4 0 study in healthy, has there been any evidence of drug-drug interactions with KALYDECO [indiscernible] 6 6 1? And I guess, I'm trying to figure out whether you guys expected that multiple doses of those 2 correctors in the CF patients when you look to the back of the year? Maybe just help us what the design of that 28-day study as you see at this stage?"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. So in terms of the Phase I studies for VX-512 and 440, we're really in the midst of those studies and we obviously can't comment on the ongoing trial. Maybe just a comment on the Phase II and we're in early days in terms of those de",80,"It's Jeff Chodakewitz. So in terms of the Phase I studies for VX-512 and 440, we're really in the midst of those studies and we obviously can't comment on the ongoing trial. Maybe just a comment on the Phase II and we're in early days in terms of those designs, but I do think it's likely that we would look to take multiple doses of the compounds into those Phase II studies to learn as much as we can."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Matt Roden of UBS.",12,"Our next question comes from the line of Matt Roden of UBS."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I also wanted to congratulate you on the milestones of turning back to profitability. So regarding the pediatric studies, I understood the primary endpoint is safety and the LCI data looks really got, which is [indiscernible] point being imported from wha",187,"I also wanted to congratulate you on the milestones of turning back to profitability. So regarding the pediatric studies, I understood the primary endpoint is safety and the LCI data looks really got, which is [indiscernible] point being imported from what's going on in Europe. Just want to get your perspective on the sort of 2.5% improvement in FEV. Have you talked to any experts or the FDA about that? I can't imagine that's going to be any kind of issue for you, but just want to see if there's anything to add on that side? And then on the commercial side, I want to ask, you've left the residual function mutations out of the KALYDECO guidance. But just to get a sense of if that were to be approved, how should we think about the onboarding of those patients on the commercial drug? Imagine you have a conversion of those that are on trial to commercial, but apart from that, would you characterize them as a highly motivated subset of patients? Or because they have a mild phenotype, could this be a slower rate of penetration?"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Hi, Matt, it's Jeff Chodakewitz. Maybe I'll start. So in terms of the pediatrics study, we were very pleased with the results of the study. We are reading both the endpoint for exposure for PK and then for safety, so that was a nice outcome. The expectati",192,"Hi, Matt, it's Jeff Chodakewitz. Maybe I'll start. So in terms of the pediatrics study, we were very pleased with the results of the study. We are reading both the endpoint for exposure for PK and then for safety, so that was a nice outcome. The expectations with the FDA is that once you've established efficacy in the same disease in older children, that as you move to younger age groups and really, it's really about that exposure and safety consistent with the design of the study. I will say that we're also quite pleased with the evidence of efficacy in the population, where it gets harder to actually demonstrate that. And I think actually, the FEV1 showing that strong trend was actually quite favorable, remembering that these kids get started at a pretty high FEV1 percentage of baseline. And as you actually noted, the fact that the LCI measure, which is in its earlier days, was 9 [ph] point positive and that's our primary endpoint in the Europeans study. And lastly, the BMI kind of measures as well. So I think overall, we're quite satisfied with the results of the trial."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Matt, it's Stuart here. Just to comment on the residual function. As you said, residual function is not included within the KALYDECO guidance that we have provided. There's about 1,500 patients with the 23 mutations that we've asked for within our fil",183,"And Matt, it's Stuart here. Just to comment on the residual function. As you said, residual function is not included within the KALYDECO guidance that we have provided. There's about 1,500 patients with the 23 mutations that we've asked for within our filing. In terms of patients transferring from Michael trials, clearly the clinical trials on which of the application is phased or which is included in the clinical trials very small. So it's not as if there's a huge bolus of patients to transition from clinical supply to commercial to supply. In terms of rate of uptake, the best analog, I think, for you there will be R117H, which by definition is a residual functional mutations. And so both in terms of peak penetration and rate of uptake, I think that's probably the best analog for you to think of in terms of the rate of uptake we might see before approved. And then just to illustrate what Ian said in his prepared remarks, if we're approved in residual function, our anticipation is that we'll update our KALYDECO guidance to reflect that."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Terence Flynn of Goldman Sachs.",13,"Our next question comes from the line of Terence Flynn of Goldman Sachs."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Samir on for Terence. Have all ORKAMBI clinical trial patients in the U.S. transitioned to commercial drug? And if not, how many have left the transition?",28,"This is Samir on for Terence. Have all ORKAMBI clinical trial patients in the U.S. transitioned to commercial drug? And if not, how many have left the transition?"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I'm not going to comment on exactly how many, but the vast majority of patients who are on clinical trial supply have now transitioned to commercial drug. Just to orient you, there was approximately 500 in total in patients in TRAFFIC and TRANSPORT were i",48,"I'm not going to comment on exactly how many, but the vast majority of patients who are on clinical trial supply have now transitioned to commercial drug. Just to orient you, there was approximately 500 in total in patients in TRAFFIC and TRANSPORT were in the U.S."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Matthew Harrison of Morgan Stanley.",10,"Our next question comes from Matthew Harrison of Morgan Stanley."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So I just had 2 quick ones. So one, just, Ian, can you back to the KALYDECO stocking comment that you made and just tell us if you think we should see some of that inventory come out of the channel this year and how that's in your guidance? And then separ",98,"So I just had 2 quick ones. So one, just, Ian, can you back to the KALYDECO stocking comment that you made and just tell us if you think we should see some of that inventory come out of the channel this year and how that's in your guidance? And then separately, just on the EU pediatrics study, how will data from that influence maybe FDA perception of a filing that you guys have? And also, how was timing of that related to when you would expect to have a PDUFA date for label expansion in the U.S.?"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, so I'll take the first one and Jeff Chodakewitz can take the second question. So firstly, the stock in question in the U.S. is, first of all, to orient people, we estimate there's approximately $6 million of inventory stocking in the fourth quarter f",239,"Yes, so I'll take the first one and Jeff Chodakewitz can take the second question. So firstly, the stock in question in the U.S. is, first of all, to orient people, we estimate there's approximately $6 million of inventory stocking in the fourth quarter for KALYDECO. What we mean by that is at the inventory was higher at December 31 compared September 30 by $6 million. That will then sell out of the channel, so it does impact future sales because it was an inventory. We have remove that from our guidance, so when we made an estimate for our 2016 KALYDECO guidance, we removed that. In fact, I think when we all met in JP Morgan in San Francisco, I gave people a simple calculation to think about how we got to our guidance for 2015 and I'll just refer to that again, which is in the fourth quarter of 2015, we get approximately $180 million with the KALYDECO revenue, $181 million to be precise, but approximately $180 million. If you multiplied that -- if you take $6 million out of that and you get $174 million for the fourth quarter run rate revenues and then multiply that by 4, you then actually deduct the patients from that annualized number and you get approximately range of the guidance we provided, which was $670 million to $690 million for KALYDECO. So it did take into account for that stocking."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Great. And it's Jeff. I think, in terms of your questions about pediatric, maybe starting with the U.S. As we said, we expect to submit our file in the second quarter of this year. We haven't yet had those discussions with the FDA of quarters by were oper",78,"Great. And it's Jeff. I think, in terms of your questions about pediatric, maybe starting with the U.S. As we said, we expect to submit our file in the second quarter of this year. We haven't yet had those discussions with the FDA of quarters by were operating under the assumption of a 6-month review time. The European study is still ongoing, it's enfolding. And I don't really see there being much interaction in terms of those processes."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Michael Yee of RBC Capital Markets.",14,"Our next question comes from the line of Michael Yee of RBC Capital Markets."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","As you release the guidance for -- Ian, I know there's no formal guidance for ORKAMBI's, but is the key message here, when I look at the consensus of $1.6 billion, is the key message to think about that discontinuations are a little bit higher and complia",161,"As you release the guidance for -- Ian, I know there's no formal guidance for ORKAMBI's, but is the key message here, when I look at the consensus of $1.6 billion, is the key message to think about that discontinuations are a little bit higher and compliance a little bit lower based on the comments that Stuart made in the U.S. And then in all U.S., Ian, I'm just trying to be clear that Germany is the only country being launched? Are there other things you think about when I look at the consensus of $345 million? Maybe you can make a comment about that and how consensus is modeling? Just want to be clear on that. and the second question is just a quick critical question. On 152 and 440, in the Phase I, even though it's healthy, is there any [indiscernible] or any of the biomarkers you're looking at that you'd disclose that can give any hints of efficacy?"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mike, Jeff Chodakewitz actually just stepped out while you ask that second question. Jeff and I [indiscernible] Jeff has a pretty bad cold so [indiscernible] I just want to make sure you heard your question. I'll take the first question and so Jeff will t",324,"Mike, Jeff Chodakewitz actually just stepped out while you ask that second question. Jeff and I [indiscernible] Jeff has a pretty bad cold so [indiscernible] I just want to make sure you heard your question. I'll take the first question and so Jeff will take the second question. So first of all, actually, we're not going to say discontinuation is a bigger issue than compliance. So I actually appreciate asking the question so we can clarify that. That's not what we're trying to say. It's not actually what we are seeing even earlier on in this launch. But I appreciate the opportunity maybe to comment on how people are thinking about the ORKAMBI launch and how we're seeing it reflected in sell side models. And specifically, 2016, let's say, forecasted that are in the sell side models. So obviously, when you look at consensus, there are a number of different models that are out there, a number of different numbers and so there's some extreme numbers and then there's some that are want to work the normal. What I would say, I don't know the assumptions that are being put into other people's models, but I would ask you to listen carefully to Stewart's comments, where we touched on when do we believe we're going to get the peak penetration, the rate of uptake of ORKAMBI? And then importantly, the persistence and compliance, because specifically compliance, if people take 6 pills out of every 10, it's straightforward, you get $6 out of every $10 of your growth price. And then obviously, there is a gross-to-net discount based on but if it got Medicaid patients. So I just -- the opportunity to comment on this call to all people at once, I just want to make sure that people are giving them a thorough consideration to all the aspects of the launch and will be happy to talk to you after the call as well."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","As far as your question regarding Germany, Germany is the only country that we expect any significant revenues from outside of the U.S. and just to give you a background in Germany, Germany has an estimated 2,500 patients. We believe that could take 12 to",149,"As far as your question regarding Germany, Germany is the only country that we expect any significant revenues from outside of the U.S. and just to give you a background in Germany, Germany has an estimated 2,500 patients. We believe that could take 12 to 18 months to reach the peak penetration in those patients and we provided people with it with a price in Germany. And it is one aspect of the sell side models that I do struggle with, because when I look at an ex-U.S. consensus on the sell side model, that's a number that's close to $300 million, I find it very challenging for us to accrue that much revenue from Germany alone. So I do appreciate you calling that out and so I just hope that people asking here consideration to all these features were modeling the ORKAMBI launch. And then over to Jeff."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Just very briefly about 152 and 440, I can't really go into the details of the ongoing studies. But as you know, the main focus for Phase I studies is got to be exposure and safety and then we learn a lot from those ongoing studies.",46,"Just very briefly about 152 and 440, I can't really go into the details of the ongoing studies. But as you know, the main focus for Phase I studies is got to be exposure and safety and then we learn a lot from those ongoing studies."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Ying Huang from Bank of America.",14,"Our next question comes from the line of Ying Huang from Bank of America."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe [indiscernible] for FDA. So ORKAMBI, you're looking at a much larger eligible patient population here. I know you guys have this clinical outcome basically on agreement with Australian government for KALYDECO. Do you expect payers to ask for some si",89,"Maybe [indiscernible] for FDA. So ORKAMBI, you're looking at a much larger eligible patient population here. I know you guys have this clinical outcome basically on agreement with Australian government for KALYDECO. Do you expect payers to ask for some similar arrangement for ORKAMBI besides Australia? And then to Jeff, talking about the preclinical data you have, what metabolism and also [indiscernible] the next generation CFTR corrector is? Do you expect any drug-drug interaction at all based on the way the drugs are being metabolized and secreted with ORKAMBI?"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Ying, Stuart here. I'll take your first question, and thanks for the question on reimbursement. And to kind of cut to the chase, I really can't speculate on exactly what our arrangement are going to look like with governments around the world because we r",144,"Ying, Stuart here. I'll take your first question, and thanks for the question on reimbursement. And to kind of cut to the chase, I really can't speculate on exactly what our arrangement are going to look like with governments around the world because we really are just at the beginning of that process and just to remind people, in most countries, it's really a 3-step process. There'll be a clinical assessment of the risk and benefit of the agent then the pharmacoeconomic assessment, and that really then is the sort of starting point for the pricing contract negotiations. Until we kind of work our way through that process, it's really impossible to speculate on exactly what the nature of any relationship that we might come to with the various governments around the world. And for the critical question, I'll hand it over to Jeff."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. So briefly, you were asking about metabolism and so forth. And as you know, it's very hard from preclinical data to speculate, specially if you really understand exposures and so forth. But we're going to understand that much better from our Phase I",85,"Sure. So briefly, you were asking about metabolism and so forth. And as you know, it's very hard from preclinical data to speculate, specially if you really understand exposures and so forth. But we're going to understand that much better from our Phase I study. I would point back to what we've said all along about our next GEN molecule that we wanted to get molecules that weren't just look good in vitro, but actually could be medicines and that's the way we approach it."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Corrie cast them off of JPMorgan.",14,"Our next question comes from the line of Corrie cast them off of JPMorgan."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So I wanted to go back to the topic of ORKAMBI outside of the U.S. Obviously, there's a lot of talk about reimbursement in time to roll out in Europe. But I wanted to go to other regions such as Canada, and you just mentioned Australia, but following the",109,"So I wanted to go back to the topic of ORKAMBI outside of the U.S. Obviously, there's a lot of talk about reimbursement in time to roll out in Europe. But I wanted to go to other regions such as Canada, and you just mentioned Australia, but following the approval in Canada. I know there's 1,500 patients of their that meet the legal criteria. Can you remind us of the market size in Australia as well? Once you do have the reimbursement in place, what would you expect the anticipated fees of uptake? And really just for the relevance of these markets to be from a commercial standpoint?"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Cory, Stuart here. As you said, the eligible patient population of F508 Delta [indiscernible] in Canada is about 1,500 patients and that's out of about 4,000 total CF patients that we estimate in Canada. Now that we've got the kind of regulatory appr",213,"Yes, Cory, Stuart here. As you said, the eligible patient population of F508 Delta [indiscernible] in Canada is about 1,500 patients and that's out of about 4,000 total CF patients that we estimate in Canada. Now that we've got the kind of regulatory approval, we can now begin to seek public reimbursement for ORKAMBI in Canada. And as you know, as I just described, the process there is again a clinical assessment, there'll be a pharmacoeconomic assessment and then there'll be a price negotiation probably through the Pan Canadian pricing alliance process that we went through with KALYDECO. In terms of rate of uptake, much as were seeing here in the U.S., I'd anticipate that the relative rate of uptake will be slower for ORKAMBI than it was with KALYDECO in Canada, and indeed, other markets outside of the U.S. for the same reason. It's just the sheer volume of patients is much larger than it is for KALYDECO and it's just more of an administrative burden to initiate patients. So much like we're seeing here in the U.S., I'd expect the relative rate of uptake for ORKAMBI to be less than it is for -- less rapid than it was for KALYDECO in Canada, and indeed, other markets outside of the U.S."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Corey, this is Jeff Leiden. Maybe just to add 1 comment. Obviously, we heard a lot from the units to work and some of the questions about the kinetics of the launch and some of the short-term modeling. I do think it's important to stand back as well and r",304,"Corey, this is Jeff Leiden. Maybe just to add 1 comment. Obviously, we heard a lot from the units to work and some of the questions about the kinetics of the launch and some of the short-term modeling. I do think it's important to stand back as well and remember with a total opportunity as, which I think where your question's going. If you think about where we are today versus where we were even 6 months ago, right, today, we have approval for 8,500 patients in U.S. and we have a launch that we're really pleased with, [indiscernible] 4,500 or 55% of the patients is already in drug in the U.S. which I think is remarkable. We have reimbursement in the U.S. that has gone actually better than we even expected, meaning every state Medicaid is now reimbursing the drug and the majority of the private insurers are. We have approval in Europe and are setting the launch in Germany integrated in the press release in ATU [ph] in France. Now we have approval in Canada, which gives us access to 1,500 private patients and the ability to negotiate reimbursement, as Stuart said, to an on additional, I think, 2,500 patients or so. And so when you look at the total opportunity, it's actually every bit of what we thought before and we've made significant progress and nothing with that has changed. It's impossible to predict the exact kinetics, what's going to happen in the in versus the second quarter/ But at least the way we look at it, as we look out over the next couple of years, we see that opportunity intact and progressing really nicely. And I think it's important to sort of see that is a big picture as well as the short-term model, so I hope that helps."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Brian Abrahams of Jefferies.",12,"Our next question comes from the line of Brian Abrahams of Jefferies."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two questions. First, on the clinical side on the 6 to 11-year-old population. I was wondering if you can talk a little bit about the natural history of untreated patient on the lung clearance index and. Where does it typically go over 6-month period in c",111,"Two questions. First, on the clinical side on the 6 to 11-year-old population. I was wondering if you can talk a little bit about the natural history of untreated patient on the lung clearance index and. Where does it typically go over 6-month period in children of this age? I guess, balancing these progression versus normal growth, this is typically was arresting flat? And then on clinical and commercial side, can you ago us any more granularity on the ongoing Phase IIIb study in the low FEV1 patients, the dosage timeline and potential impact that data might have to help patients manage through the initial side effects and stay on therapy?"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Hi, Brian, it's Jeff Chodakewitz. Maybe start with the LCI. And as we talked about a little bit, it actually isn't early measure. So the information that I can give you is somewhat imperfect, just so you know. I think its advantage, we think, is being abl",294,"Hi, Brian, it's Jeff Chodakewitz. Maybe start with the LCI. And as we talked about a little bit, it actually isn't early measure. So the information that I can give you is somewhat imperfect, just so you know. I think its advantage, we think, is being able in children who have relatively normal FEV1 but, as you know, they have significant underlying disease. there pulmonary function really is far from normal. It allows you to measure that. And over a reasonably short period of time, sort of like a 6-month period as we go that our clinical studies, there could be small decreases, but we think overall, that, that should be relatively stable. There may be modest, modest shift over time, but we think would be able to have a reasonable baseline for assessing it. So actually, that's part of why the data that we had coming out of our pediatric study, even without the control arm, was encouraging to us. Maybe I'll take a comment on the study in patients who's FEV1 is was less than word. We're still actually the process of collecting all that data. We are still involving, that we think that there's some useful information. Just in terms of the experience that we've accrued. We did you a specific question did you have part way through give investigators the opportunity to start with a lower dose and then step up to fold though. That will be -- it's not a perfect evaluation of that, but we are really trying to do what you said, which is to help explore to help patients get through those early weeks of dosing. We are going to surmise all that data and present it and use it from an education perspective as well."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Alethia Young of Crdit Suisse.",13,"Our next question comes from the line of Alethia Young of Crdit Suisse."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congrats on the nine [ph] graph and the green. Maybe just a couple. One, If something happens with the residual of the FDA may request more information, do you guys have a strategy on how you might pursue that population going forward? And then also with",100,"Congrats on the nine [ph] graph and the green. Maybe just a couple. One, If something happens with the residual of the FDA may request more information, do you guys have a strategy on how you might pursue that population going forward? And then also with the potential kind of chest tightness that sometimes happens, our [indiscernible] kind of suggest that that's happened earlier rather than early, like in the first couple of weeks? But is there a dynamic what could happen later? And did you see similarities and differences, though you probably tried the safety in the younger populations?"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Leiden. Maybe I'll take the first 1 since it's a bit of a science and a policy question, strategy question, I think. And then Jeff, you can take the second question on the chest tightness. So maybe just to give you a little background. I know yo",381,"It's Jeff Leiden. Maybe I'll take the first 1 since it's a bit of a science and a policy question, strategy question, I think. And then Jeff, you can take the second question on the chest tightness. So maybe just to give you a little background. I know you're you aware of this, but the RF application is little bit unusual compared to the application that [indiscernible] submitted on KALYDECO and ORKAMBI, which are always based on large Phase III studies. This one's different. It's basically aimed at about 1,500 patients with 23 different predations result in the residual function. And it's based predominantly on preclinical data. That's cell-based data from cells that have been engineered to have those 23 different mutations, supported by a very small Phase IIa study of about 24 patients that comprise the 8 or 9 of those 23 mutations. And so what we're really asking the FDA to look at is both the science and the medicine that we're submitting. But also there's a policy question here, how to extend the label of drugs like KALYDECO to vary of rare population and mutations. Some of these revisions only have 4 patients in the U.S. or 10 patients in the U.S. And that's a very important policy question in precision.  That is, as you know, the FDA is considering much more broadly than just in CF. And so part of the reason why it's a little difficult to handicap is one, because it's a combination of clinical and policy things. We feel very strongly for the patients that's why we did it. There are 1,500 patients in, in U.S. but today don't have any CFTR correction therapy of any sort, and it would be years before they can get to that based on large Phase III trials so for us, the step in the right thing to do for patients. And we believe the science strongly in the clinical support that behalf. But handicapping with the FDA is going to be obviously -- it's a bit more difficult. Monolith a very very and based upon what we do, will honestly, operate strategy. But again, our goal is to try to get this medicine as fully as the safety data for these patients as soon as possible."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And, Jeff Chodakewitz. Just to comment on your comment about the chest tightness. Maybe step back our Phase III results, which I think that the most definitive information. And as you noted, those adverse events did occur very early. They were manageable",111,"And, Jeff Chodakewitz. Just to comment on your comment about the chest tightness. Maybe step back our Phase III results, which I think that the most definitive information. And as you noted, those adverse events did occur very early. They were manageable in the vast majority of people and they did decrease over time. Usually the average duration was approximately 2 weeks. So I think all of that really comes out of our Phase III data and this is an early event. And the experience in our pediatric study was actually really consistent with that. It was a small number, it happened early and, in fact, nobody discontinued because of that."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of  Liisa Baykind of JMP Securities.",13,"Our next question comes from the line of  Liisa Baykind of JMP Securities."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just wanted to better understand what you were describing with Canada in terms of the private payers. I know there's 1,500 patients that are -- would be eligible for ORKAMBI. Can you break that down into how many of those would be private?",44,"I just wanted to better understand what you were describing with Canada in terms of the private payers. I know there's 1,500 patients that are -- would be eligible for ORKAMBI. Can you break that down into how many of those would be private?"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Liisa, it's Stuart here. There's 1,500 patients in total who are 12 and over who are homozygous to the F508del mutation and we estimate there's about 30% of those will be covered by some form of private insurance. Private insurance may take some time",85,"Yes, Liisa, it's Stuart here. There's 1,500 patients in total who are 12 and over who are homozygous to the F508del mutation and we estimate there's about 30% of those will be covered by some form of private insurance. Private insurance may take some time to kick in, in Canada. It's necessarily quite as rapid for them to come to a position. Certainly, that was our experience with KALYDECO. But approximately 30% of the 1,500 patients we estimate will have some form of private insurance."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, that's helpful. And then the data on the kids looks really impressive with the LCI. Can you just maybe comment on the clinical meaningful -- meaningfulness of that number? Obviously, we are not used to seeing that number as they are with FEV so was",56,"Okay, that's helpful. And then the data on the kids looks really impressive with the LCI. Can you just maybe comment on the clinical meaningful -- meaningfulness of that number? Obviously, we are not used to seeing that number as they are with FEV so was just curious if you can put some context around that?"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. It's Jeff Chodakewitz. I will say that in terms of that validation of saying what the minimally clinically important difference, it doesn't exist for that tool. I will say based on our discussions with people who are experts at the methodology, we w",92,"Sure. It's Jeff Chodakewitz. I will say that in terms of that validation of saying what the minimally clinically important difference, it doesn't exist for that tool. I will say based on our discussions with people who are experts at the methodology, we were kind of targeted a 0.7 decrease. I remember that this measure, actually, a negative number is an improvement because of the way the test is done. So I can't give an exact number, but hopefully, that gives you some context on why we were pleased with the results."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Liisa, this is Jeff. Maybe just to reiterate one thing that Jeff said before, because I think it's important. And I remember you and talking to you at one point. We are very interested in some of these alternative endpoints for a couple of reasons. On",188,"And Liisa, this is Jeff. Maybe just to reiterate one thing that Jeff said before, because I think it's important. And I remember you and talking to you at one point. We are very interested in some of these alternative endpoints for a couple of reasons. One, as Jeff said, this may be much more profitable to populations and widgets that got to measure FEV1 like the kids, particularly as they get younger. But also because, as you know, FEV1, which is really a measure of midsized airway resistance, is it's quite a bit downstream or upstream, if you will, from the problem in CF, which is really a distal airway gas exchange problem. And actually, LCI is probably much more sensitive measure closer to the actual physiology that's going on in CF. And so we've been very eager to start to see results from these kinds of studies to tell whether LCI could actually turn out to be as good or better an endpoint that FEV1 and obviously, you to provide agencies with the clinical data to support that this is the first step in that process."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Phil Nadeau of Cowen & Company.",13,"Our next question comes from the line of Phil Nadeau of Cowen & Company."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just to -- as we begin to model in the younger kids, the penetration of ORKAMBI into the kids 6 to 11, are there any issues with compliance persistence or uptake in that population that you want to point out? Or do you expect kind of similar rates of thos",96,"Just to -- as we begin to model in the younger kids, the penetration of ORKAMBI into the kids 6 to 11, are there any issues with compliance persistence or uptake in that population that you want to point out? Or do you expect kind of similar rates of those elements in the other kids as in the older? And then second, on the pipeline, I think we're expecting the ENaC monetary data [indiscernible] year. Can you give us some idea of where you're looking for that data set and what would be a good concept?"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I guess, just in terms of modeling, the kids where lucky enough to get an approval this year, I'd certainly recommend that people take into account the same consideration, the peak penetration, times of peak, persistence rate and compliance and model over",160,"I guess, just in terms of modeling, the kids where lucky enough to get an approval this year, I'd certainly recommend that people take into account the same consideration, the peak penetration, times of peak, persistence rate and compliance and model over each individually. In terms of what we've seen with KALYDECO, we have seen that the worst compliance we see tends to be in that sort of teenage to young adult. And so because kids -- our assumption is because kids are very closely monitored by their parents, particularly in that kind of 6 to 11 year age group, perhaps not surprisingly, we see high levels of compliance with that particular patient group. We tend to see a bit of a dip, perhaps unsurprisingly in the sort of teenage due to a dollars group. So we might anticipate in the 6 to 11, that would be our best compliance patient population and that's certainly what we've seen with KALYDECO."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeff, [indiscernible] just maybe a couple of comments on the ENaC program. First of all, there's an ongoing Phase II [ph] study that Parion has the lead on. That study is across all different types of genotypes in terms of the patient population and so we",202,"Jeff, [indiscernible] just maybe a couple of comments on the ENaC program. First of all, there's an ongoing Phase II [ph] study that Parion has the lead on. That study is across all different types of genotypes in terms of the patient population and so we're going to really be looking for early evidence of activity in that study and not just looking over all, but  we're going to be trying to learn looking among the different subpopulations. We still expect the result of that to come out around midyear. At the same time, we're going to be starting our study, which is very complementary to the study that is ongoing, and that is this quarter and that study is going to be in 508 homozygous patients who already are going to be receiving ORKAMBI and then looking to see whether the ENaC inhibitor can add to the efficacy for has population. And actually comes pre-critical data in our and suggest and that maybe the best way to get activity and benefit for patients from that mechanism. And so ultimately, it's going to be learning from both of those trials as we better understand what the potential for that mechanism may be."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Adam Walsh of Stifel.",12,"Our next question comes from the line of Adam Walsh of Stifel."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess, I have 2 questions. The first one is for Jeff Leiden. We have been now talking to docs, and according to them, your GPS reimbursement support program is fairly terrific. I'll start with that. But some of these docs also noted that the total out-o",197,"I guess, I have 2 questions. The first one is for Jeff Leiden. We have been now talking to docs, and according to them, your GPS reimbursement support program is fairly terrific. I'll start with that. But some of these docs also noted that the total out-of cost -- out-of-pocket cost for a lot of CF patients is really quite high, even before they try to get on ORKAMBI or KALYDECO. And I'm just curious in terms of with that in mind, how do you think about how far you can go to support patients, given the fact that a co-pay is a 20%? And that adds quite a bit of out-of-pocket expense. Where is -- how far can you go in supporting the patients there, both with your own medicine and thinking about this in the context of the portfolio of medicines that are already beyond? That's one. And then I have a question for Jeff to [indiscernible] well. You mentioned in the press release that 2 patients discontinue treatment in the ORKAMBI 6 to 11 study because of the adverse events. If you could just comment briefly on those to patients, that would be great."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks for the question. This is Jeff Leiden. I'm actually going to turn that one over to Stuart because he's really responsible for the GPS program. And he'll also be able to describe a patient assistance programs that allow us to patients to do have hig",47,"Thanks for the question. This is Jeff Leiden. I'm actually going to turn that one over to Stuart because he's really responsible for the GPS program. And he'll also be able to describe a patient assistance programs that allow us to patients to do have high co-pay."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks for the question and thanks for the positive feedback. The GPS program, just so everybody is aware of it, is service servers, which help patients and help them navigate the reimbursement process and then to provide them with ongoing education if th",152,"Thanks for the question and thanks for the positive feedback. The GPS program, just so everybody is aware of it, is service servers, which help patients and help them navigate the reimbursement process and then to provide them with ongoing education if they choose to opt in. So it's great to get the feedback on that. Now dealing with the question you raised about out-of-pocket costs for both KALYDECO and ORKAMBI, we have comprehensive patient assistance programs in terms of co-pay assistance for eligible patients. The program is such that no patient you have a co-pay who's eligible for the program, we have a monthly co-pay for either KALYDECO or ORKAMBI above $15 per month. It is for those patients who have coinsurance, we will cover coinsurance up to 30% of the price of the medicines and the program is to keep things simple for people identical to those KALYDECO and/or ORKAMBI."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And as you pointed out, the overall profile essentially is quite favorable. There were patients who discontinued. One of them was because of abnormal liver functions. The other one was because of a rash.",34,"And as you pointed out, the overall profile essentially is quite favorable. There were patients who discontinued. One of them was because of abnormal liver functions. The other one was because of a rash."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Mark Schoenebaum of Evercore ISI.",13,"Our next question comes from the line of Mark Schoenebaum of Evercore ISI."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","First question is on guidance. Should we assume your financial guidance is more or less conservative than [indiscernible] statement this call would end by 5:45? Because you missed that pretty badly, so I'm a little concerned here. Anyway, just really quic",122,"First question is on guidance. Should we assume your financial guidance is more or less conservative than [indiscernible] statement this call would end by 5:45? Because you missed that pretty badly, so I'm a little concerned here. Anyway, just really quick ones. I know it's getting late. Number one, can you just tell us when to expect data from a Phase II triple combo that you are going to start this year? I assume that's a mid-2017 event, assuming if I'm wrong on that. And the #2, I apologize if you address this. If you did, I missed it, but can you confirm the timing and your disclosure intentions around the -- what I believe is the futility analysis and [indiscernible] trial?"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So mark, it's Ian. I'll take both those questions. In your prepared remarks, you said the call will be brief as well. So he was wrong there as well. Luckily, it doesn't give financial guidance for us. So first -- your first question was regarding the trip",174,"So mark, it's Ian. I'll take both those questions. In your prepared remarks, you said the call will be brief as well. So he was wrong there as well. Luckily, it doesn't give financial guidance for us. So first -- your first question was regarding the triple. And so first of all, the timing of getting data from the triple or disclosing the data from the triple is really subject to how fast we move through the Phase I. And we've mentioned this before, the longer our Phase I take, actually the better it is because it means the less [indiscernible] dose and we're getting greater exposure of the drug is at a healthy volunteers. And based on where we expect this to go, we anticipate in the second half of that year, we'll be in the proof-of-concept triple study, which will probably push us into early 2017 to get that data. So that's how we're trying to set a timing expectation. And then your second question was on the disclosure regarding which utilities..."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Utility [indiscernible]",2,"Utility [indiscernible]"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","In terms of the improvement for that trial, it's actually growing very nicely. As you might anticipate, given that these patients have no other alternative medicine and so we anticipate that we will be complete enrollment around the middle of that year an",82,"In terms of the improvement for that trial, it's actually growing very nicely. As you might anticipate, given that these patients have no other alternative medicine and so we anticipate that we will be complete enrollment around the middle of that year and, therefore, we do expect the futility study to be done in the second half of the year. Obviously, we will be disclosing that unless we have to curtail the study, so no news would be good news on that."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Tony Butler of Guggenheim Securities.",13,"Our next question comes from the line of Tony Butler of Guggenheim Securities."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Allow me to squeeze 1 in. There are a number of respiratory articles that actually support the use of LCI as an endpoint because it does demonstrate greater sensitivity. I guess, the question is really what is the correlation between LCI and FEV, given th",109,"Allow me to squeeze 1 in. There are a number of respiratory articles that actually support the use of LCI as an endpoint because it does demonstrate greater sensitivity. I guess, the question is really what is the correlation between LCI and FEV, given that LCI apparently becomes abnormal earlier than spirometry and in the later-stage disease, it seems to correlate and, therefore, can you only use LCI in children? And my last question, I guess, that's Jeff C and my last question really for Jeff L. Are you going to publish the kinetics and functionality of 152 and 440 soon or I guess, ever in the periodic Journal?"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","[indiscernible] I'll just quickly say, maybe in terms of where we published data regarding our molecules as we move forward, obviously, you've seen a lot of publications that NACF, which is in the fall, and then obviously, the ECFS conference. So you'll p",58,"[indiscernible] I'll just quickly say, maybe in terms of where we published data regarding our molecules as we move forward, obviously, you've seen a lot of publications that NACF, which is in the fall, and then obviously, the ECFS conference. So you'll probably expect to see more data in those conferences. And then to your other question, Jeff?"
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Maybe a couple of more, that LCI. As you point out, they do have overlapping, but somewhat different sweet spots, if you will, in terms of the best way to use them. And I do think, as feel, this links back to Jeff Leiden's comments, that we're continuing",172,"Maybe a couple of more, that LCI. As you point out, they do have overlapping, but somewhat different sweet spots, if you will, in terms of the best way to use them. And I do think, as feel, this links back to Jeff Leiden's comments, that we're continuing to learn the best way to use each of them. Obviously, LCI has that potential sensitivity, advantages in children. But right now, there are only some centers that actually have the expertise to do that well and, of course, a great tool if used poorly doesn't really help anybody. So I think there are still a lot of work to be done. And then there's the other part of your question about regulatory recognition and I can't speak for the regulators. But I think it was encouraging that in Europe, LCI was accepted as our primary endpoint in our study. So I think there is a general, I'm hoping this is the continued advance in the field, but hopefully, we can contribute to that."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, great. Thank you again for joining us today. I apologize for running over. It was all Michael's fault. At the risk of running for 1 or 2 more minutes, I did want to make a couple of concluding remarks. And again, I always like to do this sort of in",351,"Well, great. Thank you again for joining us today. I apologize for running over. It was all Michael's fault. At the risk of running for 1 or 2 more minutes, I did want to make a couple of concluding remarks. And again, I always like to do this sort of in retrospect where are we today as a company as compared to where we were 6 or 12 months ago. And I must say from a personal standpoint and from the standpoint of CF patients, I'm very, very encouraged with the progress that we've made. I think we've -- it's now clear that KALYDECO and ORKAMBI together are approved for about 2,500 patients are almost 1/3 of all patients, CF patients in the world. And as we discussed with JPMorgan, it's a fairly straightforward strategy to label expansion in the younger populations and others to take that number from 25,000 to 44,000 patients in the next couple of years. And then we have a clear strategy with multiple prongs, actually, to get to the vast majority of patients, and they include the ENaC inhibitors, which are in Phase II so they can move very rapidly if we see positive results in combination with ORKAMBs. They included the nextgen correctors, which are moving along in Phase I and which we hope to have in patients in the second half of this year, and we think those have the potential to both increase the efficacy for the patients we're treating today, but also to allow us to get to that large subset of patients indiscernible] today. And then finally, the progress we've made a some of our deals, particularly the CRISPR deals. And although that's the Holy Grail, 10 or 15 years down the road, we do have a vision of potentially collecting and underlying the patient and giving patients with CF. So as I look at the world from our perspective, obviously, I'm tremendously encouraged about future opportunities, particularly the future opportunity for patients in progress we're making, and we look forward to updating over the next year as we continue that."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks very much everybody. That concludes our call. The IR team will be available for additional questions, if you have them. Thank you.",23,"Thanks very much everybody. That concludes our call. The IR team will be available for additional questions, if you have them. Thank you."
36235,321312374,921863,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, you may disconnect your lines at this time. Have a great day.",15,"Ladies and gentlemen, you may disconnect your lines at this time. Have a great day."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our fourth quarter and full year 2015 financial results conference call. [Operator Instructions] As a reminder, this conference call is recorded. A replay",310,"Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our fourth quarter and full year 2015 financial results conference call. [Operator Instructions] As a reminder, this conference call is recorded. A replay will be available following the conclusion of tonight's call.
Dr. Jeff Leiden, Chairman and CEO; and Ian Smith, Chief Financial Officer, will provide prepared remarks this evening. Stuart Arbuckle, Chief Commercial Officer; and Dr. Jeff Chodakewitz, Chief Medical Officer, will join us for the Q&A portion of the conference call.
We recently presented at the Annual JPMorgan Healthcare Conference, where we provided a comprehensive update on our business and had the opportunity to meet with many investors and analysts. As such, our remarks tonight will be brief. We expect to conclude the call by 5:45 PM.
On tonight's call, Jeff will review key priorities for our business in 2016. Ian will review our fourth quarter and full year 2015 financial results and discuss our 2016 financial guidance, which we provided also earlier this month. As always, you can access the webcast live on our website.
I will remind you that we will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the Securities and Exchange Commission. These statements, including without limitation those regarding the ongoing development and potential commercialization of our drug candidates, Vertex's other cystic fibrosis programs and Vertex's future financial performance, are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in today's financial results press release. Please also see Slide 4 of tonight's webcast.
I will now turn the call over to Dr. Jeff Leiden."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. Earlier this month, I met with many of our investors and analysts at the annual JPMorgan Healthcare Conference to talk about the important transition that Vertex has made in the last few years. As we enter 2016, Ve",1589,"Thanks, Michael. Good evening, everyone. Earlier this month, I met with many of our investors and analysts at the annual JPMorgan Healthcare Conference to talk about the important transition that Vertex has made in the last few years. As we enter 2016, Vertex is on a path towards sustained earnings and revenue growth driven by an increasing number of people being treated with our 2 approved medicines for cystic fibrosis, KALYDECO and ORKAMBI. We have a broad and deep pipeline of investigational medicines for CF that we believe may allow us to reach our goal of treating all people with CF in the future. Additionally, our pipeline of medicines for other serious diseases, including cancer, pain and other neurologic diseases, continues to progress through early-stage clinical development. In short, we are a very different company than we were just 4 years ago.
This evening, I will briefly review our key priorities for 2016 and provide some insight into upcoming milestones in CF and other parts of our business. Our #1 priority has been and continues to be to increase the number of people eligible for and treated with KALYDECO and ORKAMBI and to develop potential new medicines that they provide even greater benefit for all people with CF in the years ahead.
At this time last year, just over 3,000 people were eligible for treatment with KALYDECO. Today, approximately 25,000 people are eligible for KALYDECO or ORKAMBI, and we expect the vast majority of these people will begin treatment with these medicines to treat the cause of their CF. We also expect to increase the number of people eligible for these medicines in 2016 through label expansion efforts that could include younger patients or patients with other mutations in the CFTR gene.
Our second key priority for 2016 is to continue building a financial profile of sustained revenues and earnings growth and a strong balance sheet. In 2015, a continued expansion of the KALYDECO label and the approval of ORKAMBI resulted in a significant increase in the number of patients being treated with our medicines, which led to a significant increase in revenues. Our progress in 2015 has positioned us for continued growth, and we believe we are on the right path to achieve our goal of building a financial profile consistent with that of other global biotech companies.
And finally, our third key priority is to invest in our business to create future medicines for other serious diseases. Continued investment in our pipeline is essential for creating additional breakthrough medicines for patients. I'll spend just a few minutes reviewing our recent progress and upcoming milestones that reflect these 3 priorities.
Our first CF medicine, KALYDECO, was approved by the FDA in January 2012. And since then, our goal has been to bring this medicine to as many people as possible who may benefit. KALYDECO addresses the underlying cause of CF and is a significant medical advance for people with certain mutations in the CFTR gene. Today, approximately 4,000 people are eligible for treatment with KALYDECO in North America, Europe and Australia. We're committed to bringing this medicine to even more patients who we believe may benefit in the years ahead.
We are awaiting decision from the U.S. FDA on our application for approval of KALYDECO in people ages 2 and older with CF who have certain residual function mutations. There are approximately 1,500 people ages 2 and older in the U.S. who have the residual function mutations represented in the supplemental New Drug Application for KALYDECO. While our submission for approval in these mutations is primarily based on preclinical data and on a Phase IIa critical study in only 24 patients, we believe that KALYDECO would be beneficial to these patients given the underlying science behind this precision medicine approach of using genetic markers and predictive assays to identify patients who are likely to benefit. Importantly, we chose to seek this approval knowing that these patients would otherwise have to potentially wait years before potential approval based on Phase III data. 
With more than 4 years of safety data, we believe that this path toward potential approval is in the best interest of people with CF. However, we also recognize that the application is based upon limited available clinical data in these rare mutations. The PDUFA date for a decision from the FDA is February 7.
With ORKAMBI, we are working to bring this medicine to more patients who we believe would benefit, specifically children with 2 copies of the F508del mutation, similar to the approach we took with KALYDECO. With the approval in the European Union at the end of last year, approximately 20,500 people ages 12 and older are now eligible for treatment with ORKAMBI in the U.S. and Europe. Today, we announced the Phase III study of ORKAMBI in children ages 6 to 11 met its primary safety endpoint and supports our planned submission of a supplemental New Drug Application in the second quarter of this year in the U.S. If approved, an additional 2,400 people in the U.S. with CF would be eligible for treatment with ORKAMBI.
While this was primarily a safety study, we also saw encouraging improvements in secondary and exploratory efficacy endpoints, including a statistically significant change in the exploratory endpoint of lung clearance index or LCI. Changes in LCI are also the primary endpoint of an ongoing Phase III study to support approval of ORKAMBI in this age group in Europe. There are approximately 3,400 children ages 6 to 11 who have 2 copies of the F508del mutation in the European Union. Additional information on this data was provided in today's press release.
Today, KALYDECO and ORKAMBI are approved to treat approximately 25,000 people in North America, Europe and Australia. We believe that there are many more people who may benefit from these medicines, and we have trials ongoing or planned that could expand the number of people eligible for treatment to approximately 44,000 in the years ahead.
Beyond our approved medicines, we have a pipeline of investigational CF medicines from early-stage research programs such as gene editing with CRISPR to late-stage development programs evaluating combinations of our CFTR modulators. This pipeline represents hope for the CF community, and our goal is to one day treat all people with CF.
We have a broad Phase III program underway evaluating the corrector VX-661 in combination with ivacaftor, and we are also advancing the development of 2 next-generation correctors that would be combined with VX-661 and ivacaftor as part of a Phase II study of triple combinations planned for later this year. Both approaches are asking the same fundamental questions. First, can we enhance the benefit for patients already receiving KALYDECO or ORKAMBI? And second, can we provide benefits to new groups of people with CF not currently helped by KALYDECO or ORKAMBI, including a very large group of patients with 1 F508del mutation and a second mutation known to result in minimal CFTR function?
The VX-661 program includes 4 Phase III studies in different groups of people with CF who have at least one copy of the F508del mutation. We will begin to see the first results from the VX-661 program by early 2017, and importantly, this program is also meant to provide a significant amount of safety data to support evaluation of the next-generation corrector with VX-661 and ivacaftor as part of an investigational triple combination regimen.
At the end of 2015, we initiated a clinical development of 2 next-generation correctors, VX-152 and VX-440. Phase I studies of each compound are ongoing in healthy volunteers and are evaluating single and multiple doses of VX-152 and VX-440 as well as triple combinations with VX-661 and ivacaftor. Together with a safety data from the VX-661 program, these studies are designed to support the planned initiation of Phase II studies to evaluate triple combination regimens in patients in the second half of 2016.
Our business model is unique. The success we've achieved in CF allows us to reinvest in the discovery and development of new transformative medicines. In parallel with CF, we are advancing a number of additional development programs for cancer, pain and other serious diseases. We have significant flexibility in how we may advance these programs, either independently for those diseases that we believe are aligned with the focus of our business, specifically specialty diseases where G&A expenses are low, or in collaboration with other companies that we believe would be best suited to rapidly bring these potential medicines to patients. We believe our pipeline represents both potentially transformative future medicines for patients and significant value for our business. We've begun to provide some additional insight and data for our pipeline programs, and I look forward to providing updates on our progress throughout the coming year.
I mentioned at the start of my remarks that Vertex has undergone an important transition in recent years. We are now a global biotech company that has independently brought forward 2 breakthrough medicines to people with CF worldwide and is on the path to delivering significant earnings and cash flow. Our financial performance in 2015 and guidance for 2016 are metrics of the kind of company that we want to become, a company that consistently creates transformative new medicines for patients, generates significant value for shareholders and reinvests in scientific opportunities to create future medicines. This is our business model, and I'm pleased by our success to date and with our outlook for the coming years.
With that, I'll turn the call over to Ian."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff. For my remarks today, I will review our fourth quarter and full year 2015 financial results and discuss our 2016 financial guidance for total KALYDECO net revenues and non-GAAP operating expenses, excluding cost of revenues. I'll also discus",1297,"Thanks, Jeff. For my remarks today, I will review our fourth quarter and full year 2015 financial results and discuss our 2016 financial guidance for total KALYDECO net revenues and non-GAAP operating expenses, excluding cost of revenues. I'll also discuss our expectation for providing ORKAMBI guidance in 2016.
Financial results first. Our 2015 net CF product revenues were approximately $983 million. This includes KALYDECO net revenues of $632 million and ORKAMBI net revenues of $351 million. Total CF product revenues increased by more than 110% compared to 2014. In the fourth quarter of 2015, we reported total net CF product revenues of approximately $401 million, including KALYDECO net revenues of $181 million and ORKAMBI net revenues of $220 million.
Fourth quarter KALYDECO sales of $181 million were up 45% versus the fourth quarter of last year and up 9% versus the third quarter of 2015. This included approximately $6 million inventory stocking that occurred at the end of the fourth quarter. Growth in KALYDECO was driven by both label expansion efforts, which increased the number of eligible patients to approximately 4,000, and by the completion of key reimbursement discussions in Europe. 
With ORKAMBI, more than 1,500 patients starts in the fourth quarter, resulting in sales of $220 million, up 68% versus third quarter of 2015. As expected, we saw a very rapid uptake for ORKAMBI in the period immediately following the FDA approval with more than 3,000 people starting treatment in the third quarter. Demand from patients and physicians has been strong. But as expected, fewer patients started treatment in the fourth quarter compared to the third quarter, in line with our prior statements regarding expectations for the rate of uptake for ORKAMBI. We expect this trend to continue through the end of 2016, by which time, we expect the vast majority of the 8,500 eligible patients in the U.S. to have initiated treatment with ORKAMBI.
Gross-to-net adjustments were largely unchanged from the third quarter and were in the high single digits due primarily to a greater proportion of patients within commercial plans initiating treatment in the first 6 months following the approval of ORKAMBI as compared to government-paid plans. Each of the 50 state Medicaid programs has now paid a claim for ORKAMBI. Thus, we expect gross-to-net adjustments will increase to the mid-teens by the end of 2016 to reflect an increase in patients treated being covered by Medicaid.
As we enter 2016, we are pleased with the launch of ORKAMBI to date and remain focused on working to ensure those who need the medicine have access to it, educating health care providers and supporting adherence to ORKAMBI.
Now to operating expenses. Our fourth quarter non-GAAP operating expenses were $282 million, including R&D expenses of $204 million and SG&A expenses of $78 million. The increased R&D expense in the fourth quarter 2015 compared to 2014 were primarily the result of increased costs related to the pivotal Phase III program for VX-661 in combination with ivacaftor. The increased SG&A expenses were primarily the result of an increased investment in global commercial support for the launch of ORKAMBI.
And tonight, I'm pleased to report that for the fourth quarter 2015, we recorded a non-GAAP net profit of $43 million or $0.17 per diluted share compared to non-GAAP net loss of $132 million or $0.55 per share for the fourth quarter of 2014. Our 2015 non-GAAP net loss was $268 million or $1.11 per share compared to non-GAAP net loss of $511 million or $2.17 per share for the full year 2014.
From a balance sheet perspective, we started 2016 with a strong cash position of $1.04 billion. Vertex also has $300 million outstanding from a credit agreement that provides for a secured loan of up to $500 million.
Now let's turn to the 2016 financial guidance, which we first provided on January 10. We expect 2016 KALYDECO net revenues of $670 million to $690 million. Our guidance for KALYDECO revenues reflects the continued use of KALYDECO, as was seen in the fourth quarter of 2015, which results in revenues of $181 million, and the expectation for up to approximately 200 patients with a gating mutation to enroll in the Phase III clinical study of VX-661 in combination with ivacaftor who would otherwise have received KALYDECO, which will thus reduce 2016 KALYDECO revenues. There was also an approximately $6 million inventory stocking that occurred at the end of the fourth quarter 2015 that is not expected to recur in future quarters and is thus accounted for in our guidance. Importantly, our current guidance excludes any potential revenues from the approval of KALYDECO for people with residual function mutations. We will update our KALYDECO guidance should we receive FDA approval for residual function mutations.
With ORKAMBI, more than 4,500 people have begun treatment in the U.S. by the end of 2015. There are 4 primary pieces of information regarding the launch that will inform our decision regarding ORKAMBI guidance. First, since all patients who initiated treatment with ORKAMBI in 2015 have been on treatment for approximately 6 months or less, we are awaiting additional information on the compliance rate for patients taking ORKAMBI. While we continue to expect that the vast majority of eligible patients in the U.S. will begin treatment with ORKAMBI by the end of 2016, we are awaiting additional information on the specific rate of uptake and on the specific proportion of the 8,500 eligible patients who will begin treatment with ORKAMBI in 2016.
And finally, additional information on the persistence rate defined as how many patients remain on treatment will also be taken into account. These 4 factors, the compliance rate, the rate at which patients begin treatment, the total number of patients who initiate treatment and the persistence rate, all are important in considering our guidance for ORKAMBI.
In 2016, we expect to recognize revenues from sales of ORKAMBI in the U.S. and Germany. In Germany, there are approximately 2,500 people with CF ages 12 and older with 2 copies of F508del mutation. In Europe, country-by-country reimbursement discussions are underway. However, we do not anticipate any significant ORKAMBI revenues from countries other than the U.S. and Germany in 2016.
The final component of our financial guidance is non-GAAP operating expenses, which are comprised of R&D and SG&A expenses and exclude cost of revenues. We expect our total 2016 non-GAAP operating expenses of $1.18 billion to $1.23 billion. As a reminder, our guidance for 2015 operating expenses was for $1.05 billion to $1.1 billion. And we reported 2015 operating expenses at the low end of this range of $1.06 billion, largely as a result of cost related to VX-661 that will now occur in 2016 as opposed to 2015. The increase in expense -- expected operating expenses for 2016 as compared to 2015 is primarily a result of expanded development efforts related to the pivotal Phase III development program for VX-661 in combination with ivacaftor and for multiple Phase I and II studies of Vertex's early-stage and mid-stage pipeline of potential CF medicines and anticipated SG&A costs to support the launch of ORKAMBI in new global markets.
The components of Vertex's non-GAAP operating expenses include non-GAAP R&D expenses, which we expect to be in the range of $850 million to $880 million, and non-GAAP SG&A expenses, which we expect will be in the range of $330 million to $350 million. Vertex's expected non-GAAP R&D and SG&A expenses exclude stock-based compensation expense and certain other expenses.
In summary, we are in a strong financial position as we enter 2016. We remain committed to delivering a financial profile that is similar to many of our large cap biotech peers, which includes sustainable revenue and earnings growth, high operating margins and most importantly, continued investment to create future medicines."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thank you. Operator, we're now ready to take questions.",9,"Thank you. Operator, we're now ready to take questions."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question comes from the line of Geoff Meacham of Barclays.",14,"[Operator Instructions] Our first question comes from the line of Geoff Meacham of Barclays."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congrats on profitability. I got a commercial and clinical question for you. I guess we'll start with commercial. I want to know, Ian, if you can go in a little bit more detail about persistence rates over time with KALYDECO and then -- and whether this s",73,"Congrats on profitability. I got a commercial and clinical question for you. I guess we'll start with commercial. I want to know, Ian, if you can go in a little bit more detail about persistence rates over time with KALYDECO and then -- and whether this should be a real benchmark for ORKAMBI. I'm just curious if you guys have tracked people who have discontinued and if they later come back to therapy."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Geoff, maybe Stuart will take that question. So thanks for the comment on profitability. [indiscernible] in the fourth quarter. Stuart is going to take the question. You might also comment on some of the other features that are affecting how we're thin",48,"So Geoff, maybe Stuart will take that question. So thanks for the comment on profitability. [indiscernible] in the fourth quarter. Stuart is going to take the question. You might also comment on some of the other features that are affecting how we're thinking about the launch as well."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Geoff. It's Stuart here. So yes, let me just reiterate a couple of things that Ian said about ORKAMBI and the factors we're taking into account when thinking about the launch and that we're tracking very closely. One is obviously the peak penetration",520,"Yes, Geoff. It's Stuart here. So yes, let me just reiterate a couple of things that Ian said about ORKAMBI and the factors we're taking into account when thinking about the launch and that we're tracking very closely. One is obviously the peak penetration, so the number of eligible patients in total we get initiated on therapy over time, and we continue to expect the vast majority of 8,500 patients will. Then there's the rate of uptake, how quickly we get to that peak penetration. As you know, at the end of December, we had about 4,500 patients on therapy. That's about 55% of the total. And we expect that we'll get to peak penetration during the course of 2016. And then as you said, one of the other key components is persistence, the number of patients who stay on therapy. And obviously, it's pretty early days because whilst we've only been on the market for 6 months, we really don't have long-term experience with very many patients yet. In the Phase III study for ORKAMBI, at about 24 weeks in TRAFFIC and TRANSPORT, about 5% of patients have discontinued. At 48 weeks in the open label expansion with ORKAMBI, we were -- 15% of patients have discontinued. So that's in the ORKAMBI clinical trials, and time will tell whether we see a higher or lower number but probably a higher number who are discontinuing in the real world. With KALYDECO, in the studies we've looked at, it was about 5% of patients again discontinued in the KALYDECO clinical trials. It was actually slightly higher than that in the real world. It got closer to 10%, so in the real world over time. And largely, that was good [ph], but over a longer period of time, we did see a slightly higher number of -- a higher percentage of patients on KALYDECO discontinued versus the clinical trials. The last thing we're going to be thinking about then is obviously compliance, not the percentage of patients who actually take the pills that have been described by their physician. As you know, KALYDECO is very, very high at 85%, certainly the highest I've ever seen personally for a chronic medication of the CF medicines or around about the 60% range. I would anticipate ORKAMBI is going to be in that range, probably toward the higher part of that range but somewhere in that range. The only other question we will have to look at very closely and we -- again, we just don't have data on it, we don't have data on it in the clinical program, Geoff, and we'll have to see how it plays out in the real world, is whether physicians and patients choose to reinitiate therapy if they have discontinued for some reason. And we just have no information from the clinical trials because they just weren't set up to look at that. If the patient discontinued, they would then kind of exclude it from further therapy. So we just don't have data on that right now, Geoff. Hopefully, that gives you some perspective on what we're thinking."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, no, that's helpful. And just real quick on the clinical side. When you look at the 152 and 440 study in healthy [ph], has there been any evidence of drug-drug interactions with KALYDECO or 661? And I guess I'm trying to figure out whether you guys ex",86,"Yes, no, that's helpful. And just real quick on the clinical side. When you look at the 152 and 440 study in healthy [ph], has there been any evidence of drug-drug interactions with KALYDECO or 661? And I guess I'm trying to figure out whether you guys expect to take multiple doses of those 2 correctors in the CF patients when you look to the back of the year? Maybe just help us with the design of that 28-day study as you see at this stage."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, it's Jeff Chodakewitz. So in terms of the Phase I studies for VX-152 and 440, we're really in the midst of those studies and we obviously can't comment on the ongoing trial. Maybe just a comment on the Phase II, we're in early days in terms of thos",79,"Geoff, it's Jeff Chodakewitz. So in terms of the Phase I studies for VX-152 and 440, we're really in the midst of those studies and we obviously can't comment on the ongoing trial. Maybe just a comment on the Phase II, we're in early days in terms of those designs, but I do think it's likely that we would look to take multiple doses of the compounds into those Phase II studies to learn as much as we can."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Matt Roden of UBS.",12,"Our next question comes from the line of Matt Roden of UBS."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I also wanted to congratulate you on the milestone of turning back to profitability. So regarding the pediatric study, I understand the primary endpoint is safety. And the LCI data looked really got, which -- the latter point being important for what's go",193,"I also wanted to congratulate you on the milestone of turning back to profitability. So regarding the pediatric study, I understand the primary endpoint is safety. And the LCI data looked really got, which -- the latter point being important for what's going on in Europe. But just want to get your perspective on the sort of 2.5% improvement in FEV. Have you talked to any experts or the FDA about that? I can't imagine that's going to be any kind of issue for you, but just want to see if there's anything to add on that side. And then on the commercial side, I want to ask, you've left the residual function mutations out of the KALYDECO guidance. But just trying to get a sense for if that were to be approved, how should we think about the onboarding of those patients on the commercial drug? I would imagine that you have a conversion of those that are on trial to commercial, but apart from that, would you characterize this as a highly motivated subset of patients? Or because they have a milder phenotype, could this be a slower rate of penetration?"
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Matt, it's Jeff Chodakewitz. Maybe I'll start. So in terms of the pediatrics study, we were very pleased with the results of the study really meeting both the endpoints for exposure for PK and then for safety. So that was a nice outcome. The expectation w",189,"Matt, it's Jeff Chodakewitz. Maybe I'll start. So in terms of the pediatrics study, we were very pleased with the results of the study really meeting both the endpoints for exposure for PK and then for safety. So that was a nice outcome. The expectation with the FDA is that once you've established efficacy in the same disease in older children, that as you move to younger age groups, really, it's really about that exposure and safety consistent with the design of the study. I will say that I think we're also quite pleased with the evidence of efficacy in the population where it gets harder to actually demonstrate that. And I think actually, the FEV1 showing that strong trend was actually quite favorable, remembering that these kids started at a pretty high FEV1 percentage at baseline. And as actually you noted, the fact that the LCI measure, which is in its earlier days was nicely positive, and that's our primary endpoint in the European study. And lastly, the BMI kind of measures as well. So I think overall, we were quite satisfied with the results of the trial."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Matt, it's Stuart here. Just to comment on the residual function. So as you said, residual function is not included within the KALYDECO guidance that we have provided. There's about 1,500 patients with the 23 mutations that we've asked for within our",182,"And Matt, it's Stuart here. Just to comment on the residual function. So as you said, residual function is not included within the KALYDECO guidance that we have provided. There's about 1,500 patients with the 23 mutations that we've asked for within our filing. In terms of patients transferring from clinical trials, clearly the clinical trial on which the application is based or what's included in the clinical trial is very small. So it's not as if there's a huge bolus of patients to transition from clinical supply to commercial supply. In terms of rate of uptake, the best analog, I think, for you there would be R117H, which by definition is a residual function mutation. And so both in terms of peak penetration and rate of uptake, I think that's probably the best analog for you to think of in terms of the rate of uptake we might see before approved. And then just to illustrate what Ian said in his prepared remarks, if we're approved in residual function, our anticipation is that we'll update our KALYDECO guidance to reflect that."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Terence Flynn of Goldman Sachs.",13,"Our next question comes from the line of Terence Flynn of Goldman Sachs."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Samir on for Terence. Have all ORKAMBI clinical trial patients in the U.S. transitioned to commercial drug? And if not, how many are left to transition?",28,"This is Samir on for Terence. Have all ORKAMBI clinical trial patients in the U.S. transitioned to commercial drug? And if not, how many are left to transition?"
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I'm not going to comment on exactly how many, but the vast majority of the patients who are on clinical trial supply have now transitioned to commercial drug. Just to orient you, there was approximately 500 in total of the patients in TRAFFIC and TRANSPOR",50,"I'm not going to comment on exactly how many, but the vast majority of the patients who are on clinical trial supply have now transitioned to commercial drug. Just to orient you, there was approximately 500 in total of the patients in TRAFFIC and TRANSPORT were in the U.S."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Matthew Harrison of Morgan Stanley.",10,"Our next question comes from Matthew Harrison of Morgan Stanley."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So I just had 2 quick ones. So one, just, Ian, can you go back to the KALYDECO stocking comment that you made and just tell us if you think we could see some of that inventory come out of the channel this year and how that's in your guidance? And then sep",100,"So I just had 2 quick ones. So one, just, Ian, can you go back to the KALYDECO stocking comment that you made and just tell us if you think we could see some of that inventory come out of the channel this year and how that's in your guidance? And then separately, just on the EU pediatric study, how will data from that influence maybe FDA perception of the filing that you guys have? And also, how was timing of that related to when you would expect to have a PDUFA date for the label expansion in the U.S.?"
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, so I'll take the first one and Jeff Chodakewitz can take the second question. So firstly, the stocking question in the U.S. is -- first of all, to orient people, we have estimated there's approximately $6 million of inventory stocking in the fourth q",238,"Yes, so I'll take the first one and Jeff Chodakewitz can take the second question. So firstly, the stocking question in the U.S. is -- first of all, to orient people, we have estimated there's approximately $6 million of inventory stocking in the fourth quarter for KALYDECO. What we mean by that is the inventory was higher at December 31 compared to September 30 by $6 million. That will then sell out of the channel, so it does impact future sales because it was an inventory. We have removed that from our guidance. So when we made an estimate for our 2016 KALYDECO guidance, we removed that. In fact, I think when we all met in JPMorgan in San Francisco, I gave people a simple calculation to think about how we got to our guidance for 2016. I'll just refer to that again, which is in the fourth quarter of 2015, we did approximately $180 million with the KALYDECO revenues, $181 million to be precise, but approximately $180 million. If you multiply that -- if you take $6 million out of that, you get $174 million with the fourth quarter run rate revenues and then multiply that by 4, you then actually deduct the patients from that annualized number and you get to approximate range of the guidance that we provided, which was $670 million to $690 million for KALYDECO. So it did take account for that stocking."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Great. And it's Jeff. I think in terms of your questions about pediatric, so maybe starting with the U.S. As we said, we expect to submit our file in the second quarter of this year. We haven't yet had those discussions with the FDA, of course, but we're",79,"Great. And it's Jeff. I think in terms of your questions about pediatric, so maybe starting with the U.S. As we said, we expect to submit our file in the second quarter of this year. We haven't yet had those discussions with the FDA, of course, but we're operating under the assumption of a 6-month review time. The European study is still ongoing. It's enrolling. And I don't really see there being much interaction in terms of those processes."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Michael Yee of RBC Capital Markets.",14,"Our next question comes from the line of Michael Yee of RBC Capital Markets."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","As it relates -- well, like guidance, for Ian, I know there's no formal guidance for ORKAMBI, but is the key message here -- when I look at the consensus of $1.6 billion, is the key message to think about that discontinuations are a little bit higher and",170,"As it relates -- well, like guidance, for Ian, I know there's no formal guidance for ORKAMBI, but is the key message here -- when I look at the consensus of $1.6 billion, is the key message to think about that discontinuations are a little bit higher and compliance a little bit lower based on the comments that Stuart made in the U.S.? And then on O [ph] U.S., Ian, as it -- I'm just trying to be clear that Germany is the only country being launched? Are there other things that I need to think about when I look at the consensus of $345 million? Maybe you can make a comment about that and how consensus is modeling? Just so I'm clear on that. And the second question is just a quick clinical question. On 152 and 440, in the Phase I, even though it's healthy, is there any [indiscernible] record or any of the biomarkers you're looking at that you'll disclose that could give any hints of efficacy?"
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for the questions, Mike. Jeff Chodakewitz actually just stepped out while you asked that second question.",18,"Yes, thanks for the questions, Mike. Jeff Chodakewitz actually just stepped out while you asked that second question."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","No, I heard. I was able to tell.",8,"No, I heard. I was able to tell."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeff and I -- Jeff has a pretty bad cold so [indiscernible].",12,"Jeff and I -- Jeff has a pretty bad cold so [indiscernible]."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I just want to make sure he heard your question. I'll take the first question, and so Jeff will take the second question. So first of all, actually, no, we're not trying to say discontinuations is of a bigger issue than compliance. So I actually appreciat",303,"I just want to make sure he heard your question. I'll take the first question, and so Jeff will take the second question. So first of all, actually, no, we're not trying to say discontinuations is of a bigger issue than compliance. So I actually appreciate asking the question so we can clarify that. That's not what we're trying to say. It's not actually what we are seeing even earlier on in this launch. But I appreciate the opportunity maybe to comment on how people are thinking about the ORKAMBI launch and how we're seeing it reflected in sell side models. And specifically, 2016, let's say, forecasted that are in the sell side models. So obviously, when you look at consensus, there are a number of different models that are out there, a number of different numbers. And so there's some extreme numbers and then there's some that are more towards the normal. What I would say, I don't know the assumptions that are being put into other people's models, but I would ask you to listen carefully to Stuart's comments, where we touch on when do we believe we're going to get to peak penetration, the rate of uptake of ORKAMBI? And then importantly, the persistence and compliance, because specifically compliance, if people take 6 pills out of every 10, it's straightforward, you get $6 out of every $10 of your growth price. And then obviously, there is a gross-to-net discount based on whether you've got Medicaid patients versus private-paying patients. And so I just -- the opportunity to comment on this call to all people at once is I just want to make sure that people are giving a thorough consideration to all these aspects of the launch, and we'd be happy to talk to you after the call as well."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Again, as far as your question regarding Germany, Germany is the only country that we expect any significant revenues from outside of the U.S. And just to give you a background of Germany, Germany has an estimated 2,500 patients. We believe it could take",153,"Again, as far as your question regarding Germany, Germany is the only country that we expect any significant revenues from outside of the U.S. And just to give you a background of Germany, Germany has an estimated 2,500 patients. We believe it could take 12 to 18 months to reach the peak penetration in those patients, and we provided people with it with a price in Germany. And it is one aspect of the sell side models that I do struggle with, because when I look at an ex U.S. consensus of the sell side model, that's a number that's close to $300 million. I find it very challenging for us to accrue that much revenue from Germany alone. And so I do appreciate you calling that out, and so I just hope that people ask here in consideration to all these features when modeling the ORKAMBI launch. And then over to Jeff."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, so just very briefly about 152 and 440, I can't go into the details of the ongoing studies. But as you know, the main focus for Phase I studies is got to be exposure and safety, and then we learn a lot from those ongoing studies.",47,"Yes, so just very briefly about 152 and 440, I can't go into the details of the ongoing studies. But as you know, the main focus for Phase I studies is got to be exposure and safety, and then we learn a lot from those ongoing studies."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Ying Huang of Bank of America.",14,"Our next question comes from the line of Ying Huang of Bank of America."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe first one is for Stu. So ORKAMBI, you're looking at a much larger eligible patient population here. I know you guys have this clinical outcome-based reimbursement agreement with the Australian government for KALYDECO. Do you expect government payers",101,"Maybe first one is for Stu. So ORKAMBI, you're looking at a much larger eligible patient population here. I know you guys have this clinical outcome-based reimbursement agreement with the Australian government for KALYDECO. Do you expect government payers to ask for some similar arrangement for ORKAMBI besides Australia? And second, as on clinical side is maybe for Jeff, talking about the preclinical data you have, what the metabolism and also secretion route for the 2 sets of next-generation CFTR correctors? Do you expect any drug-drug interaction at all based on the way the drugs have metabolized and secreted with ORKAMBI?"
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Ying, Stuart here. I'll take your first question. Thanks for the question on reimbursement. And to kind of cut to the chase, I really can't speculate on exactly what our arrangements are going to look like with governments around the world because we real",145,"Ying, Stuart here. I'll take your first question. Thanks for the question on reimbursement. And to kind of cut to the chase, I really can't speculate on exactly what our arrangements are going to look like with governments around the world because we really are just at the beginning of that process. And just to remind people, in most countries, it's really a 3-step process. There'll be a clinical assessment of the risks and benefits of the agent, then the pharmacoeconomic assessment. And that really then is the sort of starting point for the price and contracting negotiations. And until we kind of work our way through that process, it's really impossible to speculate on exactly what the nature of any relationship that we might come to with the various governments around the world. And for the clinical question, I'll hand that over to Jeff."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. So briefly, you were asking about metabolism and so forth. And as you know, it's very hard from preclinical data to speculate, specially until you really understand exposures and so forth. But we're going to understand that much better from our Phas",84,"Sure. So briefly, you were asking about metabolism and so forth. And as you know, it's very hard from preclinical data to speculate, specially until you really understand exposures and so forth. But we're going to understand that much better from our Phase I study. I would point back to what we've said all along about our next-gen molecule that we wanted to get molecules that weren't just look good in vitro, but actually could be medicines. And that's the way we've approach it."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Cory Kasimov of JPMorgan.",12,"Our next question comes from the line of Cory Kasimov of JPMorgan."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So I wanted to go back to the topic of ORKAMBI outside of the U.S. Obviously, there's a lot of talk about reimbursement in time to roll out in Europe. But I wanted to go to other regions such as Canada. You just mentioned Australia, but following the appr",108,"So I wanted to go back to the topic of ORKAMBI outside of the U.S. Obviously, there's a lot of talk about reimbursement in time to roll out in Europe. But I wanted to go to other regions such as Canada. You just mentioned Australia, but following the approval in Canada. I know there's 1,500 patients there that meet the label criteria. Can you remind us of the market size in Australia as well? And once you do have the reimbursement in place, what would you expect the anticipated pace of uptake? And really just the overall relevance of these markets to be from a commercial standpoint?"
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Cory, Stuart here. So yes, as you said, the eligible patient population of F508 Delta homozygotes in Canada is about 1,500 patients, and that's out of about 4,000 total CF patients that we estimate in Canada. Now that we've got the kind of regulatory",214,"Yes, Cory, Stuart here. So yes, as you said, the eligible patient population of F508 Delta homozygotes in Canada is about 1,500 patients, and that's out of about 4,000 total CF patients that we estimate in Canada. Now that we've got the kind of regulatory approval, we can now begin to seek public reimbursement for ORKAMBI in Canada. And as you know, as I've just described, the process there is, again a clinical assessment, there'll be a pharmacoeconomic assessment, and then, there'll be a price negotiation probably through the pan-Canadian Pricing Alliance process that we went through with KALYDECO. In terms of rate of uptake, much as we're seeing here in the U.S., I'd anticipate that the relative rate of uptake will be slower for ORKAMBI than it was with KALYDECO in Canada, and indeed, other markets outside of the U.S. for the same reason. It's just the sheer volume of patients is much larger than it is for KALYDECO, and it's just more of an administrative burden to initiate patients. So much like we're seeing here in the U.S., I'd expect the relative rate of uptake for ORKAMBI to be less than it is for -- less rapid than it was for KALYDECO in Canada, and indeed, other markets outside of the U.S."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Corey, this is Jeff Leiden. Maybe just to add one comment. Obviously, we've heard a lot from Ian and Stuart on some of the questions about the kinetics of the launch and some of the short-term modeling. I do think it's important to stand back as well and",308,"Corey, this is Jeff Leiden. Maybe just to add one comment. Obviously, we've heard a lot from Ian and Stuart on some of the questions about the kinetics of the launch and some of the short-term modeling. I do think it's important to stand back as well and remember what the total opportunity is, which, I think is where your question is going. So if you think about where we are today versus where we were even 6 months ago, right, today, we have approval for 8,500 patients in U.S. and we have a launch that we're really pleased with, with more than 4,500 or 55% of the patients already on the drug in the U.S., which I think is remarkable. We have reimbursement in the U.S. that's gone actually better than we even expected, meaning every state Medicaid is now reimbursing the drug and the majority of the private insurers are. We have approval in Europe, and are starting a launch in Germany, as you heard in the press release; an ATU in France. Now we have approval in Canada, which gives us access to 1,500 private patients and the ability to negotiate reimbursement, as Stuart said, to an additional, I think, 2,500 patients or so. And so when you look at the total opportunity, it's actually every bit of what we thought before, and we've made significant progress. And nothing with that has changed. It's impossible to predict the exact kinetics, what's going to happen in the first quarter versus the second quarter. But at least, the way we look at it, as we look out over the next couple of years, we see that opportunity intact and progressing really nicely. And I think it's important to sort of see that in the big picture as well as the short-term model. So I hope that helps."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Brian Abrahams of Jefferies.",12,"Our next question comes from the line of Brian Abrahams of Jefferies."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two questions. First, on the clinical side on the 6 to 11-year-old population. I was wondering if you could talk a little bit about the natural history of untreated patients on the lung clearance index endpoint. Where does it typically go over a 6-month p",115,"Two questions. First, on the clinical side on the 6 to 11-year-old population. I was wondering if you could talk a little bit about the natural history of untreated patients on the lung clearance index endpoint. Where does it typically go over a 6-month period in children of this age? I guess, balancing disease progression versus normal growth, does it typically worsen or stay flat? And then on the clinical/commercial side, can you give us any more granularity on the ongoing Phase IIIb study in low FEV1 patients, the doses, timeline and potential impact that data might have to help patients -- help these patients manage through the initial side effects and stay on therapy?"
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Brian, it's Jeff Chodakewitz. So let's maybe start with the LCI. And as we talked about a little bit, this actually isn't early measures. So the information I can give you is somewhat imperfect, just so you know. I think its advantage, we think, is being",296,"Brian, it's Jeff Chodakewitz. So let's maybe start with the LCI. And as we talked about a little bit, this actually isn't early measures. So the information I can give you is somewhat imperfect, just so you know. I think its advantage, we think, is being able, in children, who have relatively normal FEV1s, but as you know, they have significant underlying disease. Their pulmonary function really is far from normal. It allows you to measure that. And over reasonably short periods of time, sort of like a 6-month period, as we go in our clinical studies, there could be small decreases. But we think overall, that, that should be relatively stable. There may be modest shift over time, but we think we'd be able to have a reasonable baseline for assessing it. So -- and actually, that's part of why the data that we had coming out of our pediatric study, even without the control arm, was encouraging to us. Maybe I'll take a comment on the study in patients whose FEV1s are less than 40. We're still actually the process of collecting all that data. We are still enrolling. But we think that there's some useful information. They are just in terms of the experience that we've accrued. We did -- to your specific question, did give -- partway through give investigators the opportunity to start with a lower dose, and then step up to full dose. That will be -- it's not a perfect evaluation of that, but we are really trying to do what you said, which is to help explore what could help patients get through those early weeks of dosing. We are going to summarize all that data and present it and use it from an education perspective as well."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Alethia Young of Crdit Suisse.",13,"Our next question comes from the line of Alethia Young of Crdit Suisse."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And congrats on the 9 draft and the green. Maybe just a couple. One, if something happens with the residual, where the FDA may request more information, do you guys have a strategy on how you might pursue that population going forward? And then also with",105,"And congrats on the 9 draft and the green. Maybe just a couple. One, if something happens with the residual, where the FDA may request more information, do you guys have a strategy on how you might pursue that population going forward? And then also with the potential kind of chest tightness that sometimes happens, our checks kind of suggested that, that happened earlier rather than later, like in the first couple of weeks? But is there a dynamic where it could happen later? And did you see similarities and differences, though you've probably tight traded in the safety as well in the younger populations?"
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Alethia, it's Jeff Leiden. Maybe I'll take the first one, since it's a bit of a science and a policy question -- strategy question, I think. And then Jeff, you can take the second question on the chest tightness. So maybe just to give you a little ba",399,"Yes, Alethia, it's Jeff Leiden. Maybe I'll take the first one, since it's a bit of a science and a policy question -- strategy question, I think. And then Jeff, you can take the second question on the chest tightness. So maybe just to give you a little background, and I know you're you aware of this, but the RF application is a little bit unusual compared to the applications that Vertex has submitted on KALYDECO and ORKAMBI, which are always based on large Phase III studies. This one's different. It's basically aimed at about 1,500 patients, with 23 different mutations resulting in residual function. And it's based predominantly on preclinical data. That is cell-based data from cells that have been engineered to have those 23 different mutations, supported by a very small Phase IIa study of about 24 patients that comprise the 8 or 9 of those 23 mutations. And so what we're really asking the FDA to look at is both the science and the medicine that we're submitting. But also there's a policy question here, which is, how do you extend the label of drugs like KALYDECO to very rare population and mutations. Some of these mutations only have 4 patients in the U.S. or 10 patients in the U.S. And that's a very important policy question in precision medicine. As you know, the FDA is considering much more broadly than just in CF. And so part of the reason why it's a little difficult handicap is, one, because it's this combination of clinical and policy sort of things. We feel very strongly, the right thing to do for patients, that's why we did it. There are 1,500 patients in the U.S. that today don't have any CFTR correction therapy of any sort, and it would be years before they could get them based on large Phase III trials. And so for us, this is definitely the right thing to do for patients. And we believe in the science strongly and in the clinical support that we have. But handicapping what the FDA is going to do, obviously, it's a bit more difficult. We'll know by February 7. And then based upon what we do, we'd obviously come up with a strategy. But again, our goal is to try to get this medicine as fully as a safety data to these patients as soon as possible."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Jeff Chodakewitz, just to comment on your questions about the chest tightness. Maybe first step back to our Phase III results, which, I think are the most definitive information. And as you noted, those adverse events did occur very early. They were m",115,"And Jeff Chodakewitz, just to comment on your questions about the chest tightness. Maybe first step back to our Phase III results, which, I think are the most definitive information. And as you noted, those adverse events did occur very early. They were manageable in the vast majority of people, and they did decrease over time. Usually, the average duration was approximately 2 weeks. So I think all of that really comes out of our Phase III data, and it's suggested, it is an early event. And the experience in our pediatric study was actually completely consistent with that. It was a small number, it happened early and, in fact, nobody discontinued because of that."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of  Liisa Bayko of JMP Securities.",13,"Our next question comes from the line of  Liisa Bayko of JMP Securities."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just wanted to better understand what you were describing here with Canada in terms of the private payers. I know there's 1,500 patients that are -- would be eligible for ORKAMBI. Can you break that down into how many of those would be private?",45,"I just wanted to better understand what you were describing here with Canada in terms of the private payers. I know there's 1,500 patients that are -- would be eligible for ORKAMBI. Can you break that down into how many of those would be private?"
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Liisa, it's Stuart here. Yes, there's 1,500 patients in total, who are 12 and over, who are homozygous to the F508 Del mutation. And we estimate that about 30% of those will be covered by some form of private insurance. Private insurance may take som",88,"Yes, Liisa, it's Stuart here. Yes, there's 1,500 patients in total, who are 12 and over, who are homozygous to the F508 Del mutation. And we estimate that about 30% of those will be covered by some form of private insurance. Private insurance may take some time to kick in. In Canada, it's not necessarily quite as rapid for them to come to a decision. Certainly, that was our experience with KALYDECO. But approximately 30% of the 1,500 patients, we estimate, will have some form of private insurance."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, thanks, that's helpful. And then the data on the kids looks really impressive with the LCI. Can you just maybe comment on the clinical meaning -- meaningfulness of that number? Obviously, we're not as used to seeing that number as we are with FEV. S",58,"Okay, thanks, that's helpful. And then the data on the kids looks really impressive with the LCI. Can you just maybe comment on the clinical meaning -- meaningfulness of that number? Obviously, we're not as used to seeing that number as we are with FEV. So I'd just be curious if you could put some context around that."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. It's Jeff Chodakewitz. And I will say that in terms of that kind of validation of saying what's a minimally clinically important difference, it doesn't exist for that tool. I will say based on our discussions with people who are experts in the metho",99,"Sure. It's Jeff Chodakewitz. And I will say that in terms of that kind of validation of saying what's a minimally clinically important difference, it doesn't exist for that tool. I will say based on our discussions with people who are experts in the methodology, we were -- we kind of targeted a 0.7 decrease. And remember that in this measure, actually, a negative number is an improvement because of the way the test is done. So I can't give you an exact number, but hopefully, that gives you some context in why we were pleased with the results."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay. And Liisa, this is Jeff. Maybe just to reiterate one thing that Jeff -- he said before, because I think it's important. And I remember you and I talking about this at one point that we are very interested in some of these alternative endpoints for a",195,"Okay. And Liisa, this is Jeff. Maybe just to reiterate one thing that Jeff -- he said before, because I think it's important. And I remember you and I talking about this at one point that we are very interested in some of these alternative endpoints for a couple of reasons. One, as Jeff said, this may be much more applicable to populations in which it's difficult to measure FEV1, like the kids, particularly as they get younger. But also because, as you know, FEV1, which is really a measure of mid-sized airway resistance, is it's quite a bit downstream or upstream, if you will, from the problem in CF, which is really a distal airway gas-exchange problem. And actually, LCI is a probably much more sensitive measure, closer to the actual physiology of what's going on in CF. And so we've been very eager to start to see results from these kinds of studies that tell whether LCI could actually turn out to be as good or better an endpoint that FEV1 and, obviously, you need to provide agencies with clinical data to support that. And this is the first step in that process."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Phil Nadeau of Cowen & Company.",13,"Our next question comes from the line of Phil Nadeau of Cowen & Company."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just to -- as we begin to model the younger kids, the penetration of ORKAMBI into the kids aged 6 to 11, are there any issues with compliance persistence or uptake in that population that you want to point out? Or do you expect kind of similar rates of th",96,"Just to -- as we begin to model the younger kids, the penetration of ORKAMBI into the kids aged 6 to 11, are there any issues with compliance persistence or uptake in that population that you want to point out? Or do you expect kind of similar rates of those elements in the other kids as in the older? And then second, on the pipeline, I think we're expecting the ENaC monotherapy data in the year. Can you give us some idea of where you're looking for that data set? And what would be this concept?"
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, just in terms of modeling, the kids, we're lucky enough to get an approval this year. I'd certainly recommend that people take into account the same consideration that the peak penetration, times of peak, persistence rate and compliance, and model ov",153,"Yes, just in terms of modeling, the kids, we're lucky enough to get an approval this year. I'd certainly recommend that people take into account the same consideration that the peak penetration, times of peak, persistence rate and compliance, and model over each individually. In terms of what we've seen with KALYDECO, we have seen that the worst compliance we see tends to be in that sort of teenage to young adult still. And so because kids -- our assumption, because kids are very closely monitored by their parents, particularly in that kind of 6-to-11-year age group, perhaps not surprisingly, we see high levels of compliance with that particular patient group. We tend to see a bit of a dip, perhaps unsurprisingly, in the sort of teenage-to-young-adults group. So we might anticipate in the 6-to-11 group that, that would be our best complying patient population. And that's certainly what we've seen with KALYDECO."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Jeffrey Chodakewitz. Just maybe a couple of comments on the ENaC program. So first of all, there's an ongoing Phase II study that Parion has the lead on. That study is across all different types of genotypes in terms of the patient population, and so",205,"And Jeffrey Chodakewitz. Just maybe a couple of comments on the ENaC program. So first of all, there's an ongoing Phase II study that Parion has the lead on. That study is across all different types of genotypes in terms of the patient population, and so we're going to really be looking for early evidence of activity in that study. And not just looking over all, but  we're going to be trying to learn looking among the different subpopulations. And we still expect the result of that to come out around midyear. At the same time, we're going to be starting our study, which is very complementary to the study that's ongoing, and that is this quarter. And that study is going to be in 508 homozygous patients who already are going to be receiving ORKAMBI, and then looking to see whether the ENaC inhibitor can add to the efficacy for that population. And actually, comes preclinical data in our hands actually suggest that, that may be the best way to get activity and benefit for patients from that mechanism. And so ultimately, it's going to be learning from both of those trials as we better understand what the potential for that mechanism may be."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Adam Walsh of Stifel.",12,"Our next question comes from the line of Adam Walsh of Stifel."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess, I have 2 questions. The first one is for Jeff Leiden. We've been out talking to docs, and according to them, your GPS reimbursement support program is really terrific. I'll start with that. But some of these docs also noted that the total out-of",200,"I guess, I have 2 questions. The first one is for Jeff Leiden. We've been out talking to docs, and according to them, your GPS reimbursement support program is really terrific. I'll start with that. But some of these docs also noted that the total out-of cost -- out-of-pocket cost burden for a lot of CF patients is really quite high, even before they try to get on ORKAMBI or KALYDECO. And I'm just curious in terms of -- with that in mind, how do you think about how far you can go to support patients, given the fact that if a co-pay is a 20%, and that adds quite a bit of out-of-pocket expense, where is -- how far can you go in supporting the patients there, both with your own medicines and thinking about this in the context of the portfolio of medicines that are already beyond? That's one. And then I have a question for Jeff Chodakewitz as well. It was mentioned in the press release that 2 patients discontinued treatment in the ORKAMBI 6 to 11 study because of the adverse events. If you could just comment briefly on those to patients that would be great."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks for the question. This is Jeff Leiden. I'm actually going to turn that one over to Stuart because he's really responsible for the GPS program. And he'll also be able to describe the patient assistance program that's allowed us to help patients who",48,"Thanks for the question. This is Jeff Leiden. I'm actually going to turn that one over to Stuart because he's really responsible for the GPS program. And he'll also be able to describe the patient assistance program that's allowed us to help patients who do have high co-pays."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Adam, thanks for the question, and thanks for the positive feedback. The GPS program, just so everybody is aware of it, is a service, which is there to help patients and help them navigate the reimbursement process, and there to provide them with ong",157,"Yes, Adam, thanks for the question, and thanks for the positive feedback. The GPS program, just so everybody is aware of it, is a service, which is there to help patients and help them navigate the reimbursement process, and there to provide them with ongoing education if they choose to opt in. So it's great to get the feedback on that. Now dealing with the question you raised about out-of-pocket costs for both KALYDECO and ORKAMBI, we have comprehensive patient assistance programs in terms of co-pay assistance for eligible patients. The program is such that no patient who have a co-pay who's eligible for the program who have a monthly co-pay for either KALYDECO or ORKAMBI above $15 per month. And then for those patients who have coinsurance, we will cover coinsurance up to 30% of the price of the medicines. And the program is to keep things simple for people identical to both KALYDECO and ORKAMBI."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And it's Jeffrey Chodakewitz. In terms of the pediatrics study, as you pointed out, the overall profile was actually quite favorable. There were 2 patients who discontinued. One of them was because of abnormal liver functions. One of them was because of a",45,"And it's Jeffrey Chodakewitz. In terms of the pediatrics study, as you pointed out, the overall profile was actually quite favorable. There were 2 patients who discontinued. One of them was because of abnormal liver functions. One of them was because of a rash."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Mark Schoenebaum of Evercore ISI.",13,"Our next question comes from the line of Mark Schoenebaum of Evercore ISI."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","First question is on guidance. Should we assume your financial guidance is more or less conservative than Partridge's statement that this call would end by 5:45? Because you missed that pretty badly, so I'm a little concerned here. Anyway, just really qui",124,"First question is on guidance. Should we assume your financial guidance is more or less conservative than Partridge's statement that this call would end by 5:45? Because you missed that pretty badly, so I'm a little concerned here. Anyway, just really quick ones. I know it's getting late. Number one, can you just tell us when to expect data from the Phase II triple combo that you're going to start this year? I assume that's a mid-'17 event, assuming if I'm wrong on that. And then number 2, I apologize if you've addressed this. If you did, I missed it, but can you confirm the timing and your disclosure intentions around the -- what I believe is the futility analysis in the het-min trial?"
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Mark, it's Ian. I'll take both those questions. In his prepared remarks, he said the call would be brief as well. So he was wrong there as well. Luckily, he doesn't give financial guidance for us. So first -- your first question was regarding the tripl",172,"So Mark, it's Ian. I'll take both those questions. In his prepared remarks, he said the call would be brief as well. So he was wrong there as well. Luckily, he doesn't give financial guidance for us. So first -- your first question was regarding the triple. And so first of all, the timing of getting data from the triple or disclosing the data from the triple is really subject to how fast we move through the Phase I. And we've mentioned this before, the longer our Phase I takes, actually, the better it is, because it means less collating the dose and we're getting greater exposure of the drug into the healthy volunteers. And based on where we expect this to go, we anticipate in the second half of the year, we'll be in the proof-of-concept triple studies, which will probably push us into early 2017 to get that data. So that's how we're trying to set a timing expectation. And then your second question was on the disclosure regarding which..."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Futility.",1,"Futility."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Het-min futility.",3,"Het-min futility."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So for the het-min, in terms of recruitment for that trial, it's actually going very nicely, as you might anticipate, given that these patients have no other alternative medicine. And so we anticipate that we will be completed enrollment around the middle",86,"So for the het-min, in terms of recruitment for that trial, it's actually going very nicely, as you might anticipate, given that these patients have no other alternative medicine. And so we anticipate that we will be completed enrollment around the middle of that year and, therefore, we do expect the futility study to be done in the second half of the year. Obviously, we won't be disclosing that unless we have to curtail the study. So no news would be good news on that."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Tony Butler of Guggenheim Securities.",13,"Our next question comes from the line of Tony Butler of Guggenheim Securities."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","There are a number of respiratory articles that actually support the use of LCI as an endpoint because it does demonstrate greater sensitivity. I guess, the question is really what is the correlation between LCI and FEV, given that LCI apparently becomes",107,"There are a number of respiratory articles that actually support the use of LCI as an endpoint because it does demonstrate greater sensitivity. I guess, the question is really what is the correlation between LCI and FEV, given that LCI apparently becomes abnormal earlier than spirometry and yet, in the later-stage disease, it seems to correlate. And then therefore, can you only use LCI in children? And my last question, I guess, that's for Jeff C. And my last question, really for Jeff L. Are you going to publish the kinetics and functionality of 152 and 440 soon? Or, I guess, ever in the periodic [ph] Journal?"
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeffrey Chodakewitz [indiscernible]",3,"Jeffrey Chodakewitz [indiscernible]"
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","[indiscernible] I'll just quickly say the -- we'll maybe purpose steps in terms of where we published it and regarding our molecules as we move forward. Obviously, you've seen a lot of publications that NACF, which is in the fall, and then overseas, the E",64,"[indiscernible] I'll just quickly say the -- we'll maybe purpose steps in terms of where we published it and regarding our molecules as we move forward. Obviously, you've seen a lot of publications that NACF, which is in the fall, and then overseas, the ECFS conference. So you'll probably expect to see more data at those conferences. And then to your other questions, Jeff?"
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Maybe a couple of more comments on LCI. And as you point out, they do have such overlapping, but somewhat different sweet spots, if you will, in terms of the best way to use them. And I do think, as a field, this links back to Jeff Leiden's comments, that",174,"Maybe a couple of more comments on LCI. And as you point out, they do have such overlapping, but somewhat different sweet spots, if you will, in terms of the best way to use them. And I do think, as a field, this links back to Jeff Leiden's comments, that we're continuing to learn the best way to use each of them. Obviously, LCI has that potential sensitivity, advantages in children. But right now, there are only some centers that actually have the expertise to do that well and, of course, a great tool, if used poorly, doesn't really help anybody. So I think there are still a lot of work to be done. And then there's the other part of your question about regulatory recognition, and I can't speak for the regulators. But I think it was encouraging that in Europe, LCI was accepted as our primary endpoint in our study. So I think there is, in general, I'm hoping this continues to advance the field. And hopefully, we can contribute to that."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Great, well, thank you again for joining us tonight. Apologies for running over. It was all Michael's fault. At the risk of running for 1 or 2 more minutes, I did want to make a couple of concluding remarks. And again, I always like to do this sort of in",364,"Great, well, thank you again for joining us tonight. Apologies for running over. It was all Michael's fault. At the risk of running for 1 or 2 more minutes, I did want to make a couple of concluding remarks. And again, I always like to do this sort of in retrospect and say, where are we today as a company as compared to where we were 6 or 12 months ago. And I must say from a personal standpoint and from the standpoint of CF patients, I'm very, very encouraged with the progress that we've made. I think we've -- it's now clear that KALYDECO and ORKAMBI together are approved for about 2,500 patients, or almost 1/3 of all patients, CF patients in the world. And as we discussed at JPMorgan, it's a fairly straightforward strategy to label expansion in the younger populations and others to take that number from 25,000 to 44,000 patients in the next couple of years. 
And then we have a clear strategy with multiple prongs, actually, to get to the vast majority of patients, and they include the ENaC inhibitors, which are in Phase II, so they can move very rapidly if we see positive results there in combination with ORKAMBI. They include the next-gen correctors, which are moving along in Phase I, and which we hope to have in patients in the second half of this year. And we think those have the potential to both increase the efficacy for the patients we're treating today, but also to let us to get to that large subset of het-min patients that don't have anything today. 
And then finally, the progress we've made with some of our deals, particularly the CRISPR deal here. And although that's the Holy Grail, 10 or 15 years down the road, we do have a vision of potentially correcting the underlying mutation in curing patients with CF. 
And so as I look at the world from our perspective, obviously, I'm tremendously encouraged about the future opportunity, and particularly, the future opportunity for patients and improves with the progress we're making. And we look forward to updating you over the next year as we continue that."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks very much everybody. That concludes tonight's call. The IR team will be available in our offices for additional questions, if you have them. Thank you.",26,"Thanks very much everybody. That concludes tonight's call. The IR team will be available in our offices for additional questions, if you have them. Thank you."
36235,321312374,921946,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, you may disconnect your lines at this time. Have a great day.",15,"Ladies and gentlemen, you may disconnect your lines at this time. Have a great day."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our Fourth Quarter and Full Year 2015 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is recorded. A replay",310,"Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our Fourth Quarter and Full Year 2015 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is recorded. A replay will be available following the conclusion of tonight's call.
Dr. Jeff Leiden, Chairman and CEO; and Ian Smith, Chief Financial Officer, will provide prepared remarks this evening. Stuart Arbuckle, Chief Commercial Officer; and Dr. Jeff Chodakewitz, Chief Medical Officer, will join us for the Q&A portion of the conference call.
We recently presented at the Annual JPMorgan Healthcare Conference, where we provided a comprehensive update on our business and had the opportunity to meet with many investors and analysts. As such, our remarks tonight will be brief. We expect to conclude the call by 5:45 PM.
On tonight's call, Jeff will review key priorities for our business in 2016. Ian will review our fourth quarter and full year 2015 financial results and discuss our 2016 financial guidance, which we provided also earlier this month. As always, you can access the webcast live on our website.
I will remind you that we will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the Securities and Exchange Commission. These statements, including without limitation those regarding the ongoing development and potential commercialization of our drug candidates, Vertex's other cystic fibrosis programs and Vertex's future financial performance, are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in today's financial results press release. Please also see Slide 4 of tonight's webcast.
I will now turn the call over to Dr. Jeff Leiden."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. Earlier this month, I met with many of our investors and analysts at the annual JPMorgan Healthcare Conference to talk about the important transition that Vertex has made in the last few years. As we enter 2016, Ve",1588,"Thanks, Michael. Good evening, everyone. Earlier this month, I met with many of our investors and analysts at the annual JPMorgan Healthcare Conference to talk about the important transition that Vertex has made in the last few years. As we enter 2016, Vertex is on a path towards sustained earnings and revenue growth driven by an increasing number of people being treated with our 2 approved medicines for cystic fibrosis, KALYDECO and ORKAMBI. We have a broad and deep pipeline of investigational medicines for CF that we believe may allow us to reach our goal of treating all people with CF in the future. Additionally, our pipeline of medicines for other serious diseases, including cancer, pain and other neurologic diseases, continues to progress through early-stage clinical development. In short, we are a very different company than we were just 4 years ago.
This evening, I will briefly review our key priorities for 2016 and provide some insight into upcoming milestones in CF and other parts of our business. Our #1 priority has been and continues to be to increase the number of people eligible for and treated with KALYDECO and ORKAMBI and to develop potential new medicines that may provide even greater benefit for all people with CF in the years ahead.
At this time last year, just over 3,000 people were eligible for treatment with KALYDECO. Today, approximately 25,000 people are eligible for KALYDECO or ORKAMBI, and we expect the vast majority of these people will begin treatment with these medicines to treat the cause of their CF. We also expect to increase the number of people eligible for these medicines in 2016 through label expansion efforts that could include younger patients or patients with other mutations in the CFTR gene.
Our second key priority for 2016 is to continue building a financial profile of sustained revenues and earnings growth and a strong balance sheet. In 2015, the continued expansion of the KALYDECO label and the approval of ORKAMBI resulted in a significant increase in the number of patients being treated with our medicines, which led to a significant increase in revenues. Our progress in 2015 has positioned us for continued growth, and we believe we are on the right path to achieve our goal of building a financial profile consistent with that of other global biotech companies.
And finally, our third key priority is to invest in our business to create future medicines for other serious diseases. Continued investment in our pipeline is essential for creating additional breakthrough medicines for patients. I'll spend just a few minutes reviewing our recent progress and upcoming milestones that reflect these 3 priorities.
Our first CF medicine, KALYDECO, was approved by the FDA in January 2012. And since then, our goal has been to bring this medicine to as many people as possible who may benefit. KALYDECO addresses the underlying cause of CF and is a significant medical advance for people with certain mutations in the CFTR gene. Today, approximately 4,000 people are eligible for treatment with KALYDECO in North America, Europe and Australia. We're committed to bringing this medicine to even more patients who we believe may benefit in the years ahead.
We are awaiting decision from the U.S. FDA on our application for approval of KALYDECO in people ages 2 and older with CF who have certain residual function mutations. There are approximately 1,500 people ages 2 and older in the U.S. who have the residual function mutations represented in the supplemental New Drug Application for KALYDECO. While our submission for approval in these mutations is primarily based on preclinical data and on a Phase IIa critical study in only 24 patients, we believe that KALYDECO would be beneficial to these patients given the underlying science behind this precision medicine approach of using genetic markers and predictive assays to identify patients who are likely to benefit. Importantly, we chose to seek this approval knowing that these patients would otherwise have to potentially wait years before potential approval based on Phase III data. 
With more than 4 years of safety data, we believe that this path toward potential approval is in the best interest of people with CF. However, we also recognize that the application is based upon limited available clinical data in these rare mutations. The PDUFA date for a decision from the FDA is February 7.
With ORKAMBI, we are working to bring this medicine to more patients who we believe would benefit, specifically children with 2 copies of the F508del mutation, similar to the approach we took with KALYDECO. With the approval in the European Union at the end of last year, approximately 20,500 people ages 12 and older are now eligible for treatment with ORKAMBI in the U.S. and Europe. Today, we announced the Phase III study of ORKAMBI in children ages 6 to 11 met its primary safety endpoint and supports our planned submission of a supplemental New Drug Application in the second quarter of this year in the U.S. If approved, an additional 2,400 people in the U.S. with CF would be eligible for treatment with ORKAMBI.
While this was primarily a safety study, we also saw encouraging improvements in secondary and exploratory efficacy endpoints, including a statistically significant change in the exploratory endpoint of lung clearance index or LCI. Changes in LCI are also the primary endpoint of an ongoing Phase III study to support approval of ORKAMBI in this age group in Europe. There are approximately 3,400 children ages 6 to 11 who have 2 copies of the F508del mutation in the European Union. Additional information on this data was provided in today's press release.
Today, KALYDECO and ORKAMBI are approved to treat approximately 25,000 people in North America, Europe and Australia. We believe that there are many more people who may benefit from these medicines, and we have trials ongoing or planned that could expand the number of people eligible for treatment to approximately 44,000 in the years ahead.
Beyond our approved medicines, we have a pipeline of investigational CF medicines from early-stage research programs such as gene editing with CRISPR to late-stage development programs evaluating combinations of our CFTR modulators. This pipeline represents hope for the CF community, and our goal is to one day treat all people with CF.
We have a broad Phase III program underway evaluating the corrector VX-661 in combination with ivacaftor, and we are also advancing the development of 2 next-generation correctors that would be combined with VX-661 and ivacaftor as part of a Phase II study of triple combinations planned for later this year. Both approaches are asking the same fundamental questions. First, can we enhance the benefit for patients already receiving KALYDECO or ORKAMBI? And second, can we provide benefits to new groups of people with CF not currently helped by KALYDECO or ORKAMBI, including a very large group of patients with 1 F508del mutation and a second mutation known to result in minimal CFTR function?
The VX-661 program includes 4 Phase III studies in different groups of people with CF who have at least one copy of the F508del mutation. We will begin to see the first results from the VX-661 program by early 2017, and importantly, this program is also meant to provide a significant amount of safety data to support evaluation of a next-generation corrector with VX-661 and ivacaftor as part of an investigational triple combination regimen.
At the end of 2015, we initiated clinical development of 2 next-generation correctors, VX-152 and VX-440. Phase I studies of each compound are ongoing in healthy volunteers and are evaluating single and multiple doses of VX-152 and VX-440 as well as triple combinations with VX-661 and ivacaftor. Together with the safety data from the VX-661 program, these studies are designed to support the planned initiation of Phase II studies to evaluate triple combination regimens in patients in the second half of 2016.
Our business model is unique. The success we've achieved in CF allows us to reinvest in the discovery and development of new transformative medicines. In parallel with CF, we are advancing a number of additional development programs for cancer, pain and other serious diseases. We have significant flexibility in how we may advance these programs, either independently for those diseases that we believe are aligned with the focus of our business, specifically specialty diseases where G&A expenses are low, or in collaboration with other companies that we believe would be best suited to rapidly bring these potential medicines to patients. We believe our pipeline represents both potentially transformative future medicines for patients and significant value for our business. We've begun to provide some additional insight and data for our pipeline programs, and I look forward to providing updates on our progress throughout the coming year.
I mentioned at the start of my remarks that Vertex has undergone an important transition in recent years. We are now a global biotech company that has independently brought forward 2 breakthrough medicines to people with CF worldwide and is on the path to delivering significant earnings and cash flow. Our financial performance in 2015 and guidance for 2016 are metrics of the kind of company that we want to become, a company that consistently creates transformative new medicines for patients, generates significant value for shareholders and reinvests in scientific opportunities to create future medicines. This is our business model, and I'm pleased by our success to date and with our outlook for the coming years.
With that, I'll turn the call over to Ian."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff. For my remarks today, I will review our fourth quarter and full year 2015 financial results and discuss our 2016 financial guidance for total KALYDECO net revenues and non-GAAP operating expenses, excluding cost of revenues. I'll also discus",1298,"Thanks, Jeff. For my remarks today, I will review our fourth quarter and full year 2015 financial results and discuss our 2016 financial guidance for total KALYDECO net revenues and non-GAAP operating expenses, excluding cost of revenues. I'll also discuss our expectation for providing ORKAMBI guidance in 2016.
Financial results first. Our 2015 net CF product revenues were approximately $983 million. This includes KALYDECO net revenues of $632 million and ORKAMBI net revenues of $351 million. Total CF product revenues increased by more than 110% compared to 2014. In the fourth quarter of 2015, we reported total net CF product revenues of approximately $401 million, including KALYDECO net revenues of $181 million and ORKAMBI net revenues of $220 million.
Fourth quarter KALYDECO sales of $181 million were up 45% versus the fourth quarter of last year and up 9% versus the third quarter of 2015. This included approximately $6 million in inventory stocking that occurred at the end of the fourth quarter. Growth in KALYDECO was driven by both label expansion efforts, which increased the number of eligible patients to approximately 4,000, and by the completion of key reimbursement discussions in Europe. 
With ORKAMBI, more than 1,500 patients started in the fourth quarter, resulting in sales of $220 million, up 68% versus third quarter of 2015. As expected, we saw a very rapid uptake for ORKAMBI in the period immediately following the FDA approval with more than 3,000 people starting treatment in the third quarter. Demand from patients and physicians has been strong. But as expected, fewer patients started treatment in the fourth quarter compared to the third quarter, in line with our prior statements regarding expectations for the rate of uptake for ORKAMBI. We expect this trend to continue through the end of 2016, by which time we expect the vast majority of the 8,500 eligible patients in the U.S. to have initiated treatment with ORKAMBI.
Gross-to-net adjustments were largely unchanged from the third quarter and were in the high single digits due primarily to a greater proportion of patients within commercial plans initiating treatment in the first 6 months following the approval of ORKAMBI as compared to government-paid plans. Each of the 50 state Medicaid programs has now paid a claim for ORKAMBI. Thus, we expect gross-to-net adjustments will increase to the mid-teens by the end of 2016 to reflect an increase in patients treated being covered by Medicaid.
As we enter 2016, we are pleased with the launch of ORKAMBI to date and remain focused on working to ensure those who need the medicine have access to it, educating health care providers and supporting adherence to ORKAMBI.
Now to operating expenses. Our fourth quarter non-GAAP operating expenses were $282 million, including R&D expenses of $204 million and SG&A expenses of $78 million. The increased R&D expense in the fourth quarter 2015 compared to 2014 were primarily the result of increased costs related to the pivotal Phase III program for VX-661 in combination with ivacaftor. The increased SG&A expenses were primarily the result of an increased investment in global commercial support for the launch of ORKAMBI.
And tonight, I'm pleased to report that for the fourth quarter 2015, we recorded a non-GAAP net profit of $43 million or $0.17 per diluted share compared to non-GAAP net loss of $132 million or $0.55 per share for the fourth quarter of 2014. Our 2015 non-GAAP net loss was $268 million or $1.11 per share compared to non-GAAP net loss of $511 million or $2.17 per share for the full year 2014.
From a balance sheet perspective, we started 2016 with a strong cash position of $1.04 billion. Vertex also has $300 million outstanding from a credit agreement that provides for a secured loan of up to $500 million.
Now let's turn to the 2016 financial guidance, which we first provided on January 10. We expect 2016 KALYDECO net revenues of $670 million to $690 million. Our guidance for KALYDECO revenues reflects the continued use of KALYDECO, as was seen in the fourth quarter of 2015, which resulted in revenues of $181 million, and the expectation for up to approximately 200 patients with a gating mutation to enroll in the Phase III clinical study of VX-661 in combination with ivacaftor who would otherwise have received KALYDECO, which will thus reduce 2016 KALYDECO revenues. There was also an approximately $6 million inventory stocking that occurred at the end of the fourth quarter 2015 that is not expected to occur in future quarters and is thus accounted for in our guidance. Importantly, our current guidance excludes any potential revenues from the approval of KALYDECO for people with residual function mutations. We will update our KALYDECO guidance should we receive FDA approval for residual function mutations.
With ORKAMBI, more than 4,500 people have begun treatment in the U.S. by the end of 2015. There are 4 primary pieces of information regarding the launch that will inform our decision regarding ORKAMBI guidance. First, since all patients who initiated treatment with ORKAMBI in 2015 have been on treatment for approximately 6 months or less, we are awaiting additional information on the compliance rate for patients taking ORKAMBI. While we continue to expect that the vast majority of eligible patients in the U.S. will begin treatment with ORKAMBI by the end of 2016, we are awaiting additional information on the specific rate of uptake and on the specific proportion of the 8,500 eligible patients who will begin treatment with ORKAMBI in 2016.
And finally, additional information on the persistence rate defined as how many patients remain on treatment will also be taken into account. These 4 factors, the compliance rate, the rate at which patients begin treatment, the total number of patients who initiate treatment and the persistence rate, all are important in considering our guidance for ORKAMBI.
In 2016, we expect to recognize revenues from sales of ORKAMBI in the U.S. and Germany. In Germany, there are approximately 2,500 people with CF ages 12 and older with 2 copies of F508del mutation. In Europe, country-by-country reimbursement discussions are underway. However, we do not anticipate any significant ORKAMBI revenues from countries other than the U.S. and Germany in 2016.
The final component of our financial guidance is non-GAAP operating expenses, which are comprised of R&D and SG&A expenses and exclude cost of revenues. We expect our total 2016 non-GAAP operating expenses of $1.18 billion to $1.23 billion. As a reminder, our guidance for 2015 operating expenses was for $1.05 billion to $1.1 billion. And we reported 2015 operating expenses at the low end of this range of $1.06 billion, largely as a result of cost related to VX-661 that will now occur in 2016 as opposed to 2015. The increase in expense -- expected operating expenses for 2016 as compared to 2015 is primarily a result of expanded development efforts related to the pivotal Phase III development program for VX-661 in combination with ivacaftor and for multiple Phase I and II studies of Vertex's early-stage and mid-stage pipeline of potential CF medicines and anticipated SG&A costs to support the launch of ORKAMBI in new global markets.
The components of Vertex's non-GAAP operating expenses include non-GAAP R&D expenses, which we expect to be in the range of $850 million to $880 million, and non-GAAP SG&A expenses, which we expect will be in the range of $330 million to $350 million. Vertex's expected non-GAAP R&D and SG&A expenses exclude stock-based compensation expense and certain other expenses.
In summary, we are in a strong financial position as we enter 2016. We remain committed to delivering a financial profile that is similar to many of our large cap biotech peers, which includes sustainable revenue and earnings growth, high operating margins and most importantly, continued investment to create future medicines."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thank you. Operator, we're now ready to take questions.",9,"Thank you. Operator, we're now ready to take questions."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question comes from the line of Geoff Meacham of Barclays.",14,"[Operator Instructions] Our first question comes from the line of Geoff Meacham of Barclays."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congrats on profitability. I got a commercial and a clinical question for you. I guess I'll start with commercial. I want to know, Ian, if you can go in a little bit more detail about persistence rates over time with KALYDECO and then -- and whether this",74,"Congrats on profitability. I got a commercial and a clinical question for you. I guess I'll start with commercial. I want to know, Ian, if you can go in a little bit more detail about persistence rates over time with KALYDECO and then -- and whether this should be a real benchmark for ORKAMBI. I'm just curious if you guys have tracked people who have discontinued and if they later come back to therapy."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Geoff, maybe Stuart will take that question. So thanks for the comment on profitability. [indiscernible] in the fourth quarter. Stuart is going to take the question. You might also comment on some of the other features that are affecting how we're thin",48,"So Geoff, maybe Stuart will take that question. So thanks for the comment on profitability. [indiscernible] in the fourth quarter. Stuart is going to take the question. You might also comment on some of the other features that are affecting how we're thinking about the launch as well."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Geoff. It's Stuart here. So yes, let me just reiterate a couple of things that Ian said about ORKAMBI and the factors we're taking into account when thinking about the launch and that we're tracking very closely. One is obviously the peak penetration",519,"Yes, Geoff. It's Stuart here. So yes, let me just reiterate a couple of things that Ian said about ORKAMBI and the factors we're taking into account when thinking about the launch and that we're tracking very closely. One is obviously the peak penetration, so the number of eligible patients in total who get initiated on therapy over time, and we continue to expect the vast majority of 8,500 patients will. Then there's the rate of uptake, how quickly we get to that peak penetration. As you know, at the end of December, we had about 4,500 patients on therapy. That's about 55% of the total. And we expect that we'll get to peak penetration during the course of 2016. And then as you said, one of the other key components is persistence, the number of patients who stay on therapy. And obviously, it's pretty early days because whilst we've only been on the market for 6 months, we really don't have long-term experience with very many patients yet. In the Phase III study for ORKAMBI, at about 24 weeks in TRAFFIC and TRANSPORT, about 5% of patients had discontinued. At 48 weeks in the open label extension with ORKAMBI, we were at 15% of patients had discontinued. So that's in the ORKAMBI clinical trials, and time will tell whether we see a higher or lower number but probably a higher number who are discontinuing in the real world. With KALYDECO, in the studies we've looked at, it was about 5% of patients again discontinued in the KALYDECO clinical trials. It was actually slightly higher than that in the real world. It got closer to 10%, so in the real world over time. And largely, that was because it was over a longer period of time. We did see a slightly higher number of -- a higher percentage of patients on KALYDECO discontinued versus the clinical trials. The last thing we're going to be thinking about then is obviously compliance, and that's the percentage of patients who actually take the pills that have been prescribed by their physician. As you know, KALYDECO is very, very high at 85%, certainly the highest I've ever seen, personally, for a chronic medication. Other CF medicines are around about the 60% range. I would anticipate ORKAMBI is going to be in that range, probably toward the higher part of that range but somewhere in that range. The only other question we will have to look at very closely and we -- again, we just don't have data on it, we don't have data on it in the clinical program, Geoff, and we'll have to see how it plays out in the real world, is whether physicians and patients choose to reinitiate therapy if they have discontinued for some reason. And we just have no information from the clinical trials because they just weren't set up to look at that. If a patient discontinued, they would then kind of excluded from further therapy. So we just don't have data on that right now, Geoff. Hopefully, that gives you some perspective on what we're thinking."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, no, that's helpful. And just real quick on the clinical side. When you look at the 152 and 440 study in healthies, has there been any evidence of drug-drug interactions with KALYDECO or 661? And I guess I'm trying to figure out whether you guys expec",86,"Yes, no, that's helpful. And just real quick on the clinical side. When you look at the 152 and 440 study in healthies, has there been any evidence of drug-drug interactions with KALYDECO or 661? And I guess I'm trying to figure out whether you guys expect to take multiple doses of those 2 correctors in the CF patients when you look to the back of the year? Maybe just help us with the design of that 28-day study as you see it at this stage."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, it's Jeff Chodakewitz. So in terms of the Phase I studies for VX-152 and 440, we're really in the midst of those studies and we obviously can't comment on the ongoing trials. Maybe just a comment on those in Phase II, and we're in early days in ter",81,"Geoff, it's Jeff Chodakewitz. So in terms of the Phase I studies for VX-152 and 440, we're really in the midst of those studies and we obviously can't comment on the ongoing trials. Maybe just a comment on those in Phase II, and we're in early days in terms of those designs, but I do think it's likely that we would look to take multiple doses of the compounds into those Phase II studies to learn as much as we can."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Matt Roden of UBS.",12,"Our next question comes from the line of Matt Roden of UBS."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I also wanted to congratulate you on the milestone of turning back to profitability. So regarding the pediatric study, I understand the primary endpoint is safety. And the LCI data looked really good, which -- the latter point being important for what's g",192,"I also wanted to congratulate you on the milestone of turning back to profitability. So regarding the pediatric study, I understand the primary endpoint is safety. And the LCI data looked really good, which -- the latter point being important for what's going on in Europe. But just want to get your perspective on the sort of 2.5% improvement in FEV. Have you talked to any experts or the FDA about that? I can't imagine that's going to be any kind of issue for you, but just wanted to see if there's anything to add on that side. And then on the commercial side, I wanted to ask, you've left the residual function mutations out of the KALYDECO guidance. But just trying to get a sense for if that were to be approved, how should we think about the onboarding of those patients onto commercial drug? I would imagine that you have a conversion of those that are on trial to commercial, but apart from that, would you characterize this as a highly motivated subset of patients? Or because they have a milder phenotype, could this be a slower rate of penetration?"
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Matt, it's Jeff Chodakewitz. Maybe I'll start. So in terms of the pediatric study, we were very pleased with the results of the study, really, meeting both the endpoints for exposure for PK and then for safety, as you said. So that was a nice outcome. The",193,"Matt, it's Jeff Chodakewitz. Maybe I'll start. So in terms of the pediatric study, we were very pleased with the results of the study, really, meeting both the endpoints for exposure for PK and then for safety, as you said. So that was a nice outcome. The expectation with the FDA is that once you've established efficacy in the same disease in older children, that as you move to younger age groups, really, it's really about that exposure and safety consistent with the design of the study. I will say that I think we were also quite pleased with the evidence of efficacy in the population where it gets harder to actually demonstrate that. And I think actually, the FEV1 showing that strong trend was actually quite favorable, remembering that these kids started at a pretty high FEV1 percentage at baseline. And as actually you noted, the fact that the LCI measure, which is in its earlier days was nicely positive, and that's our primary endpoint in the European study. And lastly, the BMI kind of measures as well. So I think overall, we were quite satisfied with the results of the trial."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Matt, it's Stuart here. Just to comment on the residual function. So as you said, residual function is not included within the KALYDECO guidance that we have provided. There's about 1,500 patients with the 23 mutations that we've asked for within our",183,"And Matt, it's Stuart here. Just to comment on the residual function. So as you said, residual function is not included within the KALYDECO guidance that we have provided. There's about 1,500 patients with the 23 mutations that we've asked for within our filing. In terms of patients transferring from clinical trials, clearly the clinical trial on which the application is based or what's included in the clinical trial is very small. So it's not as if there's a huge bolus of patients to transition from clinical supply to commercial supply. In terms of rate of uptake, the best analog, I think, for you there would be R117H, which by definition is a residual function mutation. And so both in terms of peak penetration and rate of uptake, I think that's probably the best analog for you to think of in terms of the rate of uptake we might see if we're approved. And then just to illustrate what Ian said in his prepared remarks, if we're approved in residual function, our anticipation is that we'll update our KALYDECO guidance to reflect that."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Terence Flynn of Goldman Sachs.",13,"Our next question comes from the line of Terence Flynn of Goldman Sachs."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Samir on for Terence. Have all ORKAMBI clinical trial patients in the U.S. transitioned to commercial drug? And if not, how many are left to transition?",28,"This is Samir on for Terence. Have all ORKAMBI clinical trial patients in the U.S. transitioned to commercial drug? And if not, how many are left to transition?"
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I'm not going to comment on exactly how many, but the vast majority of the patients who are on clinical trial supply have now transitioned to commercial drug. Just to orient you, there was approximately 500 in total of the patients in TRAFFIC and TRANSPOR",50,"I'm not going to comment on exactly how many, but the vast majority of the patients who are on clinical trial supply have now transitioned to commercial drug. Just to orient you, there was approximately 500 in total of the patients in TRAFFIC and TRANSPORT were in the U.S."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Matthew Harrison of Morgan Stanley.",10,"Our next question comes from Matthew Harrison of Morgan Stanley."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So I just had 2 quick ones. So one, just, Ian, can you go back to the KALYDECO stocking comment that you made and just tell us if you think we should see some of that inventory come out of the channel this year and how that's in your guidance? And then se",100,"So I just had 2 quick ones. So one, just, Ian, can you go back to the KALYDECO stocking comment that you made and just tell us if you think we should see some of that inventory come out of the channel this year and how that's in your guidance? And then separately, just on the EU pediatric study, how will data from that influence maybe FDA perception of the filing that you guys have? And also, how was timing of that related to when you would expect to have a PDUFA date for the label expansion in the U.S.?"
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, so I'll take the first one and Jeff Chodakewitz can take the second question. So firstly, the stocking question in the U.S. is -- first of all, to orient people, we have estimated there's approximately $6 million of inventory stocking in the fourth q",238,"Yes, so I'll take the first one and Jeff Chodakewitz can take the second question. So firstly, the stocking question in the U.S. is -- first of all, to orient people, we have estimated there's approximately $6 million of inventory stocking in the fourth quarter for KALYDECO. What we mean by that is the inventory was higher at December 31 compared to September 30 by $6 million. That will then sell out of the channel, so it does impact future sales because it was in inventory. We have removed that from our guidance. So when we made an estimate for our 2016 KALYDECO guidance, we removed that. In fact, I think when we all met in JPMorgan in San Francisco, I gave people a simple calculation to think about how we got to our guidance for 2016. I'll just refer to that again, which is in the fourth quarter of 2015, we did approximately $180 million with the KALYDECO revenues, $181 million to be precise, but approximately $180 million. If you multiply that -- if you take $6 million out of that, you get $174 million with the fourth quarter run rate revenues and then multiply that by 4. You then actually deduct the patients from that annualized number and you get to approximate range of the guidance that we provided, which was $670 million to $690 million for KALYDECO. So it did take account for that stocking."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Great. And it's Jeff. I think in terms of your questions about pediatric, maybe starting with the U.S. As we said that we expect to submit our file in the second quarter of this year. We haven't yet had those discussions with the FDA, of course, but we're",79,"Great. And it's Jeff. I think in terms of your questions about pediatric, maybe starting with the U.S. As we said that we expect to submit our file in the second quarter of this year. We haven't yet had those discussions with the FDA, of course, but we're operating under the assumption of a 6-month review time. The European study is still ongoing. It's enrolling. And I don't really see there being much interaction in terms of those processes."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Michael Yee of RBC Capital Markets.",14,"Our next question comes from the line of Michael Yee of RBC Capital Markets."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","As it relates -- well, like guidance, for Ian, I know there's no formal guidance for ORKAMBI, but is the key message here -- when I look at the consensus of $1.6 billion, is the key message to think about that discontinuations are a little bit higher and",168,"As it relates -- well, like guidance, for Ian, I know there's no formal guidance for ORKAMBI, but is the key message here -- when I look at the consensus of $1.6 billion, is the key message to think about that discontinuations are a little bit higher and compliance a little bit lower based on the comments that Stuart made in the U.S.? And then on OUS, Ian, as it -- do I need to be clear that Germany is the only country being launched? Are there other things that I need to think about when I look at the consensus of $345 million? Maybe you can make a comment about that and how consensus is modeling? Just so I'm clear on that. And the second question is just a quick clinical question. On 152 and 440, in the Phase I, even though it's healthies, is there any [indiscernible] record or any of the biomarkers you're looking at that you'll disclose that could give any hints of efficacy?"
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for the questions, Mike. Jeff Chodakewitz actually just stepped out while you asked that second question.",18,"Yes, thanks for the questions, Mike. Jeff Chodakewitz actually just stepped out while you asked that second question."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeff and I -- you might be able to tell, Jeff has a pretty bad cold so he didn't want to blow [indiscernible]room.",23,"Jeff and I -- you might be able to tell, Jeff has a pretty bad cold so he didn't want to blow [indiscernible]room."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I just wanted to make sure he heard your question. I'll take the first question, then so Jeff will take the second question. So first of all, actually, no, we're not trying to say discontinuations is a bigger issue than compliance. So I actually appreciat",452,"I just wanted to make sure he heard your question. I'll take the first question, then so Jeff will take the second question. So first of all, actually, no, we're not trying to say discontinuations is a bigger issue than compliance. So I actually appreciate asking the question so we can clarify that. That's not what we're trying to say, and it's not actually what we are seeing even earlier on in this launch. But I appreciate the opportunity maybe to comment on how people are thinking about the ORKAMBI launch and how we're seeing it reflected in sell side models. And specifically, 2016, let's say, forecasted that are in the sell side models. So obviously, when you look at consensus, there are a number of different models that are out there, a number of different numbers. And so there's some extreme numbers and then there's some that are more towards the normal. What I would say, I don't know the assumptions that are being put into other people's models, but I would ask you to listen carefully to Stuart's comments, where we touch on when do we believe we're going to get to peak penetration, the rate of uptake of ORKAMBI? And then importantly, the persistence and compliance, because specifically compliance, if people take 6 pills out of every 10, it's straightforward, you get $6 out of every $10 of your gross price. And then obviously, there is a gross-to-net discount based on whether you've got Medicaid patients versus private-payer patients. And so I just -- the opportunity to comment on this call to all people at once is I just want to make sure that people are giving thorough consideration to all these aspects of the launch, and we'd be happy to talk to you after the call as well. 
And as far as your question regarding Germany, Germany is the only country that we expect any significant revenues from outside of the U.S. And just to give you the background of Germany, Germany has an estimated 2,500 patients. We believe it could take 12 to 18 months to reach the peak penetration in those patients, and we provided people with a price in Germany. And it is one aspect of the sell side models that I do struggle with, because when I look at an ex U.S. consensus of the sell side model, that's a number that's close to $300 million. I find it very challenging for us to accrue that much revenue from Germany alone. And so I do appreciate you calling that out, and so I just hope that people are giving consideration to all these features when modeling the ORKAMBI launch. And then over to Jeff."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, so just very briefly about 152 and 440, I really can't go into the details of the ongoing studies. But as you know, the main focus for Phase I studies has got to be exposure and safety, and then we learn a lot from those ongoing studies.",48,"Yes, so just very briefly about 152 and 440, I really can't go into the details of the ongoing studies. But as you know, the main focus for Phase I studies has got to be exposure and safety, and then we learn a lot from those ongoing studies."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Ying Huang of Bank of America.",14,"Our next question comes from the line of Ying Huang of Bank of America."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe first one is for Stu. So ORKAMBI, you're going to look at a much larger eligible patient population here. I know you guys have this clinical outcome-based reimbursement agreement with the Australian government for KALYDECO. Do you expect government",104,"Maybe first one is for Stu. So ORKAMBI, you're going to look at a much larger eligible patient population here. I know you guys have this clinical outcome-based reimbursement agreement with the Australian government for KALYDECO. Do you expect government payers to ask for some similar arrangement for ORKAMBI besides Australia? And then second, as on clinical side is maybe for Jeff, talking about the preclinical data you have, what the metabolism and also secretion route for the 2 sets of next-generation CFTR correctors? Do you expect any drug-drug interaction at all based on the way the drugs are metabolized and secreted with ORKAMBI?"
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Ying, Stuart here. I'll take your first question. Thanks for the question on reimbursement. And kind of to cut to the chase, I really can't speculate on exactly what our arrangements are going to look like with governments around the world because we real",147,"Ying, Stuart here. I'll take your first question. Thanks for the question on reimbursement. And kind of to cut to the chase, I really can't speculate on exactly what our arrangements are going to look like with governments around the world because we really are just at the beginning of that process. And just to remind people, in most countries, it's really a 3-step process. There'll be a clinical assessment of the risks and benefits of the agent, then there's a pharmacoeconomic assessment. And that really then is the sort of starting point for then the price and contracting negotiations. And until we kind of work our way through that process, it's really impossible to speculate on exactly what the nature of any relationship that we might come to with the various governments around the world. And for the clinical question, I'll hand that over to Jeff."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. So briefly, you were asking about metabolism and so forth. And as you know, it's very hard from preclinical data to speculate, especially until you really understand exposures and so forth. But we're going to understand that much better from our Pha",85,"Sure. So briefly, you were asking about metabolism and so forth. And as you know, it's very hard from preclinical data to speculate, especially until you really understand exposures and so forth. But we're going to understand that much better from our Phase I study. I would point back to what we've said all along about our next-gen molecule that we wanted to get molecules that weren't just -- looked good in vitro, but actually could be medicines. And that's the way we've approached it."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Cory Kasimov of JPMorgan.",12,"Our next question comes from the line of Cory Kasimov of JPMorgan."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So I wanted to go back to the topic of ORKAMBI outside of the U.S. Obviously, there's a lot of talk about reimbursement and time to roll out in Europe. But I wanted to go to other regions such as Canada. You just mentioned Australia, but following the app",108,"So I wanted to go back to the topic of ORKAMBI outside of the U.S. Obviously, there's a lot of talk about reimbursement and time to roll out in Europe. But I wanted to go to other regions such as Canada. You just mentioned Australia, but following the approval in Canada. I know there's 1,500 patients there that meet the label criteria. Can you remind us of the market size in Australia as well? And once you do have the reimbursement in place, what would you expect the anticipated pace of uptake and, really, just the overall relevance of these markets to be from a commercial standpoint?"
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Cory, Stuart here. So yes, as you said, the eligible patient population of F508 Delta homozygotes in Canada is about 1,500 patients, and that's out of about 4,000 total CF patients that we estimate in Canada. Now that we've got the kind of regulatory",214,"Yes, Cory, Stuart here. So yes, as you said, the eligible patient population of F508 Delta homozygotes in Canada is about 1,500 patients, and that's out of about 4,000 total CF patients that we estimate in Canada. Now that we've got the kind of regulatory approval, we can now begin to seek public reimbursement for ORKAMBI in Canada. And as you know, as I've just described, the process there is, again a clinical assessment, there'll be a pharmacoeconomic assessment, and then, there'll be a price negotiation probably through the pan-Canadian Pricing Alliance process that we went through with KALYDECO. In terms of rate of uptake, much as we're seeing here in the U.S., I'd anticipate that the relative rate of uptake will be slower for ORKAMBI than it was with KALYDECO in Canada, and indeed, other markets outside of the U.S. for the same reason. It's just the sheer volume of patients is much larger than it is for KALYDECO, and it's just more of an administrative burden to initiate patients. So much like we're seeing here in the U.S., I'd expect the relative rate of uptake for ORKAMBI to be less than it is for -- less rapid than it was for KALYDECO in Canada, and indeed, other markets outside of the U.S."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Corey, this is Jeff Leiden. Maybe just to add one comment. Obviously, we've heard a lot from Ian and Stuart on some of the questions about the kinetics of the launch and some of the short-term modeling. I do think it's important to stand back as well and",307,"Corey, this is Jeff Leiden. Maybe just to add one comment. Obviously, we've heard a lot from Ian and Stuart on some of the questions about the kinetics of the launch and some of the short-term modeling. I do think it's important to stand back as well and remember what the total opportunity is, which, I think is where your question is going. So if you think about where we are today versus where we were even 6 months ago, right? Today, we have approval for 8,500 patients in U.S. and we have a launch that we're really pleased with, with more than 4,500 or 55% of the patients already on drug in the U.S., which I think is remarkable. We have reimbursement in the U.S. that's gone actually better than we even expected, meaning every state Medicaid is now reimbursing the drug and the majority of the private insurers are. We have approval in Europe, and are starting a launch in Germany, as you heard in the press release; an ATU in France. Now we have approval in Canada, which gives us access to 1,500 private patients and the ability to negotiate reimbursement, as Stuart said, to an additional, I think, 2,500 patients or so. And so when you look at the total opportunity, it's actually every bit of what we thought before, and we've made significant progress. And nothing with that has changed. It's impossible to predict the exact kinetics, what's going to happen in the first quarter versus the second quarter. But at least, the way we look at it, as we look out over the next couple of years, we see that opportunity intact and progressing really nicely. And I think it's important to sort of see that in the big picture as well as the short-term model. So I hope that helps."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Brian Abrahams of Jefferies.",12,"Our next question comes from the line of Brian Abrahams of Jefferies."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two questions. First, on the clinical side on the 6- to 11-year-old population. I was wondering if you could talk a little bit about the natural history of untreated patients on the lung clearance index endpoint. Where does it typically go over a 6-month",115,"Two questions. First, on the clinical side on the 6- to 11-year-old population. I was wondering if you could talk a little bit about the natural history of untreated patients on the lung clearance index endpoint. Where does it typically go over a 6-month period in children of this age? I guess, balancing disease progression versus normal growth, does it typically worsen or stay flat? And then on the clinical/commercial side, can you give us any more granularity on the ongoing Phase IIIb study in low FEV1 patients, the doses, timeline and potential impact that data might have to help patients -- help these patients manage through the initial side effects and stay on therapy?"
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Brian, it's Jeff Chodakewitz. So let's maybe start with the LCI. And as we talked about a little bit, this actually isn't [ph] early measures. So the information I can give you is somewhat imperfect, just so you know. I think its advantage, we think, is b",301,"Brian, it's Jeff Chodakewitz. So let's maybe start with the LCI. And as we talked about a little bit, this actually isn't [ph] early measures. So the information I can give you is somewhat imperfect, just so you know. I think its advantage, we think, is being able in children, who have relatively normal FEV1s, but as you know, they have significant underlying disease. Their pulmonary function really is far from normal. It allows you to measure that. And over reasonably short periods of time, sort of like a 6-month period, as we go in our clinical studies, there could be small decreases. But we think overall, that, that should be relatively stable. There may be modest shift over time, but we think we'd be able to have a reasonable baseline for assessing it. So -- and actually, that's part of why the data that we had coming out of our pediatric study, even without the control arm, was encouraging to us. Maybe I'll take a comment on the less than -- on the study in patients whose FEV1s are less than 40. We're still actually in the process of collecting all that data. We are still enrolling. But we think that there's some useful information there just in terms of the experience that we've accrued. We did, to your specific question, did give -- partway through give investigators the opportunity to start with a lower dose, and then step up to full dose. That will be -- it's not a perfect evaluation of that, but we are really trying to do what you said, which is to help explore what could help patients get through those early weeks of dosing. We are going to summarize all that data and present it and use it from an education perspective as well."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Alethia Young of Crdit Suisse.",13,"Our next question comes from the line of Alethia Young of Crdit Suisse."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe just a couple. One, if something happens with the residual, where the FDA may request more information, do you guys have a strategy on how you might pursue that population going forward? And then also with the potential kind of chest tightness that",96,"Maybe just a couple. One, if something happens with the residual, where the FDA may request more information, do you guys have a strategy on how you might pursue that population going forward? And then also with the potential kind of chest tightness that sometimes happens, our checks kind of suggested that, that happened earlier rather than later, like in the first couple of weeks? But is there a dynamic where it could happen later? And did you see similarities and differences, though you've probably titrated in the safety in the -- in the younger populations?"
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Alethia, it's Jeff Leiden. Maybe I'll take the first one, since it's a bit of a science and a policy question -- strategy question, I think. And then Jeff, you can take the second question on the chest tightness. So maybe just to give you a little ba",405,"Yes, Alethia, it's Jeff Leiden. Maybe I'll take the first one, since it's a bit of a science and a policy question -- strategy question, I think. And then Jeff, you can take the second question on the chest tightness. So maybe just to give you a little background, and I know you're you aware of this, but the RF application is a little bit unusual compared to the other applications that Vertex has submitted on KALYDECO and ORKAMBI, which are always based on large Phase III studies. This one's different. It's basically aimed at about 1,500 patients, with 23 different mutations resulting in residual function. And it's based predominantly on preclinical data. That is cell-based data from cells that have been engineered to have those 23 different mutations, supported by a very small Phase IIa study of about 24 patients that comprise the 8 or 9 of those 23 mutations. And so what we're really asking the FDA to look at is both the science and the medicine that we're submitting. But also there's a policy question here, which is, how do you extend the label of drugs like KALYDECO to very rare population and mutations. Some of these mutations only have 4 patients in the U.S. or 10 patients in the U.S. And that's a very important policy question in precision medicine that as you know, the FDA is considering much more broadly than just in CF. And so part of the reason why it's a little difficult to handicap this one is because it's this combination of clinical and policy sorts of things. We feel very strongly, it's the right thing to do for patients, that's why we did it. There are 1,500 patients in the U.S. that today don't have any CFTR correction therapy of any sort, and it would be years before they could get them based on large Phase III trials. And so for us, this is definitely the right thing to do for patients. And we believe in the science strongly and in the clinical support that we have. But handicapping what the FDA is going to do, obviously, it's a bit more difficult. We'll know by February 7. And then based upon what we do, we'd obviously come up with a strategy. But again, our goal is to try to get this medicine that has 4 years of safety data to these patients as soon as possible."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Jeff Chodakewitz, just to comment on your questions about the chest tightness. Maybe first step back to our Phase III results, which, I think are the most definitive information. And as you noted, those adverse events did occur very early. They were m",115,"And Jeff Chodakewitz, just to comment on your questions about the chest tightness. Maybe first step back to our Phase III results, which, I think are the most definitive information. And as you noted, those adverse events did occur very early. They were manageable in the vast majority of people, and they did decrease over time. Usually, the average duration was approximately 2 weeks. So I think all of that really comes out of our Phase III data, and as suggested it is an early event. And the experience in our pediatric study was actually completely consistent with that. It was a small number, it happened early and, in fact, nobody discontinued because of that."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Liisa Bayko of JMP Securities.",13,"Our next question comes from the line of Liisa Bayko of JMP Securities."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just wanted to better understand what you were describing with Canada in terms of the private payers. I know there's 1,500 patients that are -- would be eligible for ORKAMBI. Can you break that down into how many of those would be private?",44,"I just wanted to better understand what you were describing with Canada in terms of the private payers. I know there's 1,500 patients that are -- would be eligible for ORKAMBI. Can you break that down into how many of those would be private?"
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Liisa, it's Stuart here. Yes, there's 1,500 patients in total, who are 12 and over, who are homozygous to the F508 Del mutation. And we estimate there's about 30% of those would be covered by some form of private insurance. Private insurance may take",88,"Yes, Liisa, it's Stuart here. Yes, there's 1,500 patients in total, who are 12 and over, who are homozygous to the F508 Del mutation. And we estimate there's about 30% of those would be covered by some form of private insurance. Private insurance may take some time to kick in. In Canada, it's not necessarily quite as rapid for them to come to a decision. Certainly, that was our experience with KALYDECO. But approximately 30% of the 1,500 patients, we estimate, will have some form of private insurance."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, thanks, that's helpful. And then the data on the kids look really impressive with the LCI. Can you just maybe comment on the clinical meaning -- meaningfulness of that number? Obviously, we're not as used to seeing that number as we are with FEV. So",58,"Okay, thanks, that's helpful. And then the data on the kids look really impressive with the LCI. Can you just maybe comment on the clinical meaning -- meaningfulness of that number? Obviously, we're not as used to seeing that number as we are with FEV. So I'd just be curious if you could put some context around that."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. It's Jeff Chodakewitz. And I will say that in terms of that kind of validation of saying what's a minimally clinically important difference, it doesn't exist for that tool. I will say based on our discussions with people who are experts in the metho",99,"Sure. It's Jeff Chodakewitz. And I will say that in terms of that kind of validation of saying what's a minimally clinically important difference, it doesn't exist for that tool. I will say based on our discussions with people who are experts in the methodology, we were -- we kind of targeted a 0.7 decrease. And remember that in this measure, actually, a negative number is an improvement because of the way the test is done. So I can't give you an exact number, but hopefully, that gives you some context in why we were pleased with the results."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay. And Liisa, this is Jeff. Maybe just to reiterate one thing that Jeff -- he said before, because I think it's important. And I remember you and I talking about this at one point that we are very interested in some of these alternative endpoints for a",195,"Okay. And Liisa, this is Jeff. Maybe just to reiterate one thing that Jeff -- he said before, because I think it's important. And I remember you and I talking about this at one point that we are very interested in some of these alternative endpoints for a couple of reasons. One, as Jeff said, these may be much more applicable to populations in which it's difficult to measure FEV1, like the kids, particularly as they get younger. But also because, as you know, FEV1, which is really a measure of mid-sized airway resistance, is it's quite a bit downstream or upstream, if you will, from the problem in CF, which is really a distal airway gas-exchange problem. And actually, LCI is probably a much more sensitive measure, closer to the actual physiology of what's going on in CF. And so we've been very eager to start to see results from these kinds of studies to tell whether LCI could actually turn out to be as good or better an endpoint than FEV1 and, obviously, you need to provide agencies with clinical data to support that. And this is the first step in that process."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Phil Nadeau of Cowen and Company.",14,"Our next question comes from the line of Phil Nadeau of Cowen and Company."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just to -- as we begin to model the younger kids, the penetration of ORKAMBI into the kids aged 6 to 11, are there any issues with compliance, persistence or uptake in that population that you want to point out? Or do you expect kind of similar rates of t",98,"Just to -- as we begin to model the younger kids, the penetration of ORKAMBI into the kids aged 6 to 11, are there any issues with compliance, persistence or uptake in that population that you want to point out? Or do you expect kind of similar rates of those elements in the other kids as in the older? And then second, on the pipeline, I think we're expecting the ENaC monotherapy data in the year. Can you give us some idea of what you're looking for in that data set? And what would be proof of concept?"
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, just in terms of modeling, the kids, were we're lucky enough to get an approval this year. I'd certainly recommend that people take into account the same consideration that the peak penetration, times of peak, persistence rate and compliance, and mod",154,"Yes, just in terms of modeling, the kids, were we're lucky enough to get an approval this year. I'd certainly recommend that people take into account the same consideration that the peak penetration, times of peak, persistence rate and compliance, and model those each individually. In terms of what we've seen with KALYDECO, we have seen that the worst compliance we see tends to be in that sort of teenage to young adult still. And so because kids -- our assumption, because kids are very closely monitored by their parents, particularly in that kind of 6-to-11-year age group, perhaps not surprisingly, we see high levels of compliance with that particular patient group. We tend to see a bit of a dip, perhaps unsurprisingly, in the sort of teenage-to-young-adults group. So we might anticipate in the 6-to-11 group that, that would be our best complying patient population. And that's certainly what we've seen with KALYDECO."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Jeff Chodakewitz. Just maybe a couple of comments on the ENaC program. So first of all, there's an ongoing Phase II study that Parion has the lead on. That study is across all different types of genotypes in terms of the patient population, and so we'",204,"And Jeff Chodakewitz. Just maybe a couple of comments on the ENaC program. So first of all, there's an ongoing Phase II study that Parion has the lead on. That study is across all different types of genotypes in terms of the patient population, and so we're going to really be looking for early evidence of activity in that study. And not just looking over all, but  we're going to be trying to learn looking among the different subpopulations. And we still expect the results of that to come out around midyear. At the same time, we're going to be starting our study, which is very complementary to the study that's ongoing, and that is this quarter. And that study is going to be in 508 homozygous patients who already are going to be receiving ORKAMBI, and then looking to see whether the ENaC inhibitor can add to the efficacy for that population. And actually, preclinical data in our hands actually suggest that, that may be the best way to get activity and benefit for patients from that mechanism. And so ultimately, it's going to be learning from both of those trials as we better understand what the potential for that mechanism may be."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Adam Walsh of Stifel.",12,"Our next question comes from the line of Adam Walsh of Stifel."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess I have 2 questions. The first one is for Jeff Leiden. We've been out talking to docs, and according to them, your GPS reimbursement support program is really terrific. I'll start with that. But some of these docs also note that the total out-of-co",197,"I guess I have 2 questions. The first one is for Jeff Leiden. We've been out talking to docs, and according to them, your GPS reimbursement support program is really terrific. I'll start with that. But some of these docs also note that the total out-of-cost -- out-of-pocket cost burden for a lot of CF patients is really quite high, even before they try to get on ORKAMBI or KALYDECO. And I'm just curious in terms of -- with that in mind, how do you think about how far you can go to support patients, given the fact that if a co-pay is, say, 20%, and that adds quite a bit of out-of-pocket expense. Where is -- how far can you go in supporting the patients there, both with your own medicines and thinking about this in the context of the portfolio of medicines they might already be on? That's one. And then I have a question for Jeff Chodakewitz as well. It mentioned in the press release that 2 patients discontinued treatment in the ORKAMBI 6-to-11 study because of the adverse events. If you could just comment briefly on those 2 patients that would be great."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks for the question. This is Jeff Leiden. I'm actually going to turn that one over to Stuart because he's really responsible for the GPS program. And he'll also be able to describe the patient assistance program that's allowed us to help patients who",48,"Thanks for the question. This is Jeff Leiden. I'm actually going to turn that one over to Stuart because he's really responsible for the GPS program. And he'll also be able to describe the patient assistance program that's allowed us to help patients who do have high co-pays."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Adam, thanks for the question, and thanks for the positive feedback. The GPS program, just so everybody is aware of it, is a service, which is there to help patients and help them navigate the reimbursement process, and there to provide them with ong",157,"Yes, Adam, thanks for the question, and thanks for the positive feedback. The GPS program, just so everybody is aware of it, is a service, which is there to help patients and help them navigate the reimbursement process, and there to provide them with ongoing education if they choose to opt in. So it's great to get the feedback on that. Now dealing with the question you raised about out-of-pocket costs for both KALYDECO and ORKAMBI, we have comprehensive patient assistance programs in terms of co-pay assistance for eligible patients. The program is such that no patient who has a co-pay who's eligible for the program would have a monthly co-pay for either KALYDECO or ORKAMBI above $15 per month. And then for those patients who have coinsurance, we will cover coinsurance up to 30% of the price of the medicines. And the program is to keep things simple for people identical for both KALYDECO and ORKAMBI."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And it's Jeff Chodakewitz. In terms of the pediatrics study, as you pointed out, the overall profile was actually quite favorable. There were 2 patients who discontinued. One of them was because of abnormal liver functions and one of them was because of a",46,"And it's Jeff Chodakewitz. In terms of the pediatrics study, as you pointed out, the overall profile was actually quite favorable. There were 2 patients who discontinued. One of them was because of abnormal liver functions and one of them was because of a rash."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Mark Schoenebaum of Evercore ISI.",13,"Our next question comes from the line of Mark Schoenebaum of Evercore ISI."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","First question is on guidance. Should we assume your financial guidance is more or less conservative than Partridge's statement that this call would end by 5:45? Because you missed that pretty badly, so I'm a little concerned here. Anyway, just really qui",127,"First question is on guidance. Should we assume your financial guidance is more or less conservative than Partridge's statement that this call would end by 5:45? Because you missed that pretty badly, so I'm a little concerned here. Anyway, just really quick ones. I know it's getting late. Number one, can you just tell us when to expect data from the Phase II triple combo that you're going to start this year? I assume that's a mid-'17 event. Just let me know if I'm wrong on that. And then number 2, I apologize if you've addressed this. If you did, I missed it, but can you confirm the timing and your disclosure intentions around the -- what I believe is the futility analysis in the het-min trial?"
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Mark, it's Ian. I'll take both those questions. In his prepared remarks, he said the call would be brief as well. So he was wrong there as well.",29,"So Mark, it's Ian. I'll take both those questions. In his prepared remarks, he said the call would be brief as well. So he was wrong there as well."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Luckily, he doesn't give financial guidance for us.",8,"Luckily, he doesn't give financial guidance for us."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So first -- your first question was regarding the triple. And so first of all, the timing of getting data from the triple or disclosing the data from the triple is really subject to how fast we move through the Phase I. And we've mentioned this before, th",135,"So first -- your first question was regarding the triple. And so first of all, the timing of getting data from the triple or disclosing the data from the triple is really subject to how fast we move through the Phase I. And we've mentioned this before, the longer our Phase I takes, actually, the better it is, because it means we're escalating the dose and we're getting greater exposure of the drug into the healthy volunteers. And based on where we expect this to go, we anticipate in the second half of the year, we'll be in the proof-of-concept triple studies, which will probably push us into early 2017 to get that data. So that's how we're trying to set a timing expectation. And then your second question was on the disclosure regarding which..."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Futility.",1,"Futility."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Het-min futility.",3,"Het-min futility."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So for the het-min, in terms of recruitment for that trial, it's actually going very nicely, as you might anticipate, given that these patients have no other alternative medicine. And so we anticipate that we will be completed enrollment around the middle",86,"So for the het-min, in terms of recruitment for that trial, it's actually going very nicely, as you might anticipate, given that these patients have no other alternative medicine. And so we anticipate that we will be completed enrollment around the middle of the year and, therefore, we do expect the futility study to be done in the second half of the year. Obviously, we won't be disclosing that unless we have to curtail the study. So no news would be good news on that."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Tony Butler of Guggenheim Securities.",13,"Our next question comes from the line of Tony Butler of Guggenheim Securities."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","There are a number of respiratory articles that actually support the use of LCI as an endpoint because it does demonstrate greater sensitivity. I guess, the question is really what is the correlation between LCI and FEV, given that LCI apparently becomes",108,"There are a number of respiratory articles that actually support the use of LCI as an endpoint because it does demonstrate greater sensitivity. I guess, the question is really what is the correlation between LCI and FEV, given that LCI apparently becomes abnormal earlier than spirometry and yet, in the later-stage disease, it seems to correlate. And then therefore, can you only use LCI in children? And my last question -- I guess that's for Jeff C. And my last question, really, for Jeff L. Are you going to publish the kinetics and functionality of 152 and 440 soon? Or, I guess, ever in a peer review journal?"
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeff Chodakewitz will take the first question and I'll just quickly say the -- we'll -- made the appropriate steps in terms of where we published data regarding our molecules as we move forward. Obviously, you've seen a lot of publications at NACF, which",73,"Jeff Chodakewitz will take the first question and I'll just quickly say the -- we'll -- made the appropriate steps in terms of where we published data regarding our molecules as we move forward. Obviously, you've seen a lot of publications at NACF, which is in the fall, and then overseas, the ECFS conference. So you'll probably expect to see more data at those conferences. And then to your other questions, Jeff?"
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Maybe a couple of more comments on LCI. And as you point out, they do have -- overlapping, but somewhat different sweet spots, if you will, in terms of the best way to use them. And I do think, as a field, this links back to Jeff Leiden's comments, that w",174,"Maybe a couple of more comments on LCI. And as you point out, they do have -- overlapping, but somewhat different sweet spots, if you will, in terms of the best way to use them. And I do think, as a field, this links back to Jeff Leiden's comments, that we're continuing to learn the best way to use each of them. Obviously, LCI has that potential sensitivity, advantages in children. But right now, there are only some centers that actually have the expertise to do that well and, of course, a great tool, if used poorly, doesn't really help anybody. So I think there is still a lot of work to be done. And then there's the other part of your question about regulatory recognition, and I can't speak for the regulators. But I think it was encouraging that in Europe, LCI was accepted as our primary endpoint in our study. So I think there is, in general, an openness to continue to advance the field. And hopefully, we can contribute to that."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Great, well, thank you again for joining us tonight. Apologies for running over. It was all Michael's fault. At the risk of running for 1 or 2 more minutes, I did want to make a couple of concluding remarks. And again, I always like to do this sort of in",365,"Great, well, thank you again for joining us tonight. Apologies for running over. It was all Michael's fault. At the risk of running for 1 or 2 more minutes, I did want to make a couple of concluding remarks. And again, I always like to do this sort of in retrospect and say where are we today as a company as compared to where we were 6 or 12 months ago. And I must say from a personal standpoint and from the standpoint of CF patients, I'm very, very encouraged with the progress that we've made. I think we've -- it's now clear that KALYDECO and ORKAMBI together are approved for about 25,000 patients, or almost 1/3 of all patients, CF patients in the world. And as we discussed at JPMorgan, it's a fairly straightforward strategy through label expansion in the younger populations and others to take that number from 25,000 to 44,000 patients in the next couple of years. 
And then we have a clear strategy with multiple prongs, actually, to get to the vast majority of patients, and they include the ENaC inhibitors, which are in Phase II, so they can move very rapidly if we see positive results there in combination with ORKAMBI. They include the next-gen correctors, which are moving along in Phase I, and which we hope to have in patients in the second half of this year. And we think those have the potential to both increase the efficacy for the patients we're treating today, but also to let us to get to that large subset of het-min patients that don't have anything today. 
And then finally, the progress we've made with some of our deals, particularly the CRISPR deal here. And although that's the Holy Grail, 10 or 15 years down the road, we do have a vision of potentially correcting the underlying mutation and curing patients with CF. 
And so as I look at the world from our perspective, obviously, I'm tremendously encouraged about the future opportunity, and particularly, the future opportunity for patients and the future of the progress we're making. And we look forward to updating you over the next year as we continue that."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks very much everybody. That concludes tonight's call. The IR team will be available in our offices for additional questions, if you have them. Thank you.",26,"Thanks very much everybody. That concludes tonight's call. The IR team will be available in our offices for additional questions, if you have them. Thank you."
36235,321312374,921981,"Vertex Pharmaceuticals Incorporated, Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, you may disconnect your lines at this time. Have a great day.",15,"Ladies and gentlemen, you may disconnect your lines at this time. Have a great day."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Michael Partridge, Vice President of Investor Relations. Welcome to our first quarter 2016 conference call. [Operator Instructions] A replay of this call will also be available to website once we've concluded.Dr. Jeff Leiden, Chairman and CEO; S",195,"This is Michael Partridge, Vice President of Investor Relations. Welcome to our first quarter 2016 conference call. [Operator Instructions] A replay of this call will also be available to website once we've concluded.
Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer will provide prepared remarks this evening. They will be joined by Dr. Jeff Chodakewitz, Chief Medical Officer, for the Q&A portion of the conference call. We will make forward-looking statements on this call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the SEC. These statements, including without limitation, those regarding the ongoing development and potential commercialization of our drug candidates, our expectations regarding our improved medicines and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in tonight's press release. I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Dr. Jeff Leiden."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. Over the last 4 years, Vertex has delivered 2 transformative medicines to people with cystic fibrosis. Today, there are approximately 27,000 people eligible for 1 of our approved CF medicines. And we have a clear p",1797,"Thanks, Michael. Good evening, everyone. Over the last 4 years, Vertex has delivered 2 transformative medicines to people with cystic fibrosis. Today, there are approximately 27,000 people eligible for 1 of our approved CF medicines. And we have a clear path toward our goal of helping potentially all people with this rare and life-shortening disease in the future.
We're confident that our experience with ORKAMBI and KALYDECO and our scientific leadership and progress in targeting the underlying biology of this disease positions us well to increase the number of people treated with our approved medicines and to develop new medicines in the years ahead that may provide even greater benefit for all people with CF.
Tonight, I'll provide brief comments on 3 key areas and service markers of our progress towards treating all people with CF, including: first, the performance of our approved medicines, ORKAMBI and KALYDECO and our road map toward treating more patients with these medicines that will drive revenue growth in 2016 and beyond; second, the role of VX-661 in helping to achieve our long-term goal in CF; and third, our pipeline of additional CFTR modulators and other mechanisms we are advancing as part of collaborations. These approaches include the ENaC inhibition and in the longer-term, gene editing with CRISPR-Cas9 and may position us to help all people with CF.
We're approximately 9 months into the launch of ORKAMBI in the U.S. for people with 2 copies of the F508del CFTR mutation ages 12 and older. As of the end of March, approximately 65%, or 5,500 of the 8,500 currently eligible patients in the U.S. have initiated treatment with ORKAMBI. We expect the number of patients who've initiated treatment with ORKAMBI will continue to grow during 2016. And we continue to expect that by the end of the year, the vast majority of all eligible patients ages 12 and older in the U.S. will have initiated treatment.
We've seen excellent reimbursement and access for ORKAMBI from public and private payers in the U.S and the feedback from the CF community continues to be very positive. Importantly, patients across the U.S. have broad access to the medicine through public and private insurance. And we have assistance programs in place for eligible patients who need additional help. All major commercial insurers in all 50 state Medicaid programs are currently covering ORKAMBI, reflecting the important advance and value this medicine represents in the treatment of CF.
We're now moving forward to our bringing ORKAMBI to younger patients. And at the end of March, we submitted a supplemental New Drug Application to the FDA, requesting approval of ORKAMBI for children ages 6 to 11 with 2 copies of the F508del mutation. We requested priority review which if granted would provide us with a decision on the application in the second half of this year. If approved, approximately 2,400 additional patients in the U.S. would be eligible for treatment.
Outside the U.S., we have commenced discussions with reimbursement agencies in various European and other countries. Given the clinical benefits of ORKAMBI and the severity of the disease for people with 2 copies of the F508del mutation, we believe that we will achieve reimbursement from key European and other government payers just as we've seen in the U.S.
ORKAMBI is already commercially available in Germany and through early access programs in France.
In the near term, the [indiscernible] understanding of treating eligible patients with ORKAMBI gives us clarity on revenue expectations for 2016. Later in the call, Stuart and Ian will talk about the ORKAMBI  launch in detail, our guidance and how we think about revenue trends from 2015 and growth into 2016 and further into the future.
For KALYDECO, we're increasing our revenue guidance for 2016, which Stuart will discuss in his remarks. As we think about the future opportunities for ORKAMBI and KALYDECO, I want to emphasize that revenue growth in 2016 and beyond is largely a function of additional patients who are currently eligible for ORKAMBI or KALYDECO, initiating treatment with these medicines. On that basis alone, we believe there is significant growth ahead for both medicines. Consider that today, ORKAMBI and KALYDECO approved for approximately 27,000 people worldwide, but we're only currently treating approximately 1/3 of these patients. As we see additional uptake of ORKAMBI in the U.S. and achieve reimbursement for eligible patients outside the U.S., growth will continue as additional patients continue to initiate the treatment.
In addition, there are many more patients not currently eligible for treatment who may benefit from either ORKAMBI or KALYDECO. In total, we believe there are approximately 44,000 people and additional 17,000 people beyond those eligible today who could benefit from 1 or 2 of these medicines. This additional group of patients was largely comprised of the following: First, approximately 12,000 people less than 12 years of age who have 2 copies of the F508del mutation and who may be helped by ORKAMBI; and second, approximately 5,000 patients who may be helped by KALYDECO comprised mostly of patients who have a residual function mutation. Treating a substantial portion of this additional group of 17,000 patients would further drive ORKAMBI and KALYDECO  growth if we obtain future approvals for these additional groups of patients. We have ongoing studies, regulatory submissions and development plans to support these efforts, including ongoing discussions with the FDA regarding our application for approval of KALYDECO in approximately 1,500 people ages 2 and older with 1 of 23 residual function mutations as well as our recent sNDA submission to the FDA for approval of ORKAMBI in children ages 6 to 11 with 2 copies of the F508del mutation.
While we are focused on getting ORKAMBI and KALYDECO to as many patients as possible as soon as possible, we also recognize that there are many patients who are still waiting for a treatment for the underlying cause of their disease. We hear from these patients often. So I'm particularly pleased to report that our CF pipeline is advancing. This gives us great confidence that we will ultimately be able to treat the vast majority of people with CF and potentially enhance the benefit for those people currently taking our approved medicines.
I'll start with VX-661, which could play an important role in the treatment of people with CF and is currently in Phase III development.
In combination with ivacaftor, our Phase II data suggested that VX-661 may have an improved benefit risk profile compared to ORKAMBI in people with 2 copies of the F508del mutation and may provide enhanced clinical benefits over ivacaftor monotherapy for other patients with gating mutations. We're on track to obtain the first data from the ongoing Phase III program for VX-661 in early 2017 from the study in people with 2 copies of the F508del mutation.
Additionally, VX-661 is positioned to play a key role in the development of the triple combination with the next-generation corrector and ivacaftor. We believe that this triple combination approach will be fundamental for 2 reasons: first, triple combinations may allow us to treat a very large group of patients who are not held today by either ORKAMBI or KALYDECO, including those with 1 F508del mutation and a second mutation that causes minimal CFTR function; and second, these regimens could provide even greater benefit to patients currently eligible for our approved medicines who have at least 1 F508del mutation.
Today, we have 2 next-gen correctors in clinical development. VX-152 and VX-440. These potential medicines are currently being evaluated in Phase I studies in healthy volunteers. Successful completion of these studies would enable us to move rapidly into Phase II studies in the second half of 2016 to evaluate 1 or more next-generation correctors with VX-661 and ivacaftor in people with CF.
I'll now turn to our pipeline of other potential CF medicines that could be complementary to our portfolio see if CFTR modulators, and it may enable us to treat more patients and provide greater clinical benefit in the years to come. The most advanced example of this is our lead ENaC inhibitor, VX-371. Today, we announced data from a Phase II 14-day study of VX-371 in 142 people with CF, who are not receiving ORKAMBI or KALYDECO. The study met its primary endpoint of safety. 96% of the patients who enrolled in the study completed all treatment and the treatment regimens consisting of VX-371 were generally well tolerated. There were no statistically significant changes from baseline in FEV1 for those patients who received VX-371 compared to placebo. The data announced today are consistent with our in-vitro data that did not show a meaningful change in cilia beat frequency when VX-371 was used alone in human bronchial epithelial cells with 2 copies of the F508del mutation. In contrast, these in-vitro data did show a meaningful change in cilia beat frequency when VX-371 was used in combination with ORKAMBI. Together, the in-vitro and clinical safety data generated to date provide further support for our ongoing study of VX-371 in combination with ORKAMBI. This ongoing study began enrolling people with 2 copies of the F508del mutation ages 12 and older in the first quarter of this year. And the primary endpoints are safety and mean absolute change from baseline in lung function at day 28 of treatment as compared to placebo. Additional information on these studies can be found in our first quarter press release issued today.
Additionally, last year, we entered into a collaboration with CRISPR Therapeutics with the longer-term goal of discovering gene editing approaches for the treatment of genetic diseases, including CF. The use of this technology in people with CF may be many years away. But it is strategically important as we think about future advances that could fundamentally change treatment of this disease in the years to come.
Tonight, I've summarized how we think about our opportunity in CF. An opportunity that is unique both in terms of the potential benefit of ORKAMBI and KALYDECO provide to people with CF today and also for the long-term potential of our development-stage medicines to treat the vast majority of people with CF in the future.
In conclusion, I'll make just a few comments about the type of company we will become as we achieve the success in CF that I've just outlined. Vertex is on a path toward sustained earnings and and revenue growth, driven by an increasing number of people being treated with KALYDECO and ORKAMBI. We believe our business model when focused on significant investment to create value through innovation, research and development, positions us to consistently discover and deliver transformative new medicines for patients and to reinvest in scientific opportunities to create future medicines.
With that, I'll turn the call over to Stuart to make more specific comments on the ORKAMBI launch."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. Tonight, I will review our progress with the launch of ORKAMBI, the basis of our 2016 guidance for ORKAMBI product revenues and our ongoing efforts to obtain reimbursement outside the U.S. to drive further growth of ORKA",1182,"Thanks, Jeff, and hello, everyone. Tonight, I will review our progress with the launch of ORKAMBI, the basis of our 2016 guidance for ORKAMBI product revenues and our ongoing efforts to obtain reimbursement outside the U.S. to drive further growth of ORKAMBI in 2017 and beyond.
We are now just over 9 months into the launch and we are pleased that approximately 65% of eligible patients in the U.S. have initiated treatment with ORKAMBI to date. Global sales of ORKAMBI in the first quarter were $223 million, comprised of U.S. sales of approximately $214 million and ex-U.S. sales of approximately $9 million, which were mainly from Germany. 
At the beginning of the year, our intention was to provide financial guidance for 2016 ORKAMBI revenues once we have gained sufficient understanding of the dynamics of the launch in the U.S. Today, we have a deeper understanding as our doctors and patients are using the medicine based on the real world treatment patterns we've observed in more than 4,500 patients who initiated treatment in the U.S. in 2015. 
I'll now share with you our understanding of the launch dynamics that informed our guidance. First, uptake. Defined as the total proportion of the 8,500 eligible patients in the U.S. who will begin treatment with ORKAMBI by the end of 2016. And also the rate at which these patients initiate treatment.
Second, the persistence rate. Defined as the proportion of patients who start and remain on treatment. 
And third, the compliance rate, which reflects the number of pills actually taken by a patient in a given month.
First, the uptake. To date, approximately 65% of the 8,500 eligible patients in the U.S. have initiated treatment with ORKAMBI. Comprised of more than 3,000 patients who initiated treatment in the third quarter of 2015, more than 1,500 in the fourth quarter and approximately 800 in the first quarter of 2016. We have seen further initiations in April and expect that patient initiations will continue throughout 2016, albeit at a lower rate than in the first 3 quarters post launch.
We continue to expect that the vast majority of the eligible patients ages 12 and older in the U.S., will initiate treatment with ORKAMBI by the end of this year.
Second, persistence. Among patients who have initiated ORKAMBI since launch, we've seen that approximately 15% of patients discontinued treatment within 3 months of starting treatment. Our clinical trial and market research and data indicate that these discontinuations are largely related to respiratory adverse events. After the first 3 months of treatment, the discontinuation rate that is close considerably. Based on what we've observed to date from all patients taking ORKAMBI, including those have been on commercial drug for up to 9 months and those who continue to receive ORKAMBI as part of our Phase III long-term extension study, we expect that the proportion of all patients who initiate and remain on treatment will stabilize at approximately 70% to 80%.
It is also important to point out that the pattern of patient initiations and discontinuations have an offsetting effect on our first quarter ORKAMBI revenues. Specifically, because more than 4,500 patients began treatment with ORKAMBI in 2015, the impact of approximately 15% of these patients discontinuing ORKAMBI was highly evident in the first quarter. Therefore, while approximately 800 new patients initiated treatment in the first quarter, this growth was largely offset by the bolus of patients who discontinued treatment. This bolus of discontinuations began in the fourth quarter but had a larger impact on the first quarter of 2016, where there were also fewer patient initiations to offset these discontinuations.
And finally, compliance. Based on what we've observed to date from the launch, we expect the compliance rate with ORKAMBI to be between 70% and 80%.
In summary, based on our understanding of the launch dynamics for ORKAMBI and the fact that we have continued to see additional patients initiating treatment with ORKAMBI in April, we expect to deliver quarter-to-quarter revenue growth for ORKAMBI beginning in that second quarter and continuing through the end of 2016 and into 2017.
I'll now turn to the use of ORKAMBI to date outside the U.S. We are now well into the reimbursement process in all key European countries, Canada and Australia. Specifically, the clinical and cost-effectiveness assessment portions of the reimbursement process. These discussions are going as expected and have been productive. We believe that government payers across Europe recognize both the severity of this disease and the broad clinical benefits of ORKAMBI. These discussions will take time to complete. However, as Jeff mentioned earlier, we believe that we will achieve broader reimbursement from key European and other government payers, just as we've seen in the United States.
ORKAMBI is already available commercially in Germany and through early access programs in France. We are only 3 months into the launch of ORKAMBI in Germany and the uptake has been slower than we observed in the U.S. We attribute this to a number of factors, including that CFK in Germany is not concentrated in large centers as we've seen in other countries. Meaning, there are many smaller centers and also many centers and physicians who have not yet had personal experience with CFTR modulators.
In Germany, there are approximately 2,500 patients eligible for treatment. As of March 31, 2016, approximately 230 patients have initiated treatment. However, we expect the number of patients initiating treatment in Germany will grow through 2016 and into 2017.
We do not expect what we're seeing in Germany will be a representative of the uptake in other European countries. In fact, in France, where early access programs provide the opportunity for physicians to begin treating patients with ORKAMBI prior to formal reimbursement approval, we have already seen approximately 400 of the 1,500 eligible patients initiate treatment with ORKAMBI in 2016.
We took all of this information into account when we set 2016 revenue guidance for ORKAMBI of $1.0 billion to $1.1 billion. Our guidance reflect our understanding of the ongoing U.S. launch as I just discussed as well as expectations that we will receive both approval for ORKAMBI in the U.S. for patients ages 6 to 11 in the second half of 2016, and certain revenues from sales of ORKAMBI outside the U.S., primarily from Germany.
Taking a longer-term view, we expect significant further growth for ORKAMBI revenues in 2017, driven primarily by patients initiating treatment following the completion of reimbursement discussions outside the U.S.
And now to KALYDECO. Today, we are increasing our financial guidance for 2016 revenues. We now expect KALYDECO net revenues of $685 million to $705 million. The prior guidance provided on January 10, 2016, was for KALYDECO net revenues of $670 million to $690 million.
We increased our KALYDECO guidance based primarily on an increasing number of patients initiating treatment with KALYDECO globally and on expectations of a reduced impact this year from the VX-661 Phase III program. Our guidance for KALYDECO excludes any potential revenues from the approval of KALYDECO, the people with residual function mutations.
I'll now hand the call over to Ian."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thank you, Stuart, and good evening, to everyone. With the closing of the first quarter 2016 and 9 months into the launch of ORKAMBI, we are seeing significant progress across our business. Notably, we are seeing increasing number of patients being treate",560,"Thank you, Stuart, and good evening, to everyone. With the closing of the first quarter 2016 and 9 months into the launch of ORKAMBI, we are seeing significant progress across our business. Notably, we are seeing increasing number of patients being treated with our approved medicines, resulting in a growing revenue base that we expect to drive earnings growth. 
I will now review our first quarter financial results and provide some specific comments about the long-term financial trajectory of our business.
Financial results first. In the first quarter of 2016, we reported total CF product revenues of approximately $394 million, a significant increase compared to $130 million in the first quarter in 2015. With ORKAMBI, we reported sales of $223 million for the first quarter of 2016. We have recorded approximately $574 million of ORKAMBI revenues in the first 9 months since the U.S. launch in July 2015.
The first quarter KALYDECO sales of $171 million were up $41 million versus the first quarter of last year. 
Now to the operating expenses. Our first quarter on a non-GAAP operating expenses were $306 million compared to non-GAAP operating expenses of $246 million for 2015. The increased operating expenses were primarily due to increased costs related to the progression of our CF pipeline and to increased investments in global commercial support for their launch of ORKAMBI. Our non-GAAP net profit for the first quarter 2016 was $22 million or $0.09 per diluted share compared to a non-GAAP net loss of $148 million or $0.62 per share for 2015.
From a balance sheet perspective, we ended the first quarter with approximately $1.03 billion in cash, cash equivalents and marketable securities. Vertex also has $300 million outstanding from a credit agreement, repayable by the end of the third quarter of 2017. The agreement also allows for the facility to increase to $500 million. 
Now to financial trends. As to what provided 2016 ORKAMBI and KALYDECO revenue guidance on the assumptions that drive our projections and therefore, I will focus my comments on the longer-term growth opportunities that may come with achieving more patients with our currently approved medicines. 
We expect ORKAMBI revenues will continue to grow as we treat more patients in the U.S., achieve reimbursement outside the U.S. and expand the ORKAMBI label to younger patients. KALYDECO's growth is based on gaining reimbursement for certain group of patients outside the U.S, including those with R117H mutation and the people ages 2 to 5 with gating mutations.
In summary, as Jeff noted earlier, approximately 27,000 people are eligible for our CF medicines, yet we are only treating approximately 1/3 of these patients. As additional patients in the U.S. start treatment, we complete reimbursement discussions outside the us, we expect the number of patients treated with our medicines to increase significantly and we expect revenue growth will follow. 
I will note that in 2015, reported total CF revenues of $983 million. Based on 2016 guidance provided for ORKAMBI and KALYDECO, we anticipate that total CF revenues of approximately $1.7 billion to $1.8 billion, an approximate 75% increase over the prior year.
As our revenues grow over future years, we are committed to managing our operating expenses to drive earnings growth and we expect to deliver financial profile as similar to many of our large cap biotech peers.
With that, I open the line to questions."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] And our first question comes from the line of Michael Yee of RBC Capital Markets.",17,"[Operator Instructions] And our first question comes from the line of Michael Yee of RBC Capital Markets."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two part question. One is, you gave all these discontinuation persistence rates and compliance rates, which is in your guidance. Is there anything out there that you can do to either improve these things? Education, getting people to just get patients to",129,"Two part question. One is, you gave all these discontinuation persistence rates and compliance rates, which is in your guidance. Is there anything out there that you can do to either improve these things? Education, getting people to just get patients to take more drug? And can you apply any additional learnings to Europe? Are you seeing the same stuff in Germany? Are there any ways to improve it there? And then the second question is a pipeline question on the 661 you mentioned in the press release that you're changing the enrollment to 200 instead of 300. But is that assuming you actually passed the futility? Can you just clarify a little bit? I guess why we're talking about change in enrollment if we haven't passed the futility?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Hey, Mike, it's Stuart here. I'll take the first part of your question around discontinuation and compliance rates. And then I'll have Jeff and Stu to answer the pipeline questions. So on the discontinuation and compliance, and what we might be able to do",287,"Hey, Mike, it's Stuart here. I'll take the first part of your question around discontinuation and compliance rates. And then I'll have Jeff and Stu to answer the pipeline questions. So on the discontinuation and compliance, and what we might be able to do to improve those, much as we did with KALYDECO, we will be continuing to generate data on the long-term benefits and even broader benefit of ORKAMBI when used in the real world. And I suspect that data, if its compelling, may lead physicians and patients to reconsider restocking ORKAMBI. So we'll continue to develop the overall clinical profile of ORKAMBI as we have more experience in the market. In terms of compliance, really, many of the same things that we did with KALYDECO we'll be doing with ORKAMBI, and that's really providing both providers and physicians with the education materials to be able to understand how this is a product which is treating the underlying cause of their disease. And so it's a product that they want to try and stay compliant with as much as they possibly can or certainly will be leveraging all the learnings we have in KALYDECO, with ORKAMBI and those programs are already in place. Lastly, to your point about the Germany. Clearly, one of the things we're going to be doing is transferring all of the learnings from our launch experience in the U.S. to all of the other markets that we're launching into. And that's, in many ways, the benefit that those market coming on stream a little bit later is that they can learn from our experience here in the U.S. With that, I'll hand over to Jeff to answer the question on the pipeline."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Hi, Mike, it's Jeff. Maybe just to clarify, the -- we did provide some information about the timing of the interim analysis in the het-min study, but there's been no other changes for that trial. The change in sample size comes from one of our other Phase",97,"Hi, Mike, it's Jeff. Maybe just to clarify, the -- we did provide some information about the timing of the interim analysis in the het-min study, but there's been no other changes for that trial. The change in sample size comes from one of our other Phase III trials looking at 661 ivacaftor in patients who have more of a residual function mutation on one of their alleles. We did look at that and saw there was some opportunity to maintain good powering but simplify it and reduce the sample size and that's what that was about."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So still the het-min in 3Q, no change in that?",11,"So still the het-min in 3Q, no change in that?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","That's the interim, but that's correct.",7,"That's the interim, but that's correct."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Terence Flynn of Goldman Sachs.",14,"And our next question comes from the line of Terence Flynn of Goldman Sachs."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe just a follow-up on the discontinuation rate. I know you've mentioned it's mainly due to respiratory events but the 15% I think over 3 months are significantly higher than what you saw in the trials. I know you mentioned previously it could be highe",104,"Maybe just a follow-up on the discontinuation rate. I know you've mentioned it's mainly due to respiratory events but the 15% I think over 3 months are significantly higher than what you saw in the trials. I know you mentioned previously it could be higher but, I think, any more color there that drivers behind that are you going to expand on a little bit? And then on the ORKAMBI guidance, just wondering if you can provide a little bit more clarity there on the contributions from U.S., rest of world and then the patients 6 to 11 in terms of relative contribution."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","On the respiratory events, I think what I'd say there is what we're reporting today is what were seeing in the real world usage of ORKAMBI in the broad population, obviously the clinical trial population that we started in TRAFFIC and TRANSPORT it's a ver",230,"On the respiratory events, I think what I'd say there is what we're reporting today is what were seeing in the real world usage of ORKAMBI in the broad population, obviously the clinical trial population that we started in TRAFFIC and TRANSPORT it's a very controlled situation, those were patients with an FEV1 between 40 and 90. So really whilst we try to extrapolate from the clinical trial experience, the real world experience, that's one of the reasons -- that uncertainty is one of the reasons why we wanted to make sure we have sufficient time in market before we gave guidance was because you really want to see how the product we get used in the real world. In terms of the contribution of the various different parts of the world to our ORKAMBI revenue guidance that you might expect the vast majority of these revenues is going to come from here in the U.S. There will be a contribution ex-U.S. but it's going to be relatively small. And then incorporate with our guidance as we said is also an expectation that we will see an approval in 6 to 11 -year-olds in the latter part of 2016, which would give us access to an eligible population for about 2.5 and is also incorporated in our guidance by that approval is not anticipated until the back end of 2016."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Geoff Meacham of Barclays.",13,"And our next question comes from the line of Geoff Meacham of Barclays."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I'm trying to get a sense as to when you guys realize that compliance or persistent or discounts were different for ORKAMBI versus KALYDECO or commercial ORKAMBI versus Phase III. I mean, you guys had a chance 3Q call, GPM, 4Q call, to be crystal clear on",71,"I'm trying to get a sense as to when you guys realize that compliance or persistent or discounts were different for ORKAMBI versus KALYDECO or commercial ORKAMBI versus Phase III. I mean, you guys had a chance 3Q call, GPM, 4Q call, to be crystal clear on this and it's 10 months almost into the launch and now we're getting some detail. And I just have a couple of follow-ups."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Jeff, thanks for the question. So I just want to take us back a few months which as we went into JPMorgan and also year-end conference call again in January, we were very clear with what we launched to do regarding ORKAMBI guidance. Yes, that point in",259,"So Jeff, thanks for the question. So I just want to take us back a few months which as we went into JPMorgan and also year-end conference call again in January, we were very clear with what we launched to do regarding ORKAMBI guidance. Yes, that point in time, it was early in the launch my yes. In a number of patients onto ORKAMBI but it was still early the launch to understand treatment patterns. We stated that very clearly. What we've been able to do now we sit here as you point out, just over 9 months into the launch, we've been able to take significant bolus of patients. For example, 3,000 patients that initiates in the first 3 months of disapproval and we've been asked to track those 6 to 9 months. What that allows us to do was to understand compliance rates and help us understand discontinuation rates and also the kind of discontinuation as to what measure, that's been an important feature for us. So this was the -- we feel that we're in this position at this point in time where we've been able to attract a sufficient amount of patients over a good period of time to have the confidence to provide guidance for 2016. In comparison to KALYDECO, it was less relevant. For us, it was more about the treatment patterns for ORKAMBI. ORKAMBI is a different medicine than KALYDECO based on its clinical data and the patient population but we now have enough confidence to provide you with the ORKAMBI guidance."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And just as a follow-up to some of the earlier questions, gets out as it for a different way. 4 patients that are at low FEV1 at baseline and do experience proper construction is as their treatment protocol in place? We've obviously, heard of things like",72,"And just as a follow-up to some of the earlier questions, gets out as it for a different way. 4 patients that are at low FEV1 at baseline and do experience proper construction is as their treatment protocol in place? We've obviously, heard of things like have those than uptight trade or those skipping, is there something that you guys can recommend to pulmonologist, strategy for those that do experience bronchoconstriction?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Kevin, it's Jeff Chodakewitz just to give you a couple of comments about that. We don't have anything in terms of very concrete, specific guidance that we can give but we can make a couple of observations. First of all, we're clear from speaking into our",179,"Kevin, it's Jeff Chodakewitz just to give you a couple of comments about that. We don't have anything in terms of very concrete, specific guidance that we can give but we can make a couple of observations. First of all, we're clear from speaking into our investigators also to physicians in the field but clearly the support for the patients both setting expectations for the patient and for the physician and helping patients in those early weeks manage and the symptoms we think is very important and something that post some of the education questions at the very the earlier. We are also collecting information in our own study for patients to were in the process of summarizing that. We did, in that study, we give patients the option to start on a lower dose. And we said we'll get that guidance summarize it but it's not going to be the kind of data that says, here's a specific recommendation. We noted that is being used but it's really still about physicians and their patience working together to manage."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Mark Schoenebaum of Evercore.",13,"And our next question comes from the line of Mark Schoenebaum of Evercore."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Number one, I just like to have you been surprised by the way the launch unfolded? I'm sure you guys had some projections a year ago, persistence only thing significant just provided. And number two, I know you can't comment specifically on peak numbers b",79,"Number one, I just like to have you been surprised by the way the launch unfolded? I'm sure you guys had some projections a year ago, persistence only thing significant just provided. And number two, I know you can't comment specifically on peak numbers but the sales activity around $4 billion at peak for ORKAMBI, I'm just wondering, can you just talk about that? And then finally, is there any opportunity for renegotiation seeing these patients that dropout early?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","We have a list of questions that if we don't get to all of them sorry we're all scribbling down but we don't get to them, please say them again. So Michael in terms of how we feel about the launch, I'd say, we're very pleased with the way the launch has p",197,"We have a list of questions that if we don't get to all of them sorry we're all scribbling down but we don't get to them, please say them again. So Michael in terms of how we feel about the launch, I'd say, we're very pleased with the way the launch has progressed here in the U.S. From how we were able to work with payers to get access in reimbursement from ORKAMBI from early on in the launch to the rate of uptake that we've seen, I mean, to get close to 65% of eligible patients initiated within the first 9 months is a fairly steep ramp. And so what we're pleased with -- we're pleased overall, we're pleased with the launch is played out, much as we anticipated. In terms of the potential for renegotiations, we have heard anecdotally from physicians that they have tried renegotiating patients on ORKAMBI. We don't have much in the way of clinical data to be able to support that but we are certainly aware that their physicians to don that successfully and some of their patience so that's really something that will continue to watch in the marketplace."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Hi Mark, this is Jeff Leiden, maybe you'll just a little bit lead to a little bit more both KALYDECO and ORKAMBI. Like you have been involved with many, many drug launches and I think we're just putting those in perspective a little bit. From a standpoint",227,"Hi Mark, this is Jeff Leiden, maybe you'll just a little bit lead to a little bit more both KALYDECO and ORKAMBI. Like you have been involved with many, many drug launches and I think we're just putting those in perspective a little bit. From a standpoint, as an example in ORKAMBI of getting to 65% of the patients in 9 months and of course, KALYDECO is close to 90%. And that's a fairly unusually fast ramp and from the standpoint of persistence, the kind of numbers stored was talking about was 70% number we said aloud at, where is still a very, very kind number compared to most chronic medicines. And we believe that it represents the correct perception of both physicians and patients have about the value of these medicines treating the underlying cause of this disease for a long period of time. And that really underlies our thinking about the pipeline as well because as we develop this method, including next-gen and hopefully things like CRISPR, we're talking about progressively increasing the benefit risk of the of our portfolio drugs that these patients can take and that only, of course, increase both persistence and compliance rate. Overall, we're pleased to we are what lead me today to get more patients that improve the therapy but these 2 drugs have really quite prepared well far."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Geoffrey Porges of Leerink Partners.",14,"And our next question comes from the line of Geoffrey Porges of Leerink Partners."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just a few questions. First, could you help us out, just give us a breakdown between U.S. and ex-U.S. sales of KALYDECO's overall in the same page? And then I just wanted to go back to Jeff's comments. Jeff, can you really clarify this residual function c",169,"Just a few questions. First, could you help us out, just give us a breakdown between U.S. and ex-U.S. sales of KALYDECO's overall in the same page? And then I just wanted to go back to Jeff's comments. Jeff, can you really clarify this residual function change and what is altered in terms of your statistical analysis or your assumptions about the activities of the drug or the combination? End give us a sense of what the hurdle there is or ORKAMBI's affect. And then lastly, on this issue of persistence. Is it reasonable to assume that about 50% of patients of the eligible pool of around are quite a big us we keep going round and round about initiations and this contusions but clearly what's important is the number of patients who remind on drug at the end of the quarter and its 50% roughly for right now or perhaps slightly below that 45% to 50% of the eligibles. Is that the right way to think about it?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Josh, it's Stuart here, I think first question around KALYDECO revenues and I'll have it over Jeff Chodakewitz. So with the total of KALYDECO $171 million for the first quarter 2016, $95 million of that was in the U.S. and the balance, about $76 millio",49,"So Josh, it's Stuart here, I think first question around KALYDECO revenues and I'll have it over Jeff Chodakewitz. So with the total of KALYDECO $171 million for the first quarter 2016, $95 million of that was in the U.S. and the balance, about $76 million was in international."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Job come in terms of the residual function study, we really stepped back and said, is there an opportunity to reduce the end of the study somewhat without sacrificing the integrity of the trial. And we really looked at that 2 ways that we saw opportunity.",109,"Job come in terms of the residual function study, we really stepped back and said, is there an opportunity to reduce the end of the study somewhat without sacrificing the integrity of the trial. And we really looked at that 2 ways that we saw opportunity. What is that we refocused our statistical analysis on key parameters plan that will allows us to take care of that. The other thing is that we also look at the why the data and saw that the discontinuation rate from this trial was actually lower than what we had left the room for in that also is not to reduce the end."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And finally, Jeffcoat your question in ORKAMBI, you're back level of mass is approximate the right at the end of the third quarter, you're right about 50% of the eligible population were on clearly that's a moving target because it's a mix of the disconti",113,"And finally, Jeffcoat your question in ORKAMBI, you're back level of mass is approximate the right at the end of the third quarter, you're right about 50% of the eligible population were on clearly that's a moving target because it's a mix of the discontinuations and the initiations, the important thing I would add to that number is that moving forward in Q2 and beyond, we do expect patient initiations, which will continue to see in April and the U.S., obviously, we'd continue to see internationally in places like Germany, we expect to outpace discontinuation, which is why we are pretty think what on quarter growth for the remainder of 2016 and beyond."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Brian Abrahams of Jefferies.",13,"And our next question comes from the line of Brian Abrahams of Jefferies."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess.I guess my first question is I'm wondering if you're seeing any trends towards her may be less FEV1 patient going on the therapy over time, which could ORKAMBI, which is your theoretically radically improve persistence and compliance. And then o",69,"I guess.
I guess my first question is I'm wondering if you're seeing any trends towards her may be less FEV1 patient going on the therapy over time, which could ORKAMBI, which is your theoretically radically improve persistence and compliance. And then on 661, if 661 looks better tolerated but perhaps less efficacious than lumacaftor, just wondering how you a witch potential backbone to combine with the corrector into."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So in terms of entrants for the product is being used in either sicker patients are patients, to us with 65% of eligible patients being initiated, it's being used across the board. Obviously, we got a range of different positions and centers here, some us",102,"So in terms of entrants for the product is being used in either sicker patients are patients, to us with 65% of eligible patients being initiated, it's being used across the board. Obviously, we got a range of different positions and centers here, some using it in their more severe patient, others have started using it in their less severe patients that we really are seeing usage of across the whole range of FEV1 patients as you would imagine with 65% of eligible patients having been initiated. And on the backbone with the triple combination, I'll pass that over to Jeff Leiden."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, just on the triple combination, obviously, we can't speculate that exactly what will happen but I would remind you that there were a number of reasons that 661 is the preferable partner, most of those had to do with drug-drug interactions and making",95,"Yes, just on the triple combination, obviously, we can't speculate that exactly what will happen but I would remind you that there were a number of reasons that 661 is the preferable partner, most of those had to do with drug-drug interactions and making it simpler to combine it to a regimen. So I guess what I would say is all things being equal, if 661 and lumacaftor have equal efficacy in combination with KALYDECO, and certainly we're still going to go with 661 because of their former codefendant properties. Does Didn't answer the question?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes well, no, not exactly. Just wondering, I mean, we know 661 has less reaction and I was sort of wondering some of the reward ORKAMBI side effects that you're seeing are perhaps driven by not only the respiratory but driven by 3 for which we know is goi",65,"Yes well, no, not exactly. Just wondering, I mean, we know 661 has less reaction and I was sort of wondering some of the reward ORKAMBI side effects that you're seeing are perhaps driven by not only the respiratory but driven by 3 for which we know is going to Meadowood 661 and sort of how you read that if efficacious perhaps not as good."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","That's not the reason, just to be clear. So those are not driven by actions, we feel they're driven as we said before by up target bronco constriction. unit lumacaftor, we don't see 4661.",35,"That's not the reason, just to be clear. So those are not driven by actions, we feel they're driven as we said before by up target bronco constriction. unit lumacaftor, we don't see 4661."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Adam Walsh of Stifel.",12,"Our next question comes from the line of Adam Walsh of Stifel."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A few weeks ago, we published 47 physician ORKAMBI and a few things jump out at us. I want to bump it off. Most notably, our survey show that our patient can discontinue ORKAMBI due to drug-related side effects. 70% of doctors encourage these patients to",97,"A few weeks ago, we published 47 physician ORKAMBI and a few things jump out at us. I want to bump it off. Most notably, our survey show that our patient can discontinue ORKAMBI due to drug-related side effects. 70% of doctors encourage these patients to restart the drug and then a very meaningful percentage of those patients, not only successfully restart the drug but also subsequently remained on the drug long-term. So my questions are, is this consistent with your own internal research? Are patient restarts factored into your guidance? And if so, to what extent?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Adam, it's Stuart here. Thanks for the question. In terms of restart, yes, your survey is consistent with what we've heard in that we have heard from physicians that they are trying to restart ORKAMBI in some of their patients who they have -- previous",174,"So Adam, it's Stuart here. Thanks for the question. In terms of restart, yes, your survey is consistent with what we've heard in that we have heard from physicians that they are trying to restart ORKAMBI in some of their patients who they have -- previously had the discontinue the product largely because as you know, that they often firm believers trading on the Lycos of this is really a good thing for those patients if they can tolerate the medicine. In terms of the absolute volume of that, the minute it's hard to quantify, we certainly heard it anecdotally. We've heard so we heard success stories. It's a fair to say that, that within our guidance, we received relatively minimal impact from restarts because at this time, we really don't have evidence that it's happening in quite the numbers that perhaps people have said that they might do it in. So at the moment within our guidance, relatively minimal amount of restarting patients is assumed to happen in 2016 here in the U.S."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Phil Nadeau of Cowen & Company.",13,"Our next question comes from the line of Phil Nadeau of Cowen & Company."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two on question and then a quick one on the pipeline. In the commercial, can you give us some sense on how many lands outside the U.S. could gain reimbursement for ORKAMBI 2017 surely have internal estimates and rages. I'm curious what those are. And then",115,"Two on question and then a quick one on the pipeline. In the commercial, can you give us some sense on how many lands outside the U.S. could gain reimbursement for ORKAMBI 2017 surely have internal estimates and rages. I'm curious what those are. And then similarly in the younger kids, do you expect any different penetration of ORKAMBI into that population then you've seen in the older kids and adults? And then last on the triple, can you guys that if you combine all 3 drugs in healthy volunteers yet and what your discloses a strategy would be in a move into Phase II, how much data from the Phase I will we get?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Phil, it's Stuart here. I'll take those 2 1st commercial questions. In terms of the number of lives that might be eligible, the number of patients with the F508del homozygous mutation, 12 and above in Europe is somewhere around 12,000. Within our '16 g",216,"So Phil, it's Stuart here. I'll take those 2 1st commercial questions. In terms of the number of lives that might be eligible, the number of patients with the F508del homozygous mutation, 12 and above in Europe is somewhere around 12,000. Within our '16 guidance, the only country that we're assuming we're going to be able to recognize revenues for is in Germany. Yes, we're not in a position to be giving 2017 guidance at this point. I'm trying to predict exactly when this reimbursement discussions going to conclude. It's frankly important today because clearly, it's a negotiation and that the vast majority of the numbers don't have a formal timeclock and so at this point, we're not in a position to be able to speculate on when those might be concluded.
In terms of what we would be anticipating the spending in the 6 to 11-year-old population, if we are successfully in gaining approval for that here in the U.S., then our this patient would be my just we've seen with the KALYDECO that the uptake there is likely to be similarly robust as we've seen in adults, although I would remind you that for 2016 perspective, that's likely to come in the second half or in the second half the second half of 2016."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So I'll take the last question so the Phase I study in healthy volunteers so we cannot say a comment on that but in terms of disclosure and timeline, still discussed before we expect it to be in patients with triple combination in the second half of the y",98,"So I'll take the last question so the Phase I study in healthy volunteers so we cannot say a comment on that but in terms of disclosure and timeline, still discussed before we expect it to be in patients with triple combination in the second half of the year. The disclosure of the Phase I that will be relevant information that supports of the Phase II study design at this point, that is too difficult to describe and will let you know what we have that information and where we are proceeding with the Phase II study."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Cory Kasimov of JPMorgan.",12,"Our next question comes from the line of Cory Kasimov of JPMorgan."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have 2 left for you. So I realized it's early, but I wanted to us about the potential impact of the year the authorization or ORKAMBI? How come and visit how does it compare with the processes our KALYDECO. And then capital allocation question for you.",78,"I have 2 left for you. So I realized it's early, but I wanted to us about the potential impact of the year the authorization or ORKAMBI? How come and visit how does it compare with the processes our KALYDECO. And then capital allocation question for you. Now that you are profitable in growing and you're sitting on $1 billion of cash in your balance sheet, at what point would you consider buying back some of your stocks?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Cory, and payer reauthorizations. Not all players have published policies that include there the authorization criteria. That's the first thing I'd say. Of the ones you have, most have a timeclock at 6 to 12 months. They were really only now beginning",172,"So Cory, and payer reauthorizations. Not all players have published policies that include there the authorization criteria. That's the first thing I'd say. Of the ones you have, most have a timeclock at 6 to 12 months. They were really only now beginning to get to the point of patients get into the time point when they are happy to go to the reauthorization process. Having said that, for the payers that have published policies or whether reauthorization criteria are unknown, the vast majority of the in line with the label or reflect the systemic benefits of ORKAMBI and by that, I mean, they recognize that this product can have a benefits across multiple endpoints and either improvements are stabilization in those endpoints, qualifies as a successful outcome. So whilst we are only now beginning to get to see those reauthorization, I feel good about the reauthorization criteria that we've seen to date and to your last, last part of your question, they are not dissimilar to what we saw with KALYDECO."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And to the last question, we have thought about stock buyback, some terms of capital allocation. But as we think about the priority of capital allocation for our business, I'll just need a broader fall which is we're still in transitional speed of moving",208,"And to the last question, we have thought about stock buyback, some terms of capital allocation. But as we think about the priority of capital allocation for our business, I'll just need a broader fall which is we're still in transitional speed of moving into profit-making cash generation and watching the revenue curve. As we go to the revenue curve and the drive revenue growth in earnings growth, which translates into cash GEN -- more cash generation, we love to apply the capitals reimbursed back at this is of course, turning to our pipeline but been potentially outside of the company to diversify and expand our pipeline and we've already done activities in that area as you know with CRISPR and our ENaC inhibitor. So those continue to be the priorities. It's internal investments, it's the external investments. As we go up that revenue growth curve and have greater capital to allocate, we will give consideration to capital strategies such as share buyback. But at this point of time, it's a little early for us. And then if we were to move into something in the near future to make with the of a smaller scale to stop the shares outstanding to occur each year to option exercises."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Alethia Young of Credit Suisse.",13,"Our next question comes from the line of Alethia Young of Credit Suisse."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","The 3 of them are kind of around compliant. And I guess when we look at the map that within the quarter it seems like the first 2 quarters, the compliance was potentially higher, like 95% maybe in this quarter based on our math, it would've gotten us to a",162,"The 3 of them are kind of around compliant. And I guess when we look at the map that within the quarter it seems like the first 2 quarters, the compliance was potentially higher, like 95% maybe in this quarter based on our math, it would've gotten us to about 80. So I guess, one, is that analysis fair? Two, can you give us any color on the scripts written in 1 or 3 months increment? And then third, just when you think about 70% to 80% range on compliance, what actually doesn't move the model quite a bit. What kind of qualitative the think about the kind of get to you in 70% range for his 80% range as we think about the amount of these people have taken so there's a Delta in the days they miss at this kind of adding that up and thinking about it or there are some other way we should think about qualifying compliant?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So let me try and answer those sequentially. In terms of the compliance trend. Compliance is the metric that you need the longest time to measure because clearly, it's a chronic medicine and so in the first prescription, you get your kind of assumption is",301,"So let me try and answer those sequentially. In terms of the compliance trend. Compliance is the metric that you need the longest time to measure because clearly, it's a chronic medicine and so in the first prescription, you get your kind of assumption is you're 100% compliant after waiting to get the second perspective to work out exactly what its. So this is the one that really takes the longest period of time for us to get a good handle on, I don't know obviously the intricacies of your model. I just reiterate that we're based on the trends we've seen to date but expensive got with the patients will have been treated to date our expectations for the year and the assumption on, which our guess is bill that it will be somewhere between 70% and 80% for ORKAMBI this year. In terms of the 1 or 3 months script, the vast majority have written for 1 month, there are some 3 month prescriptions but the vast majority of prescriptions are written for on a monthly basis. And in terms of kind of qualitatively, what would lead you to 1 end versus the other, so this is about education and our ability to help providers to give today patients information, which educate them on the nature of the disease, the underlying defect, the fact that ORKAMBI is assigned to treat those underlying defects and to the extent they believe in the science, believe in the long-term benefits that ORKAMBI can provide to them but I think that's only likely to be the patients having higher compliance rates. We are very focused on that. We're certainly taking all the learnings we can from our expensive with KALYDECO, to support patients to take the prescriptions in line with their physician's recommendations."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Matthew Harrison of Morgan Stanley.",13,"Our next question comes from the line of Matthew Harrison of Morgan Stanley."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have 2, which are somewhat follow-ups on Phil's questions. Just on next generation correctors and those studies, can you just tell us if you saw a safety event, what kind of safety event would be disclosable versus not disclosable? And then is there a p",126,"I have 2, which are somewhat follow-ups on Phil's questions. Just on next generation correctors and those studies, can you just tell us if you saw a safety event, what kind of safety event would be disclosable versus not disclosable? And then is there a point in time that we're going to see PK data from healthy volunteers which might help us to better understand how the drug levels that we saw on the HP data might compare in patients? And then a separate commercial question. Just in the 6 to 12 pool for ORKAMBI, are your assumptions for persistence in discontinuation rate are the same as what you're seeing now in the older population? And if they're not the same, can you just explain why?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So maybe I'll take the first couple of questions. So with the next-gen disclosure, what would be required disclosures all since right FD and if there was a material adverse event, we would have to disclose that. If you want me to give an example, that wou",123,"So maybe I'll take the first couple of questions. So with the next-gen disclosure, what would be required disclosures all since right FD and if there was a material adverse event, we would have to disclose that. If you want me to give an example, that would be a discontinuation of the trial, for example. And we'd have to disclose that. Other than that, it's an ongoing trial. We need to complete the trial, gather the data that will inform us, as I said earlier, for the Phase II trial in patients with triple combination and we will provide relevant information at that point in time that supports the design of the trial. Can you just remind me of your second question?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, no. I was just wondering, will we see PK data so that we can compare sort of the drug levels that you can achieve in healthy volunteers versus the drug levels that you are achieving in the HB assays so we have some point of comparison on relative dru",51,"Yes, no. I was just wondering, will we see PK data so that we can compare sort of the drug levels that you can achieve in healthy volunteers versus the drug levels that you are achieving in the HB assays so we have some point of comparison on relative drug levels."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So we'll provided a wealth of information that helps you understand the design of the Phase II study. However, it is not our practice to provide that kind of detail on a Phase I study. And there's a number of reasons for that and I would just give you one",73,"So we'll provided a wealth of information that helps you understand the design of the Phase II study. However, it is not our practice to provide that kind of detail on a Phase I study. And there's a number of reasons for that and I would just give you one that there's a specific competitive reason that would -- we would prefer not to provide that information on the Phase I study."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And then Matt, in the 6 to 11, I mean, really the contribution of the 6 to 11 population, it was successful in getting approval. As I said, it's really going to be in the likely be in the fourth quarter. So really, the contribution there within our overal",193,"And then Matt, in the 6 to 11, I mean, really the contribution of the 6 to 11 population, it was successful in getting approval. As I said, it's really going to be in the likely be in the fourth quarter. So really, the contribution there within our overall guidance is more about uptake than it is around persistence and compliance. And much as we did with the 12 and above population, I think we'd always really watching that very, very closely, just as we have done since the launch in July. And that'll give us an ability to learn how the product performance with those patients in the real world. Again, one of the things that we have seen [indiscernible] with the young population of KALYDECO is they tend to be slightly more compliant than the average, not surprisingly, because they've got a lot of parental and caregiver supervision. But really, there was assumptions that we've given you are really much more related to the 12 and above population. But we'll see how the 6 to 11 patients play out in the real world in the course of time after the approval."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Ying Huang of Bank of America Merrill Lynch.",16,"Our next question comes from the line of Ying Huang of Bank of America Merrill Lynch."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Number one, I want to know if you guys have seen an uptick in discontinuation due to lack of efficacy? Or it's all due to the, I guess, chest tightness? And then secondly, for the ATU price you're get in France, how does that compare to the German pricing",81,"Number one, I want to know if you guys have seen an uptick in discontinuation due to lack of efficacy? Or it's all due to the, I guess, chest tightness? And then secondly, for the ATU price you're get in France, how does that compare to the German pricing of EUR 159,000 per year per patient? And lastly, I have a question on your growth net. Is that consistent with you guys have guided before, which is like mid-teens 1Q '15?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So in terms of discontinuations, based on our clinical trial experience and also what we're seeing in the market, the vast majority those discontinuations are for adverse events. And most commonly, that's the chest tightness. In terms of the ATU, we haven",148,"So in terms of discontinuations, based on our clinical trial experience and also what we're seeing in the market, the vast majority those discontinuations are for adverse events. And most commonly, that's the chest tightness. In terms of the ATU, we haven't disclosed the price within the ATU program. And in terms of the gross-to-net, the gross-to-net that we've seen and are predicting is potentially slightly lower than we originally thought that largely to the fact that the Medicaid patient population that we're seeing is slightly lower than we anticipated. This is really as a result of many of those Medicaid patients that we thought will be common by Medicaid or actually qualify for disability benefit under Medicare as a result of that are seeing lower Medicaid population and the results we're seeing -- we're particularly slightly lower gross to net of somewhere around 12% for the year."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I'd like to just add to that, Stu, which is in the coming into 2016 and 2015 with the gross-to-net on ORKAMBI was close to 7%. As we move into the Q1 of 2016, it's increased to 9%. So it is moving up slightly as we expected but as we plot out and we look",90,"I'd like to just add to that, Stu, which is in the coming into 2016 and 2015 with the gross-to-net on ORKAMBI was close to 7%. As we move into the Q1 of 2016, it's increased to 9%. So it is moving up slightly as we expected but as we plot out and we look at the patients that are coming off the drug, we anticipate that it could end the year around 12% as it gradually creeps up to that 12% level. That also plays into our guidance."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Liisa Bayko of JMP Securities.",14,"And our next question comes from the line of Liisa Bayko of JMP Securities."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just a couple of technical questions. Were there any inventory changes in the quarter?",14,"Just a couple of technical questions. Were there any inventory changes in the quarter?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","No. But the ORKAMBI inventory at the end of March was towards [indiscernible] identical to that, which it was at December 31, so there was really no inventory change for ORKAMBI at all.",33,"No. But the ORKAMBI inventory at the end of March was towards [indiscernible] identical to that, which it was at December 31, so there was really no inventory change for ORKAMBI at all."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then can you comment on gross-to-net sort of where were you for the quarter? And would that be relatively consistent for the rest of the year? Will it change in some way?",34,"And then can you comment on gross-to-net sort of where were you for the quarter? And would that be relatively consistent for the rest of the year? Will it change in some way?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Are you referring to ORKAMBI, Liisa?",6,"Are you referring to ORKAMBI, Liisa?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes.",1,"Yes."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","As you just mentioned, which is in Q1, we were approximately at 9% gross-to-net discount. And in Q4 of last year, we were at 7%. We actually expect the Q1 level of 9% to trend up to be something closer to 12% by the end of the year.",48,"As you just mentioned, which is in Q1, we were approximately at 9% gross-to-net discount. And in Q4 of last year, we were at 7%. We actually expect the Q1 level of 9% to trend up to be something closer to 12% by the end of the year."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then when you say 15% of 65% have discontinued that's like a 10% discontinuation rate, roughly? Is that the right way to think about that?",26,"And then when you say 15% of 65% have discontinued that's like a 10% discontinuation rate, roughly? Is that the right way to think about that?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","No. And it's really important, and so thanks for asking the question. It is of the patients you've initiated, 15% of them had discontinued ORKAMBI within approximately the first 3 months. And so if you think about 4,500 patients who initiated between July",116,"No. And it's really important, and so thanks for asking the question. It is of the patients you've initiated, 15% of them had discontinued ORKAMBI within approximately the first 3 months. And so if you think about 4,500 patients who initiated between July and December, 15% of those patients would have discontinued within the first of 3 months and then that rate of discontinuations slows considerably. The 65% is the number of patients you've initiated therapy by the end of March. So the 15%, you need to apply that all of the patients who initiated. It's not 15% of 65%. It's 10, it's 15% of the 65% you've initiated, they will discontinue therapy and endless the."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Right. But that got you 10%, doesn't? If multiply 55 by 15?",12,"Right. But that got you 10%, doesn't? If multiply 55 by 15?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Liisa, we'll jump on the phone with you after the call.",11,"Liisa, we'll jump on the phone with you after the call."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just have a question on the Rho inhibitor, can you just give us a little detail on that trial? What are the endpoints you're looking at? What's the timing for data?",32,"I just have a question on the Rho inhibitor, can you just give us a little detail on that trial? What are the endpoints you're looking at? What's the timing for data?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Liisa, it's Jeff. So the Rho inhibitor trial is really specifically in patients who had a pretty catastrophic injury to their cervical spine and then really have very poor functioning maybe following that injury. In the studies then, we followed those pat",134,"Liisa, it's Jeff. So the Rho inhibitor trial is really specifically in patients who had a pretty catastrophic injury to their cervical spine and then really have very poor functioning maybe following that injury. In the studies then, we followed those patients at the time of surgery they have either placebo or 1 of 2 doses of active drug and there's about 150 patients in total and then we follow them for 6 months looking at particularly how their upper extremities function because that's so important to how paves the quality of life of patients and then with some other measures of disability. And it's very hard right now. We just started the study as you said very hard to predict that can accomplish and in particular exactly when we're going to get results."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Operator, we have time for 2 more questions.",8,"Operator, we have time for 2 more questions."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Tony Butler of Guggenheim.",12,"Our next question comes from the line of Tony Butler of Guggenheim."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Briefly, Stuart, in France again in early access patients which received ORKAMBI, I think you mentioned 400, I understand reimbursement has not occurred, but given the uptick being fairly strong, if one assumes that the majority of that 1,500 will be trea",81,"Briefly, Stuart, in France again in early access patients which received ORKAMBI, I think you mentioned 400, I understand reimbursement has not occurred, but given the uptick being fairly strong, if one assumes that the majority of that 1,500 will be treated by year-end and you do get reimbursement, let's say next year, that does come in a bolus payment for that, which has occurred? Or does that payment amortize assuming those patients to stay on drug for '17 and beyond?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for the question, Tony. So the way the accounting works in France is that for the cash that we get to those patients before we get reimbursed, that those recognizes cash not as revenue. At the point that we have certainty about the selling pri",118,"Yes, thanks for the question, Tony. So the way the accounting works in France is that for the cash that we get to those patients before we get reimbursed, that those recognizes cash not as revenue. At the point that we have certainty about the selling price or very close to certainty about the selling price in France, then we will be able to, in a one-time adjustment that can build that cash to revenues. And then from that point forward, all of those will be counted as revenues going forward. And that's because whatever rebate you agreed with the French government is retroactive to the sales that you've had from the point that you launched the product."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And finally, you would call that out as an item in the quarter in which it occurs, I assume?",19,"And finally, you would call that out as an item in the quarter in which it occurs, I assume?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So maybe I'll follow on from Stuart's answer. So I'll just validate Stuart's answer as the kind of a CPA. So nice job, Stuart. In terms of revenue recognition, many of you that are on this call probably have seen other companies go through this with the A",102,"So maybe I'll follow on from Stuart's answer. So I'll just validate Stuart's answer as the kind of a CPA. So nice job, Stuart. In terms of revenue recognition, many of you that are on this call probably have seen other companies go through this with the ATU in France. And then absolutely, at the point that we are -- we get to a point where we were comfortable with the price in France, yes, we would collect out in the quarter specifically and in end that's the same point in time we recognize all of revenues in that very quarter."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our final question comes from the line of Katherine Xu of William Blair.",14,"And our final question comes from the line of Katherine Xu of William Blair."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So I just have one question on the CRISPR program. Based on the research that you have ongoing right now, what kind of mutations are the most amenable for the technology first? And how difficult it is to eventually correct the [indiscernible] which is a d",51,"So I just have one question on the CRISPR program. Based on the research that you have ongoing right now, what kind of mutations are the most amenable for the technology first? And how difficult it is to eventually correct the [indiscernible] which is a deletion, you have a base their?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, this is Jeff Leiden. Thanks for the question. I think as you know if you look today, CRISPR is most amenable to actually inactivate, making cleavages because that's what it does most efficiently. And obviously that's not what we would want to do in a",222,"Yes, this is Jeff Leiden. Thanks for the question. I think as you know if you look today, CRISPR is most amenable to actually inactivate, making cleavages because that's what it does most efficiently. And obviously that's not what we would want to do in a double rate case. Then you move to making corrections and then moved to more complex and insertions. So there's no doubt that there are still challenges to conquer both in terms of how we correct deletions like the Delta F508 but also, how we deliver because that obviously, that has been delivered efficiently to a large number of cells in the lungs and we don't know how to do that yet. So that's why we said, while we think CRISPR is an incredibly powerful technology for the future, it's going to take a number of years to conquer both the some of the editing challenges but also in particularly challenges and that's what we're working. Also, I'll just remind you that this CRISPR collaboration, we have right several targets, fixed target and some of those will be in other diseases where some of these issues [indiscernible] and editing is much more straightforward. So I think you can expect to hear from us over the next couple of years on our progress in some of this [indiscernible]"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","At this point, are there mutations that others would edit, do we know that?",14,"At this point, are there mutations that others would edit, do we know that?"
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. As I say, I think single base payer corrections are going to be a lot easier than complex deletions and insertions to correct. But nevertheless, there are lots of significant challenges reflects it out. When you move to ex vivo therapy and you move t",78,"Yes. As I say, I think single base payer corrections are going to be a lot easier than complex deletions and insertions to correct. But nevertheless, there are lots of significant challenges reflects it out. When you move to ex vivo therapy and you move to inactivation in ex vivo, [indiscernible] a whole different world in terms of efficiency. And so you will see some of those. I think from us and others as being the first application."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So I'll turn it back over to Jeff maybe for some final comments tonight.",15,"So I'll turn it back over to Jeff maybe for some final comments tonight."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. First of all, thank you for your questions, thanks for your patience, it was a long call but we do want to give you not only our guidance but detailed rationale for the guidance so that you understand our model. And we appreciate the questions on tha",346,"Yes. First of all, thank you for your questions, thanks for your patience, it was a long call but we do want to give you not only our guidance but detailed rationale for the guidance so that you understand our model. And we appreciate the questions on that. As I look at our progress as a company over the last year, I guess I would call out 3 things that I think are important. First, the continuous increase in the number of patients that we can treat, actually dramatic increase in the number of patients that we can treat with KALYDECO and ORKAMBI. And as we look forward, the increase in the number of patients that we can treat with today approval. As I mentioned, 27,000 eligible, we're still only treating 1/3e of those. And I think we have a clear path to get to the majority of those patients both in the U.S. and Europe over '16 and '17 and beyond. The second thing I would say is the pipeline progression. We're pleased with 661 progressing alone into Phase III of multiple trials and multiple patient populations. But equally important, the next-gen correctors which are progressing through Phase I with our -- and still on a timeline to get it to patients as later this year. We think that's going to be very important both for the patients we treat potentially for additional patient to find. And then finally the progression of the science. We didn't talk about that a lot today but the science in CF I think has progressed significantly. And we have a much better understanding of the folding and correction process. And the science that today driving the rest of research some of the new diseases and touched on those little CRISPR-Cas9 but also others that I hope we will be able to have a chance to talk to you about over the rest of '16 and '17. It's an important long-term growth engine for the company. So with that, maybe I'll close the call and thank again for joining us."
36235,331185758,964984,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening. This is Michael Partridge, Vice President of Investor Relations. Welcome to our First Quarter 2016 Conference Call. [Operator Instructions] A replay of tonight's call will also be available on the website once we have concluded.Dr. Jeff Le",199,"Good evening. This is Michael Partridge, Vice President of Investor Relations. Welcome to our First Quarter 2016 Conference Call. [Operator Instructions] A replay of tonight's call will also be available on the website once we have concluded.
Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer will provide prepared remarks this evening. They will be joined by Dr. Jeff Chodakewitz, Chief Medical Officer, for the Q&A portion of the conference call. 
We will make forward-looking statements on this call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the SEC. These statements, including without limitation, those regarding the ongoing development and potential commercialization of our drug candidates, our expectations regarding our improved medicines and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in tonight's press release. I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Dr. Jeff Leiden."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. Over the last 4 years, Vertex has delivered 2 transformative medicines to people with cystic fibrosis. Today, there are approximately 27,000 people eligible for 1 of our approved CF medicines, and we have a clear p",1797,"Thanks, Michael. Good evening, everyone. Over the last 4 years, Vertex has delivered 2 transformative medicines to people with cystic fibrosis. Today, there are approximately 27,000 people eligible for 1 of our approved CF medicines, and we have a clear path toward our goal of helping potentially all people with this rare and life-shortening disease in the future.
We're confident that our experience with ORKAMBI and KALYDECO, and our scientific leadership and progress in targeting the underlying biology of this disease, positions us well to increase the number of people treated with our approved medicines and to develop new medicines in the years ahead that may provide even greater benefit for all people with CF.
Tonight, I'll provide brief comments on 3 key areas which serve as markers of our progress toward treating all people with CF, including: first, the performance of our approved medicines, ORKAMBI and KALYDECO, and our road map toward treating more patients with these medicines that will drive revenue growth in 2016 and beyond; second, the role of VX-661 in helping to achieve our long-term goal in CF; and third, our pipeline of additional CFTR modulators and other mechanisms we're advancing as part of collaborations. These approaches include the ENaC inhibition, and in the longer-term, gene editing with CRISPR-Cas9, and may position us to help all people with CF.
We're approximately 9 months into the launch of ORKAMBI in the U.S. for people with 2 copies of the F508del CFTR mutation ages 12 and older. As of the end of March, approximately 65% or 5,500 of the 8,500 currently eligible patients in the U.S. have initiated treatment with ORKAMBI. We expect the number of patients who've initiated treatment with ORKAMBI will continue to grow during 2016. And we continue to expect that by the end of the year, the vast majority of all eligible patients ages 12 and older in the U.S. will have initiated treatment.
We've seen excellent reimbursement and access for ORKAMBI from public and private payers in the U.S., and the feedback from the CF community continues to be very positive. Importantly, patients across the U.S. have broad access to the medicine through public and private insurance. And we have assistance programs in place for eligible patients who need additional help. All major commercial insurers in all 50 state Medicaid programs are currently covering ORKAMBI, reflecting the important advance and value this medicine represents in the treatment of CF.
We're now moving forward to our bringing ORKAMBI to younger patients. And at the end of March, we submitted a supplemental New Drug Application to the FDA, requesting approval of ORKAMBI for children ages 6 to 11 with 2 copies of the F508del mutation. We requested priority review, which if granted, would provide us with the decision on the application in the second half of this year. If approved, approximately 2,400 additional patients in the U.S. would be eligible for treatment.
Outside the U.S., we have commenced discussions with reimbursement agencies in various European and other countries. Given the clinical benefits of ORKAMBI and the severity of the disease for people with 2 copies of the F508del mutation, we believe that we will achieve reimbursement from key European and other government payers, just as we've seen in the U.S. ORKAMBI is already commercially available in Germany and through early access programs in France.
In the near term, the progress and our understanding of treating eligible patients with ORKAMBI gives us clarity on a revenue expectation for 2016. Later in the call, Stuart and Ian will talk about the ORKAMBI launch in detail, our guidance and how we think about revenue trends from 2015 and growth into 2016 and further into the future.
For KALYDECO, we're increasing our revenue guidance for 2016, which Stuart will discuss in his remarks. As we think about the future opportunities for ORKAMBI and KALYDECO, I want to emphasize that revenue growth in 2016 and beyond is largely a function of additional patients who are currently eligible for ORKAMBI or KALYDECO and initiating treatment with these medicines. On that basis alone, we believe there's significant growth ahead for both medicines. 
Consider that today, ORKAMBI and KALYDECO are approved for approximately 27,000 people worldwide. But we're only currently treating approximately 1/3 of these patients. As we see additional uptake of ORKAMBI in the U.S. and achieve reimbursement for eligible patients outside the U.S., growth will continue as additional patients continue to initiate treatment.
In addition, there are many more patients not currently eligible for treatment who may benefit from either ORKAMBI or KALYDECO. In total, we believe there are approximately 44,000 people, an additional 17,000 people beyond those eligible today, who could benefit from 1 of these 2 medicines. This additional group of patients was largely comprised of the following: first, approximately 12,000 people less than 12 years of age who have 2 copies of the F508del mutation and who may be helped by ORKAMBI; and second, approximately 5,000 patients who may be helped by KALYDECO comprised mostly of patients who have a residual function mutation. 
Treating a substantial portion of this additional group of 17,000 patients would further drive ORKAMBI and KALYDECO growth if we obtain future approvals for these additional groups of patients. We have ongoing studies, regulatory submissions and development plans to support these efforts, including ongoing discussions with the FDA regarding our application for approval of KALYDECO in approximately 1,500 people ages 2 and older with 1 of 23 residual function mutations as well as our recent sNDA submission to the FDA for approval of ORKAMBI in children ages 6 to 11 with 2 copies of the F508del mutation.
While we are focused on getting ORKAMBI and KALYDECO to as many patients as possible as soon as possible, we also recognize that there are many patients who are still waiting for a treatment for the underlying cause of their disease. We hear from these patients often, so I'm particularly pleased to report that our CF pipeline is advancing. This gives us great confidence that we will ultimately be able to treat the vast majority of people with CF and potentially enhance the benefit for those people currently taking our approved medicines.
I'll start with VX-661, which could play an important role in the treatment of people with CF and is currently in Phase III development. In combination with ivacaftor, our Phase II data suggested that VX-661 may have an improved benefit risk profile compared to ORKAMBI in people with 2 copies of the F508del mutation and may provide enhanced clinical benefits over ivacaftor monotherapy for other patients with gating mutations. We are on track to obtain the first data from the ongoing Phase III program for VX-661 in early 2017 from the study in people with 2 copies of the F508del mutation.
Additionally, VX-661 is positioned to play a key role in the development of a triple combination with a next-generation corrector in ivacaftor. We believe that this triple-combination approach will be fundamental for 2 reasons: first, triple combinations may allow us to treat a very large group of patients who are not helped today by either ORKAMBI or KALYDECO, including those with 1 F508del mutation and a second mutation that causes minimal CFTR function; and second, these regimens could provide even greater benefit to patients currently eligible for our approved medicines who have at least 1 F508del mutation.
Today, we have 2 next-gen correctors in clinical development: VX-152 and VX-440. These potential medicines are currently being evaluated in Phase I studies in healthy volunteers. Successful completion of these studies would enable us to move rapidly into Phase II studies in the second half of 2016 to evaluate 1 or more next-generation correctors with VX-661 and ivacaftor in people with CF.
I'll now turn to our pipeline of other potential CF medicines that could be complementary to our portfolio of CFTR modulators, and it may enable us to treat more patients and provide greater clinical benefit in the years to come. The most advanced example of this is our lead ENaC inhibitor, VX-371. Today, we announced data from a Phase II 14-day study of VX-371 in 142 people with CF who are not receiving ORKAMBI or KALYDECO. The study met its primary endpoint of safety. 96% of the patients who enrolled in the study completed all treatment, and the treatment regimens consisting of VX-371 were generally well tolerated. There were no statistically significant changes from baseline in FEV1 for those patients who received VX-371 compared to placebo. 
The data announced today are consistent with our in-vitro data that did not show a meaningful change in cilia beat frequency when VX-371 was used alone in human bronchial epithelial cells with 2 copies of the F508del mutation. In contrast, these in-vitro data did show a meaningful change in cilia beat frequency when VX-371 was used in combination with ORKAMBI. Together, the in-vitro and clinical safety data generated to date provide further support for our ongoing study of VX-371 in combination with ORKAMBI. This ongoing study began enrolling people with 2 copies of the F508del mutation ages 12 and older in the first quarter of this year. And the primary endpoints are safety and mean absolute change from baseline in lung function at Day 28 of treatment as compared to placebo. Additional information on these studies can be found in our first quarter press release issued today.
Additionally, last year, we entered into a collaboration with CRISPR Therapeutics, with a longer-term goal of discovering gene-editing approaches for the treatment of genetic diseases, including CF. The use of this technology in people with CF may be many years away, but it is strategically important as we think about future advances that could fundamentally change the treatment of this disease in the years to come.
Tonight, I've summarized how we think about our opportunity in CF, an opportunity that is unique, both in terms of the potential benefit that ORKAMBI and KALYDECO provides the people with CF today and also for the long-term potential of our development-stage medicines to treat the vast majority of people with CF in the future.
In conclusion, I'll make just a few comments about the type of company we will become as we achieve the success in CF that I've just outlined. Vertex is on a path towards sustained earnings and revenue growth, driven by an increasing number of people being treated with KALYDECO and ORKAMBI. We believe our business model, one focused on significant investment to create value through innovation, research and development, positions us to consistently discover and deliver transformative new medicines for patients and to reinvest in scientific opportunities to create future medicines.
With that, I'll turn the call over to Stuart to make more specific comments on the ORKAMBI launch."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. Tonight, I will review our progress with the launch of ORKAMBI, the basis of our 2016 guidance for ORKAMBI product revenues and our ongoing efforts to obtain reimbursement outside the U.S. to drive further growth of ORKA",1180,"Thanks, Jeff, and hello, everyone. Tonight, I will review our progress with the launch of ORKAMBI, the basis of our 2016 guidance for ORKAMBI product revenues and our ongoing efforts to obtain reimbursement outside the U.S. to drive further growth of ORKAMBI in 2017 and beyond.
We are now just over 9 months into the launch, and we are pleased that approximately 65% of eligible patients in the U.S. have initiated treatment with ORKAMBI to date. Global sales of ORKAMBI in the first quarter were $223 million, comprised of U.S. sales of approximately $214 million and ex U.S. sales of approximately $9 million, which were mainly from Germany. 
At the beginning of the year, our intention was to provide financial guidance for 2016 ORKAMBI revenues once we have gained sufficient understanding of the dynamics of the launch in the U.S. Today, we have a deeper understanding if our doctors and their patients are using the medicine, based on the real-world treatment patterns we've observed in more than 4,500 patients who initiated treatment in the U.S. in 2015. 
I'll now share with you our understanding of the launch dynamics that informed our guidance. First, uptake, defined as the total proportion of the 8,500 eligible patients in the U.S. who will begin treatment with ORKAMBI by the end of 2016 and also the rate at which these patients initiate treatment. Second, the persistence rate, defined as the proportion of patients who start and remain on treatment. And third, the compliance rate, which reflects the number of pills actually taken by a patient in a given month.
First, to uptake. To date, approximately 65% of the 8,500 eligible patients in the U.S. have initiated treatment with ORKAMBI, comprised of more than 3,000 patients who initiated treatment in the third quarter of 2015, more than 1,500 in the fourth quarter and approximately 800 in the first quarter of 2016. We have seen further initiations in April and expect that patient initiations will continue throughout 2016, albeit the lower rate than in the first 3 quarters post-launch. We continue to expect that the vast majority of the eligible patients ages 12 and older in the U.S. will initiate treatment with ORKAMBI by the end of this year.
Second, persistence. Among patients who have initiated ORKAMBI since launch, we've seen that approximately 15% of patients discontinued treatment within 3 months of starting treatment. Our clinical trial and market research data indicate that these discontinuations are largely related to respiratory adverse events. After the first 3 months of treatment, the discontinuation rate then slows considerably. Based on what we've observed to date from all patients taking ORKAMBI, including those who have been on commercial drug for up to 9 months and those who continue to receive ORKAMBI as part of our Phase III long-term extension study, we expect that the proportion of all patients who initiate and remain on treatment will stabilize at approximately 70% to 80%.
It is also important to point out that the pattern of patient initiations and discontinuations have an offsetting effect on our first quarter ORKAMBI revenues. Specifically because more than 4,500 patients began treatment with ORKAMBI in 2015, the impact of approximately 15% of these patients discontinuing ORKAMBI was highly evident in the first quarter. Therefore, while approximately 800 new patients initiated treatments in the first quarter, this growth was largely offset by the bolus of patients who discontinued treatment. This bolus of discontinuations began in the fourth quarter, but had a larger impact on the first quarter of 2016 where there were also fewer patient initiations to offset these discontinuations.
And finally, compliance. Based on what we've observed to date from the launch, we expect the compliance rate with ORKAMBI to be between 70% and 80%.
In summary, based on our understanding of the launch dynamics for ORKAMBI and the fact that we have continued to see additional patients initiating treatment with ORKAMBI in April, we expect to deliver quarter-to-quarter revenue growth for ORKAMBI beginning in the second quarter and continuing through the end of 2016 and into 2017.
I will now turn to the use of ORKAMBI to date outside the U.S. We are now well into the reimbursement process in all key European countries, Canada and Australia. Specifically, the clinical and cost-effectiveness assessment portions of the reimbursement process. These discussions are going as expected and have been productive. We believe that government payers across Europe recognize both the severity of this disease and the broad clinical benefits of ORKAMBI. These discussions will take time to complete. However, as Jeff mentioned earlier, we believe that we will achieve broad reimbursement from key European and other government payers, just as we've seen in the United States.
ORKAMBI is already available commercially in Germany and through early-access programs in France. We are only 3 months into the launch of ORKAMBI in Germany, and the uptake has been slower than we observed in the U.S. We attribute this to a number of factors, including that CF care in Germany is not concentrated in large centers as is seen in other countries. Meaning, there are many smaller centers and also many centers and physicians who have not yet had personal experience with CFTR modulators.
In Germany, there are approximately 2,500 patients eligible for treatment. As of March 31, 2016, approximately 230 patients had initiated treatment. However, we expect the number of patients initiating treatment in Germany will grow through 2016 and into 2017.
We do not expect what we are seeing in Germany will be representative of the uptake in other European countries. In fact, in France, where early-access programs provide the opportunity for physicians to begin treating patients with ORKAMBI prior to formal reimbursement approval, we have already seen approximately 400 of the 1,500 eligible patients initiate treatment with ORKAMBI in 2016.
We took all of this information into account when we set 2016 revenue guidance for ORKAMBI of $1.0 billion to $1.1 billion. Our guidance reflects our understanding of the ongoing U.S. launch, as I just discussed, as well as expectations that we will receive both approval for ORKAMBI in the U.S. for patients ages 6 to 11 in the second half of 2016 and certain revenues from sales of ORKAMBI outside the U.S., primarily from Germany.
Taking a longer-term view, we expect significant further growth for ORKAMBI revenues in 2017, driven primarily by patients initiating treatment following the completion of reimbursement discussions outside the U.S.
And now to KALYDECO. Today, we are increasing our financial guidance for 2016 revenues. We now expect KALYDECO net revenues of $685 million to $705 million. The prior guidance provided on January 10, 2016, was for KALYDECO net revenues of $670 million to $690 million.
We increased our KALYDECO guidance based primarily on an increasing number of patients initiating treatment with KALYDECO globally and on expectations of a reduced impact this year from the VX-661 Phase III program. Our guidance for KALYDECO excludes any potential revenues from the approval of KALYDECO, the people with residual function mutations.
I'll now hand the call over to Ian."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thank you, Stuart, and good evening to everyone. With the closing of the first quarter of 2016 and 9 months into the launch of ORKAMBI, we are seeing significant progress across our business. Notably, we are seeing increasing number of patients being trea",560,"Thank you, Stuart, and good evening to everyone. With the closing of the first quarter of 2016 and 9 months into the launch of ORKAMBI, we are seeing significant progress across our business. Notably, we are seeing increasing number of patients being treated with our approved medicines, resulting in a growing revenue base that we expect to drive earnings growth. 
I will now review our first quarter financial results and provide some specific comments about the long-term financial trajectory of our business.
Financial results first. In the first quarter of 2016, we reported total CF product revenues of approximately $394 million, a significant increase compared to $130 million in the first quarter of 2015. With ORKAMBI, we reported sales of $223 million for the first quarter of 2016. We have recorded approximately $574 million of ORKAMBI revenues in the first 9 months since the U.S. launch in July 2015. The first quarter KALYDECO sales of $171 million were up $41 million versus the first quarter of last year. 
Now to the operating expenses. Our first quarter non-GAAP operating expenses were $306 million compared to non-GAAP operating expenses of $246 million for 2015. The increased operating expenses were primarily due to increased costs related to the progression of our CF pipeline and to increased investments in global commercial support for the launch of ORKAMBI. Our non-GAAP net profit for the first quarter of 2016 was $22 million or $0.09 per diluted share compared to a non-GAAP net loss of $148 million or $0.62 per share for 2015.
From a balance sheet perspective, we ended the first quarter with approximately $1.03 billion in cash, cash equivalents and marketable securities. Vertex also has $300 million outstanding from a credit agreement, repayable by the end of the third quarter of 2017. The agreement also allows for the facility to increase to $500 million. 
Now to financial trends. Stuart provided 2016 ORKAMBI and KALYDECO revenue guidance and the assumptions that drive our projections, and therefore, I will focus my comments on the longer-term growth opportunities that may come with treating more patients with our currently approved medicines. 
We expect ORKAMBI revenues will continue to grow as we treat more patients in the U.S., achieve reimbursement outside the U.S. and expand the ORKAMBI label to younger patients. KALYDECO's growth is based on gaining reimbursement for certain groups of patients outside the U.S, including those with R117H mutation and the people ages 2 to 5 with gating mutations.
In summary, as Jeff noted earlier, approximately 27,000 people are eligible for our CF medicines, yet we are only treating approximately 1/3 of these patients. As additional patients in the U.S. start treatment and we complete reimbursement discussions outside the U.S., we expect the number of patients treated with our medicines to increase significantly and we expect revenue growth will follow. 
I will note that in 2015, we reported total CF revenues of $983 million. Based on 2016 guidance provided for ORKAMBI and KALYDECO, we anticipate the total CF revenues of approximately $1.7 billion to $1.8 billion, an approximate 75% increase over the prior year.
As our revenues grow over future years, we are committed to managing our operating expenses to drive earnings growth, and we expect to deliver financial profile as similar to many of our large cap biotech peers.
With that, I open the line to questions."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] And our first question comes from the line of Michael Yee of RBC Capital Markets.",17,"[Operator Instructions] And our first question comes from the line of Michael Yee of RBC Capital Markets."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two-part question. One is you gave all these discontinuation and persistence rates and compliance rates, which is in your guidance. Is there anything out there that you can do to either improve these things? Education, getting people to just get patients",134,"Two-part question. One is you gave all these discontinuation and persistence rates and compliance rates, which is in your guidance. Is there anything out there that you can do to either improve these things? Education, getting people to just get patients to take more drug? And can you apply any of these learnings to Europe? Are you seeing the same stuff in Germany? Are there any ways to improve it there? And then the second question is a pipeline question on the 661 het-min. You mentioned in the press release that you're changing the enrollment to do 200 instead of 300. But is that assuming you actually pass the futility? Can you just clarify that a little bit? I guess, why are we talking about changing enrollment if we haven't passed the futility?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mike, it's Stuart here. I'll take the first part of your question around the discontinuation and compliance rates. And then I'll hand over to Jeff Chodakewitz to answer the pipeline questions. So on discontinuations and compliance and what we might be abl",287,"Mike, it's Stuart here. I'll take the first part of your question around the discontinuation and compliance rates. And then I'll hand over to Jeff Chodakewitz to answer the pipeline questions. So on discontinuations and compliance and what we might be able to do to improve those, much as we did with KALYDECO. We will be continuing to generate data on the long-term benefits and even broader benefits of ORKAMBI when used in the real world. And I suspect that data, if its compelling, may lead physicians and patients to reconsider restocking ORKAMBI. So we'll continue to develop the overall clinical profile of ORKAMBI as we have more experience in the market. In terms of compliance, really, many of the same things that we did with KALYDECO we'll be doing with ORKAMBI, and that's really providing both providers and physicians with the educational materials to be able to understand how this is a product which is treating the underlying cause of their disease and so is a product that they want to try and stay compliant with as much as they possibly can. We'll certainly be leveraging all the learnings we've had with KALYDECO, with ORKAMBI, and those programs are already in place. And lastly, to your point about -- to Germany. Clearly, one of the things we're going to be doing is transferring all of the learnings from our launch experience in the U.S. to all of the other markets that we're launching into. And that's, in many ways, the benefits of those markets coming onstream a little bit later is that they can learn from our experiences here in the U.S. With that, I'll hand over to Jeff to answer the question on the pipeline."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mike, it's Jeff. Maybe just to clarify, the -- we did provide some information about the timing of the interim analysis in the het-min study. But there's been no other changes for that trial. The change in sample size comes from one of our other Phase III",96,"Mike, it's Jeff. Maybe just to clarify, the -- we did provide some information about the timing of the interim analysis in the het-min study. But there's been no other changes for that trial. The change in sample size comes from one of our other Phase III trials, looking at 661 ivacaftor in patients who have more of a residual function mutation on one of their alleles. We did look at that and saw there was some opportunity to maintain good powering, but simplify it and reduce the sample size. And that's what that was about."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. So there's still het-min interim in Q3. No change to that. Okay.",13,"Okay. So there's still het-min interim in Q3. No change to that. Okay."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","That's the interim. That's correct.",6,"That's the interim. That's correct."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Terence Flynn of Goldman Sachs.",14,"And our next question comes from the line of Terence Flynn of Goldman Sachs."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe just a follow-up on the discontinuation rate. I know you've mentioned it's mainly due to respiratory events. But the 15%, I think, over 3 months is significantly higher than what you saw in the trials. I know you mentioned, previously, it could be h",102,"Maybe just a follow-up on the discontinuation rate. I know you've mentioned it's mainly due to respiratory events. But the 15%, I think, over 3 months is significantly higher than what you saw in the trials. I know you mentioned, previously, it could be higher. But any more color there on the drivers behind that, that you can expand on a little bit? And then on the ORKAMBI guidance, just wondering if you can provide a little bit more clarity there on the contributions from U.S., rest of world and then the patients 6 to 11 in terms of relative contribution?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure, Terence. So on the respiratory events, I think what I'd say there is what we're reporting today is what we're seeing in the real-world usage of ORKAMBI in the broad population. Obviously, the clinical trial population that we studied in TRAFFIC and",234,"Sure, Terence. So on the respiratory events, I think what I'd say there is what we're reporting today is what we're seeing in the real-world usage of ORKAMBI in the broad population. Obviously, the clinical trial population that we studied in TRAFFIC and TRANSPORT is a very controlled situation. That was patients with an FEV1 between 40 and 90. So really, whilst we try to extrapolate from the clinical trial experience to the real-world experience, that's one of the reasons -- that uncertainty is one of the reasons why we wanted to make sure we had sufficient time in market before we gave guidance. It was because we really wanted to see how the product would get used in the real world. In terms of the contribution of the various different parts of the world to our ORKAMBI revenue guidance that you might expect the vast majority of these, the revenues is going to come from here in the U.S. There will be a contribution ex U.S., but it's going to be relatively small. And then incorporated within our guidance, as we said, is also an expectation that we will see an approval in 6- to 11-year-olds in the latter part of 2016, which would give us access to an eligible population of about 2,500, and that's also incorporated within our guidance. But that approval is not anticipated until the back end of 2016."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Geoff Meacham of Barclays.",13,"And our next question comes from the line of Geoff Meacham of Barclays."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I got a couple. I'm trying to get a sense as to when you guys realize that compliance or persistent or discons were different for ORKAMBI versus KALYDECO or commercial ORKAMBI versus Phase III. I mean, you guys had a chance -- 3Q call, JPM, 4Q call, to be",75,"I got a couple. I'm trying to get a sense as to when you guys realize that compliance or persistent or discons were different for ORKAMBI versus KALYDECO or commercial ORKAMBI versus Phase III. I mean, you guys had a chance -- 3Q call, JPM, 4Q call, to be crystal clear on this. And it's 10 months almost into the launch, and now we're getting some detail. And I just had a couple of follow-ups."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Jeff, thanks for the question. It's Ian. So I just want to take us back a few months, which, as we went into JPMorgan and also our year-end conference call again in January, we were very clear with what we wanted to do regarding ORKAMBI guidance. It's",269,"So Jeff, thanks for the question. It's Ian. So I just want to take us back a few months, which, as we went into JPMorgan and also our year-end conference call again in January, we were very clear with what we wanted to do regarding ORKAMBI guidance. It's -- for us, at that point in time, it was early in the launch. Yes, we've recruited a number of patients on to ORKAMBI, but it was still early in the launch to understand treatment patterns. We stated that very clearly. What we've been able to do now as we sit here, as you point out, just over 9 months into the launch, we've been able to take a significant bolus of patients. For example, 3,000 patients that initiates in the first 3 months of disapproval, and we've been able to track those 6 to 9 months. What that allows us to do was to understand compliance rates. It helped us understand discontinuation rates and also the time of discontinuation, as Stuart mentioned. That's been an important feature for us. So this was the -- we feel as though we're in this position at this point in time where we've been able to attract a substantial amount of patients over a good period of time to have the confidence to provide guidance for 2016. The comparison to KALYDECO was less relevant for us. It was more about the treatment patterns for ORKAMBI. ORKAMBI is a different medicine than KALYDECO based on its clinical data and the patient population. But we now have enough confidence to provide you with the ORKAMBI guidance."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And just a follow-up to some earlier questions, I guess just to ask it a different way. It is for patients that are at low FEV1 at baseline and do experience bronchoconstriction, is there a treatment protocol in place? I mean, we've obviously heard",75,"Okay. And just a follow-up to some earlier questions, I guess just to ask it a different way. It is for patients that are at low FEV1 at baseline and do experience bronchoconstriction, is there a treatment protocol in place? I mean, we've obviously heard of things like half dosed and uptight trade or dose skipping. Is there something that you guys can recommend to a pulmonologist? A strategy for those that do experience bronchoconstriction?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, it's Jeff Chodakewitz. Maybe just to give you a couple of comments about that. We don't have anything in terms of very concrete, specific guidance that we can give. But we can make a couple of observations. First of all, what's clear from speaking",191,"Geoff, it's Jeff Chodakewitz. Maybe just to give you a couple of comments about that. We don't have anything in terms of very concrete, specific guidance that we can give. But we can make a couple of observations. First of all, what's clear from speaking to our investigators and also to physicians in the field, that clearly the support for the patients, both setting expectations for the patient and for the physician and helping patients in those early weeks manage any symptoms, we think is very important and something that goes back to some of the education questions that we've heard about earlier. We are also collecting information in our own study for patients who's FEV1 were less than 40, and we're in the process of summarizing that. We did, in that study, we give patients the option to start on a lower dose. And we'll set -- we'll get that added together and summarize it. But it's not going to be the kind of data that says, ""Here's a specific recommendation."" We noted that is being used, but it's really still about physicians and their patients working together to manage."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Mark Schoenebaum of Evercore.",13,"And our next question comes from the line of Mark Schoenebaum of Evercore."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Number one, I'd just like to know, have you been surprised by the way the launch has unfolded? I'm sure you had some projections a year ago for persistence, all these things. And then have you been surprised? And number two, I know you can't comment speci",87,"Number one, I'd just like to know, have you been surprised by the way the launch has unfolded? I'm sure you had some projections a year ago for persistence, all these things. And then have you been surprised? And number two, I know you can't comment specifically on peak numbers. But the sales at consensus is around $4 billion at peak for ORKAMBI. I'm just wondering, can you just talk about that? And then finally, is there any opportunity for re-initiations in these patients that drop-out early?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mark, we have a list of questions there, so if we don't get to all of them, please -- so we're all scribbling down. But if we don't get to them, please say them again. So Mark, in terms of how we feel about the launch, I'd say we're very pleased with the",204,"Mark, we have a list of questions there, so if we don't get to all of them, please -- so we're all scribbling down. But if we don't get to them, please say them again. So Mark, in terms of how we feel about the launch, I'd say we're very pleased with the way the launch has progressed here in the U.S. From how we were able to work with payers, to get access in reimbursement from ORKAMBI from early on in the launch to the rate of uptake that we've seen. I mean, to get close to 65% of eligible patients initiated within the first 9 months is a fairly steep ramp, and so one we're pleased with. So I think, overall, we're pleased how the launch has played out, much as we anticipated. In terms of the potential for re-initiations, we have heard anecdotally from physicians that they have tried re-initiating patients on ORKAMBI. We don't have much in the way of clinical data to be able to support that. But we are certainly aware that there are physicians who done that successfully [indiscernible] for some of their patients. So that normally is something that we'll continue to watch in the marketplace."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mark, this is Jeff Leiden. Maybe just to add a little bit more of a 10,000 foot view on both KALYDECO and ORKAMBI. Like you have been involved with many, many drug launches -- and I think it's worth just putting those in perspective a little bit. From the",249,"Mark, this is Jeff Leiden. Maybe just to add a little bit more of a 10,000 foot view on both KALYDECO and ORKAMBI. Like you have been involved with many, many drug launches -- and I think it's worth just putting those in perspective a little bit. From the standpoint, as an example, in ORKAMBI of getting to 65% of the patients in 9 months and of course, with KALYDECO, it was close to 90%, that's a fairly unusually fast ramp. And from the standpoint of persistence, the kind of numbers Stuart was talking about, let's say 70% to 80% is the number that we said aloud at, is still a very, very high number compared to most chronic medicines. And we believe that really represents the correct perception that both physicians and patients have about the value of these medicines and treating the underlying cause of the disease for a long period of time. And that really underlines our thinking about the pipeline as well because as we develop this next set of medicines, including next gens and hopefully, ultimately, things like CRISPR, we're talking about progressively increasing the benefit/risk profile of our portfolio of drugs that these patients can take. And that will only, of course, increase both persistence and compliance rates. So overall, very; pleased of where we are. We know we have more work to do to get to more patients and improve therapy, but these 2 drugs have really performed quite well so far."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Geoffrey Porges of Leerink Partners.",14,"And our next question comes from the line of Geoffrey Porges of Leerink Partners."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just a few questions. First, could you help us out? Just give us the breakdown between U.S. and ex U.S. sales of KALYDECO, so we're all in the same page. And then I just want to go back to Jeff's comments. Jeff, could you really clarify this residual func",169,"Just a few questions. First, could you help us out? Just give us the breakdown between U.S. and ex U.S. sales of KALYDECO, so we're all in the same page. And then I just want to go back to Jeff's comments. Jeff, could you really clarify this residual function change? And what has altered in terms of your statistical analysis or your assumptions about the activities of drug or the combination? And give us a sense of what the hurdle there is or ORKAMBI's effect. And then lastly, on this issue of persistence, is it reasonable to assume that about 50% of patients of the eligible pool are on drug right now? Because we keep going round and round about initiations and discontinuations, but surely, what's important is the number of patients who remain on drug at the end of the quarter. And is 50% roughly the right number or perhaps slightly below that, 45% to 50% of the eligibles? Is that the right way to think about it?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Geoff, it's Stuart here. I'll take your first question around KALYDECO revenues, and then I'll hand over Jeff Chodakewitz. So within the total KALYDECO revenues of $171 million for the first quarter of 2016, $95 million of that was in the U.S. and the",52,"So Geoff, it's Stuart here. I'll take your first question around KALYDECO revenues, and then I'll hand over Jeff Chodakewitz. So within the total KALYDECO revenues of $171 million for the first quarter of 2016, $95 million of that was in the U.S. and the balance, about $76 million was in international."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, in terms of the residual function study, we really stepped back and said, is there an opportunity to reduce the end of the study somewhat without sacrificing the integrity of the trial. We really looked at that 2 ways that we saw opportunity. One i",107,"Geoff, in terms of the residual function study, we really stepped back and said, is there an opportunity to reduce the end of the study somewhat without sacrificing the integrity of the trial. We really looked at that 2 ways that we saw opportunity. One is that we really focused our statistical analyses on key parameters, and that really allows us to take care of that. The other thing is that we also looked at the wider data and saw that the discontinuation rate from the trial was actually lower than what we had left room for, and that also is an opportunity to reduce the end."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And finally, Geoff, to your question in ORKAMBI. Your back-of-envelop math is approximately right. At the end of the third quarter, you're right about 50% of the eligible population were on. Clearly, that's a moving target because it's a mix of the discon",109,"And finally, Geoff, to your question in ORKAMBI. Your back-of-envelop math is approximately right. At the end of the third quarter, you're right about 50% of the eligible population were on. Clearly, that's a moving target because it's a mix of the discontinuations and the initiations. The important thing I would add to that number is that, moving forward in Q2 and beyond, we do expect patient initiations, which we've continued to see in April in the U.S. and obviously, we continue to see internationally in places like Germany. We expect to outpace discontinuations, which is why we are predicting quarter-on-quarter growth for the remainder of 2016 and beyond."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Brian Abrahams of Jefferies.",13,"And our next question comes from the line of Brian Abrahams of Jefferies."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess my first question is I'm wondering if you're seeing any trends towards maybe less sick higher FEV1 patients going on to therapy over time, which could be with ORKAMBI, which theoretically improved persistence and compliance. And then on 661, if 66",72,"I guess my first question is I'm wondering if you're seeing any trends towards maybe less sick higher FEV1 patients going on to therapy over time, which could be with ORKAMBI, which theoretically improved persistence and compliance. And then on 661, if 661 looks better tolerated but perhaps less efficacious than lumacaftor, I'm just wondering how you weigh which potential backbone to combine with the next-generation corrector into a triple combo."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So in terms of the -- any trends to where the product's being used, in either sicker patients or less sick patients, to be honest with you, Brian, with 65% of eligible patients being initiated, it's being used across the board. Obviously, we've got a rang",109,"So in terms of the -- any trends to where the product's being used, in either sicker patients or less sick patients, to be honest with you, Brian, with 65% of eligible patients being initiated, it's being used across the board. Obviously, we've got a range of different physicians and centers here. Some started using it in their more severe patients. Others started using it in their less severe patients. But we really are seeing usage across the whole range of FEV1 patients, as you would imagine, with 65% of eligible patients having been initiated. And on the backbone, the triple combination, I'll pass that over to Jeff Leiden."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Just on the triple combination, obviously, we can't speculate then exactly what will happen, but I would remind you that there were a number of reasons that 661 is the preferable partner. Most of those have to do with drug-drug interactions and makin",93,"Yes. Just on the triple combination, obviously, we can't speculate then exactly what will happen, but I would remind you that there were a number of reasons that 661 is the preferable partner. Most of those have to do with drug-drug interactions and making it simpler to combine it into a triple regimen. So I guess what I would say is, all things being equal, if 661 and lumacaftor had equal efficacy in combination with KALYDECO, we're certainly going to go with 661 because of those pharmacokinetic properties. Does that answer the question?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes -- no, not exactly. I guess, I was sort of wondering whether -- I mean, we know 661 has less CYP3A4 interactions. And sort -- I guess, I was sort of wondering whether some of the real-world ORKAMBI side effects that you're seeing are perhaps driven by",81,"Yes -- no, not exactly. I guess, I was sort of wondering whether -- I mean, we know 661 has less CYP3A4 interactions. And sort -- I guess, I was sort of wondering whether some of the real-world ORKAMBI side effects that you're seeing are perhaps driven by not only the respiratory AEs but driven by CYP3A4, which we know is going to look better with 661 and sort of how you weigh that if efficacy is perhaps not as good."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. That's not the reason just to be clear. So those AEs are not driven by CYP interactions. We feel they're driven, as we said before, by off-targeted bronchoconstriction that's unique to lumacaftor and we don't see or haven't seen with 661.",42,"Yes. That's not the reason just to be clear. So those AEs are not driven by CYP interactions. We feel they're driven, as we said before, by off-targeted bronchoconstriction that's unique to lumacaftor and we don't see or haven't seen with 661."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Adam Walsh of Stifel.",12,"Our next question comes from the line of Adam Walsh of Stifel."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A few weeks ago, we published a 47-physician ORKAMBI survey, and a few things jump out at us. I want to bounce them off you. Most notably, our survey showed that if patients discontinue ORKAMBI due to drug-related side effects, 70% of doctors encourage th",99,"A few weeks ago, we published a 47-physician ORKAMBI survey, and a few things jump out at us. I want to bounce them off you. Most notably, our survey showed that if patients discontinue ORKAMBI due to drug-related side effects, 70% of doctors encourage these patients to restart the drug, and then a very meaningful percentage of those patients not only successfully restart the drug but also subsequently remain on the drug long term. So my questions are: Is this consistent with your own internal research? Are patient restarts factored into your guidance? And if so, to what extent?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Adam, it's Stuart here. Thanks for the question. In terms of restarts, yes, your survey is consistent with what we've heard in that we have heard from physicians that they are trying to restart ORKAMBI in some of their patients, who they have previousl",175,"So Adam, it's Stuart here. Thanks for the question. In terms of restarts, yes, your survey is consistent with what we've heard in that we have heard from physicians that they are trying to restart ORKAMBI in some of their patients, who they have previously had to discontinue the product in largely because, as you know, that they are often firm believers that treating the underlying cause of the disease is clearly a good thing for those patients if they can tolerate the medicine. In terms of the absolute volume of that, at the minute, that's hard to quantify. We certainly heard it anecdotally. We've certainly heard success stories. It's fair to say though that within our guidance, we've assumed relatively minimal impact from restarts because, at this time, we really don't have evidence that it's happening in quite the numbers that perhaps people have said that they might do it in. So at the moment within our guidance, relatively minimal amount of restarting patients is assumed to happen in 2016 here in the U.S."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Phil Nadeau of Cowen and Company.",14,"Our next question comes from the line of Phil Nadeau of Cowen and Company."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two on commercial, then a quick one on the pipeline. On the commercial, can you give us some sense of how many lives outside the U.S. could gain reimbursement for ORKAMBI in 2017? Sure you have internal estimates and rages. I'm curious what those are. And",116,"Two on commercial, then a quick one on the pipeline. On the commercial, can you give us some sense of how many lives outside the U.S. could gain reimbursement for ORKAMBI in 2017? Sure you have internal estimates and rages. I'm curious what those are. And then similarly in the younger kids, do you expect any different penetration of ORKAMBI into that population than you've seen in the older kids and adults? And then last, on the triple, can you let us know if you've combined all 3 drugs in healthy volunteers yet and what your disclosure strategy will be when you move into Phase II? How much data from the Phase I will we get?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Phil, it's Stuart here. I'll take those 2 first commercial questions. In terms of the number of lives that might be eligible, the number of patients with the F508del homozygous mutation, 12 and above in Europe is somewhere around 12,000. Within our '16",216,"So Phil, it's Stuart here. I'll take those 2 first commercial questions. In terms of the number of lives that might be eligible, the number of patients with the F508del homozygous mutation, 12 and above in Europe is somewhere around 12,000. Within our '16 guidance, the only country that we're assuming we're going to be able to recognize revenues for is in Germany. We're not in a position to be able to give 2017 guidance at this point. I'm trying to predict exactly when this reimbursement discussion is going to conclude. It's frankly impossible to do because, clearly, it's a negotiation, and the vast majority of countries don't have a formal time clock. And so at this point, we're really not in a position to be able to speculate on when those might be concluded. In terms of what we would be anticipating in the 6- to 11-year-old population, if we are successful in gaining approval for that here in the U.S., then our anticipation would be much as we've seen with KALYDECO, that the uptake there is likely to be similarly robust as we've seen in adults. Although I would remind you that, from a 2016 perspective, that's likely to come in the second half or in the second half the second half of 2016."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Phil, I'll take the last question. So the Phase I study in healthy volunteers is still ongoing, so we can't basically make comment on that. But in terms of disclosure and time line, still as we've discussed before, we expect to be in patients with tri",100,"And Phil, I'll take the last question. So the Phase I study in healthy volunteers is still ongoing, so we can't basically make comment on that. But in terms of disclosure and time line, still as we've discussed before, we expect to be in patients with triple combination in the second half of the year. The disclosure of the Phase I around that will be relevant information that supports the Phase II study design. At this point, that is too difficult to describe, and we'll let you know when we have that information and we're initiating the Phase II study."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Cory Kasimov of JPMorgan.",12,"Our next question comes from the line of Cory Kasimov of JPMorgan."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have 2 left for you. So realized it's early, but wanted to ask about the potential impact of payer reauthorizations on ORKAMBI? How common is it? And how does it compare with the process you saw with KALYDECO? And then a capital allocation question for",77,"I have 2 left for you. So realized it's early, but wanted to ask about the potential impact of payer reauthorizations on ORKAMBI? How common is it? And how does it compare with the process you saw with KALYDECO? And then a capital allocation question for you. Now that you're profitable and growing and you're sitting on $1 billion in cash in your balance sheet, at what point would you consider buying back some of your stocks?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Cory, on the payer reauthorizations, not all payers have published policies that include their reauthorization criteria. That's the first thing I'd say. Of the ones you have, most have a time clock of 6 to 12 months. So we're really only now beginning",178,"So Cory, on the payer reauthorizations, not all payers have published policies that include their reauthorization criteria. That's the first thing I'd say. Of the ones you have, most have a time clock of 6 to 12 months. So we're really only now beginning to get to the point of patients getting to the time point when they are having to go through the reauthorization process. Having said that, the payers that have published policies or where their reauthorization criteria are known, the vast majority of them are either in line with the label or reflect the systemic benefits of ORKAMBI. And by that, I mean they recognize that this product can have benefits across multiple endpoints, and either improvements or stabilization in those endpoints qualifies as a successful outcome. So whilst we are only now beginning to get into the period of seeing those reauthorizations, I feel good about the reauthorization criteria that we've seen to date. And to your last part of your question, they are not dissimilar at all to what we saw with KALYDECO."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And to the last question, we have thought about stock buybacks in terms of capital allocation. But as we think about the priority of capital allocation for our business, I'll just give you a broader thought, which is we're still in this transitional perio",214,"And to the last question, we have thought about stock buybacks in terms of capital allocation. But as we think about the priority of capital allocation for our business, I'll just give you a broader thought, which is we're still in this transitional period of moving into profitability and cash generation and watching the revenue curve. As we go up the revenue curve and we drive revenue growth and therefore, earnings growth, which translates to cash gen -- more cash generation, we look to apply that capital to reinvest back in the business first, first, internally into our pipeline but then potentially outside of the company to diversify and expand our pipeline. And we've already done activities in that area, as you know, with CRISPR and our ENaC inhibitor. So those continue to be the priorities. It's the internal investments. It's the external investments. But as we go up that revenue growth curve and have greater capital to allocate, we will give consideration to capital strategies such as share buybacks, but at this point in time, it's a little early for us. And if we were to move into something in the near future, it would be of a smaller scale to stop the shares outstanding creep that occurs each year through option exercises."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Alethia Young of Crdit Suisse.",13,"Our next question comes from the line of Alethia Young of Crdit Suisse."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Thanks for taking my question. It's -- the 3 of them are kind of around compliance. And I guess, when I look at the math that we get over the quarters, it seems like the first 2 quarters, the compliance was potentially higher, like 95%, and maybe in this",180,"Thanks for taking my question. It's -- the 3 of them are kind of around compliance. And I guess, when I look at the math that we get over the quarters, it seems like the first 2 quarters, the compliance was potentially higher, like 95%, and maybe in this quarter, based on our math, it would have gotten us to about 80%. So I guess, one, is that assumption -- is that analysis fair? Two, can you give us any color on if the scripts written in 1- or 3-month increment? And then third, just when you think about 70% to 80% range on compliance, which actually does move the model quite a bit, what kind of qualitatively do you think about that kind of gets you in the 70% range versus the 80% range? Do we think about like amount of days that people are taking so that there's a delta in the days they miss and just kind of adding that up and thinking about it? Or is there some other way we should think about quantifying compliance?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So yes, let me try and answer those sequentially. In terms of the compliance trend, compliance is the metric that you need the longest period of time to measure because, clearly, this is a chronic medicine, and so in the first prescription they get, your",315,"So yes, let me try and answer those sequentially. In terms of the compliance trend, compliance is the metric that you need the longest period of time to measure because, clearly, this is a chronic medicine, and so in the first prescription they get, your kind of assumption is that you're 100% compliant. You have to wait until they get the second prescription to work out exactly what it is. So this is the one that really takes the longest period of time for us to get a good handle on. I don't know obviously the intricacies of your model. I'll just reiterate that, based on the trends that we've seen to date and the experience we've got with the patients who have been treated to date, our expectation for the year and the assumption on which our guidance is built is that it'll be somewhere between 70% and 80% for ORKAMBI this year. In terms of the 1- or 3-month script, the vast majority are written for 1 month. There are some 3-month prescriptions written, but the vast majority of prescriptions are written for -- on a monthly basis. And in terms of kind of qualitatively, what would lead you to one end versus the other, to me, this is all about education and our ability to help providers to give to their patients information, which educates them on the nature of the disease, the underlying defects, the fact that ORKAMBI is designed to treat those underlying defects, and to the extent they believe in the science, believe in the long-term benefits that ORKAMBI can provide to them, then I think that's only likely to lead to patients having a higher compliance rate. We're very focused on that. We're certainly taking all the learnings we can from our experience with KALYDECO to support patients to take the prescriptions in line with their physician's recommendations."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Matthew Harrison of Morgan Stanley.",13,"Our next question comes from the line of Matthew Harrison of Morgan Stanley."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have 2, which are somewhat follow-ups on Phil's questions. Just on next-generation correctors and those studies, can you just tell us if you saw a safety event, what kind of safety event would be disclosable versus not disclosable? And then is there a p",123,"I have 2, which are somewhat follow-ups on Phil's questions. Just on next-generation correctors and those studies, can you just tell us if you saw a safety event, what kind of safety event would be disclosable versus not disclosable? And then is there a point in time that we're going to see PK data from healthy volunteers, which might help us better understand how the drug levels that we saw on the HBE data might compare in patients? And then a separate commercial question. Just, in the 6 to 12 pool for ORKAMBI, are your assumptions for persistence in discontinuation rate the same as what you're seeing now in the older population? And if they're not the same, can you just explain why?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So maybe I'll take the first couple of questions. So with the next-gen disclosure, what would be required to disclosure of is Reg FD, and if there was a material adverse event, we would have to disclose that. If you want me to give an example, that would",132,"So maybe I'll take the first couple of questions. So with the next-gen disclosure, what would be required to disclosure of is Reg FD, and if there was a material adverse event, we would have to disclose that. If you want me to give an example, that would be a discontinuation of the trial for example, and we would have to disclose that. Other than that, it's an ongoing trial. We need to complete the trial, gather the data. That will inform us, as I said earlier, for the Phase II trial in patients with triple combination, and we will provide relevant information at that point in time that supports the design of that trial. Can you just remind me of your second question in terms of the disclosures? [indiscernible] ..."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes -- no, I was just wondering, will we see PK data so that we can compare sort of the drug levels that you can achieve in healthy volunteers versus the drug levels that you were achieving in the HBE assays, so we have some point of comparison on relativ",52,"Yes -- no, I was just wondering, will we see PK data so that we can compare sort of the drug levels that you can achieve in healthy volunteers versus the drug levels that you were achieving in the HBE assays, so we have some point of comparison on relative drug levels."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So we'll provide it in relative information that helps you understand the design of the Phase II study. However, it is not our practice to provide that kind of detail on a Phase I study. Then, there's a number of reasons for that, and I would just give yo",74,"So we'll provide it in relative information that helps you understand the design of the Phase II study. However, it is not our practice to provide that kind of detail on a Phase I study. Then, there's a number of reasons for that, and I would just give you one, that there is a specific competitive reason that would -- we would prefer not to provide that information on a Phase I study."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Matt, in the 6 to 11, I mean, really, the contribution of the 6 to 11 population, it was successful in getting approval. As I said, it's really going to be in the -- likely be in the fourth quarter. So really, the contribution there within our overall",191,"And Matt, in the 6 to 11, I mean, really, the contribution of the 6 to 11 population, it was successful in getting approval. As I said, it's really going to be in the -- likely be in the fourth quarter. So really, the contribution there within our overall guidance is more about uptake than it is around persistence and compliance. And much as we did with the 12 and above population, I think we'll obviously be watching that very, very closely just as we have done since the launch in July. And that'll give us an ability to learn how the product performs with those patients in the real world. Again, one of the things that we have seen obviously with the younger population with KALYDECO is they tend to be slightly more compliant than the average, not surprisingly, because they've got a lot of parental and caregiver supervision. But really, those assumptions that we've given you are really much more related to the 12 and above population. We'll see how the 6 to 11 patients play out in the real world in the course of time after the approval."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Ying Huang of Bank of America Merrill Lynch.",16,"Our next question comes from the line of Ying Huang of Bank of America Merrill Lynch."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Number one, I want to know if you guys have seen an uptick in discontinuation due to lack of efficacy or it's all due to the, I guess, chest tightness. And then secondly, for the ATU pricing you get in France, how does that compare to the German pricing o",83,"Number one, I want to know if you guys have seen an uptick in discontinuation due to lack of efficacy or it's all due to the, I guess, chest tightness. And then secondly, for the ATU pricing you get in France, how does that compare to the German pricing of EUR 159,000 per year per patient? And lastly, I have a question on your gross to net. Is that consistent what you guys have guided before, which is like mid-teens in 1Q '15?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So in terms of discontinuations, the -- based on our clinical trial experience and also what we are seeing in the market, the vast majority of those discontinuations are for adverse events, and most commonly, that's the chest tightness. In terms of the AT",159,"So in terms of discontinuations, the -- based on our clinical trial experience and also what we are seeing in the market, the vast majority of those discontinuations are for adverse events, and most commonly, that's the chest tightness. In terms of the ATU, we haven't disclosed the price within the ATU program. And in terms of the gross to net, the gross to net that we've seen and are predicting is potentially slightly lower than we originally thought. That's largely due to the fact that the Medicaid patient population that we're seeing is slightly lower than we anticipated. This is really as a result of many of those Medicaid patients that we thought would be covered by Medicaid or actually qualify for disability benefit under Medicare. As a result of that, we're seeing a lower Medicaid population, and in result, we're seeing -- we're predicting a slightly lower gross to net of somewhere around 12% for the year."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. I'd like to just add to that, Stu, which is in the -- coming into 2016 and 2015 with the gross to net on ORKAMBI was close to 7%. As we moved into the Q1 of 2016, it's increased to 9%. So it is moving up slightly as we expected, but as we plot out an",94,"Yes. I'd like to just add to that, Stu, which is in the -- coming into 2016 and 2015 with the gross to net on ORKAMBI was close to 7%. As we moved into the Q1 of 2016, it's increased to 9%. So it is moving up slightly as we expected, but as we plot out and we look at the patients that are coming on to the drug, we anticipate that it could end the year around 12% as it gradually creeps up to that 12% level. That also plays into our guidance."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Liisa Bayko of JMP Securities.",14,"And our next question comes from the line of Liisa Bayko of JMP Securities."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just a couple of technical questions. Were there any inventory changes in the quarter?",14,"Just a couple of technical questions. Were there any inventory changes in the quarter?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","No. The ORKAMBI inventory at the end of March was, to all intents and purposes, identical to that, which it was at December 31. So there was really no inventory change for ORKAMBI at all.",35,"No. The ORKAMBI inventory at the end of March was, to all intents and purposes, identical to that, which it was at December 31. So there was really no inventory change for ORKAMBI at all."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, great. And then can you comment on gross to net? Sort of where were you for the quarter? And would that be relatively consistent for the rest of the year? Will it change in some way?",37,"Okay, great. And then can you comment on gross to net? Sort of where were you for the quarter? And would that be relatively consistent for the rest of the year? Will it change in some way?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Are you referring to ORKAMBI, Liisa?",6,"Are you referring to ORKAMBI, Liisa?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, sorry.",2,"Yes, sorry."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. So I actually just mentioned this, which is that in Q1 we were at approximately 9% gross-to-net discount, and in Q4 of last year, we were at 7%. We actually expect the Q1 level of 9% to trend up to be something closer to 12% by the end of the year.",52,"Yes. So I actually just mentioned this, which is that in Q1 we were at approximately 9% gross-to-net discount, and in Q4 of last year, we were at 7%. We actually expect the Q1 level of 9% to trend up to be something closer to 12% by the end of the year."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then when you say 15% of 65% have discontinued, so that's like a 10% discontinuation rate roughly. Is that the right way to think about that?",27,"And then when you say 15% of 65% have discontinued, so that's like a 10% discontinuation rate roughly. Is that the right way to think about that?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","No, Liisa. So -- and it's really important, so thanks for asking the question. It is, of the patients you've initiated, 15% of them have discontinued ORKAMBI within approximately the first 3 months. The -- and so if you think about 4,500 patients who init",125,"No, Liisa. So -- and it's really important, so thanks for asking the question. It is, of the patients you've initiated, 15% of them have discontinued ORKAMBI within approximately the first 3 months. The -- and so if you think about 4,500 patients who initiated between July and December, 15% of those patients would have discontinued within the first 3 months, and then that rate of discontinuations slows considerably. The 65% is the number of patients you've initiated therapy by the end of March. So the 15%, you need to apply to all of the patients who initiated. It's -- you don't -- it's not 15% of 65% is 10%. It's 15% of the 65% who have initiated, they will discontinue therapy in our belief."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Right. But that got you 10%. Doesn't it if you multiply 65% by 15%?",14,"Right. But that got you 10%. Doesn't it if you multiply 65% by 15%?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Liisa, we'll jump on the phone with you after the call, and we'll do the math.",16,"Liisa, we'll jump on the phone with you after the call, and we'll do the math."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then I just had a question about the Rho inhibitor. Can you just give us a little detail on that trial? What are the endpoints you're looking at? What's the timing for data? That's my final question.",38,"And then I just had a question about the Rho inhibitor. Can you just give us a little detail on that trial? What are the endpoints you're looking at? What's the timing for data? That's my final question."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Liisa, it's Jeff. So the Rho inhibitor trial is really specifically in patients who had a pretty catastrophic injury to their cervical spine and then really have very poor function immediately following that injury. In the studies then, we follow those pa",140,"Liisa, it's Jeff. So the Rho inhibitor trial is really specifically in patients who had a pretty catastrophic injury to their cervical spine and then really have very poor function immediately following that injury. In the studies then, we follow those patients. At the time of surgery, they have either placebo or 1 of 2 doses of active drug, and there's about 150 patients total. And then we follow them for 6 months looking at particularly how their upper extremities function because that's so important to how paves [ph] the quality of life of patients, and then we do some other measures of disability. And it's very hard right now. We just started the study as we've said, so I think it's very hard to predict in that kind of population, in particular, exactly when we're going to get results."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Tony Butler of Guggenheim.",12,"Our next question comes from the line of Tony Butler of Guggenheim."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Briefly, Stuart, in France, again, the early-access patients which receive ORKAMBI, I think you mentioned 400. I understand reimbursement has not occurred. But given the uptake being fairly strong, if one assumes that the majority of that 1,500 will be tr",82,"Briefly, Stuart, in France, again, the early-access patients which receive ORKAMBI, I think you mentioned 400. I understand reimbursement has not occurred. But given the uptake being fairly strong, if one assumes that the majority of that 1,500 will be treated by year-end and you do get reimbursement, let's say, next year, is -- does that come in a bolus payment for that, which has occurred? Or is that payment then amortized assuming those patients stay on drug for '17 and beyond?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Thanks for the question, Tony. So the way the accounting works in France is for that the cash that we get for those patients before we get reimbursed, those recognized as cash, not as revenue. At the point that we have certainty about the selling pri",118,"Yes. Thanks for the question, Tony. So the way the accounting works in France is for that the cash that we get for those patients before we get reimbursed, those recognized as cash, not as revenue. At the point that we have certainty about the selling price or very close to certainty about the selling price in France, then we will be able to, in a onetime adjustment, convert that cash to revenues. And then from that point forward, all of those will be counted as revenues going forward. And that's because the -- whatever rebate you agree with the French government is retroactive to the sales that you've had from the point that you launched the product."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And finally, you would call that out as an item in the quarter in which it occurs, I assume.",19,"And finally, you would call that out as an item in the quarter in which it occurs, I assume."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So maybe I'll follow on from Stuart's answer. So I'll just validate Stuart's answer as the kind of a CPA. So nice job, Stuart. In terms of revenue recognition, many of you that are on this call probably have seen other companies go through this with the A",101,"So maybe I'll follow on from Stuart's answer. So I'll just validate Stuart's answer as the kind of a CPA. So nice job, Stuart. In terms of revenue recognition, many of you that are on this call probably have seen other companies go through this with the ATU in France. And then absolutely, at the point that we are -- we get to a point where we're comfortable with the price in France, yes, we would call it out in the quarter specifically. And at that same point in time, we would recognize all the revenue in that very quarter."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our final question comes from the line of Katherine Xu of William Blair.",14,"And our final question comes from the line of Katherine Xu of William Blair."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So I just have one question on the CRISPR program. Based on the research that you have ongoing right now, what kind of mutations are the most amenable for the technology first and how difficult it is to eventually correct the F508, which is a deletion you",53,"So I just have one question on the CRISPR program. Based on the research that you have ongoing right now, what kind of mutations are the most amenable for the technology first and how difficult it is to eventually correct the F508, which is a deletion you have at that single base pair?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. This is Jeff Leiden. Thanks for the question. I think, as you know, right -- if you look today, CRISPR is most amenable to actually inactivate, which is making cleavages, because that's what it does most efficiently, and obviously, that's not what we",239,"Yes. This is Jeff Leiden. Thanks for the question. I think, as you know, right -- if you look today, CRISPR is most amenable to actually inactivate, which is making cleavages, because that's what it does most efficiently, and obviously, that's not what we would want to do in a Delta 508 case. Then, you move to making corrections, and then you move to more complex deletions and insertions. So there's no doubt that there are still challenges to conquer both in terms of how we correct deletions like in Delta 508 but also how we deliver this because, obviously, this has to be delivered efficiently to large numbers of cells in the lungs, and we don't know how to do that yet. So that's why we said, while we think CRISPR is an incredibly powerful technology for the future, it's going to take a number of years to conquer both the -- some of the editing challenges but also, in particular, the delivery challenges, and that's what we're working on in CF. Now we're also -- I'll just remind you that CRISPR-Cas9 collaboration, we have rights to several targets, fixed targets, and some of those will be in other diseases where some of these issues, like delivery and editing, are much more straightforward. So I think you can expect to hear from us over the next couple of years on our progress in some of those other diseases."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So at this point, are there mutations that easier than others to edit? Do we know that?",17,"So at this point, are there mutations that easier than others to edit? Do we know that?"
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. As I say, I think single base pair corrections are going to be a lot easier than complex deletions and insertions to correct. But nevertheless, I mean, there are some pretty significant challenges in diseases like CF. When you move to ex-vivo therapy",81,"Yes. As I say, I think single base pair corrections are going to be a lot easier than complex deletions and insertions to correct. But nevertheless, I mean, there are some pretty significant challenges in diseases like CF. When you move to ex-vivo therapy and you move to inactivation in ex-vivo therapy, you're in a whole different world in terms of efficiency, and so you will see some of those, I think, from us and others as being the first application."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So I'll turn it back over to Jeff maybe for some final comments tonight.",15,"So I'll turn it back over to Jeff maybe for some final comments tonight."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. First of all, thank you for your questions, thanks for your patience. I know it was a long call, but we do want to give you not only our guidance but a detailed rationale for the guidance so that you understand our model. And we appreciate your quest",360,"Yes. First of all, thank you for your questions, thanks for your patience. I know it was a long call, but we do want to give you not only our guidance but a detailed rationale for the guidance so that you understand our model. And we appreciate your questions on that.
As I look at our progress as a company over the last year, I guess I would call out 3 things that I think are important. First, the continuous increase in the number of patients that we can treat and actually fairly dramatic increase in the number of patients that we can treat with KALYDECO and ORKAMBI; and as we look forward, the increasing number of patients that we can treat with today's approval. So as I mentioned, 27,000 eligible, we're still only treating 1/3 of those, and I think we have a clear path to get to the majority of those patients both in the U.S. and Europe over '16 and '17 and beyond.
Second thing I would say is the pipeline progression. We're pleased with 661 progressing well into Phase III of multiple trials and multiple patient populations but equally important, the next-gen correctors, which are progressing through Phase I with our -- and still on a time line to get into patients as triple combinations later this year. We think that's going to be very important both for the patients we treat and potentially for additional subsets of patients.
And then finally, the progression of the science. We didn't talk about that a lot today, but the science of CF, I think, has progressed significantly, and we have a much better understanding of the folding and correction process. And the science that David Altshuler is driving and the rest of research group in some of the new diseases, we touched on those a little bit with CRISPR-Cas9 but also others that I hope we will be able to have a chance to talk to you about over the rest of '16 and '17. It's an important long-term growth engine for the company.
So with that, maybe I'll close the call, and thanks again for joining us."
36235,331185758,965228,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening. This is Michael Partridge, Vice President of Investor Relations. Welcome to our First Quarter 2016 Conference Call. [Operator Instructions] A replay of tonight's call will also be available on the website once we have concluded.Dr. Jeff Le",199,"Good evening. This is Michael Partridge, Vice President of Investor Relations. Welcome to our First Quarter 2016 Conference Call. [Operator Instructions] A replay of tonight's call will also be available on the website once we have concluded.
Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer will provide prepared remarks this evening. They will be joined by Dr. Jeff Chodakewitz, Chief Medical Officer, for the Q&A portion of the conference call. 
We will make forward-looking statements on this call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the SEC. These statements, including without limitation, those regarding the ongoing development and potential commercialization of our drug candidates, our expectations regarding our improved medicines and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in tonight's press release. I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Dr. Jeff Leiden."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. Over the last 4 years, Vertex has delivered 2 transformative medicines to people with cystic fibrosis. Today, there are approximately 27,000 people eligible for 1 of our approved CF medicines, and we have a clear p",1797,"Thanks, Michael. Good evening, everyone. Over the last 4 years, Vertex has delivered 2 transformative medicines to people with cystic fibrosis. Today, there are approximately 27,000 people eligible for 1 of our approved CF medicines, and we have a clear path toward our goal of helping potentially all people with this rare and life-shortening disease in the future.
We're confident that our experience with ORKAMBI and KALYDECO, and our scientific leadership and progress in targeting the underlying biology of this disease, positions us well to increase the number of people treated with our approved medicines and to develop new medicines in the years ahead that may provide even greater benefit for all people with CF.
Tonight, I'll provide brief comments on 3 key areas which serve as markers of our progress toward treating all people with CF, including: first, the performance of our approved medicines, ORKAMBI and KALYDECO, and our road map toward treating more patients with these medicines that will drive revenue growth in 2016 and beyond; second, the role of VX-661 in helping to achieve our long-term goal in CF; and third, our pipeline of additional CFTR modulators and other mechanisms we're advancing as part of collaborations. These approaches include the ENaC inhibition, and in the longer-term, gene editing with CRISPR-Cas9, and may position us to help all people with CF.
We're approximately 9 months into the launch of ORKAMBI in the U.S. for people with 2 copies of the F508del CFTR mutation ages 12 and older. As of the end of March, approximately 65% or 5,500 of the 8,500 currently eligible patients in the U.S. have initiated treatment with ORKAMBI. We expect the number of patients who've initiated treatment with ORKAMBI will continue to grow during 2016. And we continue to expect that by the end of the year, the vast majority of all eligible patients ages 12 and older in the U.S. will have initiated treatment.
We've seen excellent reimbursement and access for ORKAMBI from public and private payers in the U.S., and the feedback from the CF community continues to be very positive. Importantly, patients across the U.S. have broad access to the medicine through public and private insurance. And we have assistance programs in place for eligible patients who need additional help. All major commercial insurers in all 50 state Medicaid programs are currently covering ORKAMBI, reflecting the important advance and value this medicine represents in the treatment of CF.
We're now moving forward to our bringing ORKAMBI to younger patients. And at the end of March, we submitted a supplemental New Drug Application to the FDA, requesting approval of ORKAMBI for children ages 6 to 11 with 2 copies of the F508del mutation. We requested priority review, which if granted, would provide us with the decision on the application in the second half of this year. If approved, approximately 2,400 additional patients in the U.S. would be eligible for treatment.
Outside the U.S., we have commenced discussions with reimbursement agencies in various European and other countries. Given the clinical benefits of ORKAMBI and the severity of the disease for people with 2 copies of the F508del mutation, we believe that we will achieve reimbursement from key European and other government payers, just as we've seen in the U.S. ORKAMBI is already commercially available in Germany and through early access programs in France.
In the near term, the progress and our understanding of treating eligible patients with ORKAMBI gives us clarity on a revenue expectation for 2016. Later in the call, Stuart and Ian will talk about the ORKAMBI launch in detail, our guidance and how we think about revenue trends from 2015 and growth into 2016 and further into the future.
For KALYDECO, we're increasing our revenue guidance for 2016, which Stuart will discuss in his remarks. As we think about the future opportunities for ORKAMBI and KALYDECO, I want to emphasize that revenue growth in 2016 and beyond is largely a function of additional patients who are currently eligible for ORKAMBI or KALYDECO and initiating treatment with these medicines. On that basis alone, we believe there's significant growth ahead for both medicines. 
Consider that today, ORKAMBI and KALYDECO are approved for approximately 27,000 people worldwide. But we're only currently treating approximately 1/3 of these patients. As we see additional uptake of ORKAMBI in the U.S. and achieve reimbursement for eligible patients outside the U.S., growth will continue as additional patients continue to initiate treatment.
In addition, there are many more patients not currently eligible for treatment who may benefit from either ORKAMBI or KALYDECO. In total, we believe there are approximately 44,000 people, an additional 17,000 people beyond those eligible today, who could benefit from 1 of these 2 medicines. This additional group of patients was largely comprised of the following: first, approximately 12,000 people less than 12 years of age who have 2 copies of the F508del mutation and who may be helped by ORKAMBI; and second, approximately 5,000 patients who may be helped by KALYDECO comprised mostly of patients who have a residual function mutation. 
Treating a substantial portion of this additional group of 17,000 patients would further drive ORKAMBI and KALYDECO growth if we obtain future approvals for these additional groups of patients. We have ongoing studies, regulatory submissions and development plans to support these efforts, including ongoing discussions with the FDA regarding our application for approval of KALYDECO in approximately 1,500 people ages 2 and older with 1 of 23 residual function mutations as well as our recent sNDA submission to the FDA for approval of ORKAMBI in children ages 6 to 11 with 2 copies of the F508del mutation.
While we are focused on getting ORKAMBI and KALYDECO to as many patients as possible as soon as possible, we also recognize that there are many patients who are still waiting for a treatment for the underlying cause of their disease. We hear from these patients often, so I'm particularly pleased to report that our CF pipeline is advancing. This gives us great confidence that we will ultimately be able to treat the vast majority of people with CF and potentially enhance the benefit for those people currently taking our approved medicines.
I'll start with VX-661, which could play an important role in the treatment of people with CF and is currently in Phase III development. In combination with ivacaftor, our Phase II data suggested that VX-661 may have an improved benefit risk profile compared to ORKAMBI in people with 2 copies of the F508del mutation and may provide enhanced clinical benefits over ivacaftor monotherapy for other patients with gating mutations. We are on track to obtain the first data from the ongoing Phase III program for VX-661 in early 2017 from the study in people with 2 copies of the F508del mutation.
Additionally, VX-661 is positioned to play a key role in the development of a triple combination with a next-generation corrector in ivacaftor. We believe that this triple-combination approach will be fundamental for 2 reasons: first, triple combinations may allow us to treat a very large group of patients who are not helped today by either ORKAMBI or KALYDECO, including those with 1 F508del mutation and a second mutation that causes minimal CFTR function; and second, these regimens could provide even greater benefit to patients currently eligible for our approved medicines who have at least 1 F508del mutation.
Today, we have 2 next-gen correctors in clinical development: VX-152 and VX-440. These potential medicines are currently being evaluated in Phase I studies in healthy volunteers. Successful completion of these studies would enable us to move rapidly into Phase II studies in the second half of 2016 to evaluate 1 or more next-generation correctors with VX-661 and ivacaftor in people with CF.
I'll now turn to our pipeline of other potential CF medicines that could be complementary to our portfolio of CFTR modulators, and it may enable us to treat more patients and provide greater clinical benefit in the years to come. The most advanced example of this is our lead ENaC inhibitor, VX-371. Today, we announced data from a Phase II 14-day study of VX-371 in 142 people with CF who are not receiving ORKAMBI or KALYDECO. The study met its primary endpoint of safety. 96% of the patients who enrolled in the study completed all treatment, and the treatment regimens consisting of VX-371 were generally well tolerated. There were no statistically significant changes from baseline in FEV1 for those patients who received VX-371 compared to placebo. 
The data announced today are consistent with our in-vitro data that did not show a meaningful change in cilia beat frequency when VX-371 was used alone in human bronchial epithelial cells with 2 copies of the F508del mutation. In contrast, these in-vitro data did show a meaningful change in cilia beat frequency when VX-371 was used in combination with ORKAMBI. Together, the in-vitro and clinical safety data generated to date provide further support for our ongoing study of VX-371 in combination with ORKAMBI. This ongoing study began enrolling people with 2 copies of the F508del mutation ages 12 and older in the first quarter of this year. And the primary endpoints are safety and mean absolute change from baseline in lung function at Day 28 of treatment as compared to placebo. Additional information on these studies can be found in our first quarter press release issued today.
Additionally, last year, we entered into a collaboration with CRISPR Therapeutics, with a longer-term goal of discovering gene-editing approaches for the treatment of genetic diseases, including CF. The use of this technology in people with CF may be many years away, but it is strategically important as we think about future advances that could fundamentally change the treatment of this disease in the years to come.
Tonight, I've summarized how we think about our opportunity in CF, an opportunity that is unique, both in terms of the potential benefit that ORKAMBI and KALYDECO provides the people with CF today and also for the long-term potential of our development-stage medicines to treat the vast majority of people with CF in the future.
In conclusion, I'll make just a few comments about the type of company we will become as we achieve the success in CF that I've just outlined. Vertex is on a path towards sustained earnings and revenue growth, driven by an increasing number of people being treated with KALYDECO and ORKAMBI. We believe our business model, one focused on significant investment to create value through innovation, research and development, positions us to consistently discover and deliver transformative new medicines for patients and to reinvest in scientific opportunities to create future medicines.
With that, I'll turn the call over to Stuart to make more specific comments on the ORKAMBI launch."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. Tonight, I will review our progress with the launch of ORKAMBI, the basis of our 2016 guidance for ORKAMBI product revenues and our ongoing efforts to obtain reimbursement outside the U.S. to drive further growth of ORKA",1180,"Thanks, Jeff, and hello, everyone. Tonight, I will review our progress with the launch of ORKAMBI, the basis of our 2016 guidance for ORKAMBI product revenues and our ongoing efforts to obtain reimbursement outside the U.S. to drive further growth of ORKAMBI in 2017 and beyond.
We are now just over 9 months into the launch, and we are pleased that approximately 65% of eligible patients in the U.S. have initiated treatment with ORKAMBI to date. Global sales of ORKAMBI in the first quarter were $223 million, comprised of U.S. sales of approximately $214 million and ex U.S. sales of approximately $9 million, which were mainly from Germany. 
At the beginning of the year, our intention was to provide financial guidance for 2016 ORKAMBI revenues once we have gained sufficient understanding of the dynamics of the launch in the U.S. Today, we have a deeper understanding if our doctors and their patients are using the medicine, based on the real-world treatment patterns we've observed in more than 4,500 patients who initiated treatment in the U.S. in 2015. 
I'll now share with you our understanding of the launch dynamics that informed our guidance. First, uptake, defined as the total proportion of the 8,500 eligible patients in the U.S. who will begin treatment with ORKAMBI by the end of 2016 and also the rate at which these patients initiate treatment. Second, the persistence rate, defined as the proportion of patients who start and remain on treatment. And third, the compliance rate, which reflects the number of pills actually taken by a patient in a given month.
First, to uptake. To date, approximately 65% of the 8,500 eligible patients in the U.S. have initiated treatment with ORKAMBI, comprised of more than 3,000 patients who initiated treatment in the third quarter of 2015, more than 1,500 in the fourth quarter and approximately 800 in the first quarter of 2016. We have seen further initiations in April and expect that patient initiations will continue throughout 2016, albeit the lower rate than in the first 3 quarters post-launch. We continue to expect that the vast majority of the eligible patients ages 12 and older in the U.S. will initiate treatment with ORKAMBI by the end of this year.
Second, persistence. Among patients who have initiated ORKAMBI since launch, we've seen that approximately 15% of patients discontinued treatment within 3 months of starting treatment. Our clinical trial and market research data indicate that these discontinuations are largely related to respiratory adverse events. After the first 3 months of treatment, the discontinuation rate then slows considerably. Based on what we've observed to date from all patients taking ORKAMBI, including those who have been on commercial drug for up to 9 months and those who continue to receive ORKAMBI as part of our Phase III long-term extension study, we expect that the proportion of all patients who initiate and remain on treatment will stabilize at approximately 70% to 80%.
It is also important to point out that the pattern of patient initiations and discontinuations have an offsetting effect on our first quarter ORKAMBI revenues. Specifically because more than 4,500 patients began treatment with ORKAMBI in 2015, the impact of approximately 15% of these patients discontinuing ORKAMBI was highly evident in the first quarter. Therefore, while approximately 800 new patients initiated treatments in the first quarter, this growth was largely offset by the bolus of patients who discontinued treatment. This bolus of discontinuations began in the fourth quarter, but had a larger impact on the first quarter of 2016 where there were also fewer patient initiations to offset these discontinuations.
And finally, compliance. Based on what we've observed to date from the launch, we expect the compliance rate with ORKAMBI to be between 70% and 80%.
In summary, based on our understanding of the launch dynamics for ORKAMBI and the fact that we have continued to see additional patients initiating treatment with ORKAMBI in April, we expect to deliver quarter-to-quarter revenue growth for ORKAMBI beginning in the second quarter and continuing through the end of 2016 and into 2017.
I will now turn to the use of ORKAMBI to date outside the U.S. We are now well into the reimbursement process in all key European countries, Canada and Australia. Specifically, the clinical and cost-effectiveness assessment portions of the reimbursement process. These discussions are going as expected and have been productive. We believe that government payers across Europe recognize both the severity of this disease and the broad clinical benefits of ORKAMBI. These discussions will take time to complete. However, as Jeff mentioned earlier, we believe that we will achieve broad reimbursement from key European and other government payers, just as we've seen in the United States.
ORKAMBI is already available commercially in Germany and through early-access programs in France. We are only 3 months into the launch of ORKAMBI in Germany, and the uptake has been slower than we observed in the U.S. We attribute this to a number of factors, including that CF care in Germany is not concentrated in large centers as is seen in other countries. Meaning, there are many smaller centers and also many centers and physicians who have not yet had personal experience with CFTR modulators.
In Germany, there are approximately 2,500 patients eligible for treatment. As of March 31, 2016, approximately 230 patients had initiated treatment. However, we expect the number of patients initiating treatment in Germany will grow through 2016 and into 2017.
We do not expect what we are seeing in Germany will be representative of the uptake in other European countries. In fact, in France, where early-access programs provide the opportunity for physicians to begin treating patients with ORKAMBI prior to formal reimbursement approval, we have already seen approximately 400 of the 1,500 eligible patients initiate treatment with ORKAMBI in 2016.
We took all of this information into account when we set 2016 revenue guidance for ORKAMBI of $1.0 billion to $1.1 billion. Our guidance reflects our understanding of the ongoing U.S. launch, as I just discussed, as well as expectations that we will receive both approval for ORKAMBI in the U.S. for patients ages 6 to 11 in the second half of 2016 and certain revenues from sales of ORKAMBI outside the U.S., primarily from Germany.
Taking a longer-term view, we expect significant further growth for ORKAMBI revenues in 2017, driven primarily by patients initiating treatment following the completion of reimbursement discussions outside the U.S.
And now to KALYDECO. Today, we are increasing our financial guidance for 2016 revenues. We now expect KALYDECO net revenues of $685 million to $705 million. The prior guidance provided on January 10, 2016, was for KALYDECO net revenues of $670 million to $690 million.
We increased our KALYDECO guidance based primarily on an increasing number of patients initiating treatment with KALYDECO globally and on expectations of a reduced impact this year from the VX-661 Phase III program. Our guidance for KALYDECO excludes any potential revenues from the approval of KALYDECO, the people with residual function mutations.
I'll now hand the call over to Ian."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thank you, Stuart, and good evening to everyone. With the closing of the first quarter of 2016 and 9 months into the launch of ORKAMBI, we are seeing significant progress across our business. Notably, we are seeing increasing number of patients being trea",560,"Thank you, Stuart, and good evening to everyone. With the closing of the first quarter of 2016 and 9 months into the launch of ORKAMBI, we are seeing significant progress across our business. Notably, we are seeing increasing number of patients being treated with our approved medicines, resulting in a growing revenue base that we expect to drive earnings growth. 
I will now review our first quarter financial results and provide some specific comments about the long-term financial trajectory of our business.
Financial results first. In the first quarter of 2016, we reported total CF product revenues of approximately $394 million, a significant increase compared to $130 million in the first quarter of 2015. With ORKAMBI, we reported sales of $223 million for the first quarter of 2016. We have recorded approximately $574 million of ORKAMBI revenues in the first 9 months since the U.S. launch in July 2015. The first quarter KALYDECO sales of $171 million were up $41 million versus the first quarter of last year. 
Now to the operating expenses. Our first quarter non-GAAP operating expenses were $306 million compared to non-GAAP operating expenses of $246 million for 2015. The increased operating expenses were primarily due to increased costs related to the progression of our CF pipeline and to increased investments in global commercial support for the launch of ORKAMBI. Our non-GAAP net profit for the first quarter of 2016 was $22 million or $0.09 per diluted share compared to a non-GAAP net loss of $148 million or $0.62 per share for 2015.
From a balance sheet perspective, we ended the first quarter with approximately $1.03 billion in cash, cash equivalents and marketable securities. Vertex also has $300 million outstanding from a credit agreement, repayable by the end of the third quarter of 2017. The agreement also allows for the facility to increase to $500 million. 
Now to financial trends. Stuart provided 2016 ORKAMBI and KALYDECO revenue guidance and the assumptions that drive our projections, and therefore, I will focus my comments on the longer-term growth opportunities that may come with treating more patients with our currently approved medicines. 
We expect ORKAMBI revenues will continue to grow as we treat more patients in the U.S., achieve reimbursement outside the U.S. and expand the ORKAMBI label to younger patients. KALYDECO's growth is based on gaining reimbursement for certain groups of patients outside the U.S, including those with R117H mutation and the people ages 2 to 5 with gating mutations.
In summary, as Jeff noted earlier, approximately 27,000 people are eligible for our CF medicines, yet we are only treating approximately 1/3 of these patients. As additional patients in the U.S. start treatment and we complete reimbursement discussions outside the U.S., we expect the number of patients treated with our medicines to increase significantly and we expect revenue growth will follow. 
I will note that in 2015, we reported total CF revenues of $983 million. Based on 2016 guidance provided for ORKAMBI and KALYDECO, we anticipate the total CF revenues of approximately $1.7 billion to $1.8 billion, an approximate 75% increase over the prior year.
As our revenues grow over future years, we are committed to managing our operating expenses to drive earnings growth, and we expect to deliver financial profile as similar to many of our large cap biotech peers.
With that, I open the line to questions."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] And our first question comes from the line of Michael Yee of RBC Capital Markets.",17,"[Operator Instructions] And our first question comes from the line of Michael Yee of RBC Capital Markets."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two-part question. One is you gave all these discontinuation and persistence rates and compliance rates, which is in your guidance. Is there anything out there that you can do to either improve these things? Education, getting people to just get patients",134,"Two-part question. One is you gave all these discontinuation and persistence rates and compliance rates, which is in your guidance. Is there anything out there that you can do to either improve these things? Education, getting people to just get patients to take more drug? And can you apply any of these learnings to Europe? Are you seeing the same stuff in Germany? Are there any ways to improve it there? And then the second question is a pipeline question on the 661 het-min. You mentioned in the press release that you're changing the enrollment to do 200 instead of 300. But is that assuming you actually pass the futility? Can you just clarify that a little bit? I guess, why are we talking about changing enrollment if we haven't passed the futility?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mike, its Stuart here. I'll take the first part of your question around the discontinuation and compliance rates. And then I'll hand over to Jeff Chodakewitz to answer the pipeline questions. So on discontinuations and compliance and what we might be able",287,"Mike, its Stuart here. I'll take the first part of your question around the discontinuation and compliance rates. And then I'll hand over to Jeff Chodakewitz to answer the pipeline questions. So on discontinuations and compliance and what we might be able to do to improve those, much as we did with KALYDECO. We will be continuing to generate data on the long-term benefits and even broader benefits of ORKAMBI when used in the real world. And I suspect that data, if its compelling, may lead physicians and patients to reconsider restarting ORKAMBI. So we'll continue to develop the overall clinical profile of ORKAMBI as we have more experience in the market. In terms of compliance, really, many of the same things that we did with KALYDECO we'll be doing with ORKAMBI, and that's really providing both providers and physicians with the educational materials to be able to understand how this is a product which is treating the underlying cause of their disease and so is a product that they want to try and stay compliant with as much as they possibly can. We'll certainly be leveraging all the learnings we've had with KALYDECO, with ORKAMBI, and those programs are already in place. And lastly, to your point about -- to Germany. Clearly, one of the things we're going to be doing is transferring all of the learnings from our launch experience in the U.S. to all of the other markets that we're launching into. And that's, in many ways, the benefits of those markets coming on-stream a little bit later is that they can learn from our experiences here in the U.S. With that, I'll hand over to Jeff to answer the question on the pipeline."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mike, it's Jeff. Maybe just to clarify, the -- we did provide some information about the timing of the interim analysis in the het-min study. But there's been no other changes for that trial. The change in sample size comes from one of our other Phase III",96,"Mike, it's Jeff. Maybe just to clarify, the -- we did provide some information about the timing of the interim analysis in the het-min study. But there's been no other changes for that trial. The change in sample size comes from one of our other Phase III trials, looking at 661 ivacaftor in patients who have more of a residual function mutation on one of their alleles. We did look at that and saw there was some opportunity to maintain good powering, but simplify it and reduce the sample size. And that's what that was about."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. So there's still het-min interim in Q3. No change to that. Okay.",13,"Okay. So there's still het-min interim in Q3. No change to that. Okay."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","That's the interim. That's correct.",6,"That's the interim. That's correct."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Terence Flynn of Goldman Sachs.",14,"And our next question comes from the line of Terence Flynn of Goldman Sachs."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe just a follow-up on the discontinuation rate. I know you've mentioned it's mainly due to respiratory events. But the 15%, I think, over 3 months is significantly higher than what you saw in the trials. I know you mentioned, previously, it could be h",102,"Maybe just a follow-up on the discontinuation rate. I know you've mentioned it's mainly due to respiratory events. But the 15%, I think, over 3 months is significantly higher than what you saw in the trials. I know you mentioned, previously, it could be higher. But any more color there on the drivers behind that, that you can expand on a little bit? And then on the ORKAMBI guidance, just wondering if you can provide a little bit more clarity there on the contributions from U.S., rest of world and then the patients 6 to 11 in terms of relative contribution?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure, Terence. So on the respiratory events, I think what I'd say there is what we're reporting today is what we're seeing in the real-world usage of ORKAMBI in the broad population. Obviously, the clinical trial population that we studied in TRAFFIC and",234,"Sure, Terence. So on the respiratory events, I think what I'd say there is what we're reporting today is what we're seeing in the real-world usage of ORKAMBI in the broad population. Obviously, the clinical trial population that we studied in TRAFFIC and TRANSPORT is a very controlled situation. That was patients with an FEV1 between 40 and 90. So really, whilst we try to extrapolate from the clinical trial experience to the real-world experience, that's one of the reasons -- that uncertainty is one of the reasons why we wanted to make sure we had sufficient time in market before we gave guidance. It was because we really wanted to see how the product would get used in the real world. In terms of the contribution of the various different parts of the world to our ORKAMBI revenue guidance that you might expect the vast majority of these, the revenues is going to come from here in the U.S. There will be a contribution ex U.S., but it's going to be relatively small. And then incorporated within our guidance, as we said, is also an expectation that we will see an approval in 6- to 11-year-olds in the latter part of 2016, which would give us access to an eligible population of about 2,500, and that's also incorporated within our guidance. But that approval is not anticipated until the back end of 2016."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Geoff Meacham of Barclays.",13,"And our next question comes from the line of Geoff Meacham of Barclays."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I got a couple. I'm trying to get a sense as to when you guys realize that compliance or persistent or discons were different for ORKAMBI versus KALYDECO or commercial ORKAMBI versus Phase III. I mean, you guys had a chance -- 3Q call, JPM, 4Q call, to be",75,"I got a couple. I'm trying to get a sense as to when you guys realize that compliance or persistent or discons were different for ORKAMBI versus KALYDECO or commercial ORKAMBI versus Phase III. I mean, you guys had a chance -- 3Q call, JPM, 4Q call, to be crystal clear on this. And it's 10 months almost into the launch, and now we're getting some detail. And I just had a couple of follow-ups."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Jeff, thanks for the question. It's Ian. So I just want to take us back a few months, which, as we went into JPMorgan and also our year-end conference call again in January, we were very clear with what we wanted to do regarding ORKAMBI guidance. It's",269,"So Jeff, thanks for the question. It's Ian. So I just want to take us back a few months, which, as we went into JPMorgan and also our year-end conference call again in January, we were very clear with what we wanted to do regarding ORKAMBI guidance. It's -- for us, at that point in time, it was early in the launch. Yes, we've recruited a number of patients on to ORKAMBI, but it was still early in the launch to understand treatment patterns. We stated that very clearly. What we've been able to do now as we sit here, as you point out, just over 9 months into the launch, we've been able to take a significant bolus of patients. For example, 3,000 patients that initiates in the first 3 months of disapproval, and we've been able to track those 6 to 9 months. What that allows us to do was to understand compliance rates. It helped us understand discontinuation rates and also the time of discontinuation, as Stuart mentioned. That's been an important feature for us. So this was the -- we feel as though we're in this position at this point in time where we've been able to attract a substantial amount of patients over a good period of time to have the confidence to provide guidance for 2016. The comparison to KALYDECO was less relevant for us. It was more about the treatment patterns for ORKAMBI. ORKAMBI is a different medicine than KALYDECO based on its clinical data and the patient population. But we now have enough confidence to provide you with the ORKAMBI guidance."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And just a follow-up to some earlier questions, I guess just to ask it a different way. It is for patients that are at low FEV1 at baseline and do experience bronchoconstriction, is there a treatment protocol in place? I mean, we've obviously heard",75,"Okay. And just a follow-up to some earlier questions, I guess just to ask it a different way. It is for patients that are at low FEV1 at baseline and do experience bronchoconstriction, is there a treatment protocol in place? I mean, we've obviously heard of things like half dosed and uptight trade or dose skipping. Is there something that you guys can recommend to a pulmonologist? A strategy for those that do experience bronchoconstriction?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, it's Jeff Chodakewitz. Maybe just to give you a couple of comments about that. We don't have anything in terms of very concrete, specific guidance that we can give. But we can make a couple of observations. First of all, what's clear from speaking",191,"Geoff, it's Jeff Chodakewitz. Maybe just to give you a couple of comments about that. We don't have anything in terms of very concrete, specific guidance that we can give. But we can make a couple of observations. First of all, what's clear from speaking to our investigators and also to physicians in the field, that clearly the support for the patients, both setting expectations for the patient and for the physician and helping patients in those early weeks manage any symptoms, we think is very important and something that goes back to some of the education questions that we've heard about earlier. We are also collecting information in our own study for patients who's FEV1 were less than 40, and we're in the process of summarizing that. We did, in that study, we give patients the option to start on a lower dose. And we'll set -- we'll get that data together and summarize it. But it's not going to be the kind of data that says, ""Here's a specific recommendation."" We noted that is being used, but it's really still about physicians and their patients working together to manage."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Mark Schoenebaum of Evercore.",13,"And our next question comes from the line of Mark Schoenebaum of Evercore."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Number one, I'd just like to know, have you been surprised by the way the launch has unfolded? I'm sure you had some projections a year ago for persistence, all these things. And then have you been surprised? And number two, I know you can't comment speci",87,"Number one, I'd just like to know, have you been surprised by the way the launch has unfolded? I'm sure you had some projections a year ago for persistence, all these things. And then have you been surprised? And number two, I know you can't comment specifically on peak numbers. But the sales at consensus is around $4 billion at peak for ORKAMBI. I'm just wondering, can you just talk about that? And then finally, is there any opportunity for re-initiations in these patients that drop-out early?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mark, we have a list of questions there, so if we don't get to all of them, please -- so we're all scribbling down. But if we don't get to them, please say them again. So Mark, in terms of how we feel about the launch, I'd say we're very pleased with the",204,"Mark, we have a list of questions there, so if we don't get to all of them, please -- so we're all scribbling down. But if we don't get to them, please say them again. So Mark, in terms of how we feel about the launch, I'd say we're very pleased with the way the launch has progressed here in the U.S. From how we were able to work with payers, to get access in reimbursement from ORKAMBI from early on in the launch to the rate of uptake that we've seen. I mean, to get close to 65% of eligible patients initiated within the first 9 months is a fairly steep ramp, and so one we're pleased with. So I think, overall, we're pleased how the launch has played out, much as we anticipated. In terms of the potential for re-initiations, we have heard anecdotally from physicians that they have tried re-initiating patients on ORKAMBI. We don't have much in the way of clinical data to be able to support that. But we are certainly aware that there are physicians who done that successfully so for some of their patients. So that normally is something that we'll continue to watch in the marketplace."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mark, this is Jeff Leiden. Maybe just to add a little bit more of a 10,000 foot view on both KALYDECO and ORKAMBI. Like you have been involved with many, many drug launches -- and I think it's worth just putting those in perspective a little bit. From the",249,"Mark, this is Jeff Leiden. Maybe just to add a little bit more of a 10,000 foot view on both KALYDECO and ORKAMBI. Like you have been involved with many, many drug launches -- and I think it's worth just putting those in perspective a little bit. From the standpoint, as an example, in ORKAMBI of getting to 65% of the patients in 9 months and of course, with KALYDECO, it was close to 90%, that's a fairly unusually fast ramp. And from the standpoint of persistence, the kind of numbers Stuart was talking about, let's say 70% to 80% is the number that we said aloud at, is still a very, very high number compared to most chronic medicines. And we believe that really represents the correct perception that both physicians and patients have about the value of these medicines and treating the underlying cause of the disease for a long period of time. And that really underlines our thinking about the pipeline as well because as we develop this next set of medicines, including next gens and hopefully, ultimately, things like CRISPR, we're talking about progressively increasing the benefit/risk profile of our portfolio of drugs that these patients can take. And that will only, of course, increase both persistence and compliance rates. So overall, very; pleased of where we are. We know we have more work to do to get to more patients and improve therapy, but these 2 drugs have really performed quite well so far."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Geoffrey Porges of Leerink Partners.",14,"And our next question comes from the line of Geoffrey Porges of Leerink Partners."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just a few questions. First, could you help us out? Just give us the breakdown between U.S. and ex U.S. sales of KALYDECO, so we're all in the same page. And then I just want to go back to Jeff's comments. Jeff, could you really clarify this residual func",169,"Just a few questions. First, could you help us out? Just give us the breakdown between U.S. and ex U.S. sales of KALYDECO, so we're all in the same page. And then I just want to go back to Jeff's comments. Jeff, could you really clarify this residual function change? And what has altered in terms of your statistical analysis or your assumptions about the activities of drug or the combination? And give us a sense of what the hurdle there is or ORKAMBI's effect. And then lastly, on this issue of persistence, is it reasonable to assume that about 50% of patients of the eligible pool are on drug right now? Because we keep going round and round about initiations and discontinuations, but surely, what's important is the number of patients who remain on drug at the end of the quarter. And is 50% roughly the right number or perhaps slightly below that, 45% to 50% of the eligibles? Is that the right way to think about it?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Geoff, it's Stuart here. I'll take your first question around KALYDECO revenues, and then I'll hand over Jeff Chodakewitz. So within the total KALYDECO revenues of $171 million for the first quarter of 2016, $95 million of that was in the U.S. and the",52,"So Geoff, it's Stuart here. I'll take your first question around KALYDECO revenues, and then I'll hand over Jeff Chodakewitz. So within the total KALYDECO revenues of $171 million for the first quarter of 2016, $95 million of that was in the U.S. and the balance, about $76 million was in international."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, in terms of the residual function study, we really stepped back and said, is there an opportunity to reduce the end of the study somewhat without sacrificing the integrity of the trial. We really looked at that 2 ways that we saw opportunity. One i",107,"Geoff, in terms of the residual function study, we really stepped back and said, is there an opportunity to reduce the end of the study somewhat without sacrificing the integrity of the trial. We really looked at that 2 ways that we saw opportunity. One is that we really focused our statistical analyses on key parameters, and that really allows us to take care of that. The other thing is that we also looked at the wider data and saw that the discontinuation rate from the trial was actually lower than what we had left room for, and that also is an opportunity to reduce the end."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And finally, Geoff, to your question in ORKAMBI. Your back-of-envelop math is approximately right. At the end of the third quarter, you're right about 50% of the eligible population were on. Clearly, that's a moving target because it's a mix of the discon",109,"And finally, Geoff, to your question in ORKAMBI. Your back-of-envelop math is approximately right. At the end of the third quarter, you're right about 50% of the eligible population were on. Clearly, that's a moving target because it's a mix of the discontinuations and the initiations. The important thing I would add to that number is that, moving forward in Q2 and beyond, we do expect patient initiations, which we've continued to see in April in the U.S. and obviously, we continue to see internationally in places like Germany. We expect to outpace discontinuations, which is why we are predicting quarter-on-quarter growth for the remainder of 2016 and beyond."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Brian Abrahams of Jefferies.",13,"And our next question comes from the line of Brian Abrahams of Jefferies."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess my first question is I'm wondering if you're seeing any trends towards maybe less sick higher FEV1 patients going on to therapy over time, which could be with ORKAMBI, which theoretically improved persistence and compliance. And then on 661, if 66",72,"I guess my first question is I'm wondering if you're seeing any trends towards maybe less sick higher FEV1 patients going on to therapy over time, which could be with ORKAMBI, which theoretically improved persistence and compliance. And then on 661, if 661 looks better tolerated but perhaps less efficacious than lumacaftor, I'm just wondering how you weigh which potential backbone to combine with the next-generation corrector into a triple combo."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So in terms of the -- any trends to where the product's being used, in either sicker patients or less sick patients, to be honest with you, Brian, with 65% of eligible patients being initiated, it's being used across the board. Obviously, we've got a rang",109,"So in terms of the -- any trends to where the product's being used, in either sicker patients or less sick patients, to be honest with you, Brian, with 65% of eligible patients being initiated, it's being used across the board. Obviously, we've got a range of different physicians and centers here. Some started using it in their more severe patients. Others started using it in their less severe patients. But we really are seeing usage across the whole range of FEV1 patients, as you would imagine, with 65% of eligible patients having been initiated. And on the backbone, the triple combination, I'll pass that over to Jeff Leiden."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Just on the triple combination, obviously, we can't speculate then exactly what will happen, but I would remind you that there were a number of reasons that 661 is the preferable partner. Most of those have to do with drug-drug interactions and makin",93,"Yes. Just on the triple combination, obviously, we can't speculate then exactly what will happen, but I would remind you that there were a number of reasons that 661 is the preferable partner. Most of those have to do with drug-drug interactions and making it simpler to combine it into a triple regimen. So I guess what I would say is, all things being equal, if 661 and lumacaftor had equal efficacy in combination with KALYDECO, we're certainly going to go with 661 because of those pharmacokinetic properties. Does that answer the question?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes -- well, not exactly. I guess, I was sort of wondering whether -- I mean, we know 661 has less CYP3A4 interactions. And sort -- I guess, I was sort of wondering whether some of the real-world ORKAMBI side effects that you're seeing are perhaps driven",81,"Yes -- well, not exactly. I guess, I was sort of wondering whether -- I mean, we know 661 has less CYP3A4 interactions. And sort -- I guess, I was sort of wondering whether some of the real-world ORKAMBI side effects that you're seeing are perhaps driven by not only the respiratory AEs but driven by CYP3A4, which we know is going to look better with 661 and sort of how you weigh that if efficacy is perhaps not as good."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. That's not the reason just to be clear. So those AEs are not driven by CYP interactions. We feel they're driven, as we said before, by off-targeted bronchoconstriction that's unique to lumacaftor and we don't see or haven't seen with 661.",42,"Yes. That's not the reason just to be clear. So those AEs are not driven by CYP interactions. We feel they're driven, as we said before, by off-targeted bronchoconstriction that's unique to lumacaftor and we don't see or haven't seen with 661."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Adam Walsh of Stifel.",12,"Our next question comes from the line of Adam Walsh of Stifel."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A few weeks ago, we published a 47-physician ORKAMBI survey, and a few things jump out at us. I want to bounce them off you. Most notably, our survey showed that if patients discontinue ORKAMBI due to drug-related side effects, 70% of doctors encourage th",99,"A few weeks ago, we published a 47-physician ORKAMBI survey, and a few things jump out at us. I want to bounce them off you. Most notably, our survey showed that if patients discontinue ORKAMBI due to drug-related side effects, 70% of doctors encourage these patients to restart the drug, and then a very meaningful percentage of those patients not only successfully restart the drug but also subsequently remain on the drug long term. So my questions are: Is this consistent with your own internal research? Are patient restarts factored into your guidance? And if so, to what extent?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Adam, it's Stuart here. Thanks for the question. In terms of restarts, yes, your survey is consistent with what we've heard in that we have heard from physicians that they are trying to restart ORKAMBI in some of their patients, who they have previousl",175,"So Adam, it's Stuart here. Thanks for the question. In terms of restarts, yes, your survey is consistent with what we've heard in that we have heard from physicians that they are trying to restart ORKAMBI in some of their patients, who they have previously had to discontinue the product in largely because, as you know, that they are often firm believers that treating the underlying cause of the disease is clearly a good thing for those patients if they can tolerate the medicine. In terms of the absolute volume of that, at the minute, that's hard to quantify. We certainly heard it anecdotally. We've certainly heard success stories. It's fair to say though that within our guidance, we've assumed relatively minimal impact from restarts because, at this time, we really don't have evidence that it's happening in quite the numbers that perhaps people have said that they might do it in. So at the moment within our guidance, relatively minimal amount of restarting patients is assumed to happen in 2016 here in the U.S."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Phil Nadeau of Cowen and Company.",14,"Our next question comes from the line of Phil Nadeau of Cowen and Company."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two on commercial, then a quick one on the pipeline. On the commercial, can you give us some sense of how many lives outside the U.S. could gain reimbursement for ORKAMBI in 2017? Sure you have internal estimates and ranges. I'm curious what those are. An",116,"Two on commercial, then a quick one on the pipeline. On the commercial, can you give us some sense of how many lives outside the U.S. could gain reimbursement for ORKAMBI in 2017? Sure you have internal estimates and ranges. I'm curious what those are. And then similarly in the younger kids, do you expect any different penetration of ORKAMBI into that population than you've seen in the older kids and adults? And then last, on the triple, can you let us know if you've combined all 3 drugs in healthy volunteers yet and what your disclosure strategy will be when you move into Phase II? How much data from the Phase I will we get?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Phil, it's Stuart here. I'll take those 2 first commercial questions. In terms of the number of lives that might be eligible, the number of patients with the F508del homozygous mutation, 12 and above in Europe is somewhere around 12,000. Within our '16",216,"So Phil, it's Stuart here. I'll take those 2 first commercial questions. In terms of the number of lives that might be eligible, the number of patients with the F508del homozygous mutation, 12 and above in Europe is somewhere around 12,000. Within our '16 guidance, the only country that we're assuming we're going to be able to recognize revenues for is in Germany. We're not in a position to be able to give 2017 guidance at this point. I'm trying to predict exactly when this reimbursement discussion is going to conclude. It's frankly impossible to do because, clearly, it's a negotiation, and the vast majority of countries don't have a formal time clock. And so at this point, we're really not in a position to be able to speculate on when those might be concluded. In terms of what we would be anticipating in the 6- to 11-year-old population, if we are successful in gaining approval for that here in the U.S., then our anticipation would be much as we've seen with KALYDECO, that the uptake there is likely to be similarly robust as we've seen in adults. Although I would remind you that, from a 2016 perspective, that's likely to come in the second half or in the second half the second half of 2016."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Phil, I'll take the last question. So the Phase I study in healthy volunteers is still ongoing, so we can't basically make comment on that. But in terms of disclosure and time line, still as we've discussed before, we expect to be in patients with tri",100,"And Phil, I'll take the last question. So the Phase I study in healthy volunteers is still ongoing, so we can't basically make comment on that. But in terms of disclosure and time line, still as we've discussed before, we expect to be in patients with triple combination in the second half of the year. The disclosure of the Phase I around that will be relevant information that supports the Phase II study design. At this point, that is too difficult to describe, and we'll let you know when we have that information and we're initiating the Phase II study."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Cory Kasimov of JPMorgan.",12,"Our next question comes from the line of Cory Kasimov of JPMorgan."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have 2 left for you. So realized it's early, but wanted to ask about the potential impact of payer reauthorizations on ORKAMBI? How common is it? And how does it compare with the process you saw with KALYDECO? And then a capital allocation question for",77,"I have 2 left for you. So realized it's early, but wanted to ask about the potential impact of payer reauthorizations on ORKAMBI? How common is it? And how does it compare with the process you saw with KALYDECO? And then a capital allocation question for you. Now that you're profitable and growing and you're sitting on $1 billion in cash in your balance sheet, at what point would you consider buying back some of your stocks?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Cory, on the payer reauthorizations, not all payers have published policies that include their reauthorization criteria. That's the first thing I'd say. Of the ones you have, most have a time clock of 6 to 12 months. So we're really only now beginning",178,"So Cory, on the payer reauthorizations, not all payers have published policies that include their reauthorization criteria. That's the first thing I'd say. Of the ones you have, most have a time clock of 6 to 12 months. So we're really only now beginning to get to the point of patients getting to the time point when they are having to go through the reauthorization process. Having said that, the payers that have published policies or where their reauthorization criteria are known, the vast majority of them are either in line with the label or reflect the systemic benefits of ORKAMBI. And by that, I mean they recognize that this product can have benefits across multiple endpoints, and either improvements or stabilization in those endpoints qualifies as a successful outcome. So whilst we are only now beginning to get into the period of seeing those reauthorizations, I feel good about the reauthorization criteria that we've seen to date. And to your last part of your question, they are not dissimilar at all to what we saw with KALYDECO."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And to the last question, we have thought about stock buybacks in terms of capital allocation. But as we think about the priority of capital allocation for our business, I'll just give you a broader thought, which is we're still in this transitional perio",214,"And to the last question, we have thought about stock buybacks in terms of capital allocation. But as we think about the priority of capital allocation for our business, I'll just give you a broader thought, which is we're still in this transitional period of moving into profitability and cash generation and watching the revenue curve. As we go up the revenue curve and we drive revenue growth and therefore, earnings growth, which translates to cash gen -- more cash generation, we look to apply that capital to reinvest back in the business first, first, internally into our pipeline but then potentially outside of the company to diversify and expand our pipeline. And we've already done activities in that area, as you know, with CRISPR and our ENaC inhibitor. So those continue to be the priorities. It's the internal investments. It's the external investments. But as we go up that revenue growth curve and have greater capital to allocate, we will give consideration to capital strategies such as share buybacks, but at this point in time, it's a little early for us. And if we were to move into something in the near future, it would be of a smaller scale to stop the shares outstanding creep that occurs each year through option exercises."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Alethia Young of Crdit Suisse.",13,"Our next question comes from the line of Alethia Young of Crdit Suisse."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Thanks for taking my question. It's -- the 3 of them are kind of around compliance. And I guess, when I look at the math that we get over the quarters, it seems like the first 2 quarters, the compliance was potentially higher, like 95%, and maybe in this",180,"Thanks for taking my question. It's -- the 3 of them are kind of around compliance. And I guess, when I look at the math that we get over the quarters, it seems like the first 2 quarters, the compliance was potentially higher, like 95%, and maybe in this quarter, based on our math, it would have gotten us to about 80%. So I guess, one, is that assumption -- is that analysis fair? Two, can you give us any color on if the scripts written in 1- or 3-month increment? And then third, just when you think about 70% to 80% range on compliance, which actually does move the model quite a bit, what kind of qualitatively do you think about that kind of gets you in the 70% range versus the 80% range? Do we think about like amount of days that people are taking so that there's a delta in the days they miss and just kind of adding that up and thinking about it? Or is there some other way we should think about quantifying compliance?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So yes, let me try and answer those sequentially. In terms of the compliance trend, compliance is the metric that you need the longest period of time to measure because, clearly, this is a chronic medicine, and so in the first prescription they get, your",315,"So yes, let me try and answer those sequentially. In terms of the compliance trend, compliance is the metric that you need the longest period of time to measure because, clearly, this is a chronic medicine, and so in the first prescription they get, your kind of assumption is that you're 100% compliant. You have to wait until they get the second prescription to work out exactly what it is. So this is the one that really takes the longest period of time for us to get a good handle on. I don't know obviously the intricacies of your model. I'll just reiterate that, based on the trends that we've seen to date and the experience we've got with the patients who have been treated to date, our expectation for the year and the assumption on which our guidance is built is that it'll be somewhere between 70% and 80% for ORKAMBI this year. In terms of the 1- or 3-month script, the vast majority are written for 1 month. There are some 3-month prescriptions written, but the vast majority of prescriptions are written for -- on a monthly basis. And in terms of kind of qualitatively, what would lead you to one end versus the other, to me, this is all about education and our ability to help providers to give to their patients information, which educates them on the nature of the disease, the underlying defects, the fact that ORKAMBI is designed to treat those underlying defects, and to the extent they believe in the science, believe in the long-term benefits that ORKAMBI can provide to them, then I think that's only likely to lead to patients having a higher compliance rate. We're very focused on that. We're certainly taking all the learnings we can from our experience with KALYDECO to support patients to take the prescriptions in line with their physician's recommendations."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Matthew Harrison of Morgan Stanley.",13,"Our next question comes from the line of Matthew Harrison of Morgan Stanley."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have 2, which are somewhat follow-ups on Phil's questions. Just on next-generation correctors and those studies, can you just tell us if you saw a safety event, what kind of safety event would be disclosable versus not disclosable? And then is there a p",123,"I have 2, which are somewhat follow-ups on Phil's questions. Just on next-generation correctors and those studies, can you just tell us if you saw a safety event, what kind of safety event would be disclosable versus not disclosable? And then is there a point in time that we're going to see PK data from healthy volunteers, which might help us better understand how the drug levels that we saw on the HBE data might compare in patients? And then a separate commercial question. Just, in the 6 to 12 pool for ORKAMBI, are your assumptions for persistence in discontinuation rate the same as what you're seeing now in the older population? And if they're not the same, can you just explain why?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So maybe I'll take the first couple of questions. So with the next-gen disclosure, what would be required to disclosure of is Reg FD, and if there was a material adverse event, we would have to disclose that. If you want me to give an example, that would",132,"So maybe I'll take the first couple of questions. So with the next-gen disclosure, what would be required to disclosure of is Reg FD, and if there was a material adverse event, we would have to disclose that. If you want me to give an example, that would be a discontinuation of the trial for example, and we would have to disclose that. Other than that, it's an ongoing trial. We need to complete the trial, gather the data. That will inform us, as I said earlier, for the Phase II trial in patients with triple combination, and we will provide relevant information at that point in time that supports the design of that trial. Can you just remind me of your second question in terms of the disclosures? [indiscernible] ..."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes -- no, I was just wondering, will we see PK data so that we can compare sort of the drug levels that you can achieve in healthy volunteers versus the drug levels that you were achieving in the HBE assays, so we have some point of comparison on relativ",52,"Yes -- no, I was just wondering, will we see PK data so that we can compare sort of the drug levels that you can achieve in healthy volunteers versus the drug levels that you were achieving in the HBE assays, so we have some point of comparison on relative drug levels."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So we'll provide it in relative information that helps you understand the design of the Phase II study. However, it is not our practice to provide that kind of detail on a Phase I study. Then, there's a number of reasons for that, and I would just give yo",74,"So we'll provide it in relative information that helps you understand the design of the Phase II study. However, it is not our practice to provide that kind of detail on a Phase I study. Then, there's a number of reasons for that, and I would just give you one, that there is a specific competitive reason that would -- we would prefer not to provide that information on a Phase I study."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Matt, in the 6 to 11, I mean, really, the contribution of the 6 to 11 population, it was successful in getting approval. As I said, it's really going to be in the -- likely be in the fourth quarter. So really, the contribution there within our overall",191,"And Matt, in the 6 to 11, I mean, really, the contribution of the 6 to 11 population, it was successful in getting approval. As I said, it's really going to be in the -- likely be in the fourth quarter. So really, the contribution there within our overall guidance is more about uptake than it is around persistence and compliance. And much as we did with the 12 and above population, I think we'll obviously be watching that very, very closely just as we have done since the launch in July. And that'll give us an ability to learn how the product performs with those patients in the real world. Again, one of the things that we have seen obviously with the younger population with KALYDECO is they tend to be slightly more compliant than the average, not surprisingly, because they've got a lot of parental and caregiver supervision. But really, those assumptions that we've given you are really much more related to the 12 and above population. We'll see how the 6 to 11 patients play out in the real world in the course of time after the approval."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Ying Huang of Bank of America Merrill Lynch.",16,"Our next question comes from the line of Ying Huang of Bank of America Merrill Lynch."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Number one, I want to know if you guys have seen an uptick in discontinuation due to lack of efficacy or it's all due to the, I guess, chest tightness. And then secondly, for the ATU pricing you get in France, how does that compare to the German pricing o",83,"Number one, I want to know if you guys have seen an uptick in discontinuation due to lack of efficacy or it's all due to the, I guess, chest tightness. And then secondly, for the ATU pricing you get in France, how does that compare to the German pricing of EUR 159,000 per year per patient? And lastly, I have a question on your gross to net. Is that consistent what you guys have guided before, which is like mid-teens in 1Q '15?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So in terms of discontinuations, the -- based on our clinical trial experience and also what we are seeing in the market, the vast majority of those discontinuations are for adverse events, and most commonly, that's the chest tightness. In terms of the AT",159,"So in terms of discontinuations, the -- based on our clinical trial experience and also what we are seeing in the market, the vast majority of those discontinuations are for adverse events, and most commonly, that's the chest tightness. In terms of the ATU, we haven't disclosed the price within the ATU program. And in terms of the gross to net, the gross to net that we've seen and are predicting is potentially slightly lower than we originally thought. That's largely due to the fact that the Medicaid patient population that we're seeing is slightly lower than we anticipated. This is really as a result of many of those Medicaid patients that we thought would be covered by Medicaid or actually qualifying for disability benefit under Medicare. As a result of that, we're seeing a lower Medicaid population, and in result, we're seeing -- we're predicting a slightly lower gross to net of somewhere around 12% for the year."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. I'd like to just add to that, Stu, which is in the -- coming into 2016 and 2015 with the gross to net on ORKAMBI was close to 7%. As we moved into the Q1 of 2016, it's increased to 9%. So it is moving up slightly as we expected, but as we plot out an",94,"Yes. I'd like to just add to that, Stu, which is in the -- coming into 2016 and 2015 with the gross to net on ORKAMBI was close to 7%. As we moved into the Q1 of 2016, it's increased to 9%. So it is moving up slightly as we expected, but as we plot out and we look at the patients that are coming on to the drug, we anticipate that it could end the year around 12% as it gradually creeps up to that 12% level. That also plays into our guidance."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Liisa Bayko of JMP Securities.",14,"And our next question comes from the line of Liisa Bayko of JMP Securities."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just a couple of technical questions. Were there any inventory changes in the quarter?",14,"Just a couple of technical questions. Were there any inventory changes in the quarter?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","No. The ORKAMBI inventory at the end of March was, to all intents and purposes, identical to that, which it was at December 31. So there was really no inventory change for ORKAMBI at all.",35,"No. The ORKAMBI inventory at the end of March was, to all intents and purposes, identical to that, which it was at December 31. So there was really no inventory change for ORKAMBI at all."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, great. And then can you comment on gross to net? Sort of where were you for the quarter? And would that be relatively consistent for the rest of the year? Will it change in some way?",37,"Okay, great. And then can you comment on gross to net? Sort of where were you for the quarter? And would that be relatively consistent for the rest of the year? Will it change in some way?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Are you referring to ORKAMBI, Liisa?",6,"Are you referring to ORKAMBI, Liisa?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, sorry.",2,"Yes, sorry."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. So I actually just mentioned this, which is that in Q1 we were at approximately 9% gross-to-net discount, and in Q4 of last year, we were at 7%. We actually expect the Q1 level of 9% to trend up to be something closer to 12% by the end of the year.",52,"Yes. So I actually just mentioned this, which is that in Q1 we were at approximately 9% gross-to-net discount, and in Q4 of last year, we were at 7%. We actually expect the Q1 level of 9% to trend up to be something closer to 12% by the end of the year."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then when you say 15% of 65% have discontinued, so that's like a 10% discontinuation rate roughly. Is that the right way to think about that?",27,"And then when you say 15% of 65% have discontinued, so that's like a 10% discontinuation rate roughly. Is that the right way to think about that?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","No, Liisa. So -- and it's really important, so thanks for asking the question. It is, of the patients you've initiated, 15% of them have discontinued ORKAMBI within approximately the first 3 months. The -- and so if you think about 4,500 patients who init",125,"No, Liisa. So -- and it's really important, so thanks for asking the question. It is, of the patients you've initiated, 15% of them have discontinued ORKAMBI within approximately the first 3 months. The -- and so if you think about 4,500 patients who initiated between July and December, 15% of those patients would have discontinued within the first 3 months, and then that rate of discontinuations slows considerably. The 65% is the number of patients you've initiated therapy by the end of March. So the 15%, you need to apply to all of the patients who initiated. It's -- you don't -- it's not 15% of 65% is 10%. It's 15% of the 65% who have initiated, they will discontinue therapy in our belief."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Right. But that got you 10%. Doesn't it if you multiply 65% by 15%?",14,"Right. But that got you 10%. Doesn't it if you multiply 65% by 15%?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Liisa, we'll jump on the phone with you after the call, and we'll do the math.",16,"Liisa, we'll jump on the phone with you after the call, and we'll do the math."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then I just had a question about the Rho inhibitor. Can you just give us a little detail on that trial? What are the endpoints you're looking at? What's the timing for data? That's my final question.",38,"And then I just had a question about the Rho inhibitor. Can you just give us a little detail on that trial? What are the endpoints you're looking at? What's the timing for data? That's my final question."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Liisa, it's Jeff. So the Rho inhibitor trial is really specifically in patients who had a pretty catastrophic injury to their cervical spine and then really have very poor function immediately following that injury. In the studies then, we follow those pa",139,"Liisa, it's Jeff. So the Rho inhibitor trial is really specifically in patients who had a pretty catastrophic injury to their cervical spine and then really have very poor function immediately following that injury. In the studies then, we follow those patients. At the time of surgery, they have either placebo or 1 of 2 doses of active drug, and there's about 150 patients total. And then we follow them for 6 months looking at particularly how their upper extremities function because that's so important to how patients, the quality of life of patients, and then we do some other measures of disability. And it's very hard right now. We just started the study as we've said, so I think it's very hard to predict in that kind of population, in particular, exactly when we're going to get results."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Tony Butler of Guggenheim.",12,"Our next question comes from the line of Tony Butler of Guggenheim."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Briefly, Stuart, in France, again, the early-access patients which receive ORKAMBI, I think you mentioned 400. I understand reimbursement has not occurred. But given the uptake being fairly strong, if one assumes that the majority of that 1,500 will be tr",82,"Briefly, Stuart, in France, again, the early-access patients which receive ORKAMBI, I think you mentioned 400. I understand reimbursement has not occurred. But given the uptake being fairly strong, if one assumes that the majority of that 1,500 will be treated by year-end and you do get reimbursement, let's say, next year, is -- does that come in a bolus payment for that, which has occurred? Or is that payment then amortized assuming those patients stay on drug for '17 and beyond?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Thanks for the question, Tony. So the way the accounting works in France is for that the cash that we get for those patients before we get reimbursed, those recognized as cash, not as revenue. At the point that we have certainty about the selling pri",119,"Yes. Thanks for the question, Tony. So the way the accounting works in France is for that the cash that we get for those patients before we get reimbursed, those recognized as cash, not as revenue. At the point that we have certainty about the selling price or very close to certainty about the selling price in France, then we will be able to, in a one term adjustment, convert that cash to revenues. And then from that point forward, all of those will be counted as revenues going forward. And that's because the -- whatever rebate you agree with the French government is retroactive to the sales that you've had from the point that you launched the product."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And finally, you would call that out as an item in the quarter in which it occurs, I assume.",19,"And finally, you would call that out as an item in the quarter in which it occurs, I assume."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So maybe I'll follow on from Stuart's answer. So I'll just validate Stuart's answer as the kind of a CPA. So nice job, Stuart. In terms of revenue recognition, many of you that are on this call probably have seen other companies go through this with the A",101,"So maybe I'll follow on from Stuart's answer. So I'll just validate Stuart's answer as the kind of a CPA. So nice job, Stuart. In terms of revenue recognition, many of you that are on this call probably have seen other companies go through this with the ATU in France. And then absolutely, at the point that we are -- we get to a point where we're confident with the price in France, yes, we would call it out in the quarter specifically. And at that same point in time, we would recognize all the revenue in that very quarter."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our final question comes from the line of Katherine Xu of William Blair.",14,"And our final question comes from the line of Katherine Xu of William Blair."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So I just have one question on the CRISPR program. Based on the research that you have ongoing right now, what kind of mutations are the most amenable for the technology first and how difficult it is to eventually correct the F508, which is a deletion you",53,"So I just have one question on the CRISPR program. Based on the research that you have ongoing right now, what kind of mutations are the most amenable for the technology first and how difficult it is to eventually correct the F508, which is a deletion you have at that single base pair?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. This is Jeff Leiden. Thanks for the question. I think, as you know, right -- if you look today, CRISPR is most amenable to actually inactivate, which is making cleavages, because that's what it does most efficiently, and obviously, that's not what we",239,"Yes. This is Jeff Leiden. Thanks for the question. I think, as you know, right -- if you look today, CRISPR is most amenable to actually inactivate, which is making cleavages, because that's what it does most efficiently, and obviously, that's not what we would want to do in a Delta 508 case. Then, you move to making corrections, and then you move to more complex deletions and insertions. So there's no doubt that there are still challenges to conquer both in terms of how we correct deletions like in Delta 508 but also how we deliver this because, obviously, this has to be delivered efficiently to large numbers of cells in the lungs, and we don't know how to do that yet. So that's why we said, while we think CRISPR is an incredibly powerful technology for the future, it's going to take a number of years to conquer both the -- some of the editing challenges but also, in particular, the delivery challenges, and that's what we're working on in CF. Now we're also -- I'll just remind you that CRISPR-Cas9 collaboration, we have rights to several targets, fixed targets, and some of those will be in other diseases where some of these issues, like delivery and editing, are much more straightforward. So I think you can expect to hear from us over the next couple of years on our progress in some of those other diseases."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So at this point, are there mutations that easier than others to edit? Do we know that?",17,"So at this point, are there mutations that easier than others to edit? Do we know that?"
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. As I say, I think single base pair corrections are going to be a lot easier than complex deletions and insertions to correct. But nevertheless, I mean, there are some pretty significant challenges in diseases like CF. When you move to ex-vivo therapy",81,"Yes. As I say, I think single base pair corrections are going to be a lot easier than complex deletions and insertions to correct. But nevertheless, I mean, there are some pretty significant challenges in diseases like CF. When you move to ex-vivo therapy and you move to inactivation in ex-vivo therapy, you're in a whole different world in terms of efficiency, and so you will see some of those, I think, from us and others as being the first application."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So I'll turn it back over to Jeff maybe for some final comments tonight.",15,"So I'll turn it back over to Jeff maybe for some final comments tonight."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. First of all, thank you for your questions, thanks for your patience. I know it was a long call, but we do want to give you not only our guidance but a detailed rationale for the guidance so that you understand our model. And we appreciate your quest",362,"Yes. First of all, thank you for your questions, thanks for your patience. I know it was a long call, but we do want to give you not only our guidance but a detailed rationale for the guidance so that you understand our model. And we appreciate your questions on that.
As I look at our progress as a company over the last year, I guess I would call out 3 things that I think are important. First, the continuous increase in the number of patients that we can treat and actually fairly dramatic increase in the number of patients that we can treat with KALYDECO and ORKAMBI; and as we look forward, the increasing number of patients that we can treat with today's approval. So as I mentioned, 27,000 eligible, we're still only treating 1/3 of those, and I think we have a clear path to get to the majority of those patients both in the U.S. and Europe over '16 and '17 and beyond.
Second thing I would say is the pipeline progression. We're pleased with 661 progressing well into Phase III of multiple trials and multiple patient populations but equally important, we have the next-gen correctors, which are progressing through Phase I with our -- and still on a time line to get into patients as triple combinations later this year. We think that's going to be very important both for the patients we treat and potentially for additional subsets of patients.
And then finally, the progression of the science. We didn't talk about that a lot today, but the science of CF, I think, has progressed significantly, and we have a much better understanding of the folding and correction process. And the science that David Altshuler is driving and the rest of research group in some of the new diseases, we touched on those a little bit with CRISPR-Cas9 but also others that I hope we will be able to have a chance to talk to you about over the rest of '16 and '17. It's an important long-term growth engine for the company.
So with that, maybe I'll close the call, and thanks again for joining us."
36235,331185758,965292,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening. This is Michael Partridge, Vice President of Investor Relations. Welcome to our First Quarter 2016 Conference Call. [Operator Instructions] A replay of tonight's call will also be available on the website once we have concluded.Dr. Jeff Le",199,"Good evening. This is Michael Partridge, Vice President of Investor Relations. Welcome to our First Quarter 2016 Conference Call. [Operator Instructions] A replay of tonight's call will also be available on the website once we have concluded.
Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; and Ian Smith, Chief Financial Officer will provide prepared remarks this evening. They will be joined by Dr. Jeff Chodakewitz, Chief Medical Officer, for the Q&A portion of the conference call. 
We will make forward-looking statements on this call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the SEC. These statements, including without limitation, those regarding the ongoing development and potential commercialization of our drug candidates, our expectations regarding our improved medicines and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in tonight's press release. I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Dr. Jeff Leiden."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. Over the last 4 years, Vertex has delivered 2 transformative medicines to people with cystic fibrosis. Today, there are approximately 27,000 people eligible for 1 of our approved CF medicines, and we have a clear p",1797,"Thanks, Michael. Good evening, everyone. Over the last 4 years, Vertex has delivered 2 transformative medicines to people with cystic fibrosis. Today, there are approximately 27,000 people eligible for 1 of our approved CF medicines, and we have a clear path toward our goal of helping potentially all people with this rare and life-shortening disease in the future.
We're confident that our experience with ORKAMBI and KALYDECO, and our scientific leadership and progress in targeting the underlying biology of this disease, positions us well to increase the number of people treated with our approved medicines and to develop new medicines in the years ahead that may provide even greater benefit for all people with CF.
Tonight, I'll provide brief comments on 3 key areas which serve as markers of our progress toward treating all people with CF, including: first, the performance of our approved medicines, ORKAMBI and KALYDECO, and our road map toward treating more patients with these medicines that will drive revenue growth in 2016 and beyond; second, the role of VX-661 in helping to achieve our long-term goal in CF; and third, our pipeline of additional CFTR modulators and other mechanisms we're advancing as part of collaborations. These approaches include the ENaC inhibition, and in the longer-term, gene editing with CRISPR-Cas9, and may position us to help all people with CF.
We're approximately 9 months into the launch of ORKAMBI in the U.S. for people with 2 copies of the F508del CFTR mutation ages 12 and older. As of the end of March, approximately 65% or 5,500 of the 8,500 currently eligible patients in the U.S. have initiated treatment with ORKAMBI. We expect the number of patients who've initiated treatment with ORKAMBI will continue to grow during 2016. And we continue to expect that by the end of the year, the vast majority of all eligible patients ages 12 and older in the U.S. will have initiated treatment.
We've seen excellent reimbursement and access for ORKAMBI from public and private payers in the U.S., and the feedback from the CF community continues to be very positive. Importantly, patients across the U.S. have broad access to the medicine through public and private insurance. And we have assistance programs in place for eligible patients who need additional help. All major commercial insurers in all 50 state Medicaid programs are currently covering ORKAMBI, reflecting the important advance and value this medicine represents in the treatment of CF.
We're now moving forward to our bringing ORKAMBI to younger patients. And at the end of March, we submitted a supplemental New Drug Application to the FDA, requesting approval of ORKAMBI for children ages 6 to 11 with 2 copies of the F508del mutation. We requested priority review, which if granted, would provide us with the decision on the application in the second half of this year. If approved, approximately 2,400 additional patients in the U.S. would be eligible for treatment.
Outside the U.S., we have commenced discussions with reimbursement agencies in various European and other countries. Given the clinical benefits of ORKAMBI and the severity of the disease for people with 2 copies of the F508del mutation, we believe that we will achieve reimbursement from key European and other government payers, just as we've seen in the U.S. ORKAMBI is already commercially available in Germany and through early access programs in France.
In the near term, the progress and our understanding of treating eligible patients with ORKAMBI gives us clarity on a revenue expectation for 2016. Later in the call, Stuart and Ian will talk about the ORKAMBI launch in detail, our guidance and how we think about revenue trends from 2015 and growth into 2016 and further into the future.
For KALYDECO, we're increasing our revenue guidance for 2016, which Stuart will discuss in his remarks. As we think about the future opportunities for ORKAMBI and KALYDECO, I want to emphasize that revenue growth in 2016 and beyond is largely a function of additional patients who are currently eligible for ORKAMBI or KALYDECO and initiating treatment with these medicines. On that basis alone, we believe there's significant growth ahead for both medicines. 
Consider that today, ORKAMBI and KALYDECO are approved for approximately 27,000 people worldwide. But we're only currently treating approximately 1/3 of these patients. As we see additional uptake of ORKAMBI in the U.S. and achieve reimbursement for eligible patients outside the U.S., growth will continue as additional patients continue to initiate treatment.
In addition, there are many more patients not currently eligible for treatment who may benefit from either ORKAMBI or KALYDECO. In total, we believe there are approximately 44,000 people, an additional 17,000 people beyond those eligible today, who could benefit from 1 of these 2 medicines. This additional group of patients was largely comprised of the following: first, approximately 12,000 people less than 12 years of age who have 2 copies of the F508del mutation and who may be helped by ORKAMBI; and second, approximately 5,000 patients who may be helped by KALYDECO comprised mostly of patients who have a residual function mutation. 
Treating a substantial portion of this additional group of 17,000 patients would further drive ORKAMBI and KALYDECO growth if we obtain future approvals for these additional groups of patients. We have ongoing studies, regulatory submissions and development plans to support these efforts, including ongoing discussions with the FDA regarding our application for approval of KALYDECO in approximately 1,500 people ages 2 and older with 1 of 23 residual function mutations as well as our recent sNDA submission to the FDA for approval of ORKAMBI in children ages 6 to 11 with 2 copies of the F508del mutation.
While we are focused on getting ORKAMBI and KALYDECO to as many patients as possible as soon as possible, we also recognize that there are many patients who are still waiting for a treatment for the underlying cause of their disease. We hear from these patients often, so I'm particularly pleased to report that our CF pipeline is advancing. This gives us great confidence that we will ultimately be able to treat the vast majority of people with CF and potentially enhance the benefit for those people currently taking our approved medicines.
I'll start with VX-661, which could play an important role in the treatment of people with CF and is currently in Phase III development. In combination with ivacaftor, our Phase II data suggested that VX-661 may have an improved benefit risk profile compared to ORKAMBI in people with 2 copies of the F508del mutation and may provide enhanced clinical benefits over ivacaftor monotherapy for other patients with gating mutations. We are on track to obtain the first data from the ongoing Phase III program for VX-661 in early 2017 from the study in people with 2 copies of the F508del mutation.
Additionally, VX-661 is positioned to play a key role in the development of a triple combination with a next-generation corrector in ivacaftor. We believe that this triple-combination approach will be fundamental for 2 reasons: first, triple combinations may allow us to treat a very large group of patients who are not helped today by either ORKAMBI or KALYDECO, including those with 1 F508del mutation and a second mutation that causes minimal CFTR function; and second, these regimens could provide even greater benefit to patients currently eligible for our approved medicines who have at least 1 F508del mutation.
Today, we have 2 next-gen correctors in clinical development: VX-152 and VX-440. These potential medicines are currently being evaluated in Phase I studies in healthy volunteers. Successful completion of these studies would enable us to move rapidly into Phase II studies in the second half of 2016 to evaluate 1 or more next-generation correctors with VX-661 and ivacaftor in people with CF.
I'll now turn to our pipeline of other potential CF medicines that could be complementary to our portfolio of CFTR modulators, and it may enable us to treat more patients and provide greater clinical benefit in the years to come. The most advanced example of this is our lead ENaC inhibitor, VX-371. Today, we announced data from a Phase II 14-day study of VX-371 in 142 people with CF who are not receiving ORKAMBI or KALYDECO. The study met its primary endpoint of safety. 96% of the patients who enrolled in the study completed all treatment, and the treatment regimens consisting of VX-371 were generally well tolerated. There were no statistically significant changes from baseline in FEV1 for those patients who received VX-371 compared to placebo. 
The data announced today are consistent with our in-vitro data that did not show a meaningful change in cilia beat frequency when VX-371 was used alone in human bronchial epithelial cells with 2 copies of the F508del mutation. In contrast, these in-vitro data did show a meaningful change in cilia beat frequency when VX-371 was used in combination with ORKAMBI. Together, the in-vitro and clinical safety data generated to date provide further support for our ongoing study of VX-371 in combination with ORKAMBI. This ongoing study began enrolling people with 2 copies of the F508del mutation ages 12 and older in the first quarter of this year. And the primary endpoints are safety and mean absolute change from baseline in lung function at Day 28 of treatment as compared to placebo. Additional information on these studies can be found in our first quarter press release issued today.
Additionally, last year, we entered into a collaboration with CRISPR Therapeutics, with a longer-term goal of discovering gene-editing approaches for the treatment of genetic diseases, including CF. The use of this technology in people with CF may be many years away, but it is strategically important as we think about future advances that could fundamentally change the treatment of this disease in the years to come.
Tonight, I've summarized how we think about our opportunity in CF, an opportunity that is unique, both in terms of the potential benefit that ORKAMBI and KALYDECO provides the people with CF today and also for the long-term potential of our development-stage medicines to treat the vast majority of people with CF in the future.
In conclusion, I'll make just a few comments about the type of company we will become as we achieve the success in CF that I've just outlined. Vertex is on a path towards sustained earnings and revenue growth, driven by an increasing number of people being treated with KALYDECO and ORKAMBI. We believe our business model, one focused on significant investment to create value through innovation, research and development, positions us to consistently discover and deliver transformative new medicines for patients and to reinvest in scientific opportunities to create future medicines.
With that, I'll turn the call over to Stuart to make more specific comments on the ORKAMBI launch."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. Tonight, I will review our progress with the launch of ORKAMBI, the basis of our 2016 guidance for ORKAMBI product revenues and our ongoing efforts to obtain reimbursement outside the U.S. to drive further growth of ORKA",1180,"Thanks, Jeff, and hello, everyone. Tonight, I will review our progress with the launch of ORKAMBI, the basis of our 2016 guidance for ORKAMBI product revenues and our ongoing efforts to obtain reimbursement outside the U.S. to drive further growth of ORKAMBI in 2017 and beyond.
We are now just over 9 months into the launch, and we are pleased that approximately 65% of eligible patients in the U.S. have initiated treatment with ORKAMBI to date. Global sales of ORKAMBI in the first quarter were $223 million, comprised of U.S. sales of approximately $214 million and ex U.S. sales of approximately $9 million, which were mainly from Germany. 
At the beginning of the year, our intention was to provide financial guidance for 2016 ORKAMBI revenues once we have gained sufficient understanding of the dynamics of the launch in the U.S. Today, we have a deeper understanding if our doctors and their patients are using the medicine, based on the real-world treatment patterns we've observed in more than 4,500 patients who initiated treatment in the U.S. in 2015. 
I'll now share with you our understanding of the launch dynamics that informed our guidance. First, uptake, defined as the total proportion of the 8,500 eligible patients in the U.S. who will begin treatment with ORKAMBI by the end of 2016 and also the rate at which these patients initiate treatment. Second, the persistence rate, defined as the proportion of patients who start and remain on treatment. And third, the compliance rate, which reflects the number of pills actually taken by a patient in a given month.
First, to uptake. To date, approximately 65% of the 8,500 eligible patients in the U.S. have initiated treatment with ORKAMBI, comprised of more than 3,000 patients who initiated treatment in the third quarter of 2015, more than 1,500 in the fourth quarter and approximately 800 in the first quarter of 2016. We have seen further initiations in April and expect that patient initiations will continue throughout 2016, albeit the lower rate than in the first 3 quarters post-launch. We continue to expect that the vast majority of the eligible patients ages 12 and older in the U.S. will initiate treatment with ORKAMBI by the end of this year.
Second, persistence. Among patients who have initiated ORKAMBI since launch, we've seen that approximately 15% of patients discontinued treatment within 3 months of starting treatment. Our clinical trial and market research data indicate that these discontinuations are largely related to respiratory adverse events. After the first 3 months of treatment, the discontinuation rate then slows considerably. Based on what we've observed to date from all patients taking ORKAMBI, including those who have been on commercial drug for up to 9 months and those who continue to receive ORKAMBI as part of our Phase III long-term extension study, we expect that the proportion of all patients who initiate and remain on treatment will stabilize at approximately 70% to 80%.
It is also important to point out that the pattern of patient initiations and discontinuations have an offsetting effect on our first quarter ORKAMBI revenues. Specifically because more than 4,500 patients began treatment with ORKAMBI in 2015, the impact of approximately 15% of these patients discontinuing ORKAMBI was highly evident in the first quarter. Therefore, while approximately 800 new patients initiated treatments in the first quarter, this growth was largely offset by the bolus of patients who discontinued treatment. This bolus of discontinuations began in the fourth quarter, but had a larger impact on the first quarter of 2016 where there were also fewer patient initiations to offset these discontinuations.
And finally, compliance. Based on what we've observed to date from the launch, we expect the compliance rate with ORKAMBI to be between 70% and 80%.
In summary, based on our understanding of the launch dynamics for ORKAMBI and the fact that we have continued to see additional patients initiating treatment with ORKAMBI in April, we expect to deliver quarter-to-quarter revenue growth for ORKAMBI beginning in the second quarter and continuing through the end of 2016 and into 2017.
I will now turn to the use of ORKAMBI to date outside the U.S. We are now well into the reimbursement process in all key European countries, Canada and Australia. Specifically, the clinical and cost-effectiveness assessment portions of the reimbursement process. These discussions are going as expected and have been productive. We believe that government payers across Europe recognize both the severity of this disease and the broad clinical benefits of ORKAMBI. These discussions will take time to complete. However, as Jeff mentioned earlier, we believe that we will achieve broad reimbursement from key European and other government payers, just as we've seen in the United States.
ORKAMBI is already available commercially in Germany and through early-access programs in France. We are only 3 months into the launch of ORKAMBI in Germany, and the uptake has been slower than we observed in the U.S. We attribute this to a number of factors, including that CF care in Germany is not concentrated in large centers as is seen in other countries. Meaning, there are many smaller centers and also many centers and physicians who have not yet had personal experience with CFTR modulators.
In Germany, there are approximately 2,500 patients eligible for treatment. As of March 31, 2016, approximately 230 patients had initiated treatment. However, we expect the number of patients initiating treatment in Germany will grow through 2016 and into 2017.
We do not expect what we are seeing in Germany will be representative of the uptake in other European countries. In fact, in France, where early-access programs provide the opportunity for physicians to begin treating patients with ORKAMBI prior to formal reimbursement approval, we have already seen approximately 400 of the 1,500 eligible patients initiate treatment with ORKAMBI in 2016.
We took all of this information into account when we set 2016 revenue guidance for ORKAMBI of $1.0 billion to $1.1 billion. Our guidance reflects our understanding of the ongoing U.S. launch, as I just discussed, as well as expectations that we will receive both approval for ORKAMBI in the U.S. for patients ages 6 to 11 in the second half of 2016 and certain revenues from sales of ORKAMBI outside the U.S., primarily from Germany.
Taking a longer-term view, we expect significant further growth for ORKAMBI revenues in 2017, driven primarily by patients initiating treatment following the completion of reimbursement discussions outside the U.S.
And now to KALYDECO. Today, we are increasing our financial guidance for 2016 revenues. We now expect KALYDECO net revenues of $685 million to $705 million. The prior guidance provided on January 10, 2016, was for KALYDECO net revenues of $670 million to $690 million.
We increased our KALYDECO guidance based primarily on an increasing number of patients initiating treatment with KALYDECO globally and on expectations of a reduced impact this year from the VX-661 Phase III program. Our guidance for KALYDECO excludes any potential revenues from the approval of KALYDECO, the people with residual function mutations.
I'll now hand the call over to Ian."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thank you, Stuart, and good evening to everyone. With the closing of the first quarter of 2016 and 9 months into the launch of ORKAMBI, we are seeing significant progress across our business. Notably, we are seeing increasing number of patients being trea",560,"Thank you, Stuart, and good evening to everyone. With the closing of the first quarter of 2016 and 9 months into the launch of ORKAMBI, we are seeing significant progress across our business. Notably, we are seeing increasing number of patients being treated with our approved medicines, resulting in a growing revenue base that we expect to drive earnings growth. 
I will now review our first quarter financial results and provide some specific comments about the long-term financial trajectory of our business.
Financial results first. In the first quarter of 2016, we reported total CF product revenues of approximately $394 million, a significant increase compared to $130 million in the first quarter of 2015. With ORKAMBI, we reported sales of $223 million for the first quarter of 2016. We have recorded approximately $574 million of ORKAMBI revenues in the first 9 months since the U.S. launch in July 2015. The first quarter KALYDECO sales of $171 million were up $41 million versus the first quarter of last year. 
Now to the operating expenses. Our first quarter non-GAAP operating expenses were $306 million compared to non-GAAP operating expenses of $246 million for 2015. The increased operating expenses were primarily due to increased costs related to the progression of our CF pipeline and to increased investments in global commercial support for the launch of ORKAMBI. Our non-GAAP net profit for the first quarter of 2016 was $22 million or $0.09 per diluted share compared to a non-GAAP net loss of $148 million or $0.62 per share for 2015.
From a balance sheet perspective, we ended the first quarter with approximately $1.03 billion in cash, cash equivalents and marketable securities. Vertex also has $300 million outstanding from a credit agreement, repayable by the end of the third quarter of 2017. The agreement also allows for the facility to increase to $500 million. 
Now to financial trends. Stuart provided 2016 ORKAMBI and KALYDECO revenue guidance and the assumptions that drive our projections, and therefore, I will focus my comments on the longer-term growth opportunities that may come with treating more patients with our currently approved medicines. 
We expect ORKAMBI revenues will continue to grow as we treat more patients in the U.S., achieve reimbursement outside the U.S. and expand the ORKAMBI label to younger patients. KALYDECO's growth is based on gaining reimbursement for certain groups of patients outside the U.S, including those with R117H mutation and the people ages 2 to 5 with gating mutations.
In summary, as Jeff noted earlier, approximately 27,000 people are eligible for our CF medicines, yet we are only treating approximately 1/3 of these patients. As additional patients in the U.S. start treatment and we complete reimbursement discussions outside the U.S., we expect the number of patients treated with our medicines to increase significantly and we expect revenue growth will follow. 
I will note that in 2015, we reported total CF revenues of $983 million. Based on 2016 guidance provided for ORKAMBI and KALYDECO, we anticipate the total CF revenues of approximately $1.7 billion to $1.8 billion, an approximate 75% increase over the prior year.
As our revenues grow over future years, we are committed to managing our operating expenses to drive earnings growth, and we expect to deliver financial profile as similar to many of our large cap biotech peers.
With that, I open the line to questions."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] And our first question comes from the line of Michael Yee of RBC Capital Markets.",17,"[Operator Instructions] And our first question comes from the line of Michael Yee of RBC Capital Markets."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two-part question. One is you gave all these discontinuation and persistence rates and compliance rates, which is in your guidance. Is there anything out there that you can do to either improve these things? Education, getting people to just get patients",134,"Two-part question. One is you gave all these discontinuation and persistence rates and compliance rates, which is in your guidance. Is there anything out there that you can do to either improve these things? Education, getting people to just get patients to take more drug? And can you apply any of these learnings to Europe? Are you seeing the same stuff in Germany? Are there any ways to improve it there? And then the second question is a pipeline question on the 661 het-min. You mentioned in the press release that you're changing the enrollment to do 200 instead of 300. But is that assuming you actually pass the futility? Can you just clarify that a little bit? I guess, why are we talking about changing enrollment if we haven't passed the futility?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mike, it's Stuart here. I'll take the first part of your question around the discontinuation and compliance rates. And then I'll hand over to Jeff Chodakewitz to answer the pipeline questions. So on discontinuations and compliance and what we might be abl",287,"Mike, it's Stuart here. I'll take the first part of your question around the discontinuation and compliance rates. And then I'll hand over to Jeff Chodakewitz to answer the pipeline questions. So on discontinuations and compliance and what we might be able to do to improve those, much as we did with KALYDECO. We will be continuing to generate data on the long-term benefits and even broader benefits of ORKAMBI when used in the real world. And I suspect that data, if its compelling, may lead physicians and patients to reconsider restarting ORKAMBI. So we'll continue to develop the overall clinical profile of ORKAMBI as we have more experience in the market. In terms of compliance, really, many of the same things that we did with KALYDECO we'll be doing with ORKAMBI, and that's really providing both providers and physicians with the educational materials to be able to understand how this is a product which is treating the underlying cause of their disease and so is a product that they want to try and stay compliant with as much as they possibly can. We'll certainly be leveraging all the learnings we've had with KALYDECO, with ORKAMBI, and those programs are already in place. And lastly, to your point about -- to Germany. Clearly, one of the things we're going to be doing is transferring all of the learnings from our launch experience in the U.S. to all of the other markets that we're launching into. And that's, in many ways, the benefits of those markets coming on-stream a little bit later is that they can learn from our experiences here in the U.S. With that, I'll hand over to Jeff to answer the question on the pipeline."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mike, it's Jeff. Maybe just to clarify, the -- we did provide some information about the timing of the interim analysis in the het-min study. But there's been no other changes for that trial. The change in sample size comes from one of our other Phase III",96,"Mike, it's Jeff. Maybe just to clarify, the -- we did provide some information about the timing of the interim analysis in the het-min study. But there's been no other changes for that trial. The change in sample size comes from one of our other Phase III trials, looking at 661 ivacaftor in patients who have more of a residual function mutation on one of their alleles. We did look at that and saw there was some opportunity to maintain good powering, but simplify it and reduce the sample size. And that's what that was about."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. So there's still het-min interim in Q3. No change to that. Okay.",13,"Okay. So there's still het-min interim in Q3. No change to that. Okay."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","That's the interim. That's correct.",6,"That's the interim. That's correct."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Terence Flynn of Goldman Sachs.",14,"And our next question comes from the line of Terence Flynn of Goldman Sachs."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe just a follow-up on the discontinuation rate. I know you've mentioned it's mainly due to respiratory events. But the 15%, I think, over 3 months is significantly higher than what you saw in the trials. I know you mentioned, previously, it could be h",102,"Maybe just a follow-up on the discontinuation rate. I know you've mentioned it's mainly due to respiratory events. But the 15%, I think, over 3 months is significantly higher than what you saw in the trials. I know you mentioned, previously, it could be higher. But any more color there on the drivers behind that, that you can expand on a little bit? And then on the ORKAMBI guidance, just wondering if you can provide a little bit more clarity there on the contributions from U.S., rest of world and then the patients 6 to 11 in terms of relative contribution?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure, Terence. So on the respiratory events, I think what I'd say there is what we're reporting today is what we're seeing in the real-world usage of ORKAMBI in the broad population. Obviously, the clinical trial population that we studied in TRAFFIC and",234,"Sure, Terence. So on the respiratory events, I think what I'd say there is what we're reporting today is what we're seeing in the real-world usage of ORKAMBI in the broad population. Obviously, the clinical trial population that we studied in TRAFFIC and TRANSPORT is a very controlled situation. That was patients with an FEV1 between 40 and 90. So really, whilst we try to extrapolate from the clinical trial experience to the real-world experience, that's one of the reasons -- that uncertainty is one of the reasons why we wanted to make sure we had sufficient time in market before we gave guidance. It was because we really wanted to see how the product would get used in the real world. In terms of the contribution of the various different parts of the world to our ORKAMBI revenue guidance that you might expect the vast majority of these, the revenues is going to come from here in the U.S. There will be a contribution ex U.S., but it's going to be relatively small. And then incorporated within our guidance, as we said, is also an expectation that we will see an approval in 6- to 11-year-olds in the latter part of 2016, which would give us access to an eligible population of about 2,500, and that's also incorporated within our guidance. But that approval is not anticipated until the back end of 2016."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Geoff Meacham of Barclays.",13,"And our next question comes from the line of Geoff Meacham of Barclays."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I got a couple. I'm trying to get a sense as to when you guys realize that compliance or persistent or discons were different for ORKAMBI versus KALYDECO or commercial ORKAMBI versus Phase III. I mean, you guys had a chance -- 3Q call, JPM, 4Q call, to be",75,"I got a couple. I'm trying to get a sense as to when you guys realize that compliance or persistent or discons were different for ORKAMBI versus KALYDECO or commercial ORKAMBI versus Phase III. I mean, you guys had a chance -- 3Q call, JPM, 4Q call, to be crystal clear on this. And it's 10 months almost into the launch, and now we're getting some detail. And I just had a couple of follow-ups."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Jeff, thanks for the question. It's Ian. So I just want to take us back a few months, which, as we went into JPMorgan and also our year-end conference call again in January, we were very clear with what we wanted to do regarding ORKAMBI guidance. It's",269,"So Jeff, thanks for the question. It's Ian. So I just want to take us back a few months, which, as we went into JPMorgan and also our year-end conference call again in January, we were very clear with what we wanted to do regarding ORKAMBI guidance. It's -- for us, at that point in time, it was early in the launch. Yes, we've recruited a number of patients on to ORKAMBI, but it was still early in the launch to understand treatment patterns. We stated that very clearly. What we've been able to do now as we sit here, as you point out, just over 9 months into the launch, we've been able to take a significant bolus of patients. For example, 3,000 patients that initiates in the first 3 months of disapproval, and we've been able to track those 6 to 9 months. What that allows us to do was to understand compliance rates. It helped us understand discontinuation rates and also the time of discontinuation, as Stuart mentioned. That's been an important feature for us. So this was the -- we feel as though we're in this position at this point in time where we've been able to attract a substantial amount of patients over a good period of time to have the confidence to provide guidance for 2016. The comparison to KALYDECO was less relevant for us. It was more about the treatment patterns for ORKAMBI. ORKAMBI is a different medicine than KALYDECO based on its clinical data and the patient population. But we now have enough confidence to provide you with the ORKAMBI guidance."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And just a follow-up to some earlier questions, I guess just to ask it a different way. It is for patients that are at low FEV1 at baseline and do experience bronchoconstriction, is there a treatment protocol in place? I mean, we've obviously heard",75,"Okay. And just a follow-up to some earlier questions, I guess just to ask it a different way. It is for patients that are at low FEV1 at baseline and do experience bronchoconstriction, is there a treatment protocol in place? I mean, we've obviously heard of things like half dosed and uptight trade or dose skipping. Is there something that you guys can recommend to a pulmonologist? A strategy for those that do experience bronchoconstriction?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, it's Jeff Chodakewitz. Maybe just to give you a couple of comments about that. We don't have anything in terms of very concrete, specific guidance that we can give. But we can make a couple of observations. First of all, what's clear from speaking",191,"Geoff, it's Jeff Chodakewitz. Maybe just to give you a couple of comments about that. We don't have anything in terms of very concrete, specific guidance that we can give. But we can make a couple of observations. First of all, what's clear from speaking to our investigators and also to physicians in the field, that clearly the support for the patients, both setting expectations for the patient and for the physician and helping patients in those early weeks manage any symptoms, we think is very important and something that goes back to some of the education questions that we've heard about earlier. We are also collecting information in our own study for patients who's FEV1 were less than 40, and we're in the process of summarizing that. We did, in that study, we give patients the option to start on a lower dose. And we'll set -- we'll get that data together and summarize it. But it's not going to be the kind of data that says, ""Here's a specific recommendation."" We noted that is being used, but it's really still about physicians and their patients working together to manage."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Mark Schoenebaum of Evercore.",13,"And our next question comes from the line of Mark Schoenebaum of Evercore."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Number one, I'd just like to know, have you been surprised by the way the launch has unfolded? I'm sure you had some projections a year ago for persistence, all these things. And then have you been surprised? And number two, I know you can't comment speci",87,"Number one, I'd just like to know, have you been surprised by the way the launch has unfolded? I'm sure you had some projections a year ago for persistence, all these things. And then have you been surprised? And number two, I know you can't comment specifically on peak numbers. But the sales at consensus is around $4 billion at peak for ORKAMBI. I'm just wondering, can you just talk about that? And then finally, is there any opportunity for re-initiations in these patients that drop-out early?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mark, we have a list of questions there, so if we don't get to all of them, please -- so we're all scribbling down. But if we don't get to them, please say them again. So Mark, in terms of how we feel about the launch, I'd say we're very pleased with the",204,"Mark, we have a list of questions there, so if we don't get to all of them, please -- so we're all scribbling down. But if we don't get to them, please say them again. So Mark, in terms of how we feel about the launch, I'd say we're very pleased with the way the launch has progressed here in the U.S. From how we were able to work with payers, to get access in reimbursement from ORKAMBI from early on in the launch to the rate of uptake that we've seen. I mean, to get close to 65% of eligible patients initiated within the first 9 months is a fairly steep ramp, and so one we're pleased with. So I think, overall, we're pleased how the launch has played out, much as we anticipated. In terms of the potential for re-initiations, we have heard anecdotally from physicians that they have tried re-initiating patients on ORKAMBI. We don't have much in the way of clinical data to be able to support that. But we are certainly aware that there are physicians who done that successfully so for some of their patients. So that normally is something that we'll continue to watch in the marketplace."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mark, this is Jeff Leiden. Maybe just to add a little bit more of a 10,000 foot view on both KALYDECO and ORKAMBI. Like you have been involved with many, many drug launches -- and I think it's worth just putting those in perspective a little bit. From the",249,"Mark, this is Jeff Leiden. Maybe just to add a little bit more of a 10,000 foot view on both KALYDECO and ORKAMBI. Like you have been involved with many, many drug launches -- and I think it's worth just putting those in perspective a little bit. From the standpoint, as an example, in ORKAMBI of getting to 65% of the patients in 9 months and of course, with KALYDECO, it was close to 90%, that's a fairly unusually fast ramp. And from the standpoint of persistence, the kind of numbers Stuart was talking about, let's say 70% to 80% is the number that we said aloud at, is still a very, very high number compared to most chronic medicines. And we believe that really represents the correct perception that both physicians and patients have about the value of these medicines and treating the underlying cause of the disease for a long period of time. And that really underlines our thinking about the pipeline as well because as we develop this next set of medicines, including next gens and hopefully, ultimately, things like CRISPR, we're talking about progressively increasing the benefit/risk profile of our portfolio of drugs that these patients can take. And that will only, of course, increase both persistence and compliance rates. So overall, very; pleased of where we are. We know we have more work to do to get to more patients and improve therapy, but these 2 drugs have really performed quite well so far."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Geoffrey Porges of Leerink Partners.",14,"And our next question comes from the line of Geoffrey Porges of Leerink Partners."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just a few questions. First, could you help us out? Just give us the breakdown between U.S. and ex U.S. sales of KALYDECO, so we're all in the same page. And then I just want to go back to Jeff's comments. Jeff, could you really clarify this residual func",169,"Just a few questions. First, could you help us out? Just give us the breakdown between U.S. and ex U.S. sales of KALYDECO, so we're all in the same page. And then I just want to go back to Jeff's comments. Jeff, could you really clarify this residual function change? And what has altered in terms of your statistical analysis or your assumptions about the activities of drug or the combination? And give us a sense of what the hurdle there is or ORKAMBI's effect. And then lastly, on this issue of persistence, is it reasonable to assume that about 50% of patients of the eligible pool are on drug right now? Because we keep going round and round about initiations and discontinuations, but surely, what's important is the number of patients who remain on drug at the end of the quarter. And is 50% roughly the right number or perhaps slightly below that, 45% to 50% of the eligibles? Is that the right way to think about it?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Geoff, it's Stuart here. I'll take your first question around KALYDECO revenues, and then I'll hand over Jeff Chodakewitz. So within the total KALYDECO revenues of $171 million for the first quarter of 2016, $95 million of that was in the U.S. and the",52,"So Geoff, it's Stuart here. I'll take your first question around KALYDECO revenues, and then I'll hand over Jeff Chodakewitz. So within the total KALYDECO revenues of $171 million for the first quarter of 2016, $95 million of that was in the U.S. and the balance, about $76 million was in international."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, in terms of the residual function study, we really stepped back and said, is there an opportunity to reduce the end of the study somewhat without sacrificing the integrity of the trial. We really looked at that 2 ways that we saw opportunity. One i",107,"Geoff, in terms of the residual function study, we really stepped back and said, is there an opportunity to reduce the end of the study somewhat without sacrificing the integrity of the trial. We really looked at that 2 ways that we saw opportunity. One is that we really focused our statistical analyses on key parameters, and that really allows us to take care of that. The other thing is that we also looked at the wider data and saw that the discontinuation rate from the trial was actually lower than what we had left room for, and that also is an opportunity to reduce the end."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And finally, Geoff, to your question in ORKAMBI. Your back-of-envelop math is approximately right. At the end of the third quarter, you're right about 50% of the eligible population were on. Clearly, that's a moving target because it's a mix of the discon",109,"And finally, Geoff, to your question in ORKAMBI. Your back-of-envelop math is approximately right. At the end of the third quarter, you're right about 50% of the eligible population were on. Clearly, that's a moving target because it's a mix of the discontinuations and the initiations. The important thing I would add to that number is that, moving forward in Q2 and beyond, we do expect patient initiations, which we've continued to see in April in the U.S. and obviously, we continue to see internationally in places like Germany. We expect to outpace discontinuations, which is why we are predicting quarter-on-quarter growth for the remainder of 2016 and beyond."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Brian Abrahams of Jefferies.",13,"And our next question comes from the line of Brian Abrahams of Jefferies."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess my first question is I'm wondering if you're seeing any trends towards maybe less sick higher FEV1 patients going on to therapy over time, which could be with ORKAMBI, which theoretically improved persistence and compliance. And then on 661, if 66",72,"I guess my first question is I'm wondering if you're seeing any trends towards maybe less sick higher FEV1 patients going on to therapy over time, which could be with ORKAMBI, which theoretically improved persistence and compliance. And then on 661, if 661 looks better tolerated but perhaps less efficacious than lumacaftor, I'm just wondering how you weigh which potential backbone to combine with the next-generation corrector into a triple combo."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So in terms of the -- any trends to where the product's being used, in either sicker patients or less sick patients, to be honest with you, Brian, with 65% of eligible patients being initiated, it's being used across the board. Obviously, we've got a rang",109,"So in terms of the -- any trends to where the product's being used, in either sicker patients or less sick patients, to be honest with you, Brian, with 65% of eligible patients being initiated, it's being used across the board. Obviously, we've got a range of different physicians and centers here. Some started using it in their more severe patients. Others started using it in their less severe patients. But we really are seeing usage across the whole range of FEV1 patients, as you would imagine, with 65% of eligible patients having been initiated. And on the backbone, the triple combination, I'll pass that over to Jeff Leiden."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Just on the triple combination, obviously, we can't speculate then exactly what will happen, but I would remind you that there were a number of reasons that 661 is the preferable partner. Most of those have to do with drug-drug interactions and makin",93,"Yes. Just on the triple combination, obviously, we can't speculate then exactly what will happen, but I would remind you that there were a number of reasons that 661 is the preferable partner. Most of those have to do with drug-drug interactions and making it simpler to combine it into a triple regimen. So I guess what I would say is, all things being equal, if 661 and lumacaftor had equal efficacy in combination with KALYDECO, we're certainly going to go with 661 because of those pharmacokinetic properties. Does that answer the question?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes -- well, not exactly. I guess, I was sort of wondering whether -- I mean, we know 661 has less CYP3A4 interactions. And sort -- I guess, I was sort of wondering whether some of the real-world ORKAMBI side effects that you're seeing are perhaps driven",81,"Yes -- well, not exactly. I guess, I was sort of wondering whether -- I mean, we know 661 has less CYP3A4 interactions. And sort -- I guess, I was sort of wondering whether some of the real-world ORKAMBI side effects that you're seeing are perhaps driven by not only the respiratory AEs but driven by CYP3A4, which we know is going to look better with 661 and sort of how you weigh that if efficacy is perhaps not as good."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. That's not the reason just to be clear. So those AEs are not driven by CYP interactions. We feel they're driven, as we said before, by off-targeted bronchoconstriction that's unique to lumacaftor and we don't see or haven't seen with 661.",42,"Yes. That's not the reason just to be clear. So those AEs are not driven by CYP interactions. We feel they're driven, as we said before, by off-targeted bronchoconstriction that's unique to lumacaftor and we don't see or haven't seen with 661."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Adam Walsh of Stifel.",12,"Our next question comes from the line of Adam Walsh of Stifel."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","A few weeks ago, we published a 47-physician ORKAMBI survey, and a few things jump out at us. I want to bounce them off you. Most notably, our survey showed that if patients discontinue ORKAMBI due to drug-related side effects, 70% of doctors encourage th",99,"A few weeks ago, we published a 47-physician ORKAMBI survey, and a few things jump out at us. I want to bounce them off you. Most notably, our survey showed that if patients discontinue ORKAMBI due to drug-related side effects, 70% of doctors encourage these patients to restart the drug, and then a very meaningful percentage of those patients not only successfully restart the drug but also subsequently remain on the drug long term. So my questions are: Is this consistent with your own internal research? Are patient restarts factored into your guidance? And if so, to what extent?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Adam, it's Stuart here. Thanks for the question. In terms of restarts, yes, your survey is consistent with what we've heard in that we have heard from physicians that they are trying to restart ORKAMBI in some of their patients, who they have previousl",175,"So Adam, it's Stuart here. Thanks for the question. In terms of restarts, yes, your survey is consistent with what we've heard in that we have heard from physicians that they are trying to restart ORKAMBI in some of their patients, who they have previously had to discontinue the product in largely because, as you know, that they are often firm believers that treating the underlying cause of the disease is clearly a good thing for those patients if they can tolerate the medicine. In terms of the absolute volume of that, at the minute, that's hard to quantify. We certainly heard it anecdotally. We've certainly heard success stories. It's fair to say though that within our guidance, we've assumed relatively minimal impact from restarts because, at this time, we really don't have evidence that it's happening in quite the numbers that perhaps people have said that they might do it in. So at the moment within our guidance, relatively minimal amount of restarting patients is assumed to happen in 2016 here in the U.S."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Phil Nadeau of Cowen and Company.",14,"Our next question comes from the line of Phil Nadeau of Cowen and Company."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two on commercial, then a quick one on the pipeline. On the commercial, can you give us some sense of how many lives outside the U.S. could gain reimbursement for ORKAMBI in 2017? Sure you have internal estimates and ranges. I'm curious what those are. An",116,"Two on commercial, then a quick one on the pipeline. On the commercial, can you give us some sense of how many lives outside the U.S. could gain reimbursement for ORKAMBI in 2017? Sure you have internal estimates and ranges. I'm curious what those are. And then similarly in the younger kids, do you expect any different penetration of ORKAMBI into that population than you've seen in the older kids and adults? And then last, on the triple, can you let us know if you've combined all 3 drugs in healthy volunteers yet and what your disclosure strategy will be when you move into Phase II? How much data from the Phase I will we get?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Phil, it's Stuart here. I'll take those 2 first commercial questions. In terms of the number of lives that might be eligible, the number of patients with the F508del homozygous mutation, 12 and above in Europe is somewhere around 12,000. Within our '16",216,"So Phil, it's Stuart here. I'll take those 2 first commercial questions. In terms of the number of lives that might be eligible, the number of patients with the F508del homozygous mutation, 12 and above in Europe is somewhere around 12,000. Within our '16 guidance, the only country that we're assuming we're going to be able to recognize revenues for is in Germany. We're not in a position to be able to give 2017 guidance at this point. I'm trying to predict exactly when this reimbursement discussion is going to conclude. It's frankly impossible to do because, clearly, it's a negotiation, and the vast majority of countries don't have a formal time clock. And so at this point, we're really not in a position to be able to speculate on when those might be concluded. In terms of what we would be anticipating in the 6- to 11-year-old population, if we are successful in gaining approval for that here in the U.S., then our anticipation would be much as we've seen with KALYDECO, that the uptake there is likely to be similarly robust as we've seen in adults. Although I would remind you that, from a 2016 perspective, that's likely to come in the second half or in the second half the second half of 2016."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Phil, I'll take the last question. So the Phase I study in healthy volunteers is still ongoing, so we can't basically make comment on that. But in terms of disclosure and time line, still as we've discussed before, we expect to be in patients with tri",100,"And Phil, I'll take the last question. So the Phase I study in healthy volunteers is still ongoing, so we can't basically make comment on that. But in terms of disclosure and time line, still as we've discussed before, we expect to be in patients with triple combination in the second half of the year. The disclosure of the Phase I around that will be relevant information that supports the Phase II study design. At this point, that is too difficult to describe, and we'll let you know when we have that information and we're initiating the Phase II study."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Cory Kasimov of JPMorgan.",12,"Our next question comes from the line of Cory Kasimov of JPMorgan."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have 2 left for you. So realized it's early, but wanted to ask about the potential impact of payer reauthorizations on ORKAMBI? How common is it? And how does it compare with the process you saw with KALYDECO? And then a capital allocation question for",77,"I have 2 left for you. So realized it's early, but wanted to ask about the potential impact of payer reauthorizations on ORKAMBI? How common is it? And how does it compare with the process you saw with KALYDECO? And then a capital allocation question for you. Now that you're profitable and growing and you're sitting on $1 billion in cash in your balance sheet, at what point would you consider buying back some of your stocks?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Cory, on the payer reauthorizations, not all payers have published policies that include their reauthorization criteria. That's the first thing I'd say. Of the ones you have, most have a time clock of 6 to 12 months. So we're really only now beginning",178,"So Cory, on the payer reauthorizations, not all payers have published policies that include their reauthorization criteria. That's the first thing I'd say. Of the ones you have, most have a time clock of 6 to 12 months. So we're really only now beginning to get to the point of patients getting to the time point when they are having to go through the reauthorization process. Having said that, the payers that have published policies or where their reauthorization criteria are known, the vast majority of them are either in line with the label or reflect the systemic benefits of ORKAMBI. And by that, I mean they recognize that this product can have benefits across multiple endpoints, and either improvements or stabilization in those endpoints qualifies as a successful outcome. So whilst we are only now beginning to get into the period of seeing those reauthorizations, I feel good about the reauthorization criteria that we've seen to date. And to your last part of your question, they are not dissimilar at all to what we saw with KALYDECO."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And to the last question, we have thought about stock buybacks in terms of capital allocation. But as we think about the priority of capital allocation for our business, I'll just give you a broader thought, which is we're still in this transitional perio",214,"And to the last question, we have thought about stock buybacks in terms of capital allocation. But as we think about the priority of capital allocation for our business, I'll just give you a broader thought, which is we're still in this transitional period of moving into profitability and cash generation and watching the revenue curve. As we go up the revenue curve and we drive revenue growth and therefore, earnings growth, which translates to cash gen -- more cash generation, we look to apply that capital to reinvest back in the business first, first, internally into our pipeline but then potentially outside of the company to diversify and expand our pipeline. And we've already done activities in that area, as you know, with CRISPR and our ENaC inhibitor. So those continue to be the priorities. It's the internal investments. It's the external investments. But as we go up that revenue growth curve and have greater capital to allocate, we will give consideration to capital strategies such as share buybacks, but at this point in time, it's a little early for us. And if we were to move into something in the near future, it would be of a smaller scale to stop the shares outstanding creep that occurs each year through option exercises."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Alethia Young of Crdit Suisse.",13,"Our next question comes from the line of Alethia Young of Crdit Suisse."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Thanks for taking my question. It's -- the 3 of them are kind of around compliance. And I guess, when I look at the math that we get over the quarters, it seems like the first 2 quarters, the compliance was potentially higher, like 95%, and maybe in this",180,"Thanks for taking my question. It's -- the 3 of them are kind of around compliance. And I guess, when I look at the math that we get over the quarters, it seems like the first 2 quarters, the compliance was potentially higher, like 95%, and maybe in this quarter, based on our math, it would have gotten us to about 80%. So I guess, one, is that assumption -- is that analysis fair? Two, can you give us any color on if the scripts written in 1- or 3-month increment? And then third, just when you think about 70% to 80% range on compliance, which actually does move the model quite a bit, what kind of qualitatively do you think about that kind of gets you in the 70% range versus the 80% range? Do we think about like amount of days that people are taking so that there's a delta in the days they miss and just kind of adding that up and thinking about it? Or is there some other way we should think about quantifying compliance?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So yes, let me try and answer those sequentially. In terms of the compliance trend, compliance is the metric that you need the longest period of time to measure because, clearly, this is a chronic medicine, and so in the first prescription they get, your",315,"So yes, let me try and answer those sequentially. In terms of the compliance trend, compliance is the metric that you need the longest period of time to measure because, clearly, this is a chronic medicine, and so in the first prescription they get, your kind of assumption is that you're 100% compliant. You have to wait until they get the second prescription to work out exactly what it is. So this is the one that really takes the longest period of time for us to get a good handle on. I don't know obviously the intricacies of your model. I'll just reiterate that, based on the trends that we've seen to date and the experience we've got with the patients who have been treated to date, our expectation for the year and the assumption on which our guidance is built is that it'll be somewhere between 70% and 80% for ORKAMBI this year. In terms of the 1- or 3-month script, the vast majority are written for 1 month. There are some 3-month prescriptions written, but the vast majority of prescriptions are written for -- on a monthly basis. And in terms of kind of qualitatively, what would lead you to one end versus the other, to me, this is all about education and our ability to help providers to give to their patients information, which educates them on the nature of the disease, the underlying defects, the fact that ORKAMBI is designed to treat those underlying defects, and to the extent they believe in the science, believe in the long-term benefits that ORKAMBI can provide to them, then I think that's only likely to lead to patients having a higher compliance rate. We're very focused on that. We're certainly taking all the learnings we can from our experience with KALYDECO to support patients to take the prescriptions in line with their physician's recommendations."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Matthew Harrison of Morgan Stanley.",13,"Our next question comes from the line of Matthew Harrison of Morgan Stanley."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have 2, which are somewhat follow-ups on Phil's questions. Just on next-generation correctors and those studies, can you just tell us if you saw a safety event, what kind of safety event would be disclosable versus not disclosable? And then is there a p",123,"I have 2, which are somewhat follow-ups on Phil's questions. Just on next-generation correctors and those studies, can you just tell us if you saw a safety event, what kind of safety event would be disclosable versus not disclosable? And then is there a point in time that we're going to see PK data from healthy volunteers, which might help us better understand how the drug levels that we saw on the HBE data might compare in patients? And then a separate commercial question. Just, in the 6 to 12 pool for ORKAMBI, are your assumptions for persistence in discontinuation rate the same as what you're seeing now in the older population? And if they're not the same, can you just explain why?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So maybe I'll take the first couple of questions. So with the next-gen disclosure, what would be required to disclosure of is Reg FD, and if there was a material adverse event, we would have to disclose that. If you want me to give an example, that would",132,"So maybe I'll take the first couple of questions. So with the next-gen disclosure, what would be required to disclosure of is Reg FD, and if there was a material adverse event, we would have to disclose that. If you want me to give an example, that would be a discontinuation of the trial for example, and we would have to disclose that. Other than that, it's an ongoing trial. We need to complete the trial, gather the data. That will inform us, as I said earlier, for the Phase II trial in patients with triple combination, and we will provide relevant information at that point in time that supports the design of that trial. Can you just remind me of your second question in terms of the disclosures? [indiscernible] ..."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes -- no, I was just wondering, will we see PK data so that we can compare sort of the drug levels that you can achieve in healthy volunteers versus the drug levels that you were achieving in the HBE assays, so we have some point of comparison on relativ",52,"Yes -- no, I was just wondering, will we see PK data so that we can compare sort of the drug levels that you can achieve in healthy volunteers versus the drug levels that you were achieving in the HBE assays, so we have some point of comparison on relative drug levels."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So we'll provide it in relative information that helps you understand the design of the Phase II study. However, it is not our practice to provide that kind of detail on a Phase I study. Then, there's a number of reasons for that, and I would just give yo",74,"So we'll provide it in relative information that helps you understand the design of the Phase II study. However, it is not our practice to provide that kind of detail on a Phase I study. Then, there's a number of reasons for that, and I would just give you one, that there is a specific competitive reason that would -- we would prefer not to provide that information on a Phase I study."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Matt, in the 6 to 11, I mean, really, the contribution of the 6 to 11 population, it was successful in getting approval. As I said, it's really going to be in the -- likely be in the fourth quarter. So really, the contribution there within our overall",191,"And Matt, in the 6 to 11, I mean, really, the contribution of the 6 to 11 population, it was successful in getting approval. As I said, it's really going to be in the -- likely be in the fourth quarter. So really, the contribution there within our overall guidance is more about uptake than it is around persistence and compliance. And much as we did with the 12 and above population, I think we'll obviously be watching that very, very closely just as we have done since the launch in July. And that'll give us an ability to learn how the product performs with those patients in the real world. Again, one of the things that we have seen obviously with the younger population with KALYDECO is they tend to be slightly more compliant than the average, not surprisingly, because they've got a lot of parental and caregiver supervision. But really, those assumptions that we've given you are really much more related to the 12 and above population. We'll see how the 6 to 11 patients play out in the real world in the course of time after the approval."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Ying Huang of Bank of America Merrill Lynch.",16,"Our next question comes from the line of Ying Huang of Bank of America Merrill Lynch."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Number one, I want to know if you guys have seen an uptick in discontinuation due to lack of efficacy or it's all due to the, I guess, chest tightness. And then secondly, for the ATU pricing you get in France, how does that compare to the German pricing o",83,"Number one, I want to know if you guys have seen an uptick in discontinuation due to lack of efficacy or it's all due to the, I guess, chest tightness. And then secondly, for the ATU pricing you get in France, how does that compare to the German pricing of EUR 159,000 per year per patient? And lastly, I have a question on your gross to net. Is that consistent what you guys have guided before, which is like mid-teens in 1Q '15?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So in terms of discontinuations, the -- based on our clinical trial experience and also what we are seeing in the market, the vast majority of those discontinuations are for adverse events, and most commonly, that's the chest tightness. In terms of the AT",159,"So in terms of discontinuations, the -- based on our clinical trial experience and also what we are seeing in the market, the vast majority of those discontinuations are for adverse events, and most commonly, that's the chest tightness. In terms of the ATU, we haven't disclosed the price within the ATU program. And in terms of the gross to net, the gross to net that we've seen and are predicting is potentially slightly lower than we originally thought. That's largely due to the fact that the Medicaid patient population that we're seeing is slightly lower than we anticipated. This is really as a result of many of those Medicaid patients that we thought would be covered by Medicaid or actually qualifying for disability benefit under Medicare. As a result of that, we're seeing a lower Medicaid population, and in result, we're seeing -- we're predicting a slightly lower gross to net of somewhere around 12% for the year."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. I'd like to just add to that, Stu, which is in the -- coming into 2016 and 2015 with the gross to net on ORKAMBI was close to 7%. As we moved into the Q1 of 2016, it's increased to 9%. So it is moving up slightly as we expected, but as we plot out an",94,"Yes. I'd like to just add to that, Stu, which is in the -- coming into 2016 and 2015 with the gross to net on ORKAMBI was close to 7%. As we moved into the Q1 of 2016, it's increased to 9%. So it is moving up slightly as we expected, but as we plot out and we look at the patients that are coming on to the drug, we anticipate that it could end the year around 12% as it gradually creeps up to that 12% level. That also plays into our guidance."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Liisa Bayko of JMP Securities.",14,"And our next question comes from the line of Liisa Bayko of JMP Securities."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just a couple of technical questions. Were there any inventory changes in the quarter?",14,"Just a couple of technical questions. Were there any inventory changes in the quarter?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","No. The ORKAMBI inventory at the end of March was, to all intents and purposes, identical to that, which it was at December 31. So there was really no inventory change for ORKAMBI at all.",35,"No. The ORKAMBI inventory at the end of March was, to all intents and purposes, identical to that, which it was at December 31. So there was really no inventory change for ORKAMBI at all."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, great. And then can you comment on gross to net? Sort of where were you for the quarter? And would that be relatively consistent for the rest of the year? Will it change in some way?",37,"Okay, great. And then can you comment on gross to net? Sort of where were you for the quarter? And would that be relatively consistent for the rest of the year? Will it change in some way?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Are you referring to ORKAMBI, Liisa?",6,"Are you referring to ORKAMBI, Liisa?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, sorry.",2,"Yes, sorry."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. So I actually just mentioned this, which is that in Q1 we were at approximately 9% gross-to-net discount, and in Q4 of last year, we were at 7%. We actually expect the Q1 level of 9% to trend up to be something closer to 12% by the end of the year.",52,"Yes. So I actually just mentioned this, which is that in Q1 we were at approximately 9% gross-to-net discount, and in Q4 of last year, we were at 7%. We actually expect the Q1 level of 9% to trend up to be something closer to 12% by the end of the year."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then when you say 15% of 65% have discontinued, so that's like a 10% discontinuation rate roughly. Is that the right way to think about that?",27,"And then when you say 15% of 65% have discontinued, so that's like a 10% discontinuation rate roughly. Is that the right way to think about that?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","No, Liisa. So -- and it's really important, so thanks for asking the question. It is, of the patients you've initiated, 15% of them have discontinued ORKAMBI within approximately the first 3 months. The -- and so if you think about 4,500 patients who init",125,"No, Liisa. So -- and it's really important, so thanks for asking the question. It is, of the patients you've initiated, 15% of them have discontinued ORKAMBI within approximately the first 3 months. The -- and so if you think about 4,500 patients who initiated between July and December, 15% of those patients would have discontinued within the first 3 months, and then that rate of discontinuations slows considerably. The 65% is the number of patients you've initiated therapy by the end of March. So the 15%, you need to apply to all of the patients who initiated. It's -- you don't -- it's not 15% of 65% is 10%. It's 15% of the 65% who have initiated, they will discontinue therapy in our belief."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Right. But that got you 10%. Doesn't it if you multiply 65% by 15%?",14,"Right. But that got you 10%. Doesn't it if you multiply 65% by 15%?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Liisa, we'll jump on the phone with you after the call, and we'll do the math.",16,"Liisa, we'll jump on the phone with you after the call, and we'll do the math."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then I just had a question about the Rho inhibitor. Can you just give us a little detail on that trial? What are the endpoints you're looking at? What's the timing for data? That's my final question.",38,"And then I just had a question about the Rho inhibitor. Can you just give us a little detail on that trial? What are the endpoints you're looking at? What's the timing for data? That's my final question."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Liisa, it's Jeff. So the Rho inhibitor trial is really specifically in patients who had a pretty catastrophic injury to their cervical spine and then really have very poor function immediately following that injury. In the studies then, we follow those pa",139,"Liisa, it's Jeff. So the Rho inhibitor trial is really specifically in patients who had a pretty catastrophic injury to their cervical spine and then really have very poor function immediately following that injury. In the studies then, we follow those patients. At the time of surgery, they have either placebo or 1 of 2 doses of active drug, and there's about 150 patients total. And then we follow them for 6 months looking at particularly how their upper extremities function because that's so important to how patients, the quality of life of patients, and then we do some other measures of disability. And it's very hard right now. We just started the study as we've said, so I think it's very hard to predict in that kind of population, in particular, exactly when we're going to get results."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Tony Butler of Guggenheim.",12,"Our next question comes from the line of Tony Butler of Guggenheim."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Briefly, Stuart, in France, again, the early-access patients which receive ORKAMBI, I think you mentioned 400. I understand reimbursement has not occurred. But given the uptake being fairly strong, if one assumes that the majority of that 1,500 will be tr",82,"Briefly, Stuart, in France, again, the early-access patients which receive ORKAMBI, I think you mentioned 400. I understand reimbursement has not occurred. But given the uptake being fairly strong, if one assumes that the majority of that 1,500 will be treated by year-end and you do get reimbursement, let's say, next year, is -- does that come in a bolus payment for that, which has occurred? Or is that payment then amortized assuming those patients stay on drug for '17 and beyond?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Thanks for the question, Tony. So the way the accounting works in France is for that the cash that we get for those patients before we get reimbursed, those recognized as cash, not as revenue. At the point that we have certainty about the selling pri",119,"Yes. Thanks for the question, Tony. So the way the accounting works in France is for that the cash that we get for those patients before we get reimbursed, those recognized as cash, not as revenue. At the point that we have certainty about the selling price or very close to certainty about the selling price in France, then we will be able to, in a one term adjustment, convert that cash to revenues. And then from that point forward, all of those will be counted as revenues going forward. And that's because the -- whatever rebate you agree with the French government is retroactive to the sales that you've had from the point that you launched the product."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And finally, you would call that out as an item in the quarter in which it occurs, I assume.",19,"And finally, you would call that out as an item in the quarter in which it occurs, I assume."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So maybe I'll follow on from Stuart's answer. So I'll just validate Stuart's answer as the kind of a CPA. So nice job, Stuart. In terms of revenue recognition, many of you that are on this call probably have seen other companies go through this with the A",101,"So maybe I'll follow on from Stuart's answer. So I'll just validate Stuart's answer as the kind of a CPA. So nice job, Stuart. In terms of revenue recognition, many of you that are on this call probably have seen other companies go through this with the ATU in France. And then absolutely, at the point that we are -- we get to a point where we're confident with the price in France, yes, we would call it out in the quarter specifically. And at that same point in time, we would recognize all the revenue in that very quarter."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our final question comes from the line of Katherine Xu of William Blair.",14,"And our final question comes from the line of Katherine Xu of William Blair."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So I just have one question on the CRISPR program. Based on the research that you have ongoing right now, what kind of mutations are the most amenable for the technology first and how difficult it is to eventually correct the F508, which is a deletion you",53,"So I just have one question on the CRISPR program. Based on the research that you have ongoing right now, what kind of mutations are the most amenable for the technology first and how difficult it is to eventually correct the F508, which is a deletion you have at that single base pair?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. This is Jeff Leiden. Thanks for the question. I think, as you know, right -- if you look today, CRISPR is most amenable to actually inactivate, which is making cleavages, because that's what it does most efficiently, and obviously, that's not what we",239,"Yes. This is Jeff Leiden. Thanks for the question. I think, as you know, right -- if you look today, CRISPR is most amenable to actually inactivate, which is making cleavages, because that's what it does most efficiently, and obviously, that's not what we would want to do in a Delta 508 case. Then, you move to making corrections, and then you move to more complex deletions and insertions. So there's no doubt that there are still challenges to conquer both in terms of how we correct deletions like in Delta 508 but also how we deliver this because, obviously, this has to be delivered efficiently to large numbers of cells in the lungs, and we don't know how to do that yet. So that's why we said, while we think CRISPR is an incredibly powerful technology for the future, it's going to take a number of years to conquer both the -- some of the editing challenges but also, in particular, the delivery challenges, and that's what we're working on in CF. Now we're also -- I'll just remind you that CRISPR-Cas9 collaboration, we have rights to several targets, fixed targets, and some of those will be in other diseases where some of these issues, like delivery and editing, are much more straightforward. So I think you can expect to hear from us over the next couple of years on our progress in some of those other diseases."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","So at this point, are there mutations that easier than others to edit? Do we know that?",17,"So at this point, are there mutations that easier than others to edit? Do we know that?"
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. As I say, I think single base pair corrections are going to be a lot easier than complex deletions and insertions to correct. But nevertheless, I mean, there are some pretty significant challenges in diseases like CF. When you move to ex-vivo therapy",81,"Yes. As I say, I think single base pair corrections are going to be a lot easier than complex deletions and insertions to correct. But nevertheless, I mean, there are some pretty significant challenges in diseases like CF. When you move to ex-vivo therapy and you move to inactivation in ex-vivo therapy, you're in a whole different world in terms of efficiency, and so you will see some of those, I think, from us and others as being the first application."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So I'll turn it back over to Jeff maybe for some final comments tonight.",15,"So I'll turn it back over to Jeff maybe for some final comments tonight."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. First of all, thank you for your questions, thanks for your patience. I know it was a long call, but we do want to give you not only our guidance but a detailed rationale for the guidance so that you understand our model. And we appreciate your quest",362,"Yes. First of all, thank you for your questions, thanks for your patience. I know it was a long call, but we do want to give you not only our guidance but a detailed rationale for the guidance so that you understand our model. And we appreciate your questions on that.
As I look at our progress as a company over the last year, I guess I would call out 3 things that I think are important. First, the continuous increase in the number of patients that we can treat and actually fairly dramatic increase in the number of patients that we can treat with KALYDECO and ORKAMBI; and as we look forward, the increasing number of patients that we can treat with today's approval. So as I mentioned, 27,000 eligible, we're still only treating 1/3 of those, and I think we have a clear path to get to the majority of those patients both in the U.S. and Europe over '16 and '17 and beyond.
Second thing I would say is the pipeline progression. We're pleased with 661 progressing well into Phase III of multiple trials and multiple patient populations but equally important, we have the next-gen correctors, which are progressing through Phase I with our -- and still on a time line to get into patients as triple combinations later this year. We think that's going to be very important both for the patients we treat and potentially for additional subsets of patients.
And then finally, the progression of the science. We didn't talk about that a lot today, but the science of CF, I think, has progressed significantly, and we have a much better understanding of the folding and correction process. And the science that David Altshuler is driving and the rest of research group in some of the new diseases, we touched on those a little bit with CRISPR-Cas9 but also others that I hope we will be able to have a chance to talk to you about over the rest of '16 and '17. It's an important long-term growth engine for the company.
So with that, maybe I'll close the call, and thanks again for joining us."
36235,331185758,965393,"Vertex Pharmaceuticals Incorporated, Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our Second Quarter 2016 Financial Results Conference Call. [Operator Instructions] You can access the webcast live by going to our website where a replay",207,"Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our Second Quarter 2016 Financial Results Conference Call. [Operator Instructions] You can access the webcast live by going to our website where a replay will be available tonight. Dr. Jeff Leiden, Chairman and CEO; and Ian Smith, Chief Financial Officer, will provide prepared remarks this evening. They will be joined by Stuart Arbuckle, Chief Commercial Officer; and Dr. Jeff Chodakewitz, Chief Medical Officer, for the Q&A portion of the conference call.
We will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the SEC. These statements, including without limitation, those regarding the ongoing development and potential commercialization of our drug candidates, our expectations regarding our approved medicines and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and direct reconciliation of GAAP to non-GAAP is available in tonight's press release. I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Dr. Jeff Leiden."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. It was just over 1 year ago that we received FDA approval for ORKAMBI, marking the most significant step to date in our journey to develop new medicines for people with cystic fibrosis. Tonight, I'm pleased to repo",1091,"Thanks, Michael. Good evening, everyone. It was just over 1 year ago that we received FDA approval for ORKAMBI, marking the most significant step to date in our journey to develop new medicines for people with cystic fibrosis. Tonight, I'm pleased to report on our significant and steady progress in CF, and I'll review 3 key phases in our efforts to bring all people with CF a medicine to treat the underlying cause of their disease. If we're successful in these efforts, we believe significant and sustained revenue and earnings growth will follow.
Today, there are approximately 27,000 people eligible for treatment with ORKAMBI or KALYDECO. However, we're only treating approximately 9,000 or 1/3 of these patients. The first and most significant near-term step to increase the number of eligible patients being treated for their medicines is to gain reimbursement of ORKAMBI in key European and other countries. Progress with reimbursement for ORKAMBI will enable the vast majority of currently eligible patients to be treated with one of our CF medicines. 
The second step to treat more people with CF is to further expand the labels for both ORKAMBI and KALYDECO, which could increase the total number of eligible patients from 27,000 to approximately 44,000. And the third step is to potentially treat all people with CF with new combinations of CFTR modulators as well as other approaches to treatment such as ENaC inhibition, gene editing and mRNA therapies.
First, the reimbursement for ORKAMBI. Outside the U.S., the reimbursement process is ongoing, and these discussions are progressing as anticipated across Europe, Canada and Australia. We are encouraged that many reimbursement authorities have acknowledged the significant clinical benefits that ORKAMBI provides. We believe that we will achieve reimbursement from European and other government payers just as we've seen in the U.S. We look forward to updating you as we obtain reimbursement in key countries going forward.
Second, to our label expansion efforts for both ORKAMBI and KALYDECO. Specific leaders some [ph] 12,000 additional patients younger than age 12 with 2 copies of the Delta F508 mutation whom we believe could be helped by ORKAMBI. In the second quarter, the FDA accepted for review our supplemental new drug application for the use of ORKAMBI in children ages 6 to 11 and granted our request for priority review, setting a target review date or PDUFA date September 30, 2016. If approved, we expect to be ready to bring ORKAMBI to these patients immediately following approval. 
In parallel, we're also progressing with our efforts to bring ORKAMBI to children ages 6 to 11 in Europe where we plan to submit our application for approval in the first half of next year, following the conclusion of our fully enrolled Phase III efficacy and safety study in this group of patients. We estimate that there are approximately 2,400 children ages 6 to 11 in the U.S. and 3,400 in Europe who would be eligible for ORKAMBI.
There are approximately 5,000 additional patients in North America, Europe and Australia, largely those with residual function mutations who could be helped by KALYDECO. While we received the complete response letter from the FDA earlier this year regarding our application for approval of KALYDECO in people with CF ages 2 and older who have 1 of 23 residual function mutations, our belief that KALYDECO would be beneficial to these patients is unchanged, and we continue to pursue FDA approval for these patients as was possible. There are approximately 1,500 people with CF in the U.S. who have the mutations included in our residual function sNDA. 
And third, our expanding pipeline of investigational CF medicines. Most advanced pipeline program in CF is our broad Phase III program for VX-661 in combination with ivacaftor. VX-661 plus ivacaftor may have an improved benefit risk profile compared to ORKAMBI and people with 2 copies of the Delta F508 mutation and may provide enhanced clinical benefits over ivacaftor monotherapy for other patients with gating mutations. Enrollment in the study of VX-661 plus ivacaftor in people ages 12 and older with 2 copies of the Delta F508 mutation is expected to complete in August. Data from the 6-month study are expected in the first half of 2017. The other 3 Phase III studies of VX-661 are also progressing as planned. We plan to submit a new drug application to the U.S. FDA for VX-661 in combination with ivacaftor in the second half of 2017.
Importantly, VX-661 is also positioned to play a key role in the triple-combination regimen with the next generation corrector and ivacaftor. We believe that this triple combination approach may allow us to treat an additional large group of patients, specifically those with one Delta F508 mutation and one mutation that results in minimal CFTR function. These patients do not currently have medicines to treat the cause of their disease.
Our 2 next-generation correctors, VX-152 and VX-440, are being evaluated in Phase I studies in healthy volunteers. Spending data from these studies, we expect to move into Phase II clinical development in the second half of 2016 in people with CF. These studies would evaluate 1 or both of our next generation corrector is with VX-661 and ivacaftor. Beyond the CFTR modulators, we entered into multiple strategic collaborations that broaden our ability to evaluate additional approaches to CF treatment that may be complementary to the CFTR modulation in the future. While the underlying technology and science of each approach differs, the collaborations have a shared goal to develop the best possible future treatments for all people with CF. Earlier this month, we entered into a collaboration with Therapeutics aimed at using messenger RNA to potentially enable cells in the lungs of people with CF to produce functional CF care protein. This is the second platform technology collaboration we have entered into following our agreement with CRISPR Therapeutics focused on the use of CRISPR-Cas9 for gene editing that we began in late 2015. These platform technologies add to our development stage collaboration with Sciences use of ENaC inhibition to treat CF.
As we ended the second half of 2016, I'm pleased with both the near- and long-term growth opportunities for our business. Our goal is to consistently discover and deliver conservative new medicines for patients and to reinvest in scientific opportunities to create future medicines. We believe our business model, which is focused on significant investment to create value through innovation for research and development, will position us to achieve this goal over the coming years.
With that, I'll turn the call over to Ian."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff and hello, everyone. Through the second quarter of the year, we created a great revenue base with ORKAMBI and KALYDECO, which we expect to drive future earnings growth. Tonight, I'll discuss our second quarter revenues for ORKAMBI and KALYDEC",681,"Thanks, Jeff and hello, everyone. Through the second quarter of the year, we created a great revenue base with ORKAMBI and KALYDECO, which we expect to drive future earnings growth. Tonight, I'll discuss our second quarter revenues for ORKAMBI and KALYDECO, review our 2016 financial guidance and discuss our anticipated financial trajectory for the coming years.
In the second quarter of 2016, we reported total CF product revenues of approximately $426 million, a significant increase compared to $155 million for the second quarter of last year. 
Turning to the revenues for each of our CF medicines. Global sales of ORKAMBI in the second quarter were $245 million, comprised of U.S. sales of approximately $229 million and ex U.S. sales of approximately $16 million, which were mainly from Germany. As of June 30, approximately 6,000 patients have initiated treatment with ORKAMBI in the U.S. Outside the U.S., ORKAMBI is already available commercially in Germany and also through early access programs in France. In Germany, uptake continues to be slower than we observed in the U.S as of June 30, approximately 380 of the 2,500 eligible patients in Germany had initiated treatment. In contrast, in France, we continue to see strong and rapid uptake. Approximately 700 of 1500 eligible patients in France have already initiated treatment with ORKAMBI as of June 30 as part of the country's early access programs. These programs provided the opportunity for physicians in France to begin treating patients prior to their formal reimbursement approval. We are pleased the ORKAMBI launch has continued to progress consistent with what we discussed on our first quarter call. And today, we are reiterating our expectation for 2016 ORKAMBI revenues of $1 billion to $1.1 billion. Given the slower-than-expected launch in Germany and that we are approaching peak penetration for ORKAMBI in patients aged 12 and older in the U.S., we expect the further revenue growth for ORKAMBI will occur primarily in the fourth quarter following the potential approval and launch ORKAMBI for children ages 6 to 11.
Now to KALYDECO. Second quarter KALYDECO sales were $180 million, up $25 million compared to the second quarter of last year. We continue to see small number of additional eligible patients beginning treatment in the U.S. and Europe. As with ORKAMBI, we are reiterating our 2016 revenue guidance for KALYDECO of $685 million to $705 million. Our 2016 guidance exclude any potential revenues for the approval of KALYDECO in residual function mutations where we continue to pursue the FDA approval for patients ages 2 and older in the U.S.
Now to the operating expenses. Our second quarter non-GAAP operating expenses were $306 million compared to non-GAAP operating expenses of $254 million in 2015. The increased operating expenses were mainly due to increased cost related to the progression of our CF pipeline and to increase investment in global commercial support for the launch of ORKAMBI. Our non-GAAP net profit for the second quarter of 2016 was $58 million or $0.24 per diluted share as compared to a non-GAAP net loss of $131 million or $0.54 per share for 2015. From a balance sheet perspective, we ended the second quarter with approximately $1.07 billion in cash, cash equivalents and marketable securities. Vertex also has $300 million outstanding from a credit agreement repayable by the end of the third quarter 2017.
I'll conclude tonight's call with a few brief comments and financial trends, including revenue and earnings growth. Our goal is to discover and develop new medicines for all people with CF. And as Jeff has discussed, there are 3 important phases to support these efforts: obtaining reimbursement for ORKAMBI outside the U.S; expanding labels to both ORKAMBI and KALYDECO; and developing new medicines to treat potentially all people with CF. As we progress towards this goal, significant and sustainable revenue growth will follow. Importantly, as our revenues grow over future years, we are committed to managing our operating expenses to drive earnings growth. And we expect to deliver a financial profile similar to many of our large biotech peers. With that, I open the line to questions."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question comes from the line of Jeff Needham with Barclays.",14,"[Operator Instructions] Our first question comes from the line of Jeff Needham with Barclays."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have a few commercial ones and one clinical. One, I ask you guys, either Ian or Stuart, any changes to the persistent rates in the U.S. where the new strategies to improve it? And then could you just going to little bit more detail on the EU outlook? So",70,"I have a few commercial ones and one clinical. One, I ask you guys, either Ian or Stuart, any changes to the persistent rates in the U.S. where the new strategies to improve it? And then could you just going to little bit more detail on the EU outlook? So from what I understand, flattish in 3Q from Germany and then maybe you know what's driving the fourth quarter bump?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Stuart here. So on persistence rates, what we're seeing in the U.S. is very consistent with what we outlined on our Q1 call. In fact, all the trends really in initiations, persistence and compliance are entirely in line with what we said then. Just t",254,"It's Stuart here. So on persistence rates, what we're seeing in the U.S. is very consistent with what we outlined on our Q1 call. In fact, all the trends really in initiations, persistence and compliance are entirely in line with what we said then. Just to remind you persistence, we said that our expectation was it would track towards about 70% to 80%, between 70% and 80% by the end of this year, and the same for compliance, and we continue to believe in those estimates and those estimates are what underpins our revenue guidance that we reiterated today. In terms of Europe and as you noted, Germany is relatively slow, and he mentioned that prepared remarks incorporated within our guidance really were only expecting significant contributions ex- U.S. from Germany. In terms of how we see things playing out in the rest of Europe really -- as you know that's very dependent on proceeding country by country reimbursement negotiation process what I can tell you, those are progressing as we planned, as expected. But given our learnings and the analogy to KALYDECO and the time it took there, we're really anticipating to conclude many of those reimbursement negotiations until 2017. Having said that, we recently concluded our first formal reimbursement negotiation in Australia and how it's going into effect from September 1, but we continue to believe that most of the major markets were not likely to see any major contributors -- contributions in terms of revenue growth until 2017 and beyond."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And just real quick on the clinical side, but the PK for  1 5 2 and 4 4 0, will we see any of that? And any more thoughts on kind of what the size and scope of the clinical development for the triple could entail?",47,"Okay. And just real quick on the clinical side, but the PK for  1 5 2 and 4 4 0, will we see any of that? And any more thoughts on kind of what the size and scope of the clinical development for the triple could entail?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Well, it's a little difficult to be to answer that, to be honest, Jeff. If I comment more broadly in operating expense the remainder of the year and then maybe trajectory in 2017. I think that's the easiest for this comments on it. We always planned to pr",220,"Well, it's a little difficult to be to answer that, to be honest, Jeff. If I comment more broadly in operating expense the remainder of the year and then maybe trajectory in 2017. I think that's the easiest for this comments on it. We always planned to provide guidance based on assuming success and, that were investing behind the programs. So our OpEx guidance for the year is at $1.18 billion to $1.23 billion, and we reiterated that number in the press release tonight. And that's a non-GAAP number, by the. Way, that excludes primarily stock compensation. And as we look into next year, we actually we hope expect the programs to progress. And as we look into next year as we think about OpEx more broadly, we see maybe some marginal increases in marketing investments for the launch of ORKAMBI more broadly and particularly, in Europe as we have reimbursement approval. And as we look at the development investment, maybe there's -- it's more consistent 2015 to 2016 as program cycle in and out towards the expectation that the 661 program comes to closure, and we're refiling next year, and the progression of the triple into a larger Phase II study. So that gives you an outstanding trajectory of our investment profile through this year, not into next year."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff Leiden. With respect to your question on PDA data in CF. What we said before is we'll let you know if include the Phase I study and planned the Phase II studies for the next-gen correctors, what those Phase II studies look like and provide yo",74,"This is Jeff Leiden. With respect to your question on PDA data in CF. What we said before is we'll let you know if include the Phase I study and planned the Phase II studies for the next-gen correctors, what those Phase II studies look like and provide you with some relevant data to understand the design in those studies. As we said we or's on track for the second half of this year."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Michael Yee with RBC Capital Markets.",15,"And our next question comes from the line of Michael Yee with RBC Capital Markets."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two questions as well. On the commercial side, are you -- based on long-term data for ORKAMBI are you starting to see any patients perhaps thinking about coming back? Are there are discussions out there in the field about bringing some patients back on? A",104,"Two questions as well. On the commercial side, are you -- based on long-term data for ORKAMBI are you starting to see any patients perhaps thinking about coming back? Are there are discussions out there in the field about bringing some patients back on? And what are you thinking about that standpoint. And then follow-up question on the triple, is it safe to say that well into Phase I and the longer the better is there something specific in terms of exposure levels that you're looking for relative to assay that will give you some comfort in terms of what you want to see?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff Chodakewitz. Maybe let me touch in both for both of you. I think on a long-term data perspective, we think that many meaningful to patients and to prescribers, and I think the reason for that are several fold. As you know, that information re",310,"This is Jeff Chodakewitz. Maybe let me touch in both for both of you. I think on a long-term data perspective, we think that many meaningful to patients and to prescribers, and I think the reason for that are several fold. As you know, that information really has a couple of chunks to it. One is about the long-term safety of the drug, very important. And that continues to look very favorable consistent with what we have seen before, and then we had several efficacy kind of measures. Some of that came from the study itself. Our following patients for a long time we saw that there SVG ones where they maintained their BMI, continued to improve. And although there's no active comparison there, the great in terms of pulmonary really remained low and consistent with what we saw during the trials. So that was all very impactful, we think, for physicians and for patients. The other thing we did was take the information from a mass cohort of historical patients, and what that allows you to do over that kind of time frame is to compare the rate of decline of patients on our study versus what we think the historical expectation would be, and that's really -- as we did with KALYDECO helps us understand if we're shifting that curve and slowing the rate of decline, really modifying the disease. And we were very pleased to see that approximately 40% reduction in the rate of decline. So overall, we think that data is very impactful and useful. In terms of triple combination, really can't give you a lot of details, as Jeff Leiden said actually already, that both drugs do continue in the Phase 1 studies, and our expectation of core spending data is to have one or both of those in the second half of this year."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes the line of Jeff Reports with Leerink Partners.",12,"Our next question comes the line of Jeff Reports with Leerink Partners."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Question for Stuart about the PDUFA date and the indication for ORKAMBI. Can you talk about what sort of pace you expect reimbursement to be available to the pediatric patients, doubled out us and then secondly, as you are out in the community and talking",77,"Question for Stuart about the PDUFA date and the indication for ORKAMBI. Can you talk about what sort of pace you expect reimbursement to be available to the pediatric patients, doubled out us and then secondly, as you are out in the community and talking to physicians, do you think that the adoption compliance and persistence rates in the pediatric population will be similar to the adult population or greater or less than you've observed so far?'s"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, the PDUFA date is September 30. Obviously, were deep into the planning for that launch because it's only just a couple of months away. In terms of what we might anticipate for access to answer the first part of your question, my expectation is that a",294,"Yes, the PDUFA date is September 30. Obviously, were deep into the planning for that launch because it's only just a couple of months away. In terms of what we might anticipate for access to answer the first part of your question, my expectation is that access is going to be very good for ORKAMBI when we first introduced it for the 12 and over population. And in some ways, this is a somewhat simpler review for the payers. It's a labeled extension just extending it down to a younger age. And so my expectation is that we'll secure broad access very quickly. In terms of [indiscernible] similarly, I wouldn't anticipate the demand to be robust just as it was for 12 plus. And in terms of persistence and compliance. Again, it's difficult to say exactly how it's going to play out in the real word as opposite we saw in the clinical trial. Certainly, a couple of things that I think give us some encouragement we certainly saw in the study we did that forms the basis of our application and the adverse event rate and particularly the rates of events much lower and patients discontinued adverse event but as you know that's been one of the primary reasons for discontinuation on ORKAMBI the 12 and over population and then again could help us the 6 to 11 population with KALYDECO we do see compliance rates being much higher in the younger population not surprisingly as they tend to be very heavily managed by their parents and so why we don't know exactly how it's going to play out in the real-world. I certainly expect the access to be very good, and I also expect the uptake to be very rapid as well."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeff, I'll just add on to Stuart to reiterate something I said in my comments, which is just in Q4 is where we anticipated see the growth in ORKAMBI for the remainder of the year. And obviously, that is driven by 6 to 11 that Stuart was just discussing.",49,"Jeff, I'll just add on to Stuart to reiterate something I said in my comments, which is just in Q4 is where we anticipated see the growth in ORKAMBI for the remainder of the year. And obviously, that is driven by 6 to 11 that Stuart was just discussing."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes in the line of Brian Abrahams with Jefferies.",13,"And our next question comes in the line of Brian Abrahams with Jefferies."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","As you guys see more uptick in Germany and more patients in France, I was wondering if you could talk a little about persistence and compliance patterns that you're starting to see in Europe and expect to be able to leverage her learnings in the U.S. laun",109,"As you guys see more uptick in Germany and more patients in France, I was wondering if you could talk a little about persistence and compliance patterns that you're starting to see in Europe and expect to be able to leverage her learnings in the U.S. launch plus the availability of the long-term beta now to improve that patient retention in the lunch as compared to the U.S. And then separately just wondering if you could give us a little more granularity on the next steps, any level of confidence on residual function mutation, sort of where you stand there with respect to the next step -- regulatory step."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Firstly, so I'll start off on consistency in compliance and how things are playing out in Europe. One of the benefits of launching in Europe after launching here in the U.S. is, clearly, you've been learned a lot from our experience in the U.S. And I thin",201,"Firstly, so I'll start off on consistency in compliance and how things are playing out in Europe. One of the benefits of launching in Europe after launching here in the U.S. is, clearly, you've been learned a lot from our experience in the U.S. And I think one of the things that we've been able to do is certainly sensitize people to the fact that some patients may have this adverse events and so on the lookout canceling patients in advance and one of the many learnings that we took from our experiences here in U.S. to the introduction of products in Europe. The data sources are not quite as robust as we have here in the U.S. in terms of tracking at the nonbiased level individual patient data in Europe. And I would say at this early stage, the persistence rate is certainly in line in the same kind of ballpark we saw with ORKAMBI here in the U.S. As that data matures over time, we'll be able to give you a more detail on exactly how it's playing out but at the minute, it's and I'd say it's pretty much the same kind of ballpark for persistence in compliance."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. I'll just comment on residual function. We really can't comment on when we have ongoing discussions with regulatory agencies. The only thing I could say is that we really didn't think all do preclinical data and the clinical data I",70,"It's Jeff Chodakewitz. I'll just comment on residual function. We really can't comment on when we have ongoing discussions with regulatory agencies. The only thing I could say is that we really didn't think all do preclinical data and the clinical data I really tell us that this drug is beneficial to those patients, and our goal is to figure out a way to get access for those patients."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Terence Flynn with Goldman Sachs.",13,"Our next question comes from the line of Terence Flynn with Goldman Sachs."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe just 2 for me. First on ORKAMBI in the U.S. it looks like new patient moderated somewhat this quarter, and I know you were talking about mirroring peak. So is 6,000 or 6,000-ish kind of what you're expecting now or do you think you can get to the re",97,"Maybe just 2 for me. First on ORKAMBI in the U.S. it looks like new patient moderated somewhat this quarter, and I know you were talking about mirroring peak. So is 6,000 or 6,000-ish kind of what you're expecting now or do you think you can get to the rest of the 8,500 total? And then in Germany versus France, obviously a difference in uptake. Just wondering what you think is driving that and which other countries you could think about those patents playing out. Are they going to be more like Germany or more like France?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So I'll start of the U.S. As you said with ORKAMBI, we now initiated over 6,000 patients. Here in the U.S., it's about 70% of the eligible patient population. And as you might expect where we're getting to a steeper part of the curve, adding new patient b",338,"So I'll start of the U.S. As you said with ORKAMBI, we now initiated over 6,000 patients. Here in the U.S., it's about 70% of the eligible patient population. And as you might expect where we're getting to a steeper part of the curve, adding new patient becomes a little bit Having said that, we are continuing to add new patients on a weekly and daily basis. But as Ian said in his prepared remarks in terms of U.S. growth, obviously, the next phase in growth in the U.S. is likely from the approval and 6 to 11, which we hope will come in the next couple of months. So moving on for how things are panning out in Europe. And you're right, there is a contrast in uptake between Germany and France. Germany is slower than we anticipated. And much of that I attribute to the fact that the German market is all fragmented than many of the other markets that we operate in. What I mean by that is anymore sensors treating patients and as a result, they have less experience with CFTR modulators, and the educational need is higher there. And also, we did see a slightly slower uptake of KALYDECO in Germany than we saw other EU markets. In contrast with France where 2 access programs, we have 700 patients have already been initiated in ORKAMBI, and that update in 6 months is much more U.S.-like. So based on that, based on the other research we've done, we do anticipate that Germany is more likely to be an outlier in terms of uptake, although I continue to believe that we will get the vast majority of patients in Germany over time. And in terms of rates of uptake, I would expect it to be more like France in the rest of Europe pending reimbursement that we've seen in Germany, which I continue to believe this likely to be more of the outlier based on our previous experience with KALYDECO and experience with ORKAMBI."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of with Evercore ISI.",11,"Our next question comes from the line of with Evercore ISI."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is John Miller on for Mark. And I just wanted to ask a question about these 6,000 patients started on ORKAMBI. You said it's a start. So what's the current number of patients on therapy? I'd like to know that. And my other question would be your thou",80,"This is John Miller on for Mark. And I just wanted to ask a question about these 6,000 patients started on ORKAMBI. You said it's a start. So what's the current number of patients on therapy? I'd like to know that. And my other question would be your thoughts on pricing pressure, especially in like this where pricing pressure where pricing ability is typically been very high. How do you look at that going forward as that's obviously an issue?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Just to reiterate what Ian said In terms of the actual number of patients being treated, that's clearly a very dynamic number and changes consequently. So what we have said is we initiated 6,000 patients. We continue to see more initiations, and we contin",253,"Just to reiterate what Ian said In terms of the actual number of patients being treated, that's clearly a very dynamic number and changes consequently. So what we have said is we initiated 6,000 patients. We continue to see more initiations, and we continue to believe as we did end of Q1 that the persistence rate about patient population is going to be somewhere in that 70% to 80% range as indeed we believe the compliance rate will be somewhere in the 70% 80% range. And so that's the -- what we believe at the end of Q1, we continued to perform against those expectations, and that is with the 12 and above -- in 12 and above patients in the U.S. is what underlines our revenue guidance that we reiterated today. Pricing, clearly, that's a very hot topic across the industry. We continue to believe that we are developing very high value medicines, medicines that treat the underlying cause of a horrible life-shortening disease. It's for a very small patient population, and we believe I think that's reinforced by the discussions we have with governments through the reimbursement that KALYDECO and ongoing discussions we have with ORKAMBI, this is exactly the sort of medicine they want to be able to provide to their patient population so pricing pressures because of the overall macroeconomics on every pharma and biotech company, I continue to believe sort of agents are bringing their other sorts of products the governments are going to want to pay for."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Your next question comes from the line of Matthew Harrison with Morgan Stanley.",13,"Your next question comes from the line of Matthew Harrison with Morgan Stanley."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is [indiscernible] on for Matt. A couple of questions. First, are there any efforts to improve the persistence or compliance rates in the United States?",26,"This is [indiscernible] on for Matt. A couple of questions. First, are there any efforts to improve the persistence or compliance rates in the United States?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So we have a number of programs, which are provided either through materials that we provide to health care providers who provide their patients so where appropriate to provide directly to the patients to educate them on the product, the mechanism of acti",136,"So we have a number of programs, which are provided either through materials that we provide to health care providers who provide their patients so where appropriate to provide directly to the patients to educate them on the product, the mechanism of action, the fact we treat the underlying nature of the disease. So those programs are ongoing. I think understanding and educate patients is likely to be more persistent and more compliant patient. And also, we continue to try and build the evidence base for ORKAMBI, which increases the benefit risk profile and the providers and patients continue to believe in the benefit risk profile that I think they're going to want to try and maintain the time on the product because of the both short- and long-term benefit the treatment with ORKAMBI gives them."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And the second question is when be able to recognize the revenues in France and becomes lump sum or how will be dealt with?",25,"Okay. And the second question is when be able to recognize the revenues in France and becomes lump sum or how will be dealt with?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","To answer the question, just to help everybody else behind that question, we actually are providing access to ORKAMBI in France through early access programs and other programs, and we are actually being paid for that drug. In my remarks, I did comment th",197,"To answer the question, just to help everybody else behind that question, we actually are providing access to ORKAMBI in France through early access programs and other programs, and we are actually being paid for that drug. In my remarks, I did comment that that launch in France is going very well. We're accessing a lot of patients. We do get a payment for that drug that might be similar to how the ultimate price of the drug played out in France. However, from a GAAP perspective, we are unable to report those, let's say, access to those medicine as revenue until we have an agreed price in France. So I appreciate your question. We anticipate that would be a 2017 event. At this point, we do get approval on price, which provides uncertainty to recording those revenues because the revenues as long as they catch up. So as we've been selling drug since, let's say, January 1, 2016, all the way through the point of reimbursement approval, we will record the cash that we received as part of revenues in the quarter that we received reimbursement approval. We do think that would be a 2017 event."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. Great And then last question, is there any update to the 661 utility timing for the heterozygotes?",18,"Okay. Great And then last question, is there any update to the 661 utility timing for the heterozygotes?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff Chodakewitz. I can tell you that as we talked about previously that is on track to occur during the third quarter. And then based upon that recommendation from the DMC, remember that we won't be seeing that information. We will either stop, s",53,"This is Jeff Chodakewitz. I can tell you that as we talked about previously that is on track to occur during the third quarter. And then based upon that recommendation from the DMC, remember that we won't be seeing that information. We will either stop, study or restart enrollment and go to completion."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Your next question comes from the line of Adam Walsh with Stifel.",12,"Your next question comes from the line of Adam Walsh with Stifel."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","My first one is you talked about a large continuation in the first quarter because 15% of patients, I believe, come up in the first 3 months. I just wondered if there's any residual bolus kind of tail end into the second quarter. That's my first question.",106,"My first one is you talked about a large continuation in the first quarter because 15% of patients, I believe, come up in the first 3 months. I just wondered if there's any residual bolus kind of tail end into the second quarter. That's my first question. And then my second question is also on discontinuations. You talked about the 15% in the first 3 months and 20% to 30% longer term. Can you help us after the 15% drop out in the first 3 months, help us understand the discontinuation dynamics from that point to the 25% long-term discontinuation to the midpoint of your guidance."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So yes, we did describe bolus of discontinuation, and that was largely a function of 2 things. One, the very, very rapid uptake we saw in ORKAMBI in the launch, and we did see about 15% of patients discontinue within the first 3 months therapy largely the",150,"So yes, we did describe bolus of discontinuation, and that was largely a function of 2 things. One, the very, very rapid uptake we saw in ORKAMBI in the launch, and we did see about 15% of patients discontinue within the first 3 months therapy largely the result of respiratory adverse events. And then what we saw was the rates of discontinuations the rate substantially in flat but it certainly substantially and is the result of that that's why we gave guidance that we see the discontinuations the persistence rate discontinuations being in that 70% to 80% range by the end of 2016. And everything we've seen through Q2 continues to reinforce, I believe, that that's where we will end the year, somewhere in that 70% to 80% range. There isn't one really -- if I understand your question correctly, there wasn't really a second bolus that negatively impacted Q2."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Right. I guess the question, was there any tail end residual? You had the large number of patients starting in the first 9 months, and you said in the first quarter. As we moved into this quarter, was the bolus still moving through in terms of 15% discont",56,"Right. I guess the question, was there any tail end residual? You had the large number of patients starting in the first 9 months, and you said in the first quarter. As we moved into this quarter, was the bolus still moving through in terms of 15% discontinuation or that really end in the first quarter?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Maybe a better way to answer this is some of the assets on the call earlier was that we continuing to see the dynamics of the launch and compliance rates and consistence rates being maintained? Yes, they are. When we talk about the profile of compliance w",131,"Maybe a better way to answer this is some of the assets on the call earlier was that we continuing to see the dynamics of the launch and compliance rates and consistence rates being maintained? Yes, they are. When we talk about the profile of compliance with the medicine being between 70% and 80%, we're still seeing that. When we look at the consistence rates ending up at 70% to 80%, we're still seeing that, which means that every time there is some bolus of patients that has initiated therapy, we still continue to see discontinuations early on. However, because there is a lower initiation of patients in, let's say, Q1 or even the beginning of Q2, the impact of discontinuations in Q2 is much less than it has ever been."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Phil Nadeau at Cowen and Company.",14,"Our next question comes from the line of Phil Nadeau at Cowen and Company."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just a couple on the pipeline. So I guess first on VX-661 analysis, never disclosed exactly what the futility hurdle was. I was wondering whether you could give us some sense of the criteria or at least how you're going to -- going to interpret a go signa",95,"Just a couple on the pipeline. So I guess first on VX-661 analysis, never disclosed exactly what the futility hurdle was. I was wondering whether you could give us some sense of the criteria or at least how you're going to -- going to interpret a go signal in particular. And then a similar question on the Phase I for the second-generation correctors. Can you give us some be of what going to look at to decide which will move forward and do you have any plans to move other second-generation correctors into the clinic?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. So in terms of 661s first of all, we can't go into the details exactly what the decision tree is, but let me think about it a little bit perhaps. There's a certain tension as you make a decision based on partial information. We want",156,"It's Jeff Chodakewitz. So in terms of 661s first of all, we can't go into the details exactly what the decision tree is, but let me think about it a little bit perhaps. There's a certain tension as you make a decision based on partial information. We want to try if the drug is not benefiting patients to stop the trial. Conversely, there is uncertainty, and we also want to be careful about not missing a positive result. Therefore, there always is a certain overlap. And what we tend to do is it's clearly not working, we stop. The consequence of that is even if it goes forward, there is still uncertainty, it does not mean that it's working, it means that it may be working. And therefore, until we get to the end of the study we're really -- we really would not have had any confidence in what the results going to be."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Jeff, before you go onto the next question, I will just comment on the disclosure we get that the question a number of times. I want to be very clear on our disclosure around that consistent with what Jeff is saying if there is a discontinuation of th",119,"And Jeff, before you go onto the next question, I will just comment on the disclosure we get that the question a number of times. I want to be very clear on our disclosure around that consistent with what Jeff is saying if there is a discontinuation of the study due to the futility we will announce that the study is discontinuing appropriate announcement time we get that information. If we have pass, no guarantees, that's working in information is submissible for approval, but the only way we indicate around at this on ClinicalTrials.gov, we will open the recruitment for that study and expanded to the study for the would be announcement say that we passed the futility rules."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","In terms of your other question, I think what we've always said is bring these compounds we wanted to be medicine so we try as much as possible to have drugs that we think can have a favorable profile in patients We're going to look at all the information",78,"In terms of your other question, I think what we've always said is bring these compounds we wanted to be medicine so we try as much as possible to have drugs that we think can have a favorable profile in patients We're going to look at all the information, have safety exposure, all the things you'd expect there's really no one thing that I can say we're going to focus on really the futility profile of the drugs."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Do you have a chance to bring any other second-generation correctors into the clinic or is it dependent on Phase I?",22,"Do you have a chance to bring any other second-generation correctors into the clinic or is it dependent on Phase I?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff Leiden. As we said before, this is a large program here. We've discovered a series of second-generation correctors, and they have different mix generation correctors. They had different flavors, which is interesting. And our strategy here is",85,"This is Jeff Leiden. As we said before, this is a large program here. We've discovered a series of second-generation correctors, and they have different mix generation correctors. They had different flavors, which is interesting. And our strategy here is very straightforward. We can develop a portfolio of products and bring some of those to the clinic gives us the best fallibility of success. So our plan is to continue that program and the preclinical phase we see compounds that are interestingly good, better clinic."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Olivier Young with Crdit Suisse.",14,"And our next question comes from the line of Olivier Young with Crdit Suisse."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just one on 661, the other study. Could you give us around maybe kind of what the progress is in enrollment not the homozygous, but the other 3 studies, kind of what sequencing time line? Second one, just when you look at some of the long-term data you ge",79,"Just one on 661, the other study. Could you give us around maybe kind of what the progress is in enrollment not the homozygous, but the other 3 studies, kind of what sequencing time line? Second one, just when you look at some of the long-term data you generate on exacerbations the medical mid-year, do you think that doctors are receiving that patients or receiving that there is a very profound benefit that and ORKAMBI somewhat similar to KALYDECO?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. It's Jeff Chodakewitz. Let me first comment on the 661 sequence. First of all, as we indicated for the homozygous study, we have a lot of confidence in that finishing enrollment in August. In fact, we've actually already stopped screening patients f",327,"Sure. It's Jeff Chodakewitz. Let me first comment on the 661 sequence. First of all, as we indicated for the homozygous study, we have a lot of confidence in that finishing enrollment in August. In fact, we've actually already stopped screening patients for that study, so it's just the last patients completing the screening process and if they qualify going into the trial. We've already talked about the timing of the study in patients and the futility analysis that's going to be done. We expect that next trial that's going to be completed will be the study in patients with 508 or [indiscernible] residual function As we indicated, we expect that to complete in the second half of this year, very much as we've indicated earlier this year, really right on track. And then the last study with 508 [indiscernible] again as we've indicated previously we think in the second half of this year or early next year and as we get that will allow it to evaluate our best submission strategy and final pending data in the second half of 17. In terms of the long-term data, I want to be sure that I understand your question. We do think that the results from that long-term data are quite compelling. You asked specifically about pulmonary exacerbation, and so we do look at what basically we use in assessment of how many events are happening for the patients that we're following and think about it as and what we do see is that as you've gone out further in time, that remains quite well compared to what we had as our initial comparison. We think that is quite meaningful to patients and physicians. And actually, that linked up with the other information like body weight and particularly, the slow [indiscernible] evidence of disease modification. We think that is driving considerations like starting therapy earlier and considering whether patients who discontinue may want to think about restarting therapy."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Ying Huang with Bank of America.",14,"Our next question comes from the line of Ying Huang with Bank of America."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Can you talk about maybe the pricing you're getting in France, and how does that compare to the German pricing for ORKAMBI? And then secondly, also again on Europe, what's your thought on the U.K. and also, broadly speaking, European reimbursement for ORK",44,"Can you talk about maybe the pricing you're getting in France, and how does that compare to the German pricing for ORKAMBI? And then secondly, also again on Europe, what's your thought on the U.K. and also, broadly speaking, European reimbursement for ORKAMBI?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So the pricing in France has not been publicly disclosed, but it is very similar to the price we have established in Germany. In terms of the Brexit impact, certainly, from a financial point of view, short term, the really most tangible impact that you ca",154,"So the pricing in France has not been publicly disclosed, but it is very similar to the price we have established in Germany. In terms of the Brexit impact, certainly, from a financial point of view, short term, the really most tangible impact that you can see is really one around the impact on FX. And because of the nature of our business and the natural hedges we have, we're not expecting that to have a meaningful impact on our business. There's, obviously, a range of other legal regulatory employment and other aspects that could be impacted by Brexit as the negotiations are ongoing. We're clearly going to be tracking those very closely and making all the appropriate moves and responses as the situation becomes -- the situation becomes clear. As would many things Brexit, I think to speculate on too many other aspects of what the impact would be crystal ball gazing event."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Another one with Jeff, could you tell us when we might see CRISPR [indiscernible] released?",15,"Another one with Jeff, could you tell us when we might see CRISPR [indiscernible] released?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I appreciate your acknowledging the 2 very important collaborations that we've actually done in the last year, kind of expanding the modalities in diseases. But unfortunately, the stage as you are probably aware, and we would anticipate getting anything t",72,"I appreciate your acknowledging the 2 very important collaborations that we've actually done in the last year, kind of expanding the modalities in diseases. But unfortunately, the stage as you are probably aware, and we would anticipate getting anything to the clinic the next couple of years, probably 3 years and more from now, and we'd love to update you on that, but those have been important transactions for both companies."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Lisa Baker with JMP Securities.",13,"Our next question comes from the line of Lisa Baker with JMP Securities."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I thought you had a pretty good KALYDECO quarter. I'm just wondering if you could comment on where -- what's driving growth there? is that in a particular region or rolling out a new mutation?",35,"I thought you had a pretty good KALYDECO quarter. I'm just wondering if you could comment on where -- what's driving growth there? is that in a particular region or rolling out a new mutation?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's nice we had a talk about KALYDECO and KALYDECO had a very strong quarter, about $180 million. Most of the growth over Q2 came from the U.S. And essentially, what we continue to see is increasing new patient initiations in some of the newer indication",108,"It's nice we had a talk about KALYDECO and KALYDECO had a very strong quarter, about $180 million. Most of the growth over Q2 came from the U.S. And essentially, what we continue to see is increasing new patient initiations in some of the newer indications like the 2 to 5-year old kids and also in the [indiscernible] mutation. So we continue to see strong patient initiation. And as you know, the persistence rate and the compliance rates at KALYDECO are about as good as I've ever seen. So really, that combination of adding new patients and great persistence in client rates, particularly here in the U.S."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And then in terms of ex- U.S., is it just to make your are all the same patient only companies countries you're selling drug to patients because I know you're not really selling it in France per se, but France, Germany and the U.S. are those the tot",52,"Okay. And then in terms of ex- U.S., is it just to make your are all the same patient only companies countries you're selling drug to patients because I know you're not really selling it in France per se, but France, Germany and the U.S. are those the totality of the countries?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So outside of the U.S., France and Germany are different in a way the structure of those markets work is there are access programs that you can take advantage of that patient can get access to the products the reimbursement approval being secured on a rel",143,"So outside of the U.S., France and Germany are different in a way the structure of those markets work is there are access programs that you can take advantage of that patient can get access to the products the reimbursement approval being secured on a relatively broad basis, and that's happening in both Germany and France. And Ian talked about the fact that in France recognize those patients. In Germany, we do. There are other countries where patient basis. There are literally handfuls of patients who exceptional programs are getting access to the product where we are getting paid. The vast majority of our revenues outside of the U.S. are coming from Germany. We expect that to continue in 2016, and we don't expect it to get really meaningful revenue contributions from markets outside of Germany outside of the U.S. until 2017."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Brian Skorney with Robert W Baird.",14,"Our next question comes from the line of Brian Skorney with Robert W Baird."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two quick ones. I guess, first, can you just go over anything you said about the difference between 152 and 440? Are they distinct corrective mechanisms? I know we've always said that the intense move forward with both of us wondering if there's a potenti",95,"Two quick ones. I guess, first, can you just go over anything you said about the difference between 152 and 440? Are they distinct corrective mechanisms? I know we've always said that the intense move forward with both of us wondering if there's a potential for these 2 drugs to be complementary to each other, like 661 and just overlapping? And then when you think about the approval later this year, do you think there's any meaningful number of patients currently on ORKAMBI off-label or do you think it's really completely patient pool right now?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff Leiden. I'll take the first part. Stuart can take the second part. We haven't actually talked a lot of detail around the mechanisms of action or differences and similarities between 152 and  440, clearly different molecules, and so that's why",109,"This is Jeff Leiden. I'll take the first part. Stuart can take the second part. We haven't actually talked a lot of detail around the mechanisms of action or differences and similarities between 152 and  440, clearly different molecules, and so that's why we brought forward into the clinic. What we have said is as part of our discovery programs have discovered the portfolio of next-gen correctors, which do have distinct mechanisms of actions as well as properties and that's why we're excited about the portfolio that's why we take multiple molecules in the clinic at least in my experience that's the way to maximize your chance for success."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And on the subject of off-label usage in the 6 to 11 population, we don't track off-label usage. My expectation is it would be very, very low. The reason why I say that is the prior authorization for ORKAMBI, which enabled us to get access for ORKAMBI are",101,"And on the subject of off-label usage in the 6 to 11 population, we don't track off-label usage. My expectation is it would be very, very low. The reason why I say that is the prior authorization for ORKAMBI, which enabled us to get access for ORKAMBI are very simple but very clear. They would [indiscernible] from CF diagnosis, they have the right mutation and they check the date of birth, so they check the patient is 12 and above. So my expectation will be the number of people commercial product off-label at this point will be very, very low."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Katherine Xu with William Blair.",10,"Our next question comes from Katherine Xu with William Blair."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I'm just wondering with ORKAMBI versus KALYDECO, do you see a little bit lower compliance for ORKAMBI as compared to KALYDECO? And if that's the case, do you think it's mostly because of safety or lower efficacy or any sense on that at all?",45,"I'm just wondering with ORKAMBI versus KALYDECO, do you see a little bit lower compliance for ORKAMBI as compared to KALYDECO? And if that's the case, do you think it's mostly because of safety or lower efficacy or any sense on that at all?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Katherine, so with KALYDECO, we see very, very high levels of both persistence and compliance. We said our persistence with KALYDECO is 90% plus. And overall compliance both here in the U.S. and internationally is around 85%. And as we said, Q1 is baked i",142,"Katherine, so with KALYDECO, we see very, very high levels of both persistence and compliance. We said our persistence with KALYDECO is 90% plus. And overall compliance both here in the U.S. and internationally is around 85%. And as we said, Q1 is baked into our revenue guidance, we expect persistence for ORKAMBI to be between 70% and 80% and for compliance to be in the same 70% to 80% range. So we do see both of those criteria being lower for ORKAMBI than they are for KALYDECO. And we try to attribute exactly why that is. I'm not sure I would be able to that out for you. I'm sure it's got to do with the benefit risk and tolerability profile of ORKAMBI versus KALYDECO. But exactly which factor is one way or the other, that will be impossible to differentiate."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And could you give a quick update on your oncology and pipeline candidates?",13,"And could you give a quick update on your oncology and pipeline candidates?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. Just to give you a quick comment and maybe a comment, I think, in terms of our oncology program, I think, very much consistent with where we are expressing it previously that we have our [indiscernible] 970 is really in focused clin",99,"It's Jeff Chodakewitz. Just to give you a quick comment and maybe a comment, I think, in terms of our oncology program, I think, very much consistent with where we are expressing it previously that we have our [indiscernible] 970 is really in focused clinical trials in very specific populations and trials to understand what the potential for those that drug really can be. And so those are ongoing. On the side, our VX-150 actually just as finishing -- finished enrolling the 2 POC study in osteoarthritis patients, and we expect to have some information later this year."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So I'll just pick up on that because many people ask me this, are we going to be in oncology company? I think it's a little early to suggest that, given that we have one lead molecule in early-stage studies in oncology we're going to continue to progress",160,"So I'll just pick up on that because many people ask me this, are we going to be in oncology company? I think it's a little early to suggest that, given that we have one lead molecule in early-stage studies in oncology we're going to continue to progress the study as Jeff Chodakewitz said. And based on that data, we'll make a choice at that time we provide further investments we actually look to see whether that's served working with other companies. And we're looking more of a portfolio approach to drive forward, let's say, our oncology opportunities. We do have other mechanisms. One of its in the clinic and a couple that's late preclinical right now. So we have a late preclinical a couple of compounds and also early clinical compounds, and that's the term oncology portfolio and we'll make the decision of how to progress that greatest value once we see the data from the [indiscernible] program."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Alan Carr with Needham and Company.",14,"Our next question comes from the line of Alan Carr with Needham and Company."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess a couple of them here. One of them is the only one haven't touched on is 210. Wondering if you could give us an update on that in spinal cord. And then also with respect to your sNDA around residual mutations for KALYDECO, what sort of options do",60,"I guess a couple of them here. One of them is the only one haven't touched on is 210. Wondering if you could give us an update on that in spinal cord. And then also with respect to your sNDA around residual mutations for KALYDECO, what sort of options do you have available here in your discussions with the FDA?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeff Chodakewitz. So [indiscernible] first of all, I'd say in terms of VX-210, that study is up and enrolling like we have had enrollment now in the trial, but [indiscernible] these are purely injured people, and so we have always expected that enrollment",84,"Jeff Chodakewitz. So [indiscernible] first of all, I'd say in terms of VX-210, that study is up and enrolling like we have had enrollment now in the trial, but [indiscernible] these are purely injured people, and so we have always expected that enrollment will be slow and, so we are really pretty much on track. In terms of residual function, as we talked about earlier, it's really just nothing in terms of ongoing discussions with the regulatory agency that I can talk about further."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Can you comment -- I'm wondering if you can comment on what sort of what the outcomes might be here is it something might be resolved this year or does this potentially involve more studies can you comment from that perspective?",41,"Can you comment -- I'm wondering if you can comment on what sort of what the outcomes might be here is it something might be resolved this year or does this potentially involve more studies can you comment from that perspective?"
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, it's Jeff Leiden. As you know, we just don't comment on regulatory discussions, probably because they are not predictable, and they are not totally under our control. I think the important point is we do believe that KALYDECO [indiscernible] the set",80,"Yes, it's Jeff Leiden. As you know, we just don't comment on regulatory discussions, probably because they are not predictable, and they are not totally under our control. I think the important point is we do believe that KALYDECO [indiscernible] the set of patients based on those preclinical and preclinical data, and we have an ongoing discussion with the regulators how to get access to these patients with KALYDECO. When we have an answer, we'll certainly disclose that for you."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Thank you. And I'm showing no further questions at this time I would now like to turn the conference back over to Mr. Michael Partridge for any closing remarks.",29,"Thank you. And I'm showing no further questions at this time I would now like to turn the conference back over to Mr. Michael Partridge for any closing remarks."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, operator. We appreciate everyone joining us tonight we are happy to take additional follow-up questions after the call the Investor Relations steam will be in the office so please reach out and have a good night.",37,"Thanks, operator. We appreciate everyone joining us tonight we are happy to take additional follow-up questions after the call the Investor Relations steam will be in the office so please reach out and have a good night."
36235,374694421,1014265,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for participating in today's conference. It does conclude the program. You may all disconnect. Everyone have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. It does conclude the program. You may all disconnect. Everyone have a great day."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our Second Quarter 2016 Financial Results Conference Call. [Operator Instructions] You can access the webcast live by going to our website where a replay",209,"Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our Second Quarter 2016 Financial Results Conference Call. [Operator Instructions] You can access the webcast live by going to our website where a replay will also be available later tonight. Dr. Jeff Leiden, Chairman and CEO; and Ian Smith, Chief Financial Officer, will provide prepared remarks this evening. They will be joined by Stuart Arbuckle, Chief Commercial Officer; and Dr. Jeff Chodakewitz, Chief Medical Officer, for the Q&A portion of the conference call.
We will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the SEC. These statements, including without limitation, those regarding the ongoing development and potential commercialization of our drug candidates, our expectations regarding our approved medicines and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in tonight's press release. I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Dr. Jeff Leiden."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. It was just over 1 year ago that we received FDA approval for ORKAMBI, marking the most significant step to date in our journey to develop new medicines for people with cystic fibrosis. Tonight, I'm pleased to repo",1092,"Thanks, Michael. Good evening, everyone. It was just over 1 year ago that we received FDA approval for ORKAMBI, marking the most significant step to date in our journey to develop new medicines for people with cystic fibrosis. Tonight, I'm pleased to report on our significant and steady progress in CF, and I'll review 3 key phases in our efforts to bring all people with CF a medicine to treat the underlying cause of their disease. If we're successful in these efforts, we believe significant and sustained revenue and earnings growth will follow.
Today, there are approximately 27,000 people eligible for treatment with ORKAMBI or KALYDECO. However, we're only treating approximately 9,000 or 1/3 of these patients. The first and most significant near-term step to increase the number of eligible patients being treated for their medicines is to gain reimbursement of ORKAMBI in key European and other countries. Progress with reimbursement for ORKAMBI would enable the vast majority of currently eligible patients to be treated with one of our CF medicines. 
The second step to treat more people with CF is to further expand the labels for both ORKAMBI and KALYDECO, which could increase the total number of eligible patients from 27,000 to approximately 44,000. And the third step is to potentially treat all people with CF with new combinations of CFTR modulators as well as other approaches to treatments such as ENaC inhibition, gene editing and mRNA therapies.
First, the reimbursement for ORKAMBI. Outside the U.S., the reimbursement process is ongoing, and these discussions are progressing as anticipated across Europe, Canada and Australia. We're encouraged that many reimbursement authorities have acknowledged the significant clinical benefits that ORKAMBI provides. We believe that we will achieve reimbursement from European and other government payers just as we've seen in the U.S. We look forward to updating you as we obtain reimbursement in key countries going forward.
Second, to our label expansion efforts for both ORKAMBI and KALYDECO. Specifically, there's some 12,000 additional patients younger than age 12 with 2 copies of the Delta F508 mutation whom we believe could be helped by ORKAMBI. In the second quarter, the FDA accepted for review our supplemental new drug application for the use of ORKAMBI in children ages 6 to 11, and granted our request for priority review, setting a target review date or PDUFA date September 30, 2016. If approved, we expect to be ready to bring ORKAMBI to these patients immediately following approval. 
In parallel, we're also progressing with our efforts to bring ORKAMBI to children ages 6 to 11 in Europe where we plan to submit our application for approval in the first half of next year, following the conclusion of our fully enrolled Phase III efficacy and safety study in this group of patients. We estimate that there are approximately 2,400 children ages 6 to 11 in the U.S., and 3,400 in Europe who would be eligible for ORKAMBI.
There are approximately 5,000 additional patients in North America, Europe and Australia, largely those with residual function mutations who could be helped by KALYDECO. While we received the complete response letter from the FDA earlier this year regarding our application for approval of KALYDECO in people with CF ages 2 and older who have 1 of 23 residual function mutations, our belief that KALYDECO would be beneficial to these patients is unchanged, and we continue to pursue FDA approval for these patients as soon as possible. There are approximately 1,500 people with CF in the U.S. who have the mutations included in our residual function sNDA. 
And third, to our expanding pipeline of investigational CF medicine. The most advanced pipeline program in CF is our broad Phase III program for VX-661 in combination with ivacaftor. VX-661 plus ivacaftor may have an improved benefit risk profile compared to ORKAMBI in people with 2 copies of the Delta F508 mutation and may provide enhanced clinical benefits over ivacaftor monotherapy for other patients with gating mutations. Enrollment in the study of VX-661 plus ivacaftor in people ages 12 and older with 2 copies of the Delta F508 mutation is expected to complete in August. Data from the 6-month study are expected in the first half of 2017. The other 3 Phase III studies of VX-661 are also progressing as planned. We plan to submit a new drug application to the U.S. FDA for VX-661 in combination with ivacaftor in the second half of 2017.
Importantly, VX-661 is also positioned to play a key role in a triple-combination regimen with a next-generation corrector and ivacaftor. We believe that this triple combination approach may allow us to treat an additional large group of patients, specifically those with one Delta F508 mutation and one mutation that results in minimal CFTR function. These patients do not currently have medicines to treat the cause of their disease.
Our 2 next-generation correctors, VX-152 and VX-440, are being evaluated in Phase I studies in healthy volunteers. Pending data from these studies, we expect to move into Phase II clinical development in the second half of 2016 in people with CF. These studies would evaluate 1 or both of our next generation correctors with VX-661 and ivacaftor. 
Beyond our CFTR modulators, we've entered into multiple strategic collaborations that broaden our ability to evaluate additional approaches to CF treatment that may be complementary to CFTR modulation in the future. While the underlying technology and science of each approach differs, the collaborations have a shared goal to develop the best possible future treatments for all people with CF. Earlier this month, we entered into a collaboration with Moderna Therapeutics aimed at using messenger RNA to potentially enable cells in the lungs of people with CF to produce functional CFTR protein. This is the second platform technology collaboration we have entered into, following our agreement with CRISPR Therapeutics focused on the use of CRISPR-Cas9 for gene editing that we began in late 2015. These platform technologies add to our development stage collaboration with Parion Sciences focused on the use of ENaC inhibition to treat CF.
As we ended the second half of 2016, I'm pleased with both the near and long-term growth opportunities for our business. Our goal is to consistently discover and deliver transformative new medicines for patients and to reinvest in scientific opportunities to create future medicines. We believe our business model, which is focused on significant investment to create value through innovation, research and development, will position us to achieve this goal over the coming years.
With that, I'll turn the call over to Ian."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. Through the second quarter of the year, we've created a growing revenue base with ORKAMBI and KALYDECO, which we expect to drive future earnings growth. Tonight, I'll discuss our second quarter revenues for ORKAMBI and K",683,"Thanks, Jeff, and hello, everyone. Through the second quarter of the year, we've created a growing revenue base with ORKAMBI and KALYDECO, which we expect to drive future earnings growth. Tonight, I'll discuss our second quarter revenues for ORKAMBI and KALYDECO, review our 2016 financial guidance and discuss our anticipated financial trajectory for the coming years.
In the second quarter of 2016, we reported total CF product revenues of approximately $426 million, a significant increase compared to $155 million for the second quarter of last year. 
Turning to the revenues for each of our CF medicines. Global sales of ORKAMBI in the second quarter were $245 million, comprised of U.S. sales of approximately $229 million, and ex-U.S. sales of approximately $16 million, which were mainly from Germany. As of June 30, approximately 6,000 patients have initiated treatment with ORKAMBI in the U.S. Outside the U.S., ORKAMBI is already available commercially in Germany, and also through early access programs in France. In Germany, uptake continues to be slower than we observed in the U.S. As of June 30, approximately 380 of the 2,500 eligible patients in Germany had initiated treatment. 
In contrast, in France, we continue to see strong and rapid uptake. Approximately 700 of 1,500 eligible patients in France have already initiated treatment with ORKAMBI as of June 30 as part of the country's early access programs. These programs provided the opportunity for physicians in France to begin treating patients prior to their formal reimbursement approval. We are pleased the ORKAMBI launch has continued to progress consistent with what we discussed on our first quarter call. And today, we are reiterating our expectation for 2016 ORKAMBI revenues of $1 billion to $1.1 billion. 
Given the slower than expected launch in Germany and that we are approaching peak penetration for ORKAMBI in patients aged 12 and older in the U.S., we expect that revenue growth for ORKAMBI will occur primarily in the fourth quarter, following the potential approval and launch of ORKAMBI for children ages 6 to 11.
Now to KALYDECO. Second quarter KALYDECO sales were $180 million, up $25 million compared to the second quarter of last year. We continue to see small number of additional eligible patients beginning treatment in the U.S. and Europe. As with ORKAMBI, we are reiterating our 2016 revenue guidance for KALYDECO of $685 million to $705 million. Our 2016 guidance exclude any potential revenues for the approval of KALYDECO in residual function mutations where we continue to pursue the FDA approval for patients ages 2 and older in the U.S.
Now to the operating expenses. Our second quarter non-GAAP operating expenses were $306 million compared to non-GAAP operating expenses of $254 million in 2015. The increased operating expenses were mainly due to increased costs related to the progression of our CF pipeline and to increase investment in global commercial support for the launch of ORKAMBI. Our non-GAAP net profit for the second quarter of 2016 was $58 million or $0.24 per diluted share as compared to a non-GAAP net loss of $131 million or $0.54 per share for 2015. 
From a balance sheet perspective, we ended the second quarter with approximately $1.07 billion in cash, cash equivalents and marketable securities. Vertex also has $300 million outstanding from a credit agreement repayable by the end of the third quarter 2017.
I'll conclude tonight's call with a few brief comments on financial trends, including revenue and earnings growth. Our goal is to discover and develop new medicines for all people with CF. And as Jeff has discussed, there are 3 important phases to support these efforts: obtaining reimbursement for ORKAMBI outside the U.S.; expanding labels for both ORKAMBI and KALYDECO; and developing new medicines to treat potentially all people with CF. As we progress towards this goal, significant and sustainable revenue growth will follow. Importantly, as our revenues grow over future years, we are committed to managing our operating expenses to drive earnings growth. And we expect to deliver a financial profile similar to many of our large cap biotech peers. 
With that, I open the line to questions."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] And our first question comes from the line of Geoff Meacham with Barclays.",15,"[Operator Instructions] And our first question comes from the line of Geoff Meacham with Barclays."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have a few commercial ones and one clinical. I wanted to ask you guys, either Ian or Stuart, any changes to the persistence rates in the U.S., what are the new strategies to improve it? And then, can you just go into a little bit more detail on the EU o",71,"I have a few commercial ones and one clinical. I wanted to ask you guys, either Ian or Stuart, any changes to the persistence rates in the U.S., what are the new strategies to improve it? And then, can you just go into a little bit more detail on the EU outlook? So from what I understand, flattish in 3Q from Germany? And then, maybe what's driving the fourth quarter bump?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, it's Stuart here. So on persistence rates, what we're seeing in the U.S. is very consistent with what we outlined on our Q1 call. In fact, all the trends really in initiations, persistence and compliance are entirely in line with what we said then.",270,"Geoff, it's Stuart here. So on persistence rates, what we're seeing in the U.S. is very consistent with what we outlined on our Q1 call. In fact, all the trends really in initiations, persistence and compliance are entirely in line with what we said then. Just to remind you and others on the phone, for persistence, we said that our expectation was it would track towards about 70% to 80%, between 70% and 80% by the end of this year, and the same for compliance, and we continue to believe in those estimates, and those estimates are what underpins our revenue guidance that we reiterated today. In terms of Europe, and as you noted, Germany's uptake is relatively slow, and Ian mentioned that in his prepared remarks. Incorporated within our guidance, really, we're only expecting significant contributions ex-U.S. from Germany. In terms of how we see things playing out in the rest of Europe, really, as you know, that's going to be very dependent on us proceeding through country by country reimbursement negotiation processes. And what I can tell you is that those are progressing as we planned, as expected. But given our learnings and the analogy to KALYDECO and the time it took there, we're really not anticipating to conclude many of those reimbursement negotiations until 2017. Having said that, we recently concluded our first formal reimbursement negotiation in Austria, and that will go into effect from September 1, but we continue to believe that most of the major markets were not likely to see any major contributors -- contributions in terms of revenue growth until 2017 and beyond."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And just real quick on the clinical side, I know it's less interesting, but the PK for 152 and 440, will we see any of that in any CF? And any more thoughts on kind of what the size and scope of the clinical development for the triple could entail?",51,"Okay. And just real quick on the clinical side, I know it's less interesting, but the PK for 152 and 440, will we see any of that in any CF? And any more thoughts on kind of what the size and scope of the clinical development for the triple could entail?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, it's a little difficult to answer that, to be honest, Geoff. To say the size of the triple -- I mean, if I comment more broadly on our operating expense for the remainder of the year and then maybe kind of the trajectory in 2017, I think, that's an",245,"Well, it's a little difficult to answer that, to be honest, Geoff. To say the size of the triple -- I mean, if I comment more broadly on our operating expense for the remainder of the year and then maybe kind of the trajectory in 2017, I think, that's an easy way for me to comment on it. We always plan and provide guidance based on assuming success and that's why we're investing behind the programs. So our OpEx guidance for the year is at $1.18 billion to $1.23 billion, and we reiterated that number in the press release tonight. And that's a non-GAAP number, by the way. Excludes primarily stock compensation. And then, as we look into next year, we actually -- we hope and expect the programs to progress. And as we look into next year, as we think about OpEx more broadly, we see maybe some marginal increases in marketing investments for the launch of ORKAMBI more broadly, and particularly in Europe as we get reimbursement approval. And as we look at the development investment, maybe there's -- it's more consistent with 2015 to 2016 as programs cycle in and out with the expectation that the 661 Phase III program comes to closure, and we're refiling next year, and the progression of the triple into a larger Phase II study. So hopefully, that gives you an understanding of the trajectory of our investment profile through this year and then into next year."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, this is Jeff Leiden. With respect to your question on the PK data in CF. What we said before is that we'll let you know if we include the Phase I studies and plan the Phase II studies for the next-gen correctors, what those Phase II studies will lo",83,"Geoff, this is Jeff Leiden. With respect to your question on the PK data in CF. What we said before is that we'll let you know if we include the Phase I studies and plan the Phase II studies for the next-gen correctors, what those Phase II studies will look like and we'll provide you with some relevant data so you understand the design of those studies. And those studies, as we said, are on track for the second half of this year."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Michael Yee with RBC Capital Markets.",15,"And our next question comes from the line of Michael Yee with RBC Capital Markets."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two questions as well. On the commercial side, are you -- based on long-term data for ORKAMBI, are you starting to see any patients perhaps thinking about coming back? Are there discussions out there in the field about bringing some patients back on? And",112,"Two questions as well. On the commercial side, are you -- based on long-term data for ORKAMBI, are you starting to see any patients perhaps thinking about coming back? Are there discussions out there in the field about bringing some patients back on? And what are you thinking about that standpoint? And then, a follow-up question on the triple, is it safe to say that you've gone well into Phase I and the longer the better. Is there something specific in terms of exposure levels that you're looking for relative to assays that would give you some comfort in terms of what you want to see in terms of exposure of [indiscernible]"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. Maybe let me just touch on both of those for you. I think, from a long-term data perspective, we think that is very meaningful to patients and to prescribers. And I think, the reason for that are several fold. As you know, that info",323,"It's Jeff Chodakewitz. Maybe let me just touch on both of those for you. I think, from a long-term data perspective, we think that is very meaningful to patients and to prescribers. And I think, the reason for that are several fold. As you know, that information really has a couple of chunks to it. One is about the long-term safety of the drug, which is very important. And that continues to look very favorable, consistent with what we have seen before. And then, we had several for efficacy kind of measure. Some of that came from the study itself, our following patients for a long time and we saw that their FEV1s where maintained, their BMI continued to improve. And although there's no active comparison there, the event rate in terms of pulmonary exacerbation really remained low and consistent with what we saw during the trials. So that was all very impactful, we think, for physicians and for patients. The other thing we did was take the information from a mass cohort of historical patients, and what that allows you to do over that kind of time frame is to compare the rate of decline of patients' FEV1s who were on our study versus what we think the historical expectation would be, and that really then, as we did with KALYDECO, helps us understand if we're shifting that curve and slowing the rate of decline, really modifying the disease. And we were very pleased to see that approximately 40% reduction in the rate of decline. So overall, we think that data is very impactful and useful. In terms of triple combination, really can't give you a lot of details, as Jeff Leiden said actually already, that, that -- both drugs do continue in Phase 1 studies, and our expectation, of course, pending data, is that one or both of those will start in patients in the second half of this year."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes the line of Geoffrey Porges with Leerink Partners.",13,"And our next question comes the line of Geoffrey Porges with Leerink Partners."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Question for Stuart perhaps, I think, about the PDUFA date and the pediatric indication for ORKAMBI. Could you talk about what sort of pace you expect reimbursement to be available to the pediatric patients on the side of several deltas? And then, secondl",84,"Question for Stuart perhaps, I think, about the PDUFA date and the pediatric indication for ORKAMBI. Could you talk about what sort of pace you expect reimbursement to be available to the pediatric patients on the side of several deltas? And then, secondly, as you are out in the community and talking to physicians, do you think that the adoption compliance and persistence rates in the pediatric population will be similar to the adult population or greater or less than you've observed so far?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for those questions. So yes, the PDUFA date is September 30. Obviously, we're deep into the planning for that launch because it's only just a couple of months away. In terms of what we might anticipate for access, to answer the first part of y",330,"Yes, thanks for those questions. So yes, the PDUFA date is September 30. Obviously, we're deep into the planning for that launch because it's only just a couple of months away. In terms of what we might anticipate for access, to answer the first part of your question, my expectation is that access is going to be very good, just as it was for ORKAMBI when we first introduced it for the 12 and over population. And in some ways, this is a somewhat simpler review for the payers. It's a labeled extension just extending it down to a younger age. And so my expectation is that we'll secure broad access very quickly. In terms of rate of uptake, similarly, I would anticipate the demand to be robust, just as it was for 12 plus. And in terms of persistence and compliance, again, it's difficult to say exactly how it's going to play out in the real world as opposed to what we saw in the clinical trial setting. Certainly, a couple of things that I think give us some encouragement, we certainly saw in the study that we did that forms the basis of our application that the adverse event rate and particularly the rate of respiratory adverse events was much lower and none of the patients discontinued for that adverse event, and as you know, that's been one of the primary reasons for discontinuations on ORKAMBI in the 12 and over population. And then, again, one thing could help us, the 6 to 11 population, certainly with KALYDECO, we do tend to see compliance rates being much higher in the younger population, not surprisingly, as they tend to be very heavily managed by their parents. And so whilst I don't know exactly how it's going to play out in the real world, I certainly expect access to be very good and us to secure that quickly, and I'd also expect the uptake to be very rapid as well."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, I'll just add on to Stuart to reiterate something I said in my comments, which is that Q4 is where we anticipate to see the growth in ORKAMBI for the remainder of the year. And obviously, that is driven by 6 to 11 that Stuart was just discussing.",49,"Geoff, I'll just add on to Stuart to reiterate something I said in my comments, which is that Q4 is where we anticipate to see the growth in ORKAMBI for the remainder of the year. And obviously, that is driven by 6 to 11 that Stuart was just discussing."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Brian Abrahams with Jefferies.",13,"And our next question comes from the line of Brian Abrahams with Jefferies."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","As you guys see more uptake in Germany and more patients going on treatment in France, I was wondering if you could talk a little bit about persistence and compliance patterns that you're starting to see in Europe? Do you expect to be able to leverage you",116,"As you guys see more uptake in Germany and more patients going on treatment in France, I was wondering if you could talk a little bit about persistence and compliance patterns that you're starting to see in Europe? Do you expect to be able to leverage your learnings from the U.S. launch plus the availability of the long-term data now to improve that patient retention in the European launch as compared to the U.S.? And then, separately, just wondering if you could give us a little bit more granularity on the next steps, any level of confidence on residual function mutations, sort of where you stand there with respect to the next step -- regulatory steps?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay, Brian. So I'll start off on the persistency and compliance and how things are playing out in Europe. I mean, one of the benefits of launching in Europe after launching here in the U.S. is, clearly, we've been able to learn a lot from our experiences",228,"Okay, Brian. So I'll start off on the persistency and compliance and how things are playing out in Europe. I mean, one of the benefits of launching in Europe after launching here in the U.S. is, clearly, we've been able to learn a lot from our experiences here in the U.S. And I think, one of the things that we've been able to do is certainly sensitize people to the fact that some patients may have these respiratory adverse events, and so to be on the lookout for them, to be canceling patients in advance, and that certainly has been one of the many learnings that we took from our experiences here in U.S. to the introduction of the products in Europe. The data sources are not quite as robust as we have here in the U.S. in terms of tracking at a non-biased level individual patient data in Europe. And I would say, at this relatively early stage, the persistence rates are certainly in line in the same kind of ballpark as we saw with ORKAMBI here in the U.S. As that data matures over time, we'll be able to give you kind of more detail on exactly how it's playing out, but at the minute, the data is relatively immature. I would say it's pretty much in the same kind of ballpark for persistence and compliance."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Brian, it's Jeff Chodakewitz, just to comment on residual function. We really can't comment on when we have ongoing discussions with regulatory agencies. The only thing I can say is that we do really think all the data of both the preclinical data and the",73,"Brian, it's Jeff Chodakewitz, just to comment on residual function. We really can't comment on when we have ongoing discussions with regulatory agencies. The only thing I can say is that we do really think all the data of both the preclinical data and the clinical data really tell us that this drug is beneficial to those patients, and our goal is to figure out a way to get access for those patients."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Terence Flynn with Goldman Sachs.",14,"And our next question comes from the line of Terence Flynn with Goldman Sachs."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe just 2 for me. First on ORKAMBI in the U.S. It looks like new patient adds have moderated somewhat this quarter, and I know you were talking about nearing peaks. So is 6,000 or 6,000-ish kind of what you're expecting now or do you think you can get",99,"Maybe just 2 for me. First on ORKAMBI in the U.S. It looks like new patient adds have moderated somewhat this quarter, and I know you were talking about nearing peaks. So is 6,000 or 6,000-ish kind of what you're expecting now or do you think you can get to the rest of the 8,500 total? And then, in Germany versus France, obviously, a difference in uptake, just wondering what you think is driving that and which other countries you could think about those patterns playing out? Are they going to be more like Germany or more like France?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Terence, I'll start with the U.S. So as you said, with ORKAMBI, we've now initiated over 6,000 patients here in the U.S., which is about 70% of the eligible patient population. And as you might expect with the launch where we're getting to a steeper part",359,"Terence, I'll start with the U.S. So as you said, with ORKAMBI, we've now initiated over 6,000 patients here in the U.S., which is about 70% of the eligible patient population. And as you might expect with the launch where we're getting to a steeper part of the curve, adding new patient becomes a little bit tricky. Having said that, we are continuing to add new patients on a weekly and daily basis. But as Ian said in his prepared remarks in terms of U.S. growth, obviously, the next phase in growth in the U.S. is likely to be from the approval in 6 to 11s, which we hope will come in the next couple of months. So moving on to how things are panning out in Europe, and you're right, there is a contrast in uptake between Germany and France. Germany is slower than we anticipated. And much of that I attribute to the fact that the German market is more fragmented than many of the other markets that we operate in. What I mean by that is there's many more centers treating CF patients, and as a result, they've had less experience with CFTR modulators, and therefore, the kind of the educational need is higher there. And also, we did see a slightly slower uptake for KALYDECO in Germany than we saw in other EU markets. Contrast with France where through early access programs, we have 700 patients have already been initiated on ORKAMBI, and that uptake in 6 months is much more U.S.-like. So based on that, based on all the other research we've done, we do anticipate that Germany is more likely to be an outlier in terms of rate of uptake, although I continue to believe that we will get to the vast majority of patients in Germany over time. And in terms of rate of uptake, I would expect it to be more like France in the rest of Europe, pending reimbursements than we've seen in Germany, which I continue to believe is likely to be more of the outlier based on our previous experience with KALYDECO and comparing to experience with ORKAMBI."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Mark Schoenebaum with Evercore ISI.",13,"Our next question comes from the line of Mark Schoenebaum with Evercore ISI."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is John Miller on for Mark. And I just wanted to ask a question about these 6,000 patients that have started on ORKAMBI. You said it's a start. So I don't think -- what's the current number of patients on therapy? I'd love to know that. And my other",91,"This is John Miller on for Mark. And I just wanted to ask a question about these 6,000 patients that have started on ORKAMBI. You said it's a start. So I don't think -- what's the current number of patients on therapy? I'd love to know that. And my other question, I suppose, would be your thoughts on pricing pressure, especially in a disease like this where pricing pressure -- where pricing ability has typically been very high. How do you look at that going forward as that's obviously an issue?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, just reiterate what Ian said in terms of the actual number of patients being treated, that's clearly a very dynamic number and changes constantly. So what we have said is that we've, to date, initiated 6,000 patients. We continue to see more initiat",277,"Well, just reiterate what Ian said in terms of the actual number of patients being treated, that's clearly a very dynamic number and changes constantly. So what we have said is that we've, to date, initiated 6,000 patients. We continue to see more initiations, and we continue to believe, as we did at the end of Q1, that the persistence rate of that patient population is going to be somewhere in the 70% to 80% range, as indeed, we believe the compliance rate will be somewhere in the 70% to 80% range. And so that's the -- what we believe at the end of Q1, we continue to perform against those expectations, and that is in the 12 and above -- in 12 and above patients in the U.S. is what underlies our revenue guidance that we reiterated today. So in terms of pricing, clearly, that's a very hot topic across the industry. We continue to believe that we are developing very high value medicines, medicines that treat the underlying cause of what is a horrible life-shortening disease. It's for a very small patient population, and we believe, and I think that's reinforced by the discussions we've had with governments through the reimbursement of KALYDECO and the ongoing discussions we're having with ORKAMBI, this is exactly the sort of medicine that they want to be able to provide to their patient population, so whilst there will be pricing pressures because of the overall macroeconomics on every pharma and biotech company, I continue to believe that sort of agents we are bringing to bear are the sorts of products that governments are going to want to pay for."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Matthew Harrison with Morgan Stanley.",14,"And our next question comes from the line of Matthew Harrison with Morgan Stanley."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Cyrus on for Matt. A couple of questions. First, are there any efforts to improve the persistence or compliance rates in the United States?",26,"This is Cyrus on for Matt. A couple of questions. First, are there any efforts to improve the persistence or compliance rates in the United States?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So we have a number of programs which are provided either through materials that we provide to health care providers to provide to their patients, or where appropriate, to provide directly to the patients to educate them on the product, the mechanism of a",145,"So we have a number of programs which are provided either through materials that we provide to health care providers to provide to their patients, or where appropriate, to provide directly to the patients to educate them on the product, the mechanism of action, the fact that they treat the underlying nature of the disease. And so those programs are ongoing. And I think understanding and an educated patient is likely to be a more persistent and more compliant patient. And also, we continue to try and build the evidence base for ORKAMBI, which increases the benefit risk profile. And to the extent that providers and patients continue to believe in the benefit risk profile, then I think they're going to want to try and maintain their time on the product because of the both short and long-term benefit the treatment with ORKAMBI gives them."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And the second question is when will you be able to recognize the revenues in France and will they come as a lump sum, or how will it be dealt with?",32,"Okay. And the second question is when will you be able to recognize the revenues in France and will they come as a lump sum, or how will it be dealt with?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So thanks for that question, just to kind of help everybody else what's behind that question, we actually are providing access to ORKAMBI in France through early access programs and other programs, and we are actually being paid for that drug. And in my r",212,"So thanks for that question, just to kind of help everybody else what's behind that question, we actually are providing access to ORKAMBI in France through early access programs and other programs, and we are actually being paid for that drug. And in my remarks, I did comment that, that launch in France is going very well and that we're accessing a lot of patients. We do get a payment for that drug that might be similar to how the ultimate price of the drug plays out in France. However, from a GAAP perspective, we are unable to report those, let's say, access to those medicine as revenue until we have an agreed price in France. So I appreciate your question. We'd anticipate that, that would be a 2017 event. At this point, if we do get approval on price, which provides uncertainty to recording those revenues, we actually record the revenues as long, big catch-up. So as we've been selling drug since, let's say, January 1, 2016, all the way through to the point of reimbursement approval, we will record that cash that we will have ultimately have received as part of revenues in the quarter that we received reimbursement approval, and we do think that would be a 2017 event."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. Great. And then, last question, is there any update to the 661's utility and the office timing for the heterozygotes?",21,"Okay. Great. And then, last question, is there any update to the 661's utility and the office timing for the heterozygotes?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So it's Jeff Chodakewitz. I can tell you that as we've talked about previously, that is on track to occur during the third quarter. And then, based upon that recommendation from the DMC, remember that we won't be seeing that information. We will either st",55,"So it's Jeff Chodakewitz. I can tell you that as we've talked about previously, that is on track to occur during the third quarter. And then, based upon that recommendation from the DMC, remember that we won't be seeing that information. We will either stop the study or restart enrollment and go to completion."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Adam Walsh with Stifel.",13,"And our next question comes from the line of Adam Walsh with Stifel."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","My first one is you talked about a large bolus of discontinuations in the first quarter because 15% of patients, I believe, you said had come up in the first 3 months. I just wondered if there was any residual bolus kind of tail end into the second quarte",114,"My first one is you talked about a large bolus of discontinuations in the first quarter because 15% of patients, I believe, you said had come up in the first 3 months. I just wondered if there was any residual bolus kind of tail end into the second quarter? That's my first question. And then, my second question is also on discontinuations. You talked about the 15% in the first 3 months, and 20% to 30% longer term. Can you help us, after the 15% drop out in the first 3 months, help us understand the discontinuation dynamics from that point to the 25% long-term discontinuation rate, which is the midpoint of your guidance?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So yes -- thanks for the question. So yes, we did describe this kind of bolus of discontinuations, and that was largely a function of 2 things. One, the very, very rapid uptake we saw in ORKAMBI posting the initial launch. And then, we did see about 15% o",177,"So yes -- thanks for the question. So yes, we did describe this kind of bolus of discontinuations, and that was largely a function of 2 things. One, the very, very rapid uptake we saw in ORKAMBI posting the initial launch. And then, we did see about 15% of patients discontinue within the first 3 months therapy, largely as a result of respiratory adverse events. And then, what we saw with the rate of adverse -- rate of discontinuations ameliorated substantially, didn't soften, didn't flatten, but it certainly ameliorated substantially. And is a result of that, that's why we gave the guidance that we see the discontinuations, or the persistence rate, which is the opposite of discontinuations being in that 70% to 80% range by the end of 2016. And everything we've seen through Q2 continues to reinforce, I believe, that, that's where we will end the year, somewhere in that 70% to 80% range. There isn't -- wasn't really -- if I understand your question correctly, there wasn't really a second bolus that negatively impacted Q2."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Right. I guess, the question was, was there any tail end residual? You had the large number of patients start in the first 9 months, and you said that in the first quarter. As we move into this quarter, was the bolus still moving through in terms of the 1",60,"Right. I guess, the question was, was there any tail end residual? You had the large number of patients start in the first 9 months, and you said that in the first quarter. As we move into this quarter, was the bolus still moving through in terms of the 15% discontinuations, or do that really end in the first quarter?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Maybe a better way to answer this is that when somebody asked this on the call earlier was that are we continuing to see the dynamics of the launch and if the compliance rates and persistence rates being maintained? And yes, they are. So when we talk abou",137,"Maybe a better way to answer this is that when somebody asked this on the call earlier was that are we continuing to see the dynamics of the launch and if the compliance rates and persistence rates being maintained? And yes, they are. So when we talk about the profile of compliance with the medicine being between 70% and 80%, we're still seeing that. When we look at the persistence rates ending up at 70% to 80%, we're still seeing that, which means that every time there is a bolus of patients that is initiating therapy, we still continue to see discontinuations early on. However, because there is a lower initiation of patients in, let's say, Q1 or even the beginning of Q2, the impact of discontinuations in Q2 is much less than it has ever been."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Phil Nadeau with Cowen and Company.",15,"And our next question comes from the line of Phil Nadeau with Cowen and Company."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just a couple on the pipeline. So I guess, first on VX-661 happening and futility analysis, never disclosed exactly what the futility hurdle was. I was wondering whether you could give us some sense of the criteria or at least how you're going to interpre",97,"Just a couple on the pipeline. So I guess, first on VX-661 happening and futility analysis, never disclosed exactly what the futility hurdle was. I was wondering whether you could give us some sense of the criteria or at least how you're going to interpret a go signal in particular? And then, a similar question on the Phase I for the second-generation correctors. Can you give us some idea of what criteria you're going to look at to decide which will move forward and do you have any plans to move other second-generation correctors into the clinic?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. So in terms of 661's futility, I think, first of all, we really can't go into the details of exactly what the decision tree is. But let me help you think about it a little bit perhaps. There's a certain tension as you make a decisio",165,"It's Jeff Chodakewitz. So in terms of 661's futility, I think, first of all, we really can't go into the details of exactly what the decision tree is. But let me help you think about it a little bit perhaps. There's a certain tension as you make a decision based on partial information. We want to try if the drug is not benefiting patients to stop the trial. Conversely, there is uncertainty, and we also want to be careful about not missing a positive result. Therefore, there always is a certain overlap. And what we tend to do is then say if it's clearly not working, we stop. The consequence of that is even if it goes forward, there is still uncertainty, it does not mean that it's working, it just means that it may be working. And therefore, until we get to the end of the study, we really would not have had any confidence in what the result is going to be."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Jeff, maybe before you go onto the next question, I would just comment from the disclosure, the fact that we get asked this question a number of times. I want to be very clear on our disclosure around that. Consistent with what Jeff is saying, if ther",140,"And Jeff, maybe before you go onto the next question, I would just comment from the disclosure, the fact that we get asked this question a number of times. I want to be very clear on our disclosure around that. Consistent with what Jeff is saying, if there is a discontinuation of the study due to the futility rule, we'll announce that the study is discontinuing, and that would be an appropriate announcement at the time that we get that information. If we pass, no guarantees that it's working, and therefore, this drug -- this information is submissible for approval, but the only way we would communicate around that is on clinicaltrials.gov, we will reopen the recruitment for that study and we'd expand the recruitment into the study, but there wouldn't be announcements saying that we passed the futility rules."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And just in terms of your other question, I think, what we've always said is that what we want to do is bring these medicines -- these compounds forward, but we want them to be medicines that we tried as much as possible to have drugs that we think can ha",101,"And just in terms of your other question, I think, what we've always said is that what we want to do is bring these medicines -- these compounds forward, but we want them to be medicines that we tried as much as possible to have drugs that we think can have a favorable profile in patients so that they can continue. We're going to look at all the information, have safety exposure, all the things you'd expect. There's really no one thing that I can say we're going to focus in on, it's really the totality of profile of the drug."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. Do you have any plans to move in any other second-generation correctors into the clinic or is that really dependent on what you see in the Phase I?",29,"Okay. Do you have any plans to move in any other second-generation correctors into the clinic or is that really dependent on what you see in the Phase I?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff Leiden. Thanks for the question. As we said before, this is a large program here. We've discovered a series of second-generation correctors, and they have different -- or mix generation correctors, they have different flavors, which is intere",114,"This is Jeff Leiden. Thanks for the question. As we said before, this is a large program here. We've discovered a series of second-generation correctors, and they have different -- or mix generation correctors, they have different flavors, which is interesting. And our strategy here is very straightforward. If we can develop a portfolio of products and bring some of those forward into the clinic and compare them, it gives us the best probability of success. So our plan is to continue that program in the research and preclinical phase, and if we see compounds that are interestingly good, better than the ones we have, we certainly will bring them forward into the clinic."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Alethia Young with Crdit Suisse.",14,"And our next question comes from the line of Alethia Young with Crdit Suisse."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just one on 661 and the other studies. Can you give us a flavor around like maybe kind of what the progress is in enrollment, not the homozygous, but the other 3 studies, like kind of what sequencing we might expect for the timeline? Second one, just when",98,"Just one on 661 and the other studies. Can you give us a flavor around like maybe kind of what the progress is in enrollment, not the homozygous, but the other 3 studies, like kind of what sequencing we might expect for the timeline? Second one, just when you look at some of the long-term data that you generate on exacerbations like the medical meetings midyear, do you think that doctors who are receiving that patients are receiving that, that there is like a very kind of profound benefit to staying on ORKAMBI even somewhat similar to KALYDECO?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. So it's Jeff Chodakewitz. Let me first comment on the 661 sequence. First of all, as we indicated for the homozygous study, we have a lot of confidence in that finishing enrollment in August. In fact, we've actually already stopped screening patient",355,"Sure. So it's Jeff Chodakewitz. Let me first comment on the 661 sequence. First of all, as we indicated for the homozygous study, we have a lot of confidence in that finishing enrollment in August. In fact, we've actually already stopped screening patients for that study, so it's just having the last patients completing the screening process and if they qualify going into the trial. We've already talked about the timing of the study in patients and the futility analysis that's going to be done. We expect that the next trial that's going to be completed will be the study in patients with 508 on one allele and a residual function mutation on the other allele. And as we've indicated, we expect that to complete in the second half of this year, very much as we've indicated earlier this year, it's really right on track. And then, the last study with 508 and in gating on the other allele, again, as we've indicated previously, we think, in the second half of this year or early next year, and as we get the data, then that will allow us to evaluate our best submission strategy and file a pending data in the second half of '17. In terms of the long-term data, I want to be sure that I understand your question. We do think that the results from that long-term data are quite compelling. You asked specifically about pulmonary exacerbations, and so we do look at what basically we use in assessment of how many events are happening for the patients that we're following and think about it as an event rate, and what we do see is that as we've gone out further in time, that remains quite low compared to what we had as our initial comparison. We think that is quite meaningful to patients and physicians. And actually, that's linked up with the other information like body weight and particularly the change in [indiscernible] FEV1 evidence of disease modification, we think that is driving considerations like starting therapy earlier and considering whether patients who discontinued may want to think about restarting therapy."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Ying Huang with Bank of America.",15,"And our next question comes from the line of Ying Huang with Bank of America."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Can you talk about maybe the ATU pricing you're getting in France? And how does that compare to the German pricing for ORKAMBI? And then, secondly, also again on Europe, what's your thought on the Brexit on the U.K. and also, broadly speaking, European re",48,"Can you talk about maybe the ATU pricing you're getting in France? And how does that compare to the German pricing for ORKAMBI? And then, secondly, also again on Europe, what's your thought on the Brexit on the U.K. and also, broadly speaking, European reimbursement for ORKAMBI?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So the ATU pricing in France has not been publicly disclosed, but it is very similar to the list price that we have established in Germany. In terms of the thoughts on the Brexit impact, certainly, from a financial point of view in the short term, the rea",162,"So the ATU pricing in France has not been publicly disclosed, but it is very similar to the list price that we have established in Germany. In terms of the thoughts on the Brexit impact, certainly, from a financial point of view in the short term, the really most tangible impact that you can see is really one around the impact on FX. And because of the nature of our business and the natural hedges we have, we're not expecting that to have a meaningful impact on our business. There's obviously a range of other legal regulatory employment and other aspects that could be impacted by the Brexit as the negotiations are ongoing. We're clearly going to be tracking those very closely and making all the appropriate moves and responses as the situation becomes clear. But as with many things, Brexit, I think, to speculate on too many other aspects of what the impact would be, would crystal ball gazing at best."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then, maybe another one for Jeff. Can you tell us when might we see CRISPR and also the Moderna program getting to the clinic at earliest?",27,"And then, maybe another one for Jeff. Can you tell us when might we see CRISPR and also the Moderna program getting to the clinic at earliest?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So thanks for the question. I appreciate you acknowledging the 2 very important collaborations that we've actually done in the last year, kind of expanding the modalities getting to other diseases. But unfortunately, they are early stage, as you are proba",82,"So thanks for the question. I appreciate you acknowledging the 2 very important collaborations that we've actually done in the last year, kind of expanding the modalities getting to other diseases. But unfortunately, they are early stage, as you are probably aware, and we wouldn't anticipate getting anything to the clinic in the next couple of years. It's probably 3 years or more from now. And we'd love to update you on that, but those have been important transactions for the company."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Liisa Bayko with JMP Securities.",14,"And our next question comes from the line of Liisa Bayko with JMP Securities."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I thought you had a pretty good KALYDECO quarter. I'm just wondering if you could comment on where -- what's driving growth there? Is it from particular region or rolling out in a new mutation?",35,"I thought you had a pretty good KALYDECO quarter. I'm just wondering if you could comment on where -- what's driving growth there? Is it from particular region or rolling out in a new mutation?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Liisa, I'm thrilled with the question. It's nice to be able to talk about KALYDECO, and thanks for noticing. Yes, KALYDECO had a very strong quarter, about $180 million. Most of the growth over Q2 came from the U.S. And essentially, what we continue to se",119,"Liisa, I'm thrilled with the question. It's nice to be able to talk about KALYDECO, and thanks for noticing. Yes, KALYDECO had a very strong quarter, about $180 million. Most of the growth over Q2 came from the U.S. And essentially, what we continue to see is increasing new patient initiations in some of the newer indications like the 2 to 5-year old kids and also in the R117H mutation. So we continue to see strong patient initiation. And as you know, the persistence rates and the compliance rates with KALYDECO are about as good as I've ever seen. So really, it's that combination of adding new patients and great persistence and compliance rates, particularly here in the U.S."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And then, in terms of ex-U.S., is it just -- just to make we're all on the same page, the only countries you're selling any drug -- or I mean, distributing drug to patients because I know you're not really selling in France per se, but France, Germa",59,"Okay. And then, in terms of ex-U.S., is it just -- just to make we're all on the same page, the only countries you're selling any drug -- or I mean, distributing drug to patients because I know you're not really selling in France per se, but France, Germany and the U.S., are those the totality of the countries?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So outside of the U.S., France and Germany are different to many of the other markets in that the way that the structure of those markets work is that there are access programs that you can take advantage of where patients can get access to the product's",165,"So outside of the U.S., France and Germany are different to many of the other markets in that the way that the structure of those markets work is that there are access programs that you can take advantage of where patients can get access to the product's price before the reimbursement approval being secured on a relatively broad basis, and that's happening in both Germany and France. And Ian talked about the fact that with France, we don't recognize those patients from a revenue perspective. In Germany, we do. There are other countries where we're on a named patient basis. There are literally handfuls of patients who, through exceptional programs, are getting access to the product where we are getting paid. But the vast majority of our revenues outside of the U.S. are coming from Germany. We expect that to continue in 2016, and we don't expect to get really meaningful revenue contributions from markets outside of Germany, outside of the U.S. until 2017."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Brian Skorney with Robert W. Baird.",15,"And our next question comes from the line of Brian Skorney with Robert W. Baird."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two quick ones. I guess, first, could you just go over anything you've said about the differences between 152 and 440? Are they distinct corrective mechanisms? I know you've always said that the intent is to move forward with both, but I was just wonderin",107,"Two quick ones. I guess, first, could you just go over anything you've said about the differences between 152 and 440? Are they distinct corrective mechanisms? I know you've always said that the intent is to move forward with both, but I was just wondering if there's a potential for these 2 drugs to actually be complementary to each other, like 661 and lumacaftor, they're just overlapping? And then, when we think about the [indiscernible] approval later this year, do you think there's any meaningful numbers of [indiscernible] patients currently on or ORKAMBI off-label, or do you think that it's really completely untapped patient pool right now?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Brian, this is Jeff Leiden. I'll take the first part and then Stuart can take the second part. We haven't actually talked a lot of detail about the mechanisms of action or the differences or similarities between 152 and 440, they're clearly different mole",125,"Brian, this is Jeff Leiden. I'll take the first part and then Stuart can take the second part. We haven't actually talked a lot of detail about the mechanisms of action or the differences or similarities between 152 and 440, they're clearly different molecules. And so that's why we brought them both forward into the clinic. What we have said is that we, as part of our discovery program, have discovered a portfolio of next-gen correctors, which do have distinct mechanisms of action as well as distinct drug life properties, and that's why we're excited about the portfolio and that's why we plan to take multiple molecules into the clinic because at least in my experience, that's the way to maximize your chance for success."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Again, Brian, on the subject of off-label usage in the 6 to 11 population, we don't track off-label usage. My expectation is that it would be very, very low. And the reason why I say that is the prior authorization criteria that's been for ORKAMBI, which",122,"Again, Brian, on the subject of off-label usage in the 6 to 11 population, we don't track off-label usage. My expectation is that it would be very, very low. And the reason why I say that is the prior authorization criteria that's been for ORKAMBI, which have enabled us to get very good access for ORKAMBI are very simple but very clear. And they would tend to say, the first nurse to have a CF diagnosis, they have to have the right mutation type and they check the date of birth, they check the patient is 12 and above. And so my expectation would be that the number of people receiving commercial product off-label at this point would be very, very low."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Katherine Xu with William Blair.",11,"And our next question comes from Katherine Xu with William Blair."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I'm just wondering, with ORKAMBI versus KALYDECO, do you see a little bit lower compliance or persistence for ORKAMBI as compared to KALYDECO? And if that's the case, do you think it's mostly because of safety or lower efficacy or both, any sense on that",48,"I'm just wondering, with ORKAMBI versus KALYDECO, do you see a little bit lower compliance or persistence for ORKAMBI as compared to KALYDECO? And if that's the case, do you think it's mostly because of safety or lower efficacy or both, any sense on that at all?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Katherine, so with KALYDECO, we see very, very high levels of both persistence and compliance. We've said that our persistence with KALYDECO is 90% plus. And overall compliance both here in the U.S. and internationally is around 85%. And as we said at Q1,",149,"Katherine, so with KALYDECO, we see very, very high levels of both persistence and compliance. We've said that our persistence with KALYDECO is 90% plus. And overall compliance both here in the U.S. and internationally is around 85%. And as we said at Q1, and it's baked into our revenue guidance, we expect persistence for ORKAMBI to be between 70% and 80%, and for compliance to be in the same 70% to 80% range. So we do see both of those criteria being lower for ORKAMBI than they are for KALYDECO. And try to attribute exactly why that is. I'm not sure I would be able to tease that out for you. I'm sure it's got to do with the benefit risk and tolerability profile of ORKAMBI versus KALYDECO. But exactly which factor is weighting it one way or the other, I think that would be impossible to differentiate."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And could you give a quick update on your oncology in [indiscernible] pipeline candidates?",14,"And could you give a quick update on your oncology in [indiscernible] pipeline candidates?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So maybe -- it's Jeff Chodakewitz. Just to give you a quick comment and then maybe Ian has a comment. I think, in terms of our oncology program, I think, very much consistent with where we were discussing it previously that we do have [indiscernible] VX-9",110,"So maybe -- it's Jeff Chodakewitz. Just to give you a quick comment and then maybe Ian has a comment. I think, in terms of our oncology program, I think, very much consistent with where we were discussing it previously that we do have [indiscernible] VX-970 is really in focused clinical trials in very specific populations and non-comparative trials to understand what the potential for those -- for that drug really can be. And so those are ongoing. On the [indiscernible] side, our VX-150 actually just is finishing -- has finished enrolling a Phase II POC study in osteoarthritis patients, and we expect to have some information later this year."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Jeff, thanks for that. I'll just pick up on that and say, because many people ask me this, are we going to be an oncology company? And I think that's a little early to suggest that, given that we have one lead molecule at the moment in early stage stud",185,"So Jeff, thanks for that. I'll just pick up on that and say, because many people ask me this, are we going to be an oncology company? And I think that's a little early to suggest that, given that we have one lead molecule at the moment in early stage studies in oncology. We're going to continue to progress those studies, as Jeff Chodakewitz said. And based on that data, we will make a choice at that time whether we'd provide further investments. Well, we actually look to see whether the mechanism is better served working with other companies. And therefore, looking more of a portfolio approach to drive forward, let's say, our oncology opportunities. We do have other mechanisms. One of the -- is in the clinic and then a couple at -- are just late preclinical right now. So we have a late preclinical, a couple of compounds and also early clinical compounds, and that's what determines our oncology portfolio and we'll make a decision of how to progress that best for greatest value once we receive the data from VX-970 lead program."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Alan Carr with Needham and Company.",15,"And our next question comes from the line of Alan Carr with Needham and Company."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess, a couple of them here. One of them, it looks like, the only program you haven't touched on is 210. Wondering if you can give us an update on that in the spinal cord? And then, also with respect to your sNDA around residual mutations for KALYDECO,",64,"I guess, a couple of them here. One of them, it looks like, the only program you haven't touched on is 210. Wondering if you can give us an update on that in the spinal cord? And then, also with respect to your sNDA around residual mutations for KALYDECO, what sort of options do you have available here in your discussions with the FDA?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeff Chodakewitz. So Alan, I'd say, first of all, in terms of VX-210, that study is up and enrolling, we have had enrollment now in the trial, but these are acutely ill, acutely injured people, and so we have always expected that enrollment will be slow,",84,"Jeff Chodakewitz. So Alan, I'd say, first of all, in terms of VX-210, that study is up and enrolling, we have had enrollment now in the trial, but these are acutely ill, acutely injured people, and so we have always expected that enrollment will be slow, and so we are really pretty much on track. In terms of residual function, as we talked about earlier, there's really just nothing in terms of ongoing discussions with the regulatory agency that I can talk about further."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Can you comment -- I mean, I'm wondering if you can comment on what sort of what the outcomes might be here? Is this something that might be resolved this year or does this potentially involve more studies? What can you comment from that perspective?",45,"Can you comment -- I mean, I'm wondering if you can comment on what sort of what the outcomes might be here? Is this something that might be resolved this year or does this potentially involve more studies? What can you comment from that perspective?"
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Alan, it's Jeff Leiden. So as you know, we just don't comment on ongoing regulatory discussions, probably because they are not predictable and they are not totally within our control. I think, the important point is we do believe that KALYDECO is act",86,"Yes, Alan, it's Jeff Leiden. So as you know, we just don't comment on ongoing regulatory discussions, probably because they are not predictable and they are not totally within our control. I think, the important point is we do believe that KALYDECO is active in these set of patients based on both preclinical and clinical data, and that we're having ongoing discussions with the regulators about how to get access to these patients with KALYDECO. When we have an answer, we'll certainly disclose that for you."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Thank you. And I'm showing no further questions at this time, I would like to turn the conference back over to Mr. Michael Partridge for any final remarks.",28,"Thank you. And I'm showing no further questions at this time, I would like to turn the conference back over to Mr. Michael Partridge for any final remarks."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay. Thanks, operator. We appreciate everyone joining us tonight. We are happy to take additional follow-up questions after the call. The Investor Relations team will be in the office, so please reach out, and have a good night.",38,"Okay. Thanks, operator. We appreciate everyone joining us tonight. We are happy to take additional follow-up questions after the call. The Investor Relations team will be in the office, so please reach out, and have a good night."
36235,374694421,1014593,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program. You may all disconnect. Everyone, have a great day."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our Second Quarter 2016 Financial Results Conference Call. [Operator Instructions] You can access the webcast live by going to our website where a replay",209,"Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our Second Quarter 2016 Financial Results Conference Call. [Operator Instructions] You can access the webcast live by going to our website where a replay will also be available later tonight. Dr. Jeff Leiden, Chairman and CEO; and Ian Smith, Chief Financial Officer, will provide prepared remarks this evening. They will be joined by Stuart Arbuckle, Chief Commercial Officer; and Dr. Jeff Chodakewitz, Chief Medical Officer, for the Q&A portion of the conference call.
We will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the SEC. These statements, including without limitation, those regarding the ongoing development and potential commercialization of our drug candidates, our expectations regarding our approved medicines and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in tonight's press release. I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Dr. Jeff Leiden."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. It was just over 1 year ago that we received FDA approval for ORKAMBI, marking the most significant step to date in our journey to develop new medicines for people with cystic fibrosis. Tonight, I'm pleased to repo",1092,"Thanks, Michael. Good evening, everyone. It was just over 1 year ago that we received FDA approval for ORKAMBI, marking the most significant step to date in our journey to develop new medicines for people with cystic fibrosis. Tonight, I'm pleased to report on our significant and steady progress in CF, and I'll review 3 key phases in our efforts to bring all people with CF a medicine to treat the underlying cause of their disease. If we're successful in these efforts, we believe significant and sustained revenue and earnings growth will follow.
Today, there are approximately 27,000 people eligible for treatment with ORKAMBI or KALYDECO. However, we're only treating approximately 9,000 or 1/3 of these patients. The first and most significant near-term step to increase the number of eligible patients being treated for their medicines is to gain reimbursement of ORKAMBI in key European and other countries. Progress with reimbursement for ORKAMBI would enable the vast majority of currently eligible patients to be treated with one of our CF medicines. 
The second step to treat more people with CF is to further expand the labels for both ORKAMBI and KALYDECO, which could increase the total number of eligible patients from 27,000 to approximately 44,000. And the third step is to potentially treat all people with CF with new combinations of CFTR modulators as well as other approaches to treatments such as ENaC inhibition, gene editing and mRNA therapies.
First, the reimbursement for ORKAMBI. Outside the U.S., the reimbursement process is ongoing, and these discussions are progressing as anticipated across Europe, Canada and Australia. We're encouraged that many reimbursement authorities have acknowledged the significant clinical benefits that ORKAMBI provides. We believe that we will achieve reimbursement from European and other government payers just as we've seen in the U.S. We look forward to updating you as we obtain reimbursement in key countries going forward.
Second, to our label expansion efforts for both ORKAMBI and KALYDECO. Specifically, there's some 12,000 additional patients younger than age 12 with 2 copies of the Delta F508 mutation whom we believe could be helped by ORKAMBI. In the second quarter, the FDA accepted for review our supplemental new drug application for the use of ORKAMBI in children ages 6 to 11, and granted our request for priority review, setting a target review date or PDUFA date September 30, 2016. If approved, we expect to be ready to bring ORKAMBI to these patients immediately following approval. 
In parallel, we're also progressing with our efforts to bring ORKAMBI to children ages 6 to 11 in Europe where we plan to submit our application for approval in the first half of next year, following the conclusion of our fully enrolled Phase III efficacy and safety study in this group of patients. We estimate that there are approximately 2,400 children ages 6 to 11 in the U.S., and 3,400 in Europe who would be eligible for ORKAMBI.
There are approximately 5,000 additional patients in North America, Europe and Australia, largely those with residual function mutations who could be helped by KALYDECO. While we received the complete response letter from the FDA earlier this year regarding our application for approval of KALYDECO in people with CF ages 2 and older who have 1 of 23 residual function mutations, our belief that KALYDECO would be beneficial to these patients is unchanged, and we continue to pursue FDA approval for these patients as soon as possible. There are approximately 1,500 people with CF in the U.S. who have the mutations included in our residual function sNDA. 
And third, to our expanding pipeline of investigational CF medicine. The most advanced pipeline program in CF is our broad Phase III program for VX-661 in combination with ivacaftor. VX-661 plus ivacaftor may have an improved benefit risk profile compared to ORKAMBI in people with 2 copies of the Delta F508 mutation and may provide enhanced clinical benefits over ivacaftor monotherapy for other patients with gating mutations. Enrollment in the study of VX-661 plus ivacaftor in people ages 12 and older with 2 copies of the Delta F508 mutation is expected to complete in August. Data from the 6-month study are expected in the first half of 2017. The other 3 Phase III studies of VX-661 are also progressing as planned. We plan to submit a new drug application to the U.S. FDA for VX-661 in combination with ivacaftor in the second half of 2017.
Importantly, VX-661 is also positioned to play a key role in a triple-combination regimen with a next-generation corrector and ivacaftor. We believe that this triple combination approach may allow us to treat an additional large group of patients, specifically those with one Delta F508 mutation and one mutation that results in minimal CFTR function. These patients do not currently have medicines to treat the cause of their disease.
Our 2 next-generation correctors, VX-152 and VX-440, are being evaluated in Phase I studies in healthy volunteers. Pending data from these studies, we expect to move into Phase II clinical development in the second half of 2016 in people with CF. These studies would evaluate 1 or both of our next generation correctors with VX-661 and ivacaftor. 
Beyond our CFTR modulators, we've entered into multiple strategic collaborations that broaden our ability to evaluate additional approaches to CF treatment that may be complementary to CFTR modulation in the future. While the underlying technology and science of each approach differs, the collaborations have a shared goal to develop the best possible future treatments for all people with CF. Earlier this month, we entered into a collaboration with Moderna Therapeutics aimed at using messenger RNA to potentially enable cells in the lungs of people with CF to produce functional CFTR protein. This is the second platform technology collaboration we have entered into, following our agreement with CRISPR Therapeutics focused on the use of CRISPR-Cas9 for gene editing that we began in late 2015. These platform technologies add to our development stage collaboration with Parion Sciences focused on the use of ENaC inhibition to treat CF.
As we ended the second half of 2016, I'm pleased with both the near and long-term growth opportunities for our business. Our goal is to consistently discover and deliver transformative new medicines for patients and to reinvest in scientific opportunities to create future medicines. We believe our business model, which is focused on significant investment to create value through innovation, research and development, will position us to achieve this goal over the coming years.
With that, I'll turn the call over to Ian."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. Through the second quarter of the year, we've created a growing revenue base with ORKAMBI and KALYDECO, which we expect to drive future earnings growth. Tonight, I'll discuss our second quarter revenues for ORKAMBI and K",683,"Thanks, Jeff, and hello, everyone. Through the second quarter of the year, we've created a growing revenue base with ORKAMBI and KALYDECO, which we expect to drive future earnings growth. Tonight, I'll discuss our second quarter revenues for ORKAMBI and KALYDECO, review our 2016 financial guidance and discuss our anticipated financial trajectory for the coming years.
In the second quarter of 2016, we reported total CF product revenues of approximately $426 million, a significant increase compared to $155 million for the second quarter of last year. 
Turning to the revenues for each of our CF medicines. Global sales of ORKAMBI in the second quarter were $245 million, comprised of U.S. sales of approximately $229 million, and ex-U.S. sales of approximately $16 million, which were mainly from Germany. As of June 30, approximately 6,000 patients have initiated treatment with ORKAMBI in the U.S. Outside the U.S., ORKAMBI is already available commercially in Germany, and also through early access programs in France. In Germany, uptake continues to be slower than we observed in the U.S. As of June 30, approximately 380 of the 2,500 eligible patients in Germany had initiated treatment. 
In contrast, in France, we continue to see strong and rapid uptake. Approximately 700 of 1,500 eligible patients in France have already initiated treatment with ORKAMBI as of June 30 as part of the country's early access programs. These programs provided the opportunity for physicians in France to begin treating patients prior to their formal reimbursement approval. We are pleased the ORKAMBI launch has continued to progress consistent with what we discussed on our first quarter call. And today, we are reiterating our expectation for 2016 ORKAMBI revenues of $1 billion to $1.1 billion. 
Given the slower than expected launch in Germany and that we are approaching peak penetration for ORKAMBI in patients aged 12 and older in the U.S., we expect that revenue growth for ORKAMBI will occur primarily in the fourth quarter, following the potential approval and launch of ORKAMBI for children ages 6 to 11.
Now to KALYDECO. Second quarter KALYDECO sales were $180 million, up $25 million compared to the second quarter of last year. We continue to see small number of additional eligible patients beginning treatment in the U.S. and Europe. As with ORKAMBI, we are reiterating our 2016 revenue guidance for KALYDECO of $685 million to $705 million. Our 2016 guidance exclude any potential revenues for the approval of KALYDECO in residual function mutations where we continue to pursue the FDA approval for patients ages 2 and older in the U.S.
Now to the operating expenses. Our second quarter non-GAAP operating expenses were $306 million compared to non-GAAP operating expenses of $254 million in 2015. The increased operating expenses were mainly due to increased costs related to the progression of our CF pipeline and to increase investment in global commercial support for the launch of ORKAMBI. Our non-GAAP net profit for the second quarter of 2016 was $58 million or $0.24 per diluted share as compared to a non-GAAP net loss of $131 million or $0.54 per share for 2015. 
From a balance sheet perspective, we ended the second quarter with approximately $1.07 billion in cash, cash equivalents and marketable securities. Vertex also has $300 million outstanding from a credit agreement repayable by the end of the third quarter 2017.
I'll conclude tonight's call with a few brief comments on financial trends, including revenue and earnings growth. Our goal is to discover and develop new medicines for all people with CF. And as Jeff has discussed, there are 3 important phases to support these efforts: obtaining reimbursement for ORKAMBI outside the U.S.; expanding labels for both ORKAMBI and KALYDECO; and developing new medicines to treat potentially all people with CF. As we progress towards this goal, significant and sustainable revenue growth will follow. Importantly, as our revenues grow over future years, we are committed to managing our operating expenses to drive earnings growth. And we expect to deliver a financial profile similar to many of our large cap biotech peers. 
With that, I open the line to questions."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] And our first question comes from the line of Geoff Meacham with Barclays.",15,"[Operator Instructions] And our first question comes from the line of Geoff Meacham with Barclays."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have a few commercial ones and one clinical. I wanted to ask you guys, either Ian or Stuart, any changes to the persistence rates in the U.S., what are the new strategies to improve it? And then, can you just go into a little bit more detail on the EU o",71,"I have a few commercial ones and one clinical. I wanted to ask you guys, either Ian or Stuart, any changes to the persistence rates in the U.S., what are the new strategies to improve it? And then, can you just go into a little bit more detail on the EU outlook? So from what I understand, flattish in 3Q from Germany? And then, maybe what's driving the fourth quarter bump?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, it's Stuart here. So on persistence rates, what we're seeing in the U.S. is very consistent with what we outlined on our Q1 call. In fact, all the trends really in initiations, persistence and compliance are entirely in line with what we said then.",270,"Geoff, it's Stuart here. So on persistence rates, what we're seeing in the U.S. is very consistent with what we outlined on our Q1 call. In fact, all the trends really in initiations, persistence and compliance are entirely in line with what we said then. Just to remind you and others on the phone, for persistence, we said that our expectation was it would track towards about 70% to 80%, between 70% and 80% by the end of this year, and the same for compliance, and we continue to believe in those estimates, and those estimates are what underpins our revenue guidance that we reiterated today. In terms of Europe, and as you noted, Germany's uptake is relatively slow, and Ian mentioned that in his prepared remarks. Incorporated within our guidance, really, we're only expecting significant contributions ex-U.S. from Germany. In terms of how we see things playing out in the rest of Europe, really, as you know, that's going to be very dependent on us proceeding through country by country reimbursement negotiation processes. And what I can tell you is that those are progressing as we planned, as expected. But given our learnings and the analogy to KALYDECO and the time it took there, we're really not anticipating to conclude many of those reimbursement negotiations until 2017. Having said that, we recently concluded our first formal reimbursement negotiation in Austria, and that will go into effect from September 1, but we continue to believe that most of the major markets were not likely to see any major contributors -- contributions in terms of revenue growth until 2017 and beyond."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And just real quick on the clinical side, I know it's less interesting, but the PK for 152 and 440, will we see any of that in any CF? And any more thoughts on kind of what the size and scope of the clinical development for the triple could entail?",51,"Okay. And just real quick on the clinical side, I know it's less interesting, but the PK for 152 and 440, will we see any of that in any CF? And any more thoughts on kind of what the size and scope of the clinical development for the triple could entail?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, it's a little difficult to answer that, to be honest, Geoff. To say the size of the triple -- I mean, if I comment more broadly on our operating expense for the remainder of the year and then maybe kind of the trajectory in 2017, I think, that's an",245,"Well, it's a little difficult to answer that, to be honest, Geoff. To say the size of the triple -- I mean, if I comment more broadly on our operating expense for the remainder of the year and then maybe kind of the trajectory in 2017, I think, that's an easy way for me to comment on it. We always plan and provide guidance based on assuming success and that's why we're investing behind the programs. So our OpEx guidance for the year is at $1.18 billion to $1.23 billion, and we reiterated that number in the press release tonight. And that's a non-GAAP number, by the way. Excludes primarily stock compensation. And then, as we look into next year, we actually -- we hope and expect the programs to progress. And as we look into next year, as we think about OpEx more broadly, we see maybe some marginal increases in marketing investments for the launch of ORKAMBI more broadly, and particularly in Europe as we get reimbursement approval. And as we look at the development investment, maybe there's -- it's more consistent with 2015 to 2016 as programs cycle in and out with the expectation that the 661 Phase III program comes to closure, and we're refiling next year, and the progression of the triple into a larger Phase II study. So hopefully, that gives you an understanding of the trajectory of our investment profile through this year and then into next year."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, this is Jeff Leiden. With respect to your question on the PK data in CF. What we said before is that we'll let you know if we include the Phase I studies and plan the Phase II studies for the next-gen correctors, what those Phase II studies will lo",83,"Geoff, this is Jeff Leiden. With respect to your question on the PK data in CF. What we said before is that we'll let you know if we include the Phase I studies and plan the Phase II studies for the next-gen correctors, what those Phase II studies will look like and we'll provide you with some relevant data so you understand the design of those studies. And those studies, as we said, are on track for the second half of this year."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Michael Yee with RBC Capital Markets.",15,"And our next question comes from the line of Michael Yee with RBC Capital Markets."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two questions as well. On the commercial side, are you -- based on long-term data for ORKAMBI, are you starting to see any patients perhaps thinking about coming back? Are there discussions out there in the field about bringing some patients back on? And",112,"Two questions as well. On the commercial side, are you -- based on long-term data for ORKAMBI, are you starting to see any patients perhaps thinking about coming back? Are there discussions out there in the field about bringing some patients back on? And what are you thinking about that standpoint? And then, a follow-up question on the triple, is it safe to say that you've gone well into Phase I and the longer the better. Is there something specific in terms of exposure levels that you're looking for relative to assays that would give you some comfort in terms of what you want to see in terms of exposure of [indiscernible]"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. Maybe let me just touch on both of those for you. I think, from a long-term data perspective, we think that is very meaningful to patients and to prescribers. And I think, the reason for that are several fold. As you know, that info",323,"It's Jeff Chodakewitz. Maybe let me just touch on both of those for you. I think, from a long-term data perspective, we think that is very meaningful to patients and to prescribers. And I think, the reason for that are several fold. As you know, that information really has a couple of chunks to it. One is about the long-term safety of the drug, which is very important. And that continues to look very favorable, consistent with what we have seen before. And then, we had several for efficacy kind of measure. Some of that came from the study itself, our following patients for a long time and we saw that their FEV1s where maintained, their BMI continued to improve. And although there's no active comparison there, the event rate in terms of pulmonary exacerbation really remained low and consistent with what we saw during the trials. So that was all very impactful, we think, for physicians and for patients. The other thing we did was take the information from a mass cohort of historical patients, and what that allows you to do over that kind of time frame is to compare the rate of decline of patients' FEV1s who were on our study versus what we think the historical expectation would be, and that really then, as we did with KALYDECO, helps us understand if we're shifting that curve and slowing the rate of decline, really modifying the disease. And we were very pleased to see that approximately 40% reduction in the rate of decline. So overall, we think that data is very impactful and useful. In terms of triple combination, really can't give you a lot of details, as Jeff Leiden said actually already, that, that -- both drugs do continue in Phase 1 studies, and our expectation, of course, pending data, is that one or both of those will start in patients in the second half of this year."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes the line of Geoffrey Porges with Leerink Partners.",13,"And our next question comes the line of Geoffrey Porges with Leerink Partners."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Question for Stuart perhaps, I think, about the PDUFA date and the pediatric indication for ORKAMBI. Could you talk about what sort of pace you expect reimbursement to be available to the pediatric patients on the side of several deltas? And then, secondl",84,"Question for Stuart perhaps, I think, about the PDUFA date and the pediatric indication for ORKAMBI. Could you talk about what sort of pace you expect reimbursement to be available to the pediatric patients on the side of several deltas? And then, secondly, as you are out in the community and talking to physicians, do you think that the adoption compliance and persistence rates in the pediatric population will be similar to the adult population or greater or less than you've observed so far?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for those questions. So yes, the PDUFA date is September 30. Obviously, we're deep into the planning for that launch because it's only just a couple of months away. In terms of what we might anticipate for access, to answer the first part of y",330,"Yes, thanks for those questions. So yes, the PDUFA date is September 30. Obviously, we're deep into the planning for that launch because it's only just a couple of months away. In terms of what we might anticipate for access, to answer the first part of your question, my expectation is that access is going to be very good, just as it was for ORKAMBI when we first introduced it for the 12 and over population. And in some ways, this is a somewhat simpler review for the payers. It's a labeled extension just extending it down to a younger age. And so my expectation is that we'll secure broad access very quickly. In terms of rate of uptake, similarly, I would anticipate the demand to be robust, just as it was for 12 plus. And in terms of persistence and compliance, again, it's difficult to say exactly how it's going to play out in the real world as opposed to what we saw in the clinical trial setting. Certainly, a couple of things that I think give us some encouragement, we certainly saw in the study that we did that forms the basis of our application that the adverse event rate and particularly the rate of respiratory adverse events was much lower and none of the patients discontinued for that adverse event, and as you know, that's been one of the primary reasons for discontinuations on ORKAMBI in the 12 and over population. And then, again, one thing could help us, the 6 to 11 population, certainly with KALYDECO, we do tend to see compliance rates being much higher in the younger population, not surprisingly, as they tend to be very heavily managed by their parents. And so whilst I don't know exactly how it's going to play out in the real world, I certainly expect access to be very good and us to secure that quickly, and I'd also expect the uptake to be very rapid as well."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, I'll just add on to Stuart to reiterate something I said in my comments, which is that Q4 is where we anticipate to see the growth in ORKAMBI for the remainder of the year. And obviously, that is driven by 6 to 11 that Stuart was just discussing.",49,"Geoff, I'll just add on to Stuart to reiterate something I said in my comments, which is that Q4 is where we anticipate to see the growth in ORKAMBI for the remainder of the year. And obviously, that is driven by 6 to 11 that Stuart was just discussing."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Brian Abrahams with Jefferies.",13,"And our next question comes from the line of Brian Abrahams with Jefferies."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","As you guys see more uptake in Germany and more patients going on treatment in France, I was wondering if you could talk a little bit about persistence and compliance patterns that you're starting to see in Europe? Do you expect to be able to leverage you",116,"As you guys see more uptake in Germany and more patients going on treatment in France, I was wondering if you could talk a little bit about persistence and compliance patterns that you're starting to see in Europe? Do you expect to be able to leverage your learnings from the U.S. launch plus the availability of the long-term data now to improve that patient retention in the European launch as compared to the U.S.? And then, separately, just wondering if you could give us a little bit more granularity on the next steps, any level of confidence on residual function mutations, sort of where you stand there with respect to the next step -- regulatory steps?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay, Brian. So I'll start off on the persistency and compliance and how things are playing out in Europe. I mean, one of the benefits of launching in Europe after launching here in the U.S. is, clearly, we've been able to learn a lot from our experiences",228,"Okay, Brian. So I'll start off on the persistency and compliance and how things are playing out in Europe. I mean, one of the benefits of launching in Europe after launching here in the U.S. is, clearly, we've been able to learn a lot from our experiences here in the U.S. And I think, one of the things that we've been able to do is certainly sensitize people to the fact that some patients may have these respiratory adverse events, and so to be on the lookout for them, to be canceling patients in advance, and that certainly has been one of the many learnings that we took from our experiences here in U.S. to the introduction of the products in Europe. The data sources are not quite as robust as we have here in the U.S. in terms of tracking at a non-biased level individual patient data in Europe. And I would say, at this relatively early stage, the persistence rates are certainly in line in the same kind of ballpark as we saw with ORKAMBI here in the U.S. As that data matures over time, we'll be able to give you kind of more detail on exactly how it's playing out, but at the minute, the data is relatively immature. I would say it's pretty much in the same kind of ballpark for persistence and compliance."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Brian, it's Jeff Chodakewitz, just to comment on residual function. We really can't comment on when we have ongoing discussions with regulatory agencies. The only thing I can say is that we do really think all the data of both the preclinical data and the",73,"Brian, it's Jeff Chodakewitz, just to comment on residual function. We really can't comment on when we have ongoing discussions with regulatory agencies. The only thing I can say is that we do really think all the data of both the preclinical data and the clinical data really tell us that this drug is beneficial to those patients, and our goal is to figure out a way to get access for those patients."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Terence Flynn with Goldman Sachs.",14,"And our next question comes from the line of Terence Flynn with Goldman Sachs."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe just 2 for me. First on ORKAMBI in the U.S. It looks like new patient adds have moderated somewhat this quarter, and I know you were talking about nearing peaks. So is 6,000 or 6,000-ish kind of what you're expecting now or do you think you can get",99,"Maybe just 2 for me. First on ORKAMBI in the U.S. It looks like new patient adds have moderated somewhat this quarter, and I know you were talking about nearing peaks. So is 6,000 or 6,000-ish kind of what you're expecting now or do you think you can get to the rest of the 8,500 total? And then, in Germany versus France, obviously, a difference in uptake, just wondering what you think is driving that and which other countries you could think about those patterns playing out? Are they going to be more like Germany or more like France?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Terence, I'll start with the U.S. So as you said, with ORKAMBI, we've now initiated over 6,000 patients here in the U.S., which is about 70% of the eligible patient population. And as you might expect with the launch where we're getting to a steeper part",359,"Terence, I'll start with the U.S. So as you said, with ORKAMBI, we've now initiated over 6,000 patients here in the U.S., which is about 70% of the eligible patient population. And as you might expect with the launch where we're getting to a steeper part of the curve, adding new patient becomes a little bit tricky. Having said that, we are continuing to add new patients on a weekly and daily basis. But as Ian said in his prepared remarks in terms of U.S. growth, obviously, the next phase in growth in the U.S. is likely to be from the approval in 6 to 11s, which we hope will come in the next couple of months. So moving on to how things are panning out in Europe, and you're right, there is a contrast in uptake between Germany and France. Germany is slower than we anticipated. And much of that I attribute to the fact that the German market is more fragmented than many of the other markets that we operate in. What I mean by that is there's many more centers treating CF patients, and as a result, they've had less experience with CFTR modulators, and therefore, the kind of the educational need is higher there. And also, we did see a slightly slower uptake for KALYDECO in Germany than we saw in other EU markets. Contrast with France where through early access programs, we have 700 patients have already been initiated on ORKAMBI, and that uptake in 6 months is much more U.S.-like. So based on that, based on all the other research we've done, we do anticipate that Germany is more likely to be an outlier in terms of rate of uptake, although I continue to believe that we will get to the vast majority of patients in Germany over time. And in terms of rate of uptake, I would expect it to be more like France in the rest of Europe, pending reimbursements than we've seen in Germany, which I continue to believe is likely to be more of the outlier based on our previous experience with KALYDECO and comparing to experience with ORKAMBI."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Mark Schoenebaum with Evercore ISI.",13,"Our next question comes from the line of Mark Schoenebaum with Evercore ISI."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is John Miller on for Mark. And I just wanted to ask a question about these 6,000 patients that have started on ORKAMBI. You said it's a start. So I don't think -- what's the current number of patients on therapy? I'd love to know that. And my other",92,"This is John Miller on for Mark. And I just wanted to ask a question about these 6,000 patients that have started on ORKAMBI. You said it's a start. So I don't think -- what's the current number of patients on therapy? I'd love to know that. And my other question, I suppose, would be your thoughts on pricing pressure, especially in a therapy [ph] like this where pricing pressure -- where pricing ability has typically been very high. How do you look at that going forward as that's obviously an issue?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, just reiterate what Ian said in terms of the actual number of patients being treated, that's clearly a very dynamic number and changes constantly. So what we have said is that we've, to date, initiated 6,000 patients. We continue to see more initiat",277,"Well, just reiterate what Ian said in terms of the actual number of patients being treated, that's clearly a very dynamic number and changes constantly. So what we have said is that we've, to date, initiated 6,000 patients. We continue to see more initiations, and we continue to believe, as we did at the end of Q1, that the persistence rate of that patient population is going to be somewhere in the 70% to 80% range, as indeed, we believe the compliance rate will be somewhere in the 70% to 80% range. And so that's the -- what we believe at the end of Q1, we continue to perform against those expectations, and that is in the 12 and above -- in 12 and above patients in the U.S. is what underlies our revenue guidance that we reiterated today. So in terms of pricing, clearly, that's a very hot topic across the industry. We continue to believe that we are developing very high value medicines, medicines that treat the underlying cause of what is a horrible life-shortening disease. It's for a very small patient population, and we believe, and I think that's reinforced by the discussions we've had with governments through the reimbursement of KALYDECO and the ongoing discussions we're having with ORKAMBI, this is exactly the sort of medicine that they want to be able to provide to their patient population, so whilst there will be pricing pressures because of the overall macroeconomics on every pharma and biotech company, I continue to believe that sort of agents we are bringing to bear are the sorts of products that governments are going to want to pay for."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Matthew Harrison with Morgan Stanley.",14,"And our next question comes from the line of Matthew Harrison with Morgan Stanley."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Cyrus on for Matt. A couple of questions. First, are there any efforts to improve the persistence or compliance rates in the United States?",26,"This is Cyrus on for Matt. A couple of questions. First, are there any efforts to improve the persistence or compliance rates in the United States?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So we have a number of programs which are provided either through materials that we provide to health care providers to provide to their patients, or where appropriate, to provide directly to the patients to educate them on the product, the mechanism of a",145,"So we have a number of programs which are provided either through materials that we provide to health care providers to provide to their patients, or where appropriate, to provide directly to the patients to educate them on the product, the mechanism of action, the fact that they treat the underlying nature of the disease. And so those programs are ongoing. And I think understanding and an educated patient is likely to be a more persistent and more compliant patient. And also, we continue to try and build the evidence base for ORKAMBI, which increases the benefit risk profile. And to the extent that providers and patients continue to believe in the benefit risk profile, then I think they're going to want to try and maintain their time on the product because of the both short and long-term benefit the treatment with ORKAMBI gives them."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And the second question is when will you be able to recognize the revenues in France and will they come as a lump sum, or how will it be dealt with?",32,"Okay. And the second question is when will you be able to recognize the revenues in France and will they come as a lump sum, or how will it be dealt with?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So thanks for that question, just to kind of help everybody else what's behind that question, we actually are providing access to ORKAMBI in France through early access programs and other programs, and we are actually being paid for that drug. And in my r",213,"So thanks for that question, just to kind of help everybody else what's behind that question, we actually are providing access to ORKAMBI in France through early access programs and other programs, and we are actually being paid for that drug. And in my remarks, I did comment that, that launch in France is going very well and that we're accessing a lot of patients. We do get a payment for that drug that might be similar to how the ultimate price of the drug plays out in France. However, from a GAAP perspective, we are unable to report those, let's say, access to those medicine as revenue until we have an agreed price in France. So I appreciate your question. We'd anticipate that, that would be a 2017 event. At this point, if we do get approval on price, which provides us certainty to recording those revenues, we actually record the revenues as long, big catch-up. So as we've been selling drug since, let's say, January 1, 2016, all the way through to the point of reimbursement approval, we will record that cash that we will have ultimately have received as part of revenues in the quarter that we received reimbursement approval, and we do think that would be a 2017 event."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. Great. And then, last question, is there any update to the 661's utility analysis timing for the heterozygotes?",19,"Okay. Great. And then, last question, is there any update to the 661's utility analysis timing for the heterozygotes?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So it's Jeff Chodakewitz. I can tell you that as we've talked about previously, that is on track to occur during the third quarter. And then, based upon that recommendation from the DMC, remember that we won't be seeing that information. We will either st",55,"So it's Jeff Chodakewitz. I can tell you that as we've talked about previously, that is on track to occur during the third quarter. And then, based upon that recommendation from the DMC, remember that we won't be seeing that information. We will either stop the study or restart enrollment and go to completion."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Adam Walsh with Stifel.",13,"And our next question comes from the line of Adam Walsh with Stifel."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","My first one is you talked about a large bolus of discontinuations in the first quarter because 15% of patients, I believe, you said had come up in the first 3 months. I just wondered if there was any residual bolus kind of tail end into the second quarte",114,"My first one is you talked about a large bolus of discontinuations in the first quarter because 15% of patients, I believe, you said had come up in the first 3 months. I just wondered if there was any residual bolus kind of tail end into the second quarter? That's my first question. And then, my second question is also on discontinuations. You talked about the 15% in the first 3 months, and 20% to 30% longer term. Can you help us, after the 15% drop out in the first 3 months, help us understand the discontinuation dynamics from that point to the 25% long-term discontinuation rate, which is the midpoint of your guidance?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So yes -- thanks for the question. So yes, we did describe this kind of bolus of discontinuations, and that was largely a function of 2 things. One, the very, very rapid uptake we saw in ORKAMBI posting the initial launch. And then, we did see about 15% o",177,"So yes -- thanks for the question. So yes, we did describe this kind of bolus of discontinuations, and that was largely a function of 2 things. One, the very, very rapid uptake we saw in ORKAMBI posting the initial launch. And then, we did see about 15% of patients discontinue within the first 3 months therapy, largely as a result of respiratory adverse events. And then, what we saw with the rate of adverse -- rate of discontinuations ameliorated substantially, didn't soften, didn't flatten, but it certainly ameliorated substantially. And is a result of that, that's why we gave the guidance that we see the discontinuations, or the persistence rate, which is the opposite of discontinuations being in that 70% to 80% range by the end of 2016. And everything we've seen through Q2 continues to reinforce, I believe, that, that's where we will end the year, somewhere in that 70% to 80% range. There isn't -- wasn't really -- if I understand your question correctly, there wasn't really a second bolus that negatively impacted Q2."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Right. I guess, the question was, was there any tail end residual? You had the large number of patients start in the first 9 months, and you said that in the first quarter. As we move into this quarter, was the bolus still moving through in terms of the 1",60,"Right. I guess, the question was, was there any tail end residual? You had the large number of patients start in the first 9 months, and you said that in the first quarter. As we move into this quarter, was the bolus still moving through in terms of the 15% discontinuations, or do that really end in the first quarter?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Maybe a better way to answer this is that when somebody asked this on the call earlier was that are we continuing to see the dynamics of the launch and if the compliance rates and persistence rates being maintained? And yes, they are. So when we talk abou",137,"Maybe a better way to answer this is that when somebody asked this on the call earlier was that are we continuing to see the dynamics of the launch and if the compliance rates and persistence rates being maintained? And yes, they are. So when we talk about the profile of compliance with the medicine being between 70% and 80%, we're still seeing that. When we look at the persistence rates ending up at 70% to 80%, we're still seeing that, which means that every time there is a bolus of patients that is initiating therapy, we still continue to see discontinuations early on. However, because there is a lower initiation of patients in, let's say, Q1 or even the beginning of Q2, the impact of discontinuations in Q2 is much less than it has ever been."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Phil Nadeau with Cowen and Company.",15,"And our next question comes from the line of Phil Nadeau with Cowen and Company."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just a couple on the pipeline. So I guess, first on VX-661's Hetmen [ph] futility analysis, never disclosed exactly what the futility hurdle was. I was wondering whether you could give us some sense of the criteria or at least how you're going to interpre",97,"Just a couple on the pipeline. So I guess, first on VX-661's Hetmen [ph] futility analysis, never disclosed exactly what the futility hurdle was. I was wondering whether you could give us some sense of the criteria or at least how you're going to interpret a go signal in particular? And then, a similar question on the Phase I for the second-generation correctors. Can you give us some idea of what criteria you're going to look at to decide which will move forward and do you have any plans to move other second-generation correctors into the clinic?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. So in terms of 661's futility, I think, first of all, we really can't go into the details of exactly what the decision tree is. But let me help you think about it a little bit perhaps. There's a certain tension as you make a decisio",165,"It's Jeff Chodakewitz. So in terms of 661's futility, I think, first of all, we really can't go into the details of exactly what the decision tree is. But let me help you think about it a little bit perhaps. There's a certain tension as you make a decision based on partial information. We want to try if the drug is not benefiting patients to stop the trial. Conversely, there is uncertainty, and we also want to be careful about not missing a positive result. Therefore, there always is a certain overlap. And what we tend to do is then say if it's clearly not working, we stop. The consequence of that is even if it goes forward, there is still uncertainty, it does not mean that it's working, it just means that it may be working. And therefore, until we get to the end of the study, we really would not have had any confidence in what the result is going to be."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Jeff, maybe before you go onto the next question, I would just comment from the disclosure, the fact that we get asked this question a number of times. I want to be very clear on our disclosure around that. Consistent with what Jeff is saying, if ther",140,"And Jeff, maybe before you go onto the next question, I would just comment from the disclosure, the fact that we get asked this question a number of times. I want to be very clear on our disclosure around that. Consistent with what Jeff is saying, if there is a discontinuation of the study due to the futility rule, we'll announce that the study is discontinuing, and that would be an appropriate announcement at the time that we get that information. If we pass, no guarantees that it's working, and therefore, this drug -- this information is submissible for approval, but the only way we would communicate around that is on clinicaltrials.gov, we will reopen the recruitment for that study and we'd expand the recruitment into the study, but there wouldn't be announcements saying that we passed the futility rules."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And just in terms of your other question, I think, what we've always said is that what we want to do is bring these medicines -- these compounds forward, but we want them to be medicines that we tried as much as possible to have drugs that we think can ha",101,"And just in terms of your other question, I think, what we've always said is that what we want to do is bring these medicines -- these compounds forward, but we want them to be medicines that we tried as much as possible to have drugs that we think can have a favorable profile in patients so that they can continue. We're going to look at all the information, have safety exposure, all the things you'd expect. There's really no one thing that I can say we're going to focus in on, it's really the totality of profile of the drug."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. Do you have any plans to move in any other second-generation correctors into the clinic or is that really dependent on what you see in the Phase I?",29,"Okay. Do you have any plans to move in any other second-generation correctors into the clinic or is that really dependent on what you see in the Phase I?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff Leiden. Thanks for the question. As we said before, this is a large program here. We've discovered a series of second-generation correctors, and they have different -- or mix generation correctors, they have different flavors, which is intere",114,"This is Jeff Leiden. Thanks for the question. As we said before, this is a large program here. We've discovered a series of second-generation correctors, and they have different -- or mix generation correctors, they have different flavors, which is interesting. And our strategy here is very straightforward. If we can develop a portfolio of products and bring some of those forward into the clinic and compare them, it gives us the best probability of success. So our plan is to continue that program in the research and preclinical phase, and if we see compounds that are interestingly good, better than the ones we have, we certainly will bring them forward into the clinic."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Alethia Young with Crdit Suisse.",14,"And our next question comes from the line of Alethia Young with Crdit Suisse."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just one on 661 and the other studies. Can you give us a flavor around like maybe kind of what the progress is in enrollment, not the homozygous, but the other 3 studies, like kind of what sequencing we might expect for the timeline? Second one, just when",98,"Just one on 661 and the other studies. Can you give us a flavor around like maybe kind of what the progress is in enrollment, not the homozygous, but the other 3 studies, like kind of what sequencing we might expect for the timeline? Second one, just when you look at some of the long-term data that you generate on exacerbations like the medical meetings midyear, do you think that doctors who are receiving that patients are receiving that, that there is like a very kind of profound benefit to staying on ORKAMBI even somewhat similar to KALYDECO?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. So it's Jeff Chodakewitz. Let me first comment on the 661 sequence. First of all, as we indicated for the homozygous study, we have a lot of confidence in that finishing enrollment in August. In fact, we've actually already stopped screening patient",356,"Sure. So it's Jeff Chodakewitz. Let me first comment on the 661 sequence. First of all, as we indicated for the homozygous study, we have a lot of confidence in that finishing enrollment in August. In fact, we've actually already stopped screening patients for that study, so it's just having the last patients completing the screening process and if they qualify going into the trial. We've already talked about the timing of the study of in-patients and the futility analysis that's going to be done. We expect that the next trial that's going to be completed will be the study in patients with 508 on one allele and a residual function mutation on the other allele. And as we've indicated, we expect that to complete in the second half of this year, very much as we've indicated earlier this year, it's really right on track. And then, the last study with 508 and in gating on the other allele, again, as we've indicated previously, we think, in the second half of this year or early next year, and as we get the data, then that will allow us to evaluate our best submission strategy and file a pending data in the second half of '17. In terms of the long-term data, I want to be sure that I understand your question. We do think that the results from that long-term data are quite compelling. You asked specifically about pulmonary exacerbations, and so we do look at what basically we use in assessment of how many events are happening for the patients that we're following and think about it as an event rate, and what we do see is that as we've gone out further in time, that remains quite low compared to what we had as our initial comparison. We think that is quite meaningful to patients and physicians. And actually, that's linked up with the other information like body weight and particularly the change in slope of FEV1 evidence of disease modification, we think that is driving considerations like starting therapy earlier and considering whether patients who discontinued may want to think about restarting therapy."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Ying Huang with Bank of America.",15,"And our next question comes from the line of Ying Huang with Bank of America."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Can you talk about maybe the ATU pricing you're getting in France? And how does that compare to the German pricing for ORKAMBI? And then, secondly, also again on Europe, what's your thought on the Brexit on the U.K. and also, broadly speaking, European re",48,"Can you talk about maybe the ATU pricing you're getting in France? And how does that compare to the German pricing for ORKAMBI? And then, secondly, also again on Europe, what's your thought on the Brexit on the U.K. and also, broadly speaking, European reimbursement for ORKAMBI?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So the ATU pricing in France has not been publicly disclosed, but it is very similar to the list price that we have established in Germany. In terms of the thoughts on the Brexit impact, certainly, from a financial point of view in the short term, the rea",162,"So the ATU pricing in France has not been publicly disclosed, but it is very similar to the list price that we have established in Germany. In terms of the thoughts on the Brexit impact, certainly, from a financial point of view in the short term, the really most tangible impact that you can see is really one around the impact on FX. And because of the nature of our business and the natural hedges we have, we're not expecting that to have a meaningful impact on our business. There's obviously a range of other legal, regulatory, employment and other aspects that could be impacted by the Brexit as the negotiations are ongoing. We're clearly going to be tracking those very closely and making all the appropriate moves and responses as the situation becomes clear. But as with many things, Brexit, I think, to speculate on too many other aspects of what the impact would be, would crystal ball gazing at best."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then, maybe another one for Jeff. Can you tell us when might we see CRISPR and also the Moderna program getting to the clinic at earliest?",27,"And then, maybe another one for Jeff. Can you tell us when might we see CRISPR and also the Moderna program getting to the clinic at earliest?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So thanks for the question. I appreciate you acknowledging the 2 very important collaborations that we've actually done in the last year, kind of expanding the modalities getting to other diseases. But unfortunately, they are early stage, as you are proba",82,"So thanks for the question. I appreciate you acknowledging the 2 very important collaborations that we've actually done in the last year, kind of expanding the modalities getting to other diseases. But unfortunately, they are early stage, as you are probably aware, and we wouldn't anticipate getting anything to the clinic in the next couple of years. It's probably 3 years or more from now. And we'd love to update you on that, but those have been important transactions for the company."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Liisa Bayko with JMP Securities.",14,"And our next question comes from the line of Liisa Bayko with JMP Securities."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I thought you had a pretty good KALYDECO quarter. I'm just wondering if you could comment on where -- what's driving growth there? Is it from particular region or rolling out in a new mutation?",35,"I thought you had a pretty good KALYDECO quarter. I'm just wondering if you could comment on where -- what's driving growth there? Is it from particular region or rolling out in a new mutation?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Liisa, I'm thrilled with the question. It's nice to be able to talk about KALYDECO, and thanks for noticing. Yes, KALYDECO had a very strong quarter, about $180 million. Most of the growth over Q2 came from the U.S. And essentially, what we continue to se",119,"Liisa, I'm thrilled with the question. It's nice to be able to talk about KALYDECO, and thanks for noticing. Yes, KALYDECO had a very strong quarter, about $180 million. Most of the growth over Q2 came from the U.S. And essentially, what we continue to see is increasing new patient initiations in some of the newer indications like the 2 to 5-year old kids and also in the R117H mutation. So we continue to see strong patient initiation. And as you know, the persistence rates and the compliance rates with KALYDECO are about as good as I've ever seen. So really, it's that combination of adding new patients and great persistence and compliance rates, particularly here in the U.S."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And then, in terms of ex-U.S., is it just -- just to make we're all on the same page, the only countries you're selling any drug -- or I mean, distributing drug to patients because I know you're not really selling in France per se, but France, Germa",59,"Okay. And then, in terms of ex-U.S., is it just -- just to make we're all on the same page, the only countries you're selling any drug -- or I mean, distributing drug to patients because I know you're not really selling in France per se, but France, Germany and the U.S., are those the totality of the countries?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So outside of the U.S., France and Germany are different to many of the other markets in that the way that the structure of those markets work is that there are access programs that you can take advantage of where patients can get access to the products p",166,"So outside of the U.S., France and Germany are different to many of the other markets in that the way that the structure of those markets work is that there are access programs that you can take advantage of where patients can get access to the products prior to the full reimbursement approval being secured on a relatively broad basis, and that's happening in both Germany and France. And Ian talked about the fact that with France, we don't recognize those patients from a revenue perspective. In Germany, we do. There are other countries where we're on a named patient basis. There are literally handfuls of patients who, through exceptional programs, are getting access to the product where we are getting paid. But the vast majority of our revenues outside of the U.S. are coming from Germany. We expect that to continue in 2016, and we don't expect to get really meaningful revenue contributions from markets outside of Germany, outside of the U.S. until 2017."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Brian Skorney with Robert W. Baird.",15,"And our next question comes from the line of Brian Skorney with Robert W. Baird."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two quick ones. I guess, first, could you just go over anything you've said about the differences between 152 and 440? Are they distinct corrective mechanisms? I know you've always said that the intent is to move forward with both, but I was just wonderin",107,"Two quick ones. I guess, first, could you just go over anything you've said about the differences between 152 and 440? Are they distinct corrective mechanisms? I know you've always said that the intent is to move forward with both, but I was just wondering if there's a potential for these 2 drugs to actually be complementary to each other, like 661 and lumacaftor, they're just overlapping? And then, when we think about the [indiscernible] approval later this year, do you think there's any meaningful numbers of [indiscernible] patients currently on or ORKAMBI off-label, or do you think that it's really completely untapped patient pool right now?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Brian, this is Jeff Leiden. I'll take the first part and then Stuart can take the second part. We haven't actually talked a lot of detail about the mechanisms of action or the differences or similarities between 152 and 440, they're clearly different mole",125,"Brian, this is Jeff Leiden. I'll take the first part and then Stuart can take the second part. We haven't actually talked a lot of detail about the mechanisms of action or the differences or similarities between 152 and 440, they're clearly different molecules. And so that's why we brought them both forward into the clinic. What we have said is that we, as part of our discovery program, have discovered a portfolio of next-gen correctors, which do have distinct mechanisms of action as well as distinct drug life properties, and that's why we're excited about the portfolio and that's why we plan to take multiple molecules into the clinic because at least in my experience, that's the way to maximize your chance for success."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Again, Brian, on the subject of off-label usage in the 6 to 11 population, we don't track off-label usage. My expectation is that it would be very, very low. And the reason why I say that is the prior authorization criteria that's been for ORKAMBI, which",121,"Again, Brian, on the subject of off-label usage in the 6 to 11 population, we don't track off-label usage. My expectation is that it would be very, very low. And the reason why I say that is the prior authorization criteria that's been for ORKAMBI, which have enabled us to get very good access for ORKAMBI are very simple but very clear. And they would tend to say, the person must have a CF diagnosis, they have to have the right mutation type and they check the date of birth, they check the patient is 12 and above. And so my expectation would be that the number of people receiving commercial product off-label at this point would be very, very low."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Katherine Xu with William Blair.",11,"And our next question comes from Katherine Xu with William Blair."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I'm just wondering, with ORKAMBI versus KALYDECO, do you see a little bit lower compliance or persistence for ORKAMBI as compared to KALYDECO? And if that's the case, do you think it's mostly because of safety or lower efficacy or both, any sense on that",48,"I'm just wondering, with ORKAMBI versus KALYDECO, do you see a little bit lower compliance or persistence for ORKAMBI as compared to KALYDECO? And if that's the case, do you think it's mostly because of safety or lower efficacy or both, any sense on that at all?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Katherine, so with KALYDECO, we see very, very high levels of both persistence and compliance. We've said that our persistence with KALYDECO is 90% plus. And overall compliance both here in the U.S. and internationally is around 85%. And as we said at Q1,",149,"Katherine, so with KALYDECO, we see very, very high levels of both persistence and compliance. We've said that our persistence with KALYDECO is 90% plus. And overall compliance both here in the U.S. and internationally is around 85%. And as we said at Q1, and it's baked into our revenue guidance, we expect persistence for ORKAMBI to be between 70% and 80%, and for compliance to be in the same 70% to 80% range. So we do see both of those criteria being lower for ORKAMBI than they are for KALYDECO. And try to attribute exactly why that is. I'm not sure I would be able to tease that out for you. I'm sure it's got to do with the benefit risk and tolerability profile of ORKAMBI versus KALYDECO. But exactly which factor is weighting it one way or the other, I think that would be impossible to differentiate."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And could you give a quick update on your oncology in teens [ph] pipeline candidates?",15,"And could you give a quick update on your oncology in teens [ph] pipeline candidates?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So maybe -- it's Jeff Chodakewitz. Just to give you a quick comment and then maybe Ian has a comment. I think, in terms of our oncology program, I think, very much consistent with where we were discussing it previously that we do have [indiscernible] VX-9",110,"So maybe -- it's Jeff Chodakewitz. Just to give you a quick comment and then maybe Ian has a comment. I think, in terms of our oncology program, I think, very much consistent with where we were discussing it previously that we do have [indiscernible] VX-970 is really in focused clinical trials in very specific populations and non-comparative trials to understand what the potential for those -- for that drug really can be. And so those are ongoing. On the [indiscernible] side, our VX-150 actually just is finishing -- has finished enrolling a Phase II POC study in osteoarthritis patients, and we expect to have some information later this year."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Jeff, thanks for that. I'll just pick up on that and say, because many people ask me this, are we going to be an oncology company? And I think that's a little early to suggest that, given that we have one lead molecule at the moment in early stage stud",186,"So Jeff, thanks for that. I'll just pick up on that and say, because many people ask me this, are we going to be an oncology company? And I think that's a little early to suggest that, given that we have one lead molecule at the moment in early stage studies in oncology. We're going to continue to progress those studies, as Jeff Chodakewitz said. And based on that data, we will make a choice at that time whether we'd provide further investments. Well, we actually look to see whether the mechanism is better served working with other companies. And therefore, looking more of a portfolio approach to drive forward, let's say, our oncology opportunities. We do have other mechanisms. One of the -- is in the clinic and then a couple at -- are just late preclinical right now. So we have a late preclinical, a couple of compounds and also early clinical compounds, and that's what determines our oncology portfolio and we'll make a decision of how to progress that best for greatest value once we receive the data from VX-970, our lead program."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Alan Carr with Needham and Company.",15,"And our next question comes from the line of Alan Carr with Needham and Company."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess, a couple of them here. One of them, it looks like, the only program you haven't touched on is 210. Wondering if you can give us an update on that in the spinal cord? And then, also with respect to your sNDA around residual mutations for KALYDECO,",64,"I guess, a couple of them here. One of them, it looks like, the only program you haven't touched on is 210. Wondering if you can give us an update on that in the spinal cord? And then, also with respect to your sNDA around residual mutations for KALYDECO, what sort of options do you have available here in your discussions with the FDA?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeff Chodakewitz. So Alan, I'd say, first of all, in terms of VX-210, that study is up and enrolling, we have had enrollment now in the trial, but these are acutely ill, acutely injured people, and so we have always expected that enrollment will be slow,",84,"Jeff Chodakewitz. So Alan, I'd say, first of all, in terms of VX-210, that study is up and enrolling, we have had enrollment now in the trial, but these are acutely ill, acutely injured people, and so we have always expected that enrollment will be slow, and so we are really pretty much on track. In terms of residual function, as we talked about earlier, there's really just nothing in terms of ongoing discussions with the regulatory agency that I can talk about further."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Can you comment -- I mean, I'm wondering if you can comment on what sort of what the outcomes might be here? Is this something that might be resolved this year or does this potentially involve more studies? What can you comment from that perspective?",45,"Can you comment -- I mean, I'm wondering if you can comment on what sort of what the outcomes might be here? Is this something that might be resolved this year or does this potentially involve more studies? What can you comment from that perspective?"
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Alan, it's Jeff Leiden. So as you know, we just don't comment on ongoing regulatory discussions, probably because they are not predictable and they are not totally within our control. I think, the important point is we do believe that KALYDECO is act",86,"Yes, Alan, it's Jeff Leiden. So as you know, we just don't comment on ongoing regulatory discussions, probably because they are not predictable and they are not totally within our control. I think, the important point is we do believe that KALYDECO is active in these set of patients based on both preclinical and clinical data, and that we're having ongoing discussions with the regulators about how to get access to these patients with KALYDECO. When we have an answer, we'll certainly disclose that for you."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Thank you. And I'm showing no further questions at this time, I would like to turn the conference back over to Mr. Michael Partridge for any final remarks.",28,"Thank you. And I'm showing no further questions at this time, I would like to turn the conference back over to Mr. Michael Partridge for any final remarks."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay. Thanks, operator. We appreciate everyone joining us tonight. We are happy to take additional follow-up questions after the call. The Investor Relations team will be in the office, so please reach out, and have a good night.",38,"Okay. Thanks, operator. We appreciate everyone joining us tonight. We are happy to take additional follow-up questions after the call. The Investor Relations team will be in the office, so please reach out, and have a good night."
36235,374694421,1014660,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program. You may all disconnect. Everyone, have a great day."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our Second Quarter 2016 Financial Results Conference Call. [Operator Instructions] You can access the webcast live by going to our website where a replay",209,"Good evening. This is Michael Partridge, Vice President of Investor Relations for Vertex. Welcome to our Second Quarter 2016 Financial Results Conference Call. [Operator Instructions] You can access the webcast live by going to our website where a replay will also be available later tonight. Dr. Jeff Leiden, Chairman and CEO; and Ian Smith, Chief Financial Officer, will provide prepared remarks this evening. They will be joined by Stuart Arbuckle, Chief Commercial Officer; and Dr. Jeff Chodakewitz, Chief Medical Officer, for the Q&A portion of the conference call.
We will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the SEC. These statements, including without limitation, those regarding the ongoing development and potential commercialization of our drug candidates, our expectations regarding our approved medicines and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially.
Information regarding our use of GAAP and non-GAAP financial measures and the reconciliation of GAAP to non-GAAP is available in tonight's press release. I would also refer you to Slide 4 of tonight's webcast.
I will now turn the call over to Dr. Jeff Leiden."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. It was just over 1 year ago that we received FDA approval for ORKAMBI, marking the most significant step to date in our journey to develop new medicines for people with cystic fibrosis. Tonight, I'm pleased to repo",1092,"Thanks, Michael. Good evening, everyone. It was just over 1 year ago that we received FDA approval for ORKAMBI, marking the most significant step to date in our journey to develop new medicines for people with cystic fibrosis. Tonight, I'm pleased to report on our significant and steady progress in CF, and I'll review 3 key phases in our efforts to bring all people with CF a medicine to treat the underlying cause of their disease. If we're successful in these efforts, we believe significant and sustained revenue and earnings growth will follow.
Today, there are approximately 27,000 people eligible for treatment with ORKAMBI or KALYDECO. However, we're only treating approximately 9,000 or 1/3 of these patients. The first and most significant near-term step to increase the number of eligible patients being treated for their medicines is to gain reimbursement of ORKAMBI in key European and other countries. Progress with reimbursement for ORKAMBI would enable the vast majority of currently eligible patients to be treated with one of our CF medicines. 
The second step to treat more people with CF is to further expand the labels for both ORKAMBI and KALYDECO, which could increase the total number of eligible patients from 27,000 to approximately 44,000. And the third step is to potentially treat all people with CF with new combinations of CFTR modulators as well as other approaches to treatments such as ENaC inhibition, gene editing and mRNA therapies.
First, the reimbursement for ORKAMBI. Outside the U.S., the reimbursement process is ongoing, and these discussions are progressing as anticipated across Europe, Canada and Australia. We're encouraged that many reimbursement authorities have acknowledged the significant clinical benefits that ORKAMBI provides. We believe that we will achieve reimbursement from European and other government payers just as we've seen in the U.S. We look forward to updating you as we obtain reimbursement in key countries going forward.
Second, to our label expansion efforts for both ORKAMBI and KALYDECO. Specifically, there's some 12,000 additional patients younger than age 12 with 2 copies of the Delta F508 mutation whom we believe could be helped by ORKAMBI. In the second quarter, the FDA accepted for review our supplemental new drug application for the use of ORKAMBI in children ages 6 to 11, and granted our request for priority review, setting a target review date or PDUFA date September 30, 2016. If approved, we expect to be ready to bring ORKAMBI to these patients immediately following approval. 
In parallel, we're also progressing with our efforts to bring ORKAMBI to children ages 6 to 11 in Europe where we plan to submit our application for approval in the first half of next year, following the conclusion of our fully enrolled Phase III efficacy and safety study in this group of patients. We estimate that there are approximately 2,400 children ages 6 to 11 in the U.S., and 3,400 in Europe who would be eligible for ORKAMBI.
There are approximately 5,000 additional patients in North America, Europe and Australia, largely those with residual function mutations who could be helped by KALYDECO. While we received the complete response letter from the FDA earlier this year regarding our application for approval of KALYDECO in people with CF ages 2 and older who have 1 of 23 residual function mutations, our belief that KALYDECO would be beneficial to these patients is unchanged, and we continue to pursue FDA approval for these patients as soon as possible. There are approximately 1,500 people with CF in the U.S. who have the mutations included in our residual function sNDA. 
And third, to our expanding pipeline of investigational CF medicine. The most advanced pipeline program in CF is our broad Phase III program for VX-661 in combination with ivacaftor. VX-661 plus ivacaftor may have an improved benefit risk profile compared to ORKAMBI in people with 2 copies of the Delta F508 mutation and may provide enhanced clinical benefits over ivacaftor monotherapy for other patients with gating mutations. Enrollment in the study of VX-661 plus ivacaftor in people ages 12 and older with 2 copies of the Delta F508 mutation is expected to complete in August. Data from the 6-month study are expected in the first half of 2017. The other 3 Phase III studies of VX-661 are also progressing as planned. We plan to submit a new drug application to the U.S. FDA for VX-661 in combination with ivacaftor in the second half of 2017.
Importantly, VX-661 is also positioned to play a key role in a triple-combination regimen with a next-generation corrector and ivacaftor. We believe that this triple combination approach may allow us to treat an additional large group of patients, specifically those with one Delta F508 mutation and one mutation that results in minimal CFTR function. These patients do not currently have medicines to treat the cause of their disease.
Our 2 next-generation correctors, VX-152 and VX-440, are being evaluated in Phase I studies in healthy volunteers. Pending data from these studies, we expect to move into Phase II clinical development in the second half of 2016 in people with CF. These studies would evaluate 1 or both of our next generation correctors with VX-661 and ivacaftor. 
Beyond our CFTR modulators, we've entered into multiple strategic collaborations that broaden our ability to evaluate additional approaches to CF treatment that may be complementary to CFTR modulation in the future. While the underlying technology and science of each approach differs, the collaborations have a shared goal to develop the best possible future treatments for all people with CF. Earlier this month, we entered into a collaboration with Moderna Therapeutics aimed at using messenger RNA to potentially enable cells in the lungs of people with CF to produce functional CFTR protein. This is the second platform technology collaboration we have entered into, following our agreement with CRISPR Therapeutics focused on the use of CRISPR-Cas9 for gene editing that we began in late 2015. These platform technologies add to our development stage collaboration with Parion Sciences focused on the use of ENaC inhibition to treat CF.
As we ended the second half of 2016, I'm pleased with both the near and long-term growth opportunities for our business. Our goal is to consistently discover and deliver transformative new medicines for patients and to reinvest in scientific opportunities to create future medicines. We believe our business model, which is focused on significant investment to create value through innovation, research and development, will position us to achieve this goal over the coming years.
With that, I'll turn the call over to Ian."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. Through the second quarter of the year, we've created a growing revenue base with ORKAMBI and KALYDECO, which we expect to drive future earnings growth. Tonight, I'll discuss our second quarter revenues for ORKAMBI and K",683,"Thanks, Jeff, and hello, everyone. Through the second quarter of the year, we've created a growing revenue base with ORKAMBI and KALYDECO, which we expect to drive future earnings growth. Tonight, I'll discuss our second quarter revenues for ORKAMBI and KALYDECO, review our 2016 financial guidance and discuss our anticipated financial trajectory for the coming years.
In the second quarter of 2016, we reported total CF product revenues of approximately $426 million, a significant increase compared to $155 million for the second quarter of last year. 
Turning to the revenues for each of our CF medicines. Global sales of ORKAMBI in the second quarter were $245 million, comprised of U.S. sales of approximately $229 million, and ex-U.S. sales of approximately $16 million, which were mainly from Germany. As of June 30, approximately 6,000 patients have initiated treatment with ORKAMBI in the U.S. Outside the U.S., ORKAMBI is already available commercially in Germany, and also through early access programs in France. In Germany, uptake continues to be slower than we observed in the U.S. As of June 30, approximately 380 of the 2,500 eligible patients in Germany had initiated treatment. 
In contrast, in France, we continue to see strong and rapid uptake. Approximately 700 of 1,500 eligible patients in France have already initiated treatment with ORKAMBI as of June 30 as part of the country's early access programs. These programs provided the opportunity for physicians in France to begin treating patients prior to their formal reimbursement approval. We are pleased the ORKAMBI launch has continued to progress consistent with what we discussed on our first quarter call. And today, we are reiterating our expectation for 2016 ORKAMBI revenues of $1 billion to $1.1 billion. 
Given the slower than expected launch in Germany and that we are approaching peak penetration for ORKAMBI in patients aged 12 and older in the U.S., we expect that revenue growth for ORKAMBI will occur primarily in the fourth quarter, following the potential approval and launch of ORKAMBI for children ages 6 to 11.
Now to KALYDECO. Second quarter KALYDECO sales were $180 million, up $25 million compared to the second quarter of last year. We continue to see small number of additional eligible patients beginning treatment in the U.S. and Europe. As with ORKAMBI, we are reiterating our 2016 revenue guidance for KALYDECO of $685 million to $705 million. Our 2016 guidance exclude any potential revenues for the approval of KALYDECO in residual function mutations where we continue to pursue the FDA approval for patients ages 2 and older in the U.S.
Now to the operating expenses. Our second quarter non-GAAP operating expenses were $306 million compared to non-GAAP operating expenses of $254 million in 2015. The increased operating expenses were mainly due to increased costs related to the progression of our CF pipeline and to increase investment in global commercial support for the launch of ORKAMBI. Our non-GAAP net profit for the second quarter of 2016 was $58 million or $0.24 per diluted share as compared to a non-GAAP net loss of $131 million or $0.54 per share for 2015. 
From a balance sheet perspective, we ended the second quarter with approximately $1.07 billion in cash, cash equivalents and marketable securities. Vertex also has $300 million outstanding from a credit agreement repayable by the end of the third quarter 2017.
I'll conclude tonight's call with a few brief comments on financial trends, including revenue and earnings growth. Our goal is to discover and develop new medicines for all people with CF. And as Jeff has discussed, there are 3 important phases to support these efforts: obtaining reimbursement for ORKAMBI outside the U.S.; expanding labels for both ORKAMBI and KALYDECO; and developing new medicines to treat potentially all people with CF. As we progress towards this goal, significant and sustainable revenue growth will follow. Importantly, as our revenues grow over future years, we are committed to managing our operating expenses to drive earnings growth. And we expect to deliver a financial profile similar to many of our large cap biotech peers. 
With that, I open the line to questions."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] And our first question comes from the line of Geoff Meacham with Barclays.",15,"[Operator Instructions] And our first question comes from the line of Geoff Meacham with Barclays."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have a few commercial ones and one clinical. I wanted to ask you guys, either Ian or Stuart, any changes to the persistence rates in the U.S., what are the new strategies to improve it? And then, can you just go into a little bit more detail on the EU o",71,"I have a few commercial ones and one clinical. I wanted to ask you guys, either Ian or Stuart, any changes to the persistence rates in the U.S., what are the new strategies to improve it? And then, can you just go into a little bit more detail on the EU outlook? So from what I understand, flattish in 3Q from Germany? And then, maybe what's driving the fourth quarter bump?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, it's Stuart here. So on persistence rates, what we're seeing in the U.S. is very consistent with what we outlined on our Q1 call. In fact, all the trends really in initiations, persistence and compliance are entirely in line with what we said then.",270,"Geoff, it's Stuart here. So on persistence rates, what we're seeing in the U.S. is very consistent with what we outlined on our Q1 call. In fact, all the trends really in initiations, persistence and compliance are entirely in line with what we said then. Just to remind you and others on the phone, for persistence, we said that our expectation was it would track towards about 70% to 80%, between 70% and 80% by the end of this year, and the same for compliance, and we continue to believe in those estimates, and those estimates are what underpins our revenue guidance that we reiterated today. In terms of Europe, and as you noted, Germany's uptake is relatively slow, and Ian mentioned that in his prepared remarks. Incorporated within our guidance, really, we're only expecting significant contributions ex-U.S. from Germany. In terms of how we see things playing out in the rest of Europe, really, as you know, that's going to be very dependent on us proceeding through country by country reimbursement negotiation processes. And what I can tell you is that those are progressing as we planned, as expected. But given our learnings and the analogy to KALYDECO and the time it took there, we're really not anticipating to conclude many of those reimbursement negotiations until 2017. Having said that, we recently concluded our first formal reimbursement negotiation in Austria, and that will go into effect from September 1, but we continue to believe that most of the major markets were not likely to see any major contributors -- contributions in terms of revenue growth until 2017 and beyond."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And just real quick on the clinical side, I know it's less interesting, but the PK for 152 and 440, will we see any of that in any CF? And any more thoughts on kind of what the size and scope of the clinical development for the triple could entail?",51,"Okay. And just real quick on the clinical side, I know it's less interesting, but the PK for 152 and 440, will we see any of that in any CF? And any more thoughts on kind of what the size and scope of the clinical development for the triple could entail?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, it's a little difficult to answer that, to be honest, Geoff. To say the size of the triple -- I mean, if I comment more broadly on our operating expense for the remainder of the year and then maybe kind of the trajectory in 2017, I think, that's an",245,"Well, it's a little difficult to answer that, to be honest, Geoff. To say the size of the triple -- I mean, if I comment more broadly on our operating expense for the remainder of the year and then maybe kind of the trajectory in 2017, I think, that's an easy way for me to comment on it. We always plan and provide guidance based on assuming success and that's why we're investing behind the programs. So our OpEx guidance for the year is at $1.18 billion to $1.23 billion, and we reiterated that number in the press release tonight. And that's a non-GAAP number, by the way. Excludes primarily stock compensation. And then, as we look into next year, we actually -- we hope and expect the programs to progress. And as we look into next year, as we think about OpEx more broadly, we see maybe some marginal increases in marketing investments for the launch of ORKAMBI more broadly, and particularly in Europe as we get reimbursement approval. And as we look at the development investment, maybe there's -- it's more consistent with 2015 to 2016 as programs cycle in and out with the expectation that the 661 Phase III program comes to closure, and we're refiling next year, and the progression of the triple into a larger Phase II study. So hopefully, that gives you an understanding of the trajectory of our investment profile through this year and then into next year."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, this is Jeff Leiden. With respect to your question on the PK data in CF. What we said before is that we'll let you know if we include the Phase I studies and plan the Phase II studies for the next-gen correctors, what those Phase II studies will lo",83,"Geoff, this is Jeff Leiden. With respect to your question on the PK data in CF. What we said before is that we'll let you know if we include the Phase I studies and plan the Phase II studies for the next-gen correctors, what those Phase II studies will look like and we'll provide you with some relevant data so you understand the design of those studies. And those studies, as we said, are on track for the second half of this year."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Michael Yee with RBC Capital Markets.",15,"And our next question comes from the line of Michael Yee with RBC Capital Markets."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two questions as well. On the commercial side, are you -- based on long-term data for ORKAMBI, are you starting to see any patients perhaps thinking about coming back? Are there discussions out there in the field about bringing some patients back on? And",112,"Two questions as well. On the commercial side, are you -- based on long-term data for ORKAMBI, are you starting to see any patients perhaps thinking about coming back? Are there discussions out there in the field about bringing some patients back on? And what are you thinking about that standpoint? And then, a follow-up question on the triple, is it safe to say that you've gone well into Phase I and the longer the better. Is there something specific in terms of exposure levels that you're looking for relative to assays that would give you some comfort in terms of what you want to see in terms of exposure of [indiscernible]"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. Maybe let me just touch on both of those for you. I think, from a long-term data perspective, we think that is very meaningful to patients and to prescribers. And I think, the reason for that are several fold. As you know, that info",323,"It's Jeff Chodakewitz. Maybe let me just touch on both of those for you. I think, from a long-term data perspective, we think that is very meaningful to patients and to prescribers. And I think, the reason for that are several fold. As you know, that information really has a couple of chunks to it. One is about the long-term safety of the drug, which is very important. And that continues to look very favorable, consistent with what we have seen before. And then, we had several for efficacy kind of measure. Some of that came from the study itself, our following patients for a long time and we saw that their FEV1s where maintained, their BMI continued to improve. And although there's no active comparison there, the event rate in terms of pulmonary exacerbation really remained low and consistent with what we saw during the trials. So that was all very impactful, we think, for physicians and for patients. The other thing we did was take the information from a mass cohort of historical patients, and what that allows you to do over that kind of time frame is to compare the rate of decline of patients' FEV1s who were on our study versus what we think the historical expectation would be, and that really then, as we did with KALYDECO, helps us understand if we're shifting that curve and slowing the rate of decline, really modifying the disease. And we were very pleased to see that approximately 40% reduction in the rate of decline. So overall, we think that data is very impactful and useful. In terms of triple combination, really can't give you a lot of details, as Jeff Leiden said actually already, that, that -- both drugs do continue in Phase 1 studies, and our expectation, of course, pending data, is that one or both of those will start in patients in the second half of this year."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes the line of Geoffrey Porges with Leerink Partners.",13,"And our next question comes the line of Geoffrey Porges with Leerink Partners."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Question for Stuart perhaps, I think, about the PDUFA date and the pediatric indication for ORKAMBI. Could you talk about what sort of pace you expect reimbursement to be available to the pediatric patients on the side of several deltas? And then, secondl",84,"Question for Stuart perhaps, I think, about the PDUFA date and the pediatric indication for ORKAMBI. Could you talk about what sort of pace you expect reimbursement to be available to the pediatric patients on the side of several deltas? And then, secondly, as you are out in the community and talking to physicians, do you think that the adoption compliance and persistence rates in the pediatric population will be similar to the adult population or greater or less than you've observed so far?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for those questions. So yes, the PDUFA date is September 30. Obviously, we're deep into the planning for that launch because it's only just a couple of months away. In terms of what we might anticipate for access, to answer the first part of y",330,"Yes, thanks for those questions. So yes, the PDUFA date is September 30. Obviously, we're deep into the planning for that launch because it's only just a couple of months away. In terms of what we might anticipate for access, to answer the first part of your question, my expectation is that access is going to be very good, just as it was for ORKAMBI when we first introduced it for the 12 and over population. And in some ways, this is a somewhat simpler review for the payers. It's a labeled extension just extending it down to a younger age. And so my expectation is that we'll secure broad access very quickly. In terms of rate of uptake, similarly, I would anticipate the demand to be robust, just as it was for 12 plus. And in terms of persistence and compliance, again, it's difficult to say exactly how it's going to play out in the real world as opposed to what we saw in the clinical trial setting. Certainly, a couple of things that I think give us some encouragement, we certainly saw in the study that we did that forms the basis of our application that the adverse event rate and particularly the rate of respiratory adverse events was much lower and none of the patients discontinued for that adverse event, and as you know, that's been one of the primary reasons for discontinuations on ORKAMBI in the 12 and over population. And then, again, one thing could help us, the 6 to 11 population, certainly with KALYDECO, we do tend to see compliance rates being much higher in the younger population, not surprisingly, as they tend to be very heavily managed by their parents. And so whilst I don't know exactly how it's going to play out in the real world, I certainly expect access to be very good and us to secure that quickly, and I'd also expect the uptake to be very rapid as well."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, I'll just add on to Stuart to reiterate something I said in my comments, which is that Q4 is where we anticipate to see the growth in ORKAMBI for the remainder of the year. And obviously, that is driven by 6 to 11 that Stuart was just discussing.",49,"Geoff, I'll just add on to Stuart to reiterate something I said in my comments, which is that Q4 is where we anticipate to see the growth in ORKAMBI for the remainder of the year. And obviously, that is driven by 6 to 11 that Stuart was just discussing."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Brian Abrahams with Jefferies.",13,"And our next question comes from the line of Brian Abrahams with Jefferies."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","As you guys see more uptake in Germany and more patients going on treatment in France, I was wondering if you could talk a little bit about persistence and compliance patterns that you're starting to see in Europe? Do you expect to be able to leverage you",116,"As you guys see more uptake in Germany and more patients going on treatment in France, I was wondering if you could talk a little bit about persistence and compliance patterns that you're starting to see in Europe? Do you expect to be able to leverage your learnings from the U.S. launch plus the availability of the long-term data now to improve that patient retention in the European launch as compared to the U.S.? And then, separately, just wondering if you could give us a little bit more granularity on the next steps, any level of confidence on residual function mutations, sort of where you stand there with respect to the next step -- regulatory steps?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay, Brian. So I'll start off on the persistency and compliance and how things are playing out in Europe. I mean, one of the benefits of launching in Europe after launching here in the U.S. is, clearly, we've been able to learn a lot from our experiences",228,"Okay, Brian. So I'll start off on the persistency and compliance and how things are playing out in Europe. I mean, one of the benefits of launching in Europe after launching here in the U.S. is, clearly, we've been able to learn a lot from our experiences here in the U.S. And I think, one of the things that we've been able to do is certainly sensitize people to the fact that some patients may have these respiratory adverse events, and so to be on the lookout for them, to be canceling patients in advance, and that certainly has been one of the many learnings that we took from our experiences here in U.S. to the introduction of the products in Europe. The data sources are not quite as robust as we have here in the U.S. in terms of tracking at a non-biased level individual patient data in Europe. And I would say, at this relatively early stage, the persistence rates are certainly in line in the same kind of ballpark as we saw with ORKAMBI here in the U.S. As that data matures over time, we'll be able to give you kind of more detail on exactly how it's playing out, but at the minute, the data is relatively immature. I would say it's pretty much in the same kind of ballpark for persistence and compliance."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Brian, it's Jeff Chodakewitz, just to comment on residual function. We really can't comment on when we have ongoing discussions with regulatory agencies. The only thing I can say is that we do really think all the data of both the preclinical data and the",73,"Brian, it's Jeff Chodakewitz, just to comment on residual function. We really can't comment on when we have ongoing discussions with regulatory agencies. The only thing I can say is that we do really think all the data of both the preclinical data and the clinical data really tell us that this drug is beneficial to those patients, and our goal is to figure out a way to get access for those patients."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Terence Flynn with Goldman Sachs.",14,"And our next question comes from the line of Terence Flynn with Goldman Sachs."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe just 2 for me. First on ORKAMBI in the U.S. It looks like new patient adds have moderated somewhat this quarter, and I know you were talking about nearing peaks. So is 6,000 or 6,000-ish kind of what you're expecting now or do you think you can get",99,"Maybe just 2 for me. First on ORKAMBI in the U.S. It looks like new patient adds have moderated somewhat this quarter, and I know you were talking about nearing peaks. So is 6,000 or 6,000-ish kind of what you're expecting now or do you think you can get to the rest of the 8,500 total? And then, in Germany versus France, obviously, a difference in uptake, just wondering what you think is driving that and which other countries you could think about those patterns playing out? Are they going to be more like Germany or more like France?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Terence, I'll start with the U.S. So as you said, with ORKAMBI, we've now initiated over 6,000 patients here in the U.S., which is about 70% of the eligible patient population. And as you might expect with the launch where we're getting to a steeper part",359,"Terence, I'll start with the U.S. So as you said, with ORKAMBI, we've now initiated over 6,000 patients here in the U.S., which is about 70% of the eligible patient population. And as you might expect with the launch where we're getting to a steeper part of the curve, adding new patient becomes a little bit tricky. Having said that, we are continuing to add new patients on a weekly and daily basis. But as Ian said in his prepared remarks in terms of U.S. growth, obviously, the next phase in growth in the U.S. is likely to be from the approval in 6 to 11s, which we hope will come in the next couple of months. So moving on to how things are panning out in Europe, and you're right, there is a contrast in uptake between Germany and France. Germany is slower than we anticipated. And much of that I attribute to the fact that the German market is more fragmented than many of the other markets that we operate in. What I mean by that is there's many more centers treating CF patients, and as a result, they've had less experience with CFTR modulators, and therefore, the kind of the educational need is higher there. And also, we did see a slightly slower uptake for KALYDECO in Germany than we saw in other EU markets. Contrast with France where through early access programs, we have 700 patients have already been initiated on ORKAMBI, and that uptake in 6 months is much more U.S.-like. So based on that, based on all the other research we've done, we do anticipate that Germany is more likely to be an outlier in terms of rate of uptake, although I continue to believe that we will get to the vast majority of patients in Germany over time. And in terms of rate of uptake, I would expect it to be more like France in the rest of Europe, pending reimbursements than we've seen in Germany, which I continue to believe is likely to be more of the outlier based on our previous experience with KALYDECO and comparing to experience with ORKAMBI."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Mark Schoenebaum with Evercore ISI.",13,"Our next question comes from the line of Mark Schoenebaum with Evercore ISI."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is John Miller on for Mark. And I just wanted to ask a question about these 6,000 patients that have started on ORKAMBI. You said it's a start. So I don't think -- what's the current number of patients on therapy? I'd love to know that. And my other",92,"This is John Miller on for Mark. And I just wanted to ask a question about these 6,000 patients that have started on ORKAMBI. You said it's a start. So I don't think -- what's the current number of patients on therapy? I'd love to know that. And my other question, I suppose, would be your thoughts on pricing pressure, especially in a therapy [ph] like this where pricing pressure -- where pricing ability has typically been very high. How do you look at that going forward as that's obviously an issue?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Well, just reiterate what Ian said in terms of the actual number of patients being treated, that's clearly a very dynamic number and changes constantly. So what we have said is that we've, to date, initiated 6,000 patients. We continue to see more initiat",277,"Well, just reiterate what Ian said in terms of the actual number of patients being treated, that's clearly a very dynamic number and changes constantly. So what we have said is that we've, to date, initiated 6,000 patients. We continue to see more initiations, and we continue to believe, as we did at the end of Q1, that the persistence rate of that patient population is going to be somewhere in the 70% to 80% range, as indeed, we believe the compliance rate will be somewhere in the 70% to 80% range. And so that's the -- what we believe at the end of Q1, we continue to perform against those expectations, and that is in the 12 and above -- in 12 and above patients in the U.S. is what underlies our revenue guidance that we reiterated today. So in terms of pricing, clearly, that's a very hot topic across the industry. We continue to believe that we are developing very high value medicines, medicines that treat the underlying cause of what is a horrible life-shortening disease. It's for a very small patient population, and we believe, and I think that's reinforced by the discussions we've had with governments through the reimbursement of KALYDECO and the ongoing discussions we're having with ORKAMBI, this is exactly the sort of medicine that they want to be able to provide to their patient population, so whilst there will be pricing pressures because of the overall macroeconomics on every pharma and biotech company, I continue to believe that sort of agents we are bringing to bear are the sorts of products that governments are going to want to pay for."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Matthew Harrison with Morgan Stanley.",14,"And our next question comes from the line of Matthew Harrison with Morgan Stanley."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","This is Cyrus on for Matt. A couple of questions. First, are there any efforts to improve the persistence or compliance rates in the United States?",26,"This is Cyrus on for Matt. A couple of questions. First, are there any efforts to improve the persistence or compliance rates in the United States?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So we have a number of programs which are provided either through materials that we provide to health care providers to provide to their patients, or where appropriate, to provide directly to the patients to educate them on the product, the mechanism of a",145,"So we have a number of programs which are provided either through materials that we provide to health care providers to provide to their patients, or where appropriate, to provide directly to the patients to educate them on the product, the mechanism of action, the fact that they treat the underlying nature of the disease. And so those programs are ongoing. And I think understanding and an educated patient is likely to be a more persistent and more compliant patient. And also, we continue to try and build the evidence base for ORKAMBI, which increases the benefit risk profile. And to the extent that providers and patients continue to believe in the benefit risk profile, then I think they're going to want to try and maintain their time on the product because of the both short and long-term benefit the treatment with ORKAMBI gives them."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And the second question is when will you be able to recognize the revenues in France and will they come as a lump sum, or how will it be dealt with?",32,"Okay. And the second question is when will you be able to recognize the revenues in France and will they come as a lump sum, or how will it be dealt with?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So thanks for that question, just to kind of help everybody else what's behind that question, we actually are providing access to ORKAMBI in France through early access programs and other programs, and we are actually being paid for that drug. And in my r",213,"So thanks for that question, just to kind of help everybody else what's behind that question, we actually are providing access to ORKAMBI in France through early access programs and other programs, and we are actually being paid for that drug. And in my remarks, I did comment that, that launch in France is going very well and that we're accessing a lot of patients. We do get a payment for that drug that might be similar to how the ultimate price of the drug plays out in France. However, from a GAAP perspective, we are unable to report those, let's say, access to those medicine as revenue until we have an agreed price in France. So I appreciate your question. We'd anticipate that, that would be a 2017 event. At this point, if we do get approval on price, which provides us certainty to recording those revenues, we actually record the revenues as long, big catch-up. So as we've been selling drug since, let's say, January 1, 2016, all the way through to the point of reimbursement approval, we will record that cash that we will have ultimately have received as part of revenues in the quarter that we received reimbursement approval, and we do think that would be a 2017 event."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. Great. And then, last question, is there any update to the 661's utility analysis timing for the heterozygotes?",19,"Okay. Great. And then, last question, is there any update to the 661's utility analysis timing for the heterozygotes?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So it's Jeff Chodakewitz. I can tell you that as we've talked about previously, that is on track to occur during the third quarter. And then, based upon that recommendation from the DMC, remember that we won't be seeing that information. We will either st",55,"So it's Jeff Chodakewitz. I can tell you that as we've talked about previously, that is on track to occur during the third quarter. And then, based upon that recommendation from the DMC, remember that we won't be seeing that information. We will either stop the study or restart enrollment and go to completion."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Adam Walsh with Stifel.",13,"And our next question comes from the line of Adam Walsh with Stifel."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","My first one is you talked about a large bolus of discontinuations in the first quarter because 15% of patients, I believe, you said had come up in the first 3 months. I just wondered if there was any residual bolus kind of tail end into the second quarte",114,"My first one is you talked about a large bolus of discontinuations in the first quarter because 15% of patients, I believe, you said had come up in the first 3 months. I just wondered if there was any residual bolus kind of tail end into the second quarter? That's my first question. And then, my second question is also on discontinuations. You talked about the 15% in the first 3 months, and 20% to 30% longer term. Can you help us, after the 15% drop out in the first 3 months, help us understand the discontinuation dynamics from that point to the 25% long-term discontinuation rate, which is the midpoint of your guidance?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So yes -- thanks for the question. So yes, we did describe this kind of bolus of discontinuations, and that was largely a function of 2 things. One, the very, very rapid uptake we saw in ORKAMBI posting the initial launch. And then, we did see about 15% o",177,"So yes -- thanks for the question. So yes, we did describe this kind of bolus of discontinuations, and that was largely a function of 2 things. One, the very, very rapid uptake we saw in ORKAMBI posting the initial launch. And then, we did see about 15% of patients discontinue within the first 3 months therapy, largely as a result of respiratory adverse events. And then, what we saw with the rate of adverse -- rate of discontinuations ameliorated substantially, didn't soften, didn't flatten, but it certainly ameliorated substantially. And is a result of that, that's why we gave the guidance that we see the discontinuations, or the persistence rate, which is the opposite of discontinuations being in that 70% to 80% range by the end of 2016. And everything we've seen through Q2 continues to reinforce, I believe, that, that's where we will end the year, somewhere in that 70% to 80% range. There isn't -- wasn't really -- if I understand your question correctly, there wasn't really a second bolus that negatively impacted Q2."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Right. I guess, the question was, was there any tail end residual? You had the large number of patients start in the first 9 months, and you said that in the first quarter. As we move into this quarter, was the bolus still moving through in terms of the 1",60,"Right. I guess, the question was, was there any tail end residual? You had the large number of patients start in the first 9 months, and you said that in the first quarter. As we move into this quarter, was the bolus still moving through in terms of the 15% discontinuations, or do that really end in the first quarter?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Maybe a better way to answer this is that when somebody asked this on the call earlier was that are we continuing to see the dynamics of the launch and if the compliance rates and persistence rates being maintained? And yes, they are. So when we talk abou",137,"Maybe a better way to answer this is that when somebody asked this on the call earlier was that are we continuing to see the dynamics of the launch and if the compliance rates and persistence rates being maintained? And yes, they are. So when we talk about the profile of compliance with the medicine being between 70% and 80%, we're still seeing that. When we look at the persistence rates ending up at 70% to 80%, we're still seeing that, which means that every time there is a bolus of patients that is initiating therapy, we still continue to see discontinuations early on. However, because there is a lower initiation of patients in, let's say, Q1 or even the beginning of Q2, the impact of discontinuations in Q2 is much less than it has ever been."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Phil Nadeau with Cowen and Company.",15,"And our next question comes from the line of Phil Nadeau with Cowen and Company."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just a couple on the pipeline. So I guess, first on VX-661's Hetmen [ph] futility analysis, never disclosed exactly what the futility hurdle was. I was wondering whether you could give us some sense of the criteria or at least how you're going to interpre",97,"Just a couple on the pipeline. So I guess, first on VX-661's Hetmen [ph] futility analysis, never disclosed exactly what the futility hurdle was. I was wondering whether you could give us some sense of the criteria or at least how you're going to interpret a go signal in particular? And then, a similar question on the Phase I for the second-generation correctors. Can you give us some idea of what criteria you're going to look at to decide which will move forward and do you have any plans to move other second-generation correctors into the clinic?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. So in terms of 661's futility, I think, first of all, we really can't go into the details of exactly what the decision tree is. But let me help you think about it a little bit perhaps. There's a certain tension as you make a decisio",165,"It's Jeff Chodakewitz. So in terms of 661's futility, I think, first of all, we really can't go into the details of exactly what the decision tree is. But let me help you think about it a little bit perhaps. There's a certain tension as you make a decision based on partial information. We want to try if the drug is not benefiting patients to stop the trial. Conversely, there is uncertainty, and we also want to be careful about not missing a positive result. Therefore, there always is a certain overlap. And what we tend to do is then say if it's clearly not working, we stop. The consequence of that is even if it goes forward, there is still uncertainty, it does not mean that it's working, it just means that it may be working. And therefore, until we get to the end of the study, we really would not have had any confidence in what the result is going to be."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Jeff, maybe before you go onto the next question, I would just comment from the disclosure, the fact that we get asked this question a number of times. I want to be very clear on our disclosure around that. Consistent with what Jeff is saying, if ther",140,"And Jeff, maybe before you go onto the next question, I would just comment from the disclosure, the fact that we get asked this question a number of times. I want to be very clear on our disclosure around that. Consistent with what Jeff is saying, if there is a discontinuation of the study due to the futility rule, we'll announce that the study is discontinuing, and that would be an appropriate announcement at the time that we get that information. If we pass, no guarantees that it's working, and therefore, this drug -- this information is submissible for approval, but the only way we would communicate around that is on clinicaltrials.gov, we will reopen the recruitment for that study and we'd expand the recruitment into the study, but there wouldn't be announcements saying that we passed the futility rules."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And just in terms of your other question, I think, what we've always said is that what we want to do is bring these medicines -- these compounds forward, but we want them to be medicines that we tried as much as possible to have drugs that we think can ha",101,"And just in terms of your other question, I think, what we've always said is that what we want to do is bring these medicines -- these compounds forward, but we want them to be medicines that we tried as much as possible to have drugs that we think can have a favorable profile in patients so that they can continue. We're going to look at all the information, have safety exposure, all the things you'd expect. There's really no one thing that I can say we're going to focus in on, it's really the totality of profile of the drug."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. Do you have any plans to move in any other second-generation correctors into the clinic or is that really dependent on what you see in the Phase I?",29,"Okay. Do you have any plans to move in any other second-generation correctors into the clinic or is that really dependent on what you see in the Phase I?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff Leiden. Thanks for the question. As we said before, this is a large program here. We've discovered a series of second-generation correctors, and they have different -- or mix generation correctors, they have different flavors, which is intere",114,"This is Jeff Leiden. Thanks for the question. As we said before, this is a large program here. We've discovered a series of second-generation correctors, and they have different -- or mix generation correctors, they have different flavors, which is interesting. And our strategy here is very straightforward. If we can develop a portfolio of products and bring some of those forward into the clinic and compare them, it gives us the best probability of success. So our plan is to continue that program in the research and preclinical phase, and if we see compounds that are interestingly good, better than the ones we have, we certainly will bring them forward into the clinic."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Alethia Young with Crdit Suisse.",14,"And our next question comes from the line of Alethia Young with Crdit Suisse."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just one on 661 and the other studies. Can you give us a flavor around like maybe kind of what the progress is in enrollment, not the homozygous, but the other 3 studies, like kind of what sequencing we might expect for the timeline? Second one, just when",98,"Just one on 661 and the other studies. Can you give us a flavor around like maybe kind of what the progress is in enrollment, not the homozygous, but the other 3 studies, like kind of what sequencing we might expect for the timeline? Second one, just when you look at some of the long-term data that you generate on exacerbations like the medical meetings midyear, do you think that doctors who are receiving that patients are receiving that, that there is like a very kind of profound benefit to staying on ORKAMBI even somewhat similar to KALYDECO?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. So it's Jeff Chodakewitz. Let me first comment on the 661 sequence. First of all, as we indicated for the homozygous study, we have a lot of confidence in that finishing enrollment in August. In fact, we've actually already stopped screening patient",356,"Sure. So it's Jeff Chodakewitz. Let me first comment on the 661 sequence. First of all, as we indicated for the homozygous study, we have a lot of confidence in that finishing enrollment in August. In fact, we've actually already stopped screening patients for that study, so it's just having the last patients completing the screening process and if they qualify going into the trial. We've already talked about the timing of the study of in-patients and the futility analysis that's going to be done. We expect that the next trial that's going to be completed will be the study in patients with 508 on one allele and a residual function mutation on the other allele. And as we've indicated, we expect that to complete in the second half of this year, very much as we've indicated earlier this year, it's really right on track. And then, the last study with 508 and in gating on the other allele, again, as we've indicated previously, we think, in the second half of this year or early next year, and as we get the data, then that will allow us to evaluate our best submission strategy and file a pending data in the second half of '17. In terms of the long-term data, I want to be sure that I understand your question. We do think that the results from that long-term data are quite compelling. You asked specifically about pulmonary exacerbations, and so we do look at what basically we use in assessment of how many events are happening for the patients that we're following and think about it as an event rate, and what we do see is that as we've gone out further in time, that remains quite low compared to what we had as our initial comparison. We think that is quite meaningful to patients and physicians. And actually, that's linked up with the other information like body weight and particularly the change in slope of FEV1 evidence of disease modification, we think that is driving considerations like starting therapy earlier and considering whether patients who discontinued may want to think about restarting therapy."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Ying Huang with Bank of America.",15,"And our next question comes from the line of Ying Huang with Bank of America."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Can you talk about maybe the ATU pricing you're getting in France? And how does that compare to the German pricing for ORKAMBI? And then, secondly, also again on Europe, what's your thought on the Brexit on the U.K. and also, broadly speaking, European re",48,"Can you talk about maybe the ATU pricing you're getting in France? And how does that compare to the German pricing for ORKAMBI? And then, secondly, also again on Europe, what's your thought on the Brexit on the U.K. and also, broadly speaking, European reimbursement for ORKAMBI?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So the ATU pricing in France has not been publicly disclosed, but it is very similar to the list price that we have established in Germany. In terms of the thoughts on the Brexit impact, certainly, from a financial point of view in the short term, the rea",162,"So the ATU pricing in France has not been publicly disclosed, but it is very similar to the list price that we have established in Germany. In terms of the thoughts on the Brexit impact, certainly, from a financial point of view in the short term, the really most tangible impact that you can see is really one around the impact on FX. And because of the nature of our business and the natural hedges we have, we're not expecting that to have a meaningful impact on our business. There's obviously a range of other legal, regulatory, employment and other aspects that could be impacted by the Brexit as the negotiations are ongoing. We're clearly going to be tracking those very closely and making all the appropriate moves and responses as the situation becomes clear. But as with many things, Brexit, I think, to speculate on too many other aspects of what the impact would be, would crystal ball gazing at best."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And then, maybe another one for Jeff. Can you tell us when might we see CRISPR and also the Moderna program getting to the clinic at earliest?",27,"And then, maybe another one for Jeff. Can you tell us when might we see CRISPR and also the Moderna program getting to the clinic at earliest?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So thanks for the question. I appreciate you acknowledging the 2 very important collaborations that we've actually done in the last year, kind of expanding the modalities getting to other diseases. But unfortunately, they are early stage, as you are proba",82,"So thanks for the question. I appreciate you acknowledging the 2 very important collaborations that we've actually done in the last year, kind of expanding the modalities getting to other diseases. But unfortunately, they are early stage, as you are probably aware, and we wouldn't anticipate getting anything to the clinic in the next couple of years. It's probably 3 years or more from now. And we'd love to update you on that, but those have been important transactions for the company."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Liisa Bayko with JMP Securities.",14,"And our next question comes from the line of Liisa Bayko with JMP Securities."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I thought you had a pretty good KALYDECO quarter. I'm just wondering if you could comment on where -- what's driving growth there? Is it from particular region or rolling out in a new mutation?",35,"I thought you had a pretty good KALYDECO quarter. I'm just wondering if you could comment on where -- what's driving growth there? Is it from particular region or rolling out in a new mutation?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Liisa, I'm thrilled with the question. It's nice to be able to talk about KALYDECO, and thanks for noticing. Yes, KALYDECO had a very strong quarter, about $180 million. Most of the growth over Q2 came from the U.S. And essentially, what we continue to se",119,"Liisa, I'm thrilled with the question. It's nice to be able to talk about KALYDECO, and thanks for noticing. Yes, KALYDECO had a very strong quarter, about $180 million. Most of the growth over Q2 came from the U.S. And essentially, what we continue to see is increasing new patient initiations in some of the newer indications like the 2 to 5-year old kids and also in the R117H mutation. So we continue to see strong patient initiation. And as you know, the persistence rates and the compliance rates with KALYDECO are about as good as I've ever seen. So really, it's that combination of adding new patients and great persistence and compliance rates, particularly here in the U.S."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And then, in terms of ex-U.S., is it just -- just to make we're all on the same page, the only countries you're selling any drug -- or I mean, distributing drug to patients because I know you're not really selling in France per se, but France, Germa",59,"Okay. And then, in terms of ex-U.S., is it just -- just to make we're all on the same page, the only countries you're selling any drug -- or I mean, distributing drug to patients because I know you're not really selling in France per se, but France, Germany and the U.S., are those the totality of the countries?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So outside of the U.S., France and Germany are different to many of the other markets in that the way that the structure of those markets work is that there are access programs that you can take advantage of where patients can get access to the products p",166,"So outside of the U.S., France and Germany are different to many of the other markets in that the way that the structure of those markets work is that there are access programs that you can take advantage of where patients can get access to the products prior to the full reimbursement approval being secured on a relatively broad basis, and that's happening in both Germany and France. And Ian talked about the fact that with France, we don't recognize those patients from a revenue perspective. In Germany, we do. There are other countries where we're on a named patient basis. There are literally handfuls of patients who, through exceptional programs, are getting access to the product where we are getting paid. But the vast majority of our revenues outside of the U.S. are coming from Germany. We expect that to continue in 2016, and we don't expect to get really meaningful revenue contributions from markets outside of Germany, outside of the U.S. until 2017."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Brian Skorney with Robert W. Baird.",15,"And our next question comes from the line of Brian Skorney with Robert W. Baird."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two quick ones. I guess, first, could you just go over anything you've said about the differences between 152 and 440? Are they distinct corrective mechanisms? I know you've always said that the intent is to move forward with both, but I was just wonderin",107,"Two quick ones. I guess, first, could you just go over anything you've said about the differences between 152 and 440? Are they distinct corrective mechanisms? I know you've always said that the intent is to move forward with both, but I was just wondering if there's a potential for these 2 drugs to actually be complementary to each other, like 661 and lumacaftor, they're just overlapping? And then, when we think about the [indiscernible] approval later this year, do you think there's any meaningful numbers of [indiscernible] patients currently on or ORKAMBI off-label, or do you think that it's really completely untapped patient pool right now?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Brian, this is Jeff Leiden. I'll take the first part and then Stuart can take the second part. We haven't actually talked a lot of detail about the mechanisms of action or the differences or similarities between 152 and 440, they're clearly different mole",125,"Brian, this is Jeff Leiden. I'll take the first part and then Stuart can take the second part. We haven't actually talked a lot of detail about the mechanisms of action or the differences or similarities between 152 and 440, they're clearly different molecules. And so that's why we brought them both forward into the clinic. What we have said is that we, as part of our discovery program, have discovered a portfolio of next-gen correctors, which do have distinct mechanisms of action as well as distinct drug life properties, and that's why we're excited about the portfolio and that's why we plan to take multiple molecules into the clinic because at least in my experience, that's the way to maximize your chance for success."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Again, Brian, on the subject of off-label usage in the 6 to 11 population, we don't track off-label usage. My expectation is that it would be very, very low. And the reason why I say that is the prior authorization criteria that's been for ORKAMBI, which",121,"Again, Brian, on the subject of off-label usage in the 6 to 11 population, we don't track off-label usage. My expectation is that it would be very, very low. And the reason why I say that is the prior authorization criteria that's been for ORKAMBI, which have enabled us to get very good access for ORKAMBI are very simple but very clear. And they would tend to say, the person must have a CF diagnosis, they have to have the right mutation type and they check the date of birth, they check the patient is 12 and above. And so my expectation would be that the number of people receiving commercial product off-label at this point would be very, very low."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Katherine Xu with William Blair.",11,"And our next question comes from Katherine Xu with William Blair."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I'm just wondering, with ORKAMBI versus KALYDECO, do you see a little bit lower compliance or persistence for ORKAMBI as compared to KALYDECO? And if that's the case, do you think it's mostly because of safety or lower efficacy or both, any sense on that",48,"I'm just wondering, with ORKAMBI versus KALYDECO, do you see a little bit lower compliance or persistence for ORKAMBI as compared to KALYDECO? And if that's the case, do you think it's mostly because of safety or lower efficacy or both, any sense on that at all?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Katherine, so with KALYDECO, we see very, very high levels of both persistence and compliance. We've said that our persistence with KALYDECO is 90% plus. And overall compliance both here in the U.S. and internationally is around 85%. And as we said at Q1,",149,"Katherine, so with KALYDECO, we see very, very high levels of both persistence and compliance. We've said that our persistence with KALYDECO is 90% plus. And overall compliance both here in the U.S. and internationally is around 85%. And as we said at Q1, and it's baked into our revenue guidance, we expect persistence for ORKAMBI to be between 70% and 80%, and for compliance to be in the same 70% to 80% range. So we do see both of those criteria being lower for ORKAMBI than they are for KALYDECO. And try to attribute exactly why that is. I'm not sure I would be able to tease that out for you. I'm sure it's got to do with the benefit risk and tolerability profile of ORKAMBI versus KALYDECO. But exactly which factor is weighting it one way or the other, I think that would be impossible to differentiate."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And could you give a quick update on your oncology in teens [ph] pipeline candidates?",15,"And could you give a quick update on your oncology in teens [ph] pipeline candidates?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So maybe -- it's Jeff Chodakewitz. Just to give you a quick comment and then maybe Ian has a comment. I think, in terms of our oncology program, I think, very much consistent with where we were discussing it previously that we do have [indiscernible] VX-9",110,"So maybe -- it's Jeff Chodakewitz. Just to give you a quick comment and then maybe Ian has a comment. I think, in terms of our oncology program, I think, very much consistent with where we were discussing it previously that we do have [indiscernible] VX-970 is really in focused clinical trials in very specific populations and non-comparative trials to understand what the potential for those -- for that drug really can be. And so those are ongoing. On the [indiscernible] side, our VX-150 actually just is finishing -- has finished enrolling a Phase II POC study in osteoarthritis patients, and we expect to have some information later this year."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Jeff, thanks for that. I'll just pick up on that and say, because many people ask me this, are we going to be an oncology company? And I think that's a little early to suggest that, given that we have one lead molecule at the moment in early stage stud",186,"So Jeff, thanks for that. I'll just pick up on that and say, because many people ask me this, are we going to be an oncology company? And I think that's a little early to suggest that, given that we have one lead molecule at the moment in early stage studies in oncology. We're going to continue to progress those studies, as Jeff Chodakewitz said. And based on that data, we will make a choice at that time whether we'd provide further investments. Well, we actually look to see whether the mechanism is better served working with other companies. And therefore, looking more of a portfolio approach to drive forward, let's say, our oncology opportunities. We do have other mechanisms. One of the -- is in the clinic and then a couple at -- are just late preclinical right now. So we have a late preclinical, a couple of compounds and also early clinical compounds, and that's what determines our oncology portfolio and we'll make a decision of how to progress that best for greatest value once we receive the data from VX-970, our lead program."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from the line of Alan Carr with Needham and Company.",15,"And our next question comes from the line of Alan Carr with Needham and Company."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess, a couple of them here. One of them, it looks like, the only program you haven't touched on is 210. Wondering if you can give us an update on that in the spinal cord? And then, also with respect to your sNDA around residual mutations for KALYDECO,",64,"I guess, a couple of them here. One of them, it looks like, the only program you haven't touched on is 210. Wondering if you can give us an update on that in the spinal cord? And then, also with respect to your sNDA around residual mutations for KALYDECO, what sort of options do you have available here in your discussions with the FDA?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeff Chodakewitz. So Alan, I'd say, first of all, in terms of VX-210, that study is up and enrolling, we have had enrollment now in the trial, but these are acutely ill, acutely injured people, and so we have always expected that enrollment will be slow,",84,"Jeff Chodakewitz. So Alan, I'd say, first of all, in terms of VX-210, that study is up and enrolling, we have had enrollment now in the trial, but these are acutely ill, acutely injured people, and so we have always expected that enrollment will be slow, and so we are really pretty much on track. In terms of residual function, as we talked about earlier, there's really just nothing in terms of ongoing discussions with the regulatory agency that I can talk about further."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Can you comment -- I mean, I'm wondering if you can comment on what sort of what the outcomes might be here? Is this something that might be resolved this year or does this potentially involve more studies? What can you comment from that perspective?",45,"Can you comment -- I mean, I'm wondering if you can comment on what sort of what the outcomes might be here? Is this something that might be resolved this year or does this potentially involve more studies? What can you comment from that perspective?"
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, Alan, it's Jeff Leiden. So as you know, we just don't comment on ongoing regulatory discussions, probably because they are not predictable and they are not totally within our control. I think, the important point is we do believe that KALYDECO is act",86,"Yes, Alan, it's Jeff Leiden. So as you know, we just don't comment on ongoing regulatory discussions, probably because they are not predictable and they are not totally within our control. I think, the important point is we do believe that KALYDECO is active in these set of patients based on both preclinical and clinical data, and that we're having ongoing discussions with the regulators about how to get access to these patients with KALYDECO. When we have an answer, we'll certainly disclose that for you."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Thank you. And I'm showing no further questions at this time, I would like to turn the conference back over to Mr. Michael Partridge for any final remarks.",28,"Thank you. And I'm showing no further questions at this time, I would like to turn the conference back over to Mr. Michael Partridge for any final remarks."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay. Thanks, operator. We appreciate everyone joining us tonight. We are happy to take additional follow-up questions after the call. The Investor Relations team will be in the office, so please reach out, and have a good night.",38,"Okay. Thanks, operator. We appreciate everyone joining us tonight. We are happy to take additional follow-up questions after the call. The Investor Relations team will be in the office, so please reach out, and have a good night."
36235,374694421,1014874,"Vertex Pharmaceuticals Incorporated, Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program. You may all disconnect. Everyone, have a great day."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening. This is Michael Partridge, Vice President of Investor Relations. Welcome to our Third Quarter 2016 Financial Results Conference Call. [Operator Instructions] This conference call is recorded, and there will be a replay available later tonigh",182,"Good evening. This is Michael Partridge, Vice President of Investor Relations. Welcome to our Third Quarter 2016 Financial Results Conference Call. [Operator Instructions] This conference call is recorded, and there will be a replay available later tonight. You can access the webcast live by going to our website. Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; Dr. Jeff Chodakewitz, Chief Medical Officer; and Ian Smith, Chief Financial Officer, will provide prepared remarks on this call. They will be joined by Dr. David Archuleta, Chief Technical Officer, for the Q&A portion of the call. 
We will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the SEC. These statements, including without limitation, those regarding the ongoing development and potential commercialization of our drug candidate, our expectations regarding our approved medicines and Vertex' future and financial performance are based on management's current assumptions. Actual outcomes and events -- I will now turn the call over to Dr. Jeff Leiden."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening everyone. Vertex' strategy in cystic fibrosis is to treat as many people with CF as possible and to continue to enhance the clinical benefits for those treated by our medicines. Our long-term goal is to reduce the progressive",557,"Thanks, Michael. Good evening everyone. Vertex' strategy in cystic fibrosis is to treat as many people with CF as possible and to continue to enhance the clinical benefits for those treated by our medicines. Our long-term goal is to reduce the progressive and irreversible effects of CF by treating the underlying cause of the disease. 
There are 3 key components to our strategy. First, to increase the number of eligible patients being treated with our approved medicines, mainly by obtaining reimbursement for ORKAMBI for more patients outside the U.S.; second to further expand the labels for KALYDECO and ORKAMBI around the world; and third to develop new commission regimented CFTR modulators designed to enhance benefit for all patients. 
This evening, I'm pleased to report that we continue to make excellent progress on all of these fronts. Last month, the FDA approved ORKAMBI for the treatment of children with CF ages 6 through 11 who have 2 copies of the F508 mutation. With this disapproval, approximately 29,000 patients worldwide are now eligible for our medicines. 
Today, we are treating approximately 9,000 of these 29,000 eligible patients. Going forward, we remain focused on expanding access to ORKAMBI and KALYDECO for the many eligible patients who are still awaiting treatment, largely through obtaining reimbursement for ORKAMBI in Europe, Canada and Australia.
We're also continuing to make progress in our efforts to expand the labels for KALYDECO and ORKAMBI. In the U.S., we are focused on obtaining approval for KALYDECO in patients with residual function mutations. And in the EU, we expect data this quarter from our Phase III trial of ORKAMBI in children ages 6 through 11 who are homozygous for the F508del mutation. 
If successful, these would represent approximately 5,000 additional patients who may benefit from our approved medicines.
Beyond this important progress, our long-term goal is to treat all people with CF. And during the last year, we have significantly advanced our CF pipeline, which now spans all phases of research and development. Today, we announced the planned initiation of 2 separate Phase II studies of our next-generation correctors, the VX-440 and VX-152 in people with CF. And also a Phase I study of our third next-generation corrector, VX-659 as part of a triple combination. 
These studies represent significant milestones in our efforts to treat as many people with CF as possible, and we'll provide the first safety and clinical efficacy data in patients including het min patients for a triple combination regimen that includes a next-generation corrector. 
We expect to have data from the Phase II studies in the second half of 2017. Additionally, we look forward to obtaining Phase III data for the combination regimen of VX-661, which now carries the generic name Tessa Cather and ivacaftor in the first half of 2017. 
As we entered the fourth quarter of 2016, Vertex is a global biotech company that is discovered and developed 2 breakthrough medicines for people with CF, while broadening our pipeline of future medicines. A significant revenue growth and return to profitability over the past year, our metrics are the kind of company that we are becoming, a company that consistently creates transformative medicines for patients and deliver significant and sustained revenue and earnings growth for our shareholders.
With that, I'll hand the call over to Stuart to discuss the performance of our medicines."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. Tonight, I will review the performance of ORKAMBI, our ongoing efforts to obtain reimbursement in Europe, the label expansion for children ages 6 through 11 in the United States and the outlook for KALYDECO. In the thi",722,"Thanks, Jeff, and hello, everyone. Tonight, I will review the performance of ORKAMBI, our ongoing efforts to obtain reimbursement in Europe, the label expansion for children ages 6 through 11 in the United States and the outlook for KALYDECO. 
In the third quarter, global sales of ORKAMBI were $234 million, comprised of U.S. sales of $211 million and ex-U.S. sales of $23 million.
This quarter, sales in the U.S. declined compared to the second quarter of this year, largely due to a slowing in refills during the summer months of July and August. We're announcing the vast majority of these patients refill their prescriptions. The overall compliance and persistent rates we are observing remain as we outlined earlier in the year. 
During the quarter, patients in the U.S. continue to initiate treatment at a slower rate as we approach peak penetration in the U.S. for patients aged 12 and over. As of the end of September, approximately 6,400 patients in the U.S. have initiated therapy on ORKAMBI.
Last month, we revised our 2016 ORKAMBI revenue guidance to be between $950 million and $990 million for the full year, and we are reiterating that guidance today. The U.S. treatment trends were one reason for the revised guidance. And the other main driver was the ongoing launch in Germany, which has been slower-than-expected. 
As of September 30, approximately 500 of the 2,500 eligible patients have initiated treatment in Germany. We remain confident that they will treat the vast majority of eligible patients over time in Germany, but it will take longer than we had originally anticipated to reach that goal.
In contrast to Germany, we continue to see strong demand in France where approximately 900 of the 1,500 eligible patients have initiated therapy through early access programs as of the end of September. I would note that we are not recognizing revenue for these patients in France until we achieve a formal reimbursement agreement.
Throughout Europe, reimbursement is progressing as anticipated. While there are unique aspects to each process, reimbursement typically falls into 3 phases: A clinical benefit assessment and economic evaluation and price negotiations. In several countries, benefit assessments and economic evaluations are complete. We are pleased that government payers across Europe recognize the severity of this disease and the broad clinical benefits of ORKAMBI. We have now entered the third phase of the reimbursement process, which includes price negotiations in many key countries. While the process takes time to complete, we believe that we will achieve broad reimbursement from key European and other government payers. We expect our first pricing agreement in a major European market to come in Germany this December. 
Pricing and reimbursement approvals for patients eligible for ORKAMBI outside of the U.S. are expected to drive significant revenue growth in 2017.
I will now turn to our recent sNDA approval for ORKAMBI announced last month. We were delighted the FDA approved ORKAMBI for the treatment of children ages 6 to 11 who have 2 copies of the F508del mutation. And since then, we have been working to get the medicine to the approximately 2,400 eligible patients as rapidly as possible. 
Interest in ORKAMBI for this age group has been very high, and our interactions with public and private payers have been productive. We expect broad coverage of ORKAMBI for this patient population as payers have already evaluated the product after approval last year in patients 12 years and older. Thanks to the commitment of health care providers at CF centers across the country, I am pleased to report the first children ages 6 through 11 are already receiving ORKAMBI. We expect the launch to drive revenue growth in the fourth quarter of 2016 and in 2017. 
Turning to KALYDECO. Net revenues for the product were $176 million in the third quarter. We are now treating the vast majority of currently eligible patients and, therefore, we expect this level of quarterly revenues to be maintained in the near term unless KALYDECO is approved in CF patients with residual function mutations. Today, there are approximately 29,000 people eligible for ORKAMBI or KALYDECO globally, yet we are only treating approximately 1/3 of these patients. Therefore, expanding access to both of our medicines for eligible patients around the world is our top priority. 
With that, I'll turn the call over to Jeff Chodakewitz."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stewart. Tonight, I'll review the significant progress we are making with our CF pipeline, and I'll start with the Phase III program of Tessa Cather. We believe the investigation or combination of Tessa Cather and ivacaftor could play an important",973,"Thanks, Stewart. Tonight, I'll review the significant progress we are making with our CF pipeline, and I'll start with the Phase III program of Tessa Cather. We believe the investigation or combination of Tessa Cather and ivacaftor could play an important role in the treatment of people with CF. Enrollment is now complete in the Phase III study in F508del homozygous patients and also in the study in people who have residual function mutations. 
Data from both studies are expected in the first half of 2017.  The Phase III study in people with gating mutations is expected to complete enrollment in early 2017. Pending data from the Phase III program, we plan to submit an NDA in the U.S. for Tessa Cather and ivacaftor in the second half of 2017. I'd like to turn now to the progression of our next-generation correctors and triple combination regimens. 
Our research and development strategy is to advance multiple compounds into development on the basis of our predictive preclinical assays and on Phase I safety studies, so we can choose the best combinations to evaluate in Phase III development. The advancement of VX-440 and VX-512 interface 2 and the selection of VX-6594 for clinical development reflect this strategy. VX-440 and VX-512  will evaluate triple combination dosing for 4 weeks and 2 weeks, respectively, and we'll evaluate both het min and F508del homozygous patients. 
Data from both of these studies are expected in the second half of 2017. The Phase II study of VX-440 includes 3 parts. Each has a different strategic objective, but shares the same primary endpoint of safety and efficacy as measured by absolute change among function. 
Slide 8 of the webcast outlines some of the studies' key features. Part A is focused on helping patients and Part B will enroll F508del homozygous patients. Parts A and B of the study will evaluate triple combination dosing for 4 weeks, and we expect to have the data in the second half of 2017. The potential initiation of Phase III development will depend on these data and discussions with regulatory agencies. 
Part C is designed to generate 12 weeks safety and efficacy data for triple combination dosing in het min patients and will run largely in parallel with potential Phase III development and will evaluate the contribution of the individual components to the overall triple combination regimen.
Slide 9 of our webcast outlines the Phase II study of VX-152. This study includes 2 parts, the primary endpoint of safety and tolerability, but a key focus will also be looking at measures of efficacy, including absolute change in lung function and change in sweat chloride among others. Part A will enroll het min patients and Part B will enroll F508del homozygous patient. 
The VX-152 study will evaluate triple combination dosing for 2 weeks, and data are also expected in the second half of 2017 and are intended to support the potential initiation of a longer duration Phase IIb or registration program, pending data and discussions with regulatory agencies. 
Our Phase I studies in healthy volunteers and other preclinical studies provide support for advancing both VX-440 and VX-152 interface to development and having formed the designs of the Phase II studies we're announcing today. 
Based on Phase I learnings, we believe VX-440 may have a wider therapeutic window, and this is the reason that the VX-440 study will evaluate 4-week dosing from the outset. We also noted in our press release today a specific contraception requirement for females of childbearing potential seeking to enroll in the VX-440 study. This enrollment criterion is based on recent results from preclinical development toxicology studies. Based on laboratory findings from our Phase I study of VX-152, we're also excluding patients with a deficiency from the Phase II studies of VX-152 and also VX-440. 
G6PD deficiency and CF prevalence have limit geographic overlap and, therefore, the incidence of G6PD in the CF population is very low. We estimate this impacts less than 1% of all CF patients overall. 
I will just make a few comments on the in-vitro profile for VX-659, highlighted here on Slide 10. In our HPE assays, the use of a triple combination that contains VX-659 with tezacaftor and ivacaftor resulted in maximal efficacy that was greater than that seen with VX-440 or VX-152 in triple combination. Additionally, VX-659 is highly potent in-vitro, which makes it favorable for a combination with other molecules. 
The Phase I study of VX-659 will be very similar to those we conducted for VX-440 and VX-1523. Pending data from healthy volunteers, we plan to conduct the first evaluation of VX-659 in CF patients as part of the initial Phase I study. We expect to initiate Phase II development for VX-659 in the second half of 2017, pending data from the Phase I study. 
Stepping back from the trial designs, we believe we are in a strong position to define the clinical activity of 3 different next-generation correctors in patients and have data in 2017 that enhance the probability of success for our next-generation corrector program. 
The studies we are conducting with VX-440 and VX-152 could provide data sufficient to move to a pivotal development, accelerating our ability to deliver significant clinical benefits to even more patients than we treat today. I look forward to providing updates on our triple combination regimens as they progress. Before I hand the call over to Ian, did want to mention one additional clinical milestone we expect to achieve before the end of this year. Data from a Phase III efficacy study to support approval for ORKAMBI in children ages 6 to 11 in Europe is expected in the fourth quarter. Pending data from this study, we plan to submit an MAA variation in the EU in the first half of 2017. 
With that, I'll hand the call over to Ian."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and good evening to everyone. As you've heard tonight, we continue to make significant progress across our business. In my remarks today, I'll review our third quarter financial results, review our 2016 financial guidance and discuss our a",550,"Thanks, Jeff, and good evening to everyone. As you've heard tonight, we continue to make significant progress across our business. 
In my remarks today, I'll review our third quarter financial results, review our 2016 financial guidance and discuss our anticipated financial trajectory into 2017 and longer term. 
Financial results first. In the third quarter of 2016, we reported total net CF product revenues of approximately $410 million, growing 38% compared to the third quarter of last year as the number of patients being treated with our medicines significantly increased with the launch of ORKAMBI in July 2015.
Our third quarter non-GAAP operating expenses were $298 million, including R&D expense of $214 million and SG&A expense of $84 million. The increased expenses for the third quarter of 2016 compared to 2015 were primarily the result of increased costs related to the progression of our CF pipeline and increased investments in global commercial support for the launch of ORKAMBI. 
This quarter, we recorded a non-GAAP net profit of $40 million or $0.16 per diluted share compared to a non-GAAP net loss of $32 million or $0.13 per share for the third Quarter in 2015. This turnaround in profit was driven by significant increase in revenues compared to the prior year, which outpaced a smaller increase in non-GAAP operating expenses.
From balance sheet perspective, we ended the third quarter with a strong cash position of $1.1 billion. Additionally, earlier this month, we replaced our $300 million term loan with a credit agreement that will significantly lower our interest expense and increase our available credit up to $800 million, pending certain conditions. 
We will continue to build upon our strong financial position going forward.
Now let's turn to 2016 financial guidance. We are reiterating our 2016 ORKAMBI revenue guidance of $950 million to $990 million. And within this guidance, we expect ORKAMBI revenues to grow from the third quarter to the fourth quarter of 2016 as children's ages 6 through 11 initiate treatment in the U.S. As Stewart mentioned earlier, the initial signs of these patients initiating therapy are encouraging. And as we look into 2017, we see continued growth for ORKAMBI, primarily driven by gaining reimbursement approvals throughout Europe and continuing pediatric launch in the U.S. 
We continue to anticipate 2016 KALYDECO net revenues to be between $685 million and $705 million. As we look forward, into 2017, we do not expect significant revenue growth for KALYDECO. If KALYDECO were to be approved in residual function patients, that would be the only significant driver of growth for KALYDECO in 2017. 
For our operating expenses, we continue to expect our combined non-GAAP R&D and SG&A expenses to be between $1.18 billion and $1.23 billion for the full year. As we look forward to 2017, we anticipate modest growth in operating expenses to support the progression of our CF pipeline and the launch of ORKAMBI in new geographies. 
As we continue to increase the number of patients that we treat, we expect our revenues to grow significantly in the coming years, while operating expenses will only increase modestly. We are well on track to deliver our financial profile that is similar to our large-cap biotech peers, which includes high operating margins, sustainable earnings growth and significant cash generation. 
I'll now open the line to questions."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question comes from the line of Michael Yee of RBC Capital Markets.",16,"[Operator Instructions] Our first question comes from the line of Michael Yee of RBC Capital Markets."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess my question on the next-generation compound is can you talk a little bit about what you mean by therapeutic window for 440 for 152. Talk a little bit about safety and tolerability, what you saw in U.K. Just give a little more color there, that wil",118,"I guess my question on the next-generation compound is can you talk a little bit about what you mean by therapeutic window for 440 for 152. Talk a little bit about safety and tolerability, what you saw in U.K. Just give a little more color there, that will be helpful, between the 2 programs. And then just a commercial question for you is in your guidance that you've given for the year in ORKAMBI, obviously, your launching the 6 to 11-year-olds. What type of cadence or ramp do you expect there? What's in your guidance? Is it a similar ramp to up, given that these are healthy patients. I just want to understand what you're expecting there."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeff Chodakewitz, maybe I'll start talk about the next-gen program. We're excited, as you said, with both molecules progressing into Phase II. We think that based on our Phase I results, we know that given our ability to use our preclinical assays, we can",180,"Jeff Chodakewitz, maybe I'll start talk about the next-gen program. We're excited, as you said, with both molecules progressing into Phase II. We think that based on our Phase I results, we know that given our ability to use our preclinical assays, we can look at the exposure and have a sense of where we're going to get to in the clinic. We think that both compounds are going to go into their Phase II studies with doses that are both going to be well tolerated and efficacious. I think that's very exciting. Maybe just to hone in a little bit on your question about the therapeutic window. That really comes from both compounds are generally well tolerated in VX-152. We did see some GI symptoms, mostly nausea and vomiting, and, therefore, that's the basis for that comment. So for the VX-440, we're going right to 4-week studies with the potential, therefore, to accelerate quickly into a Phase III. And then for 152, because of that, we are starting with Phase II studies and then can extend dosing from there."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Mike, just to address your question on the 6 through 11 launch, obviously, early days. The approval on the 28 of September, so we're less than a month then. But certainly, the early signs are encouraging, and you might expect interested high in using",123,"And Mike, just to address your question on the 6 through 11 launch, obviously, early days. The approval on the 28 of September, so we're less than a month then. But certainly, the early signs are encouraging, and you might expect interested high in using ORKAMBI in this younger patient population. We're making good progress with both public and commercial payers in terms of securing access and already have approval for about 50% of covered lives, which is, obviously, an important prerequisite to getting access to these younger patients. And so as a result of all that, we are expecting a similarly robust update for that, which we saw with ORKAMBI in the 12-plus population. And that's what's incorporates into our overall guidance."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Geoff Meacham from Barclays.",9,"Our next question comes from Geoff Meacham from Barclays."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just had a couple on that for either 440 or 152. Can you talk a little bit about what you're looking for FEV1 just from a powering perspective? And then in either Phase II, is there a washout period for homozygous patients who have had prior exposure to",56,"I just had a couple on that for either 440 or 152. Can you talk a little bit about what you're looking for FEV1 just from a powering perspective? And then in either Phase II, is there a washout period for homozygous patients who have had prior exposure to ORKAMBI? And I have one follow up."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeff, it's Jeff Chodakewitz. So again, I think that as you saw from our Phase II designs, we're really going to be getting a pretty robust look at how both molecules are going to perform. We're really being able to look at both het min patients and homozy",179,"Jeff, it's Jeff Chodakewitz. So again, I think that as you saw from our Phase II designs, we're really going to be getting a pretty robust look at how both molecules are going to perform. We're really being able to look at both het min patients and homozygous patients, which is, I think, very important. And the fact that we think that the doses we're going to be taking into Phase II can deliver benefit for both populations. That's really critical. The -- our Phase II studies are really not so much powered on any individual number. They're really giving us a good handle on being able to understand what the drugs are capable of doing. And to your point, we are going to actually leverage a washout from ORKAMBI, so the people can participate. And we're going to importantly look after the end of dosing because we think that, that follow-up period coming off the treatment actually has been -- can be very informative in terms of having competence in the results. So that gives you a sense."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Got you. Okay. And just real quick. In the past, you guys have talked about between 661 and 809, things like tissue penetration differences, half life  differences. Any way to generally characterize what you would say your difference between 659, 440 and",51,"Got you. Okay. And just real quick. In the past, you guys have talked about between 661 and 809, things like tissue penetration differences, half life  differences. Any way to generally characterize what you would say your difference between 659, 440 and 152, just from a maybe PK or chemistry perspective?"
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Jeff, maybe I'll just take that question. It's frequently asked. There are small differences between compounds. I think the major difference is that they are structurally different.",28,"So Jeff, maybe I'll just take that question. It's frequently asked. There are small differences between compounds. I think the major difference is that they are structurally different."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Terence Flynn of Goldman Sachs.",10,"Our next question comes from Terence Flynn of Goldman Sachs."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe 2 for me. Just on the second gen correctors, can you give us any insight in terms of the dose limiting tox in the animal models? Was the G.I. seen there? And then on 440, just wondering some more details on the design of Part C of that trial. Was wo",72,"Maybe 2 for me. Just on the second gen correctors, can you give us any insight in terms of the dose limiting tox in the animal models? Was the G.I. seen there? And then on 440, just wondering some more details on the design of Part C of that trial. Was wondering if you have regulatory sign off to run that as part of Phase II rather than include in Phase III."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So I think in terms of our Phase I, I think I've given you actually kind of flavor on what we've seen with -- in the healthy volunteers, good tolerability overall. I mentioned the nausea and vomiting. I should clarify that, that was at doses -- that was o",107,"So I think in terms of our Phase I, I think I've given you actually kind of flavor on what we've seen with -- in the healthy volunteers, good tolerability overall. I mentioned the nausea and vomiting. I should clarify that, that was at doses -- that was observed at doses higher than the doses that we're going to be taking into Phase II. That's how we think about being sure that we have a therapeutic window. In terms of preclinical data, I really can't comment on that level of detail. And, of course, everything we do as we go forward, we'll be conferring with regulatory agencies."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And on the 440 Part C?.",7,"Okay. And on the 440 Part C?."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I'm sorry. I guess I was. As far as, I was going to that part of your question. We can't comment on the individual discussions we're having with regulatory agencies. I think to your -- as we talked about that, that is good as accomplished several things.",94,"I'm sorry. I guess I was. As far as, I was going to that part of your question. We can't comment on the individual discussions we're having with regulatory agencies. I think to your -- as we talked about that, that is good as accomplished several things. It's going to help us understand the performance of the triple. It's importantly to give us data on 12 weeks of dosing. And depending on the results that we're seeing, as we said, this data actually could be  done basically in parallel with Phase III study."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. Is that the triple versus each of the subcomponent versus each mono of each of the 3 drugs? Or is it versus a doublet?",25,"Okay. Is that the triple versus each of the subcomponent versus each mono of each of the 3 drugs? Or is it versus a doublet?"
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","No. It's really be primarily about triple versus doublet.",9,"No. It's really be primarily about triple versus doublet."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Yin Huang of Bank of America.",11,"Our next question comes from Yin Huang of Bank of America."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","It's great to hear the Phase II advancing for another new corrector. So maybe for you, you mentioned that 6,400 parotid patients now have started treatment in U.S. for ORKAMBI. Now at least about another 2,000 patients. Is there a reason we should think o",120,"It's great to hear the Phase II advancing for another new corrector. So maybe for you, you mentioned that 6,400 parotid patients now have started treatment in U.S. for ORKAMBI. Now at least about another 2,000 patients. Is there a reason we should think of why those 2,000 patients will not initiate therapy if that's possible? And then secondly, I have a question on maybe Jeff on the Phase II protocols for these 2 molecules. Do you think as what we have seen with the KALYDECO in G551, patients and and F508del homozygous fibroid patients 2 weeks or even 4 weeks should be long enough to see a significant improvement in lung function, given that these patients have mutations?"
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks for the question. Yes, over 6,400 patients have initiated therapy on ORKAMBI and were obviously delighted with that. It's over 70% of the eligible patients. But as you said, that means that 2,000 are yet to be initiated. Obviously, the individual d",119,"Thanks for the question. Yes, over 6,400 patients have initiated therapy on ORKAMBI and were obviously delighted with that. It's over 70% of the eligible patients. But as you said, that means that 2,000 are yet to be initiated. Obviously, the individual decisions about whether a physician and patient want to initiate therapy is one that they have to come to themselves, but we're certainly continuing to see new patients being initiated as we deliver and develop more evidence about the long-term benefit of ORKAMBI. I think that's giving physicians and patients even more reasons to think about whether they want to be initiated it on ORKAMBI. And on the Phase II question, I'll hand it over to Jeff."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart. I, as you know, we obviously don't have data yet for the triple. But everything that we've seen across our portfolio, it's modulating CFTR really suggest that both the 2-week and the 4-week studies are going to be able to give us valuable",52,"Thanks, Stuart. I, as you know, we obviously don't have data yet for the triple. But everything that we've seen across our portfolio, it's modulating CFTR really suggest that both the 2-week and the 4-week studies are going to be able to give us valuable insights into potential efficacy of the regiment."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Alethia Young from Crdit Suisse.",10,"Our next question comes from Alethia Young from Crdit Suisse."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congrats on the progress in Phase II. On the corrector front, with some of these new correctors, I guess how do you  thing broadly about positioning in these assets? And like with the 440 and 152 compounds, what you think both into Phase III? And then I h",52,"Congrats on the progress in Phase II. On the corrector front, with some of these new correctors, I guess how do you  thing broadly about positioning in these assets? And like with the 440 and 152 compounds, what you think both into Phase III? And then I have one question about Europe."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Leiden. That's more of a strategy question, so maybe I'll take that. And first of all, I'll just remind you that our strategy all along has been to develop a portfolio of next-generation correctors really for 2 reasons: one, they do have differe",251,"It's Jeff Leiden. That's more of a strategy question, so maybe I'll take that. And first of all, I'll just remind you that our strategy all along has been to develop a portfolio of next-generation correctors really for 2 reasons: one, they do have different properties. They come in different flavors and we really want to see those different favors and people in understand how they perform; And two, there's a probability of success issue here, right. By bringing 3 or 4 of these different correctors into Phase I and now in this case, Phase II studies, it increases the probability of its success that will come up with the best regiments for each of the patient population. And while we can predict an awful lot from our preclinical study based assays predictive quite well on the efficacy front, as a couple of folks know that before they can be differences in potency and maximal efficacy in drug-like properties, and those are best seen really from these Phase I and Phase II. Trials and we're learning a lot as we go about these different molecules. Would we ever take 2 molecules into Phase III development? It's absolutely possible just as you've seen with lumacaftor and 661, 2 first generation correctors because they may also have different protocols and profile. It's just going to depend on the data that we see from these Phase II studies. But I think the important thing is to strategy we're taking is this portfolio strategies."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Great. And then on Europe, for Stewart perhaps. Maybe with some of the reimbursement conversations, do you find them kind of a different flavor as you go to each country? Is there kind of similar themes on what kind of players are you going to concerned a",49,"Great. And then on Europe, for Stewart perhaps. Maybe with some of the reimbursement conversations, do you find them kind of a different flavor as you go to each country? Is there kind of similar themes on what kind of players are you going to concerned about for ORKAMBI?"
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, I'd say the concerns and questions that we get, a leap year, are very consistent. As we've said a number of times, well, each process is different. They tend to kind of work themselves around 3 phases. One is in discussion with the clinical benefits",145,"Yes, I'd say the concerns and questions that we get, a leap year, are very consistent. As we've said a number of times, well, each process is different. They tend to kind of work themselves around 3 phases. One is in discussion with the clinical benefits of ORKAMBI. And in general, we've been very pleased that payers across Europe had recognized the broad clinical benefits of ORKAMBI. Then there is an economic evaluation. And after that phase, you enter into the price negotiation. And so while each process is different in each a different country, the tend to follow that same pattern and they are going to proceed as we anticipated. And I said the last thing is in addition to evaluating the clinical benefits an economic perspective, they are concerned about the overall budget impact if they are for them in their individual country."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Brian Abrams of Jefferies.",9,"Our next question comes from Brian Abrams of Jefferies."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","My progress for the next-gen correctors. Two questions. First of all, I was wondering if you might be able to extend upon the comments you made regarding preclinical toxic studies that led you to include contraception and exclude the PD patients for the 4",99,"My progress for the next-gen correctors. Two questions. First of all, I was wondering if you might be able to extend upon the comments you made regarding preclinical toxic studies that led you to include contraception and exclude the PD patients for the 440 study? Was that something just related to a hormonal interaction? And then on the commercial side, I realize this is very early days, but I'm just wondering if you had any sense of compliance and persistence, at least compliance, in the 6 to 11-year-old patients relative to what you've seen in adults thus far?"
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Brian, it's Jeff Chodakewitz. I'll start and then turn it over. I just want to be sure I understand your question. For the preclinical data for 440 in subject, I believe there are a set of standards that are done actually in rabbits and we test the develo",118,"Brian, it's Jeff Chodakewitz. I'll start and then turn it over. I just want to be sure I understand your question. For the preclinical data for 440 in subject, I believe there are a set of standards that are done actually in rabbits and we test the development toxicity, the effects of the drug. And we did sign for the X440 that there were some abnormalities suggesting a potential spec on the fetus. We don't know whether that actually translates to people, but the prudent thing to do clearly is to ensure that women in this study are using effective contraception and that's what we flat that we'll be doing that in our Phase II study with VX-440."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And on your compliance question. As you say, it's very early days yet. We're just 1 month into the launch in the 6 to 11-year-old children. However, I think there are some reasons to be optimistic that the compliance rate there could be higher than we see",101,"And on your compliance question. As you say, it's very early days yet. We're just 1 month into the launch in the 6 to 11-year-old children. However, I think there are some reasons to be optimistic that the compliance rate there could be higher than we see in teenagers and in young adults. Certainly, that's what we've seen with KALYDECO, and that's not atypical for what you see in other chronic diseases where clearly these young kids are largely or exclusively under the supervision of their parents and, therefore, compliance rates tend to be at the higher end of the spectrum."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have 2 things that I just wanted to ask. So, I guess, both on next-generation correctors.   One, can you just compare and contrast what you would expect to learn from 2 weeks of dosing versus 4 weeks of dosing. And how you would correlate whatever signa",85,"I have 2 things that I just wanted to ask. So, I guess, both on next-generation correctors.   One, can you just compare and contrast what you would expect to learn from 2 weeks of dosing versus 4 weeks of dosing. And how you would correlate whatever signals you're going to get out of that to how you might move those compounds ahead. And then second, can you just tell us the dose levels of 152 and 440 that you're using in these Phase II studies?"
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Matthew, Jeff Chodakewitz. So let me talk about the 2 and 4 weeks [ph] because we're actually going to have very similar end point in both. And as we spoke about earlier, actually, we think that both 2 and 4 weeks are going to be able to give us meaningfu",224,"Matthew, Jeff Chodakewitz. So let me talk about the 2 and 4 weeks [ph] because we're actually going to have very similar end point in both. And as we spoke about earlier, actually, we think that both 2 and 4 weeks are going to be able to give us meaningful information. We're also going to have some chloride being evaluated in both drugs, which are also to be valuable. Ultimately, what we're going to do is use all the information. We actually also have a lot of work being done to actually understand from a modeling perspective, so that we can get the absolute most information out of our clinical trial. And so we're going to use all that information across both to make the best decisions, and we think that, that will contribute to both. I think in terms of the specifics of the doses, as you may see in the design, we're going to go into patients with a small cohort. It's really just confirm that, that exposure is the same in patients as it is in healthy volunteers. We don't have any reason to think that it will be different, but we're going to do that just to be sure we're taking the right approach. And then we'll choose our doses from there to confirm for the rest of the trial."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Geoffrey Porges of Leerink Partners.",10,"Our next question comes from Geoffrey Porges of Leerink Partners."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congratulations on advancing some more CF compound. First, I'm just wondering if on Slide 10, you could tell us where 152 pivot compared to 440 in lumacaftor in that assay? And then a couple of commercial questions. Ian, you've been fairly clear about wha",173,"Congratulations on advancing some more CF compound. First, I'm just wondering if on Slide 10, you could tell us where 152 pivot compared to 440 in lumacaftor in that assay? And then a couple of commercial questions. Ian, you've been fairly clear about what we should be expecting for KALYDECO in 2017 and there's certainly been some ups and downs in both consensus and in guidance this year for ORKAMBI. So I'm wondering where you would suggest that we sort of should be bracketing for next year for ORKAMBI. There are certainly a lot of variables with Europe with the pediatric indication coming online in the U.S. So that would be helpful.  And then, Stewart, lastly, as you're negotiating price in Europe, could you give us a sense of how you're thinking about having a portfolio of CF combination? Are you expecting to have them at different price points? Or should we be thinking that over time, they gravitate towards a band, regardless of whether it's 2 or 3 drugs in the combination?"
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is David Altshuler. I'll take the first part. As we showed last year in the het min cells and also homozygous cells, 152 and 440 have very similar levels of mass efficacy.",33,"This is David Altshuler. I'll take the first part. As we showed last year in the het min cells and also homozygous cells, 152 and 440 have very similar levels of mass efficacy."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Jeff, 2 question on guidance. I was very clear on KALYDECO in my prepared remarks where KALYDECO is treating approximately 90% [ph] of eligible patients that has a very good persistence rate and compliance rate, and we'd anticipate that continuing on",303,"And Jeff, 2 question on guidance. I was very clear on KALYDECO in my prepared remarks where KALYDECO is treating approximately 90% [ph] of eligible patients that has a very good persistence rate and compliance rate, and we'd anticipate that continuing on into next year. So as you see, the current quarterly run rate for KALYDECO, we see that continuing on in 2017. The market that's potentially increasing would be -- if we were able to gather residual function approval. And as Jeff Chodakewitz explained, we are currently in discussions with the regulatory authorities in the U.S. regarding that approval and that continues that discussion. Regarding ORKAMBI, it's still too early to say. We're very comfortable with the guidance we provided through the end of this year of $950 million to $990 million, and that does include that the recent pediatric approval. As we look to 2017, we'll probably thinking about how we give guidance around the U.S. market and maybe Germany as well because we do have the visibility and knowledge to those markets. In terms of the other international markets and how quickly the time they come on, we just need to give that in the next few months of whether we actually try to provide a bracket around that guidance. There is a certain unknown element, but I'm sure you can only appreciate with these discussions. And sometimes the discussions push out because you are actually holding out for a price that you believe is appropriate for the medicine. And so it's about us getting to the right spots. And rather than putting lighting provide guidance, will give you some consideration of how we put a bracket around that and will get back to you early in 2017. And then to your third question, I'll pass it over to Stuart."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Jeff, in terms of pricing principles, obviously, we can't comment on the pricing of key chip product, but I'll talk to our pricing principles over all which have been very consistent for how we price KALYDECO and ORKAMBI and the 2 primary drivers are real",169,"Jeff, in terms of pricing principles, obviously, we can't comment on the pricing of key chip product, but I'll talk to our pricing principles over all which have been very consistent for how we price KALYDECO and ORKAMBI and the 2 primary drivers are really the number of patients that were able to benefit with our medicines and then the level of clinical benefit or value that we're able to bring. I think you've seen that we've adhered to those principles with ORKAMBI. And while we don't have formal pricing agreements in place across Europe yet, you have seen with the list price of ORKAMBI where they are lower than they are for KALYDECO, which reflects the fact that clearly ORKAMBI had a much wider eligible patient population despite the fact that, that medicine has in 2 different components within it. So I think you can expect that we'll be adhering to those pricing principles as we bring Next-Gen correctors and other medicines to market for eligible CF patients."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from John Scotty of Evercore ISI.",10,"Our next question comes from John Scotty of Evercore ISI."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just want to ask on VX-659. If you were to compare the preclinical toxicity profile of that asset to 440 with regard to what potential, et cetera, and then 152  with the nausea, are you confident that the chemical structure of 659 is different enough wh",119,"I just want to ask on VX-659. If you were to compare the preclinical toxicity profile of that asset to 440 with regard to what potential, et cetera, and then 152  with the nausea, are you confident that the chemical structure of 659 is different enough where we won't see those issues in humans in the clinic with regard to what we see with 440 and 152? And then, I guess, just quickly on timing. Given the trials are small and if we assume they enroll quickly, is it unreasonable to assume that we can see data more towards the next year rather than towards the end of the year? I know you've got to this, but [indiscernible]"
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","First of all, I want to pass on the best wishes to Mark and we'll proceed getting the market some points, and I'm sure I share everybody else's thoughts that are on the phone. In terms of the question, I'm just going to ask Jeff Leiden to answer it becaus",87,"First of all, I want to pass on the best wishes to Mark and we'll proceed getting the market some points, and I'm sure I share everybody else's thoughts that are on the phone. In terms of the question, I'm just going to ask Jeff Leiden to answer it because there is a whole portfolio approach here that we have, starting from 659. And the methodology of how we probably pick on molecules and monthly basis is. And you should anticipate this more modules coming. So, okay."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for the question, John. Maybe just to go back one step and remind you of how we look at these molecules and select them. The first real test with molecules is our human cells, both het min cells and homozygous cells from multiple donors. And a",355,"Yes, thanks for the question, John. Maybe just to go back one step and remind you of how we look at these molecules and select them. The first real test with molecules is our human cells, both het min cells and homozygous cells from multiple donors. And as we showed you, I think in one of the slides today, 659 actually has efficacy as measured by chloride TRANSPORT, which is significantly higher than what we were seeing 4440 and 152, which were also quite high by themselves, by the way. We've also measured the number of other things in that assay like frequency and others, and we see the same kind of difference between 659 and 440. We've entered the molecules through a pretty rigorous screen with respect to PK, tox, coformula availability, really making sure that we're bringing drugs in the clinic as opposed to molecules. And we're done with most but not all of that for 659. We're recently with, so we feel very comfortable that we have a tox profile and a PK profile that we're confident and take the interface I studies, both in normal and in patients as well. And we have not done yet with the developmental studies in rabbits, and we don't have that data yet. And, obviously, we don't have any human data, which is the final test of Pk and safety, and we always do that from the Phase I study. In addition, just as Ian mentioned, just need to be clear expectations, we have a number of other next-gen correctors in our late clinical pipeline. We expect to bring at least one of those forward into the clinic in the first half of next year and maybe more. And the reason for that again is that these molecules come in a number of different flavors, different potencies, different properties, and we want to bring multiple of them into humans as part of triple combinations to understand how to interact. I hope that gives you a flavor of where 659 fits and what we know and some things we don't yet know, but we'll know soon."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Brian Skorney of Robert W. Baird.",14,"Our next question comes from the line of Brian Skorney of Robert W. Baird."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have 2 questions. I guess, why both -- why start both programs in het min? It seems like a potentially get more information out of adding this on top of 661 ivacaftor in patients with 2 F508del alleles. Also, when we look at the relative differences  in",80,"I have 2 questions. I guess, why both -- why start both programs in het min? It seems like a potentially get more information out of adding this on top of 661 ivacaftor in patients with 2 F508del alleles. Also, when we look at the relative differences  in the 4 generations, is that reasonable to assume that 2 correctors within the same generations still are redundant? And is there any obvious redundancy to cross combining correctors of this different generations?"
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Brian, it's Jeff again. Let me answer both  really good questions. Maybe I'll answer your second question first. Really, the portfolio of production is based upon the fact that while the molecules may bind to the same, may even have the same mechanism of",182,"Brian, it's Jeff again. Let me answer both  really good questions. Maybe I'll answer your second question first. Really, the portfolio of production is based upon the fact that while the molecules may bind to the same, may even have the same mechanism of action, there are obviously a number of other properties that are going to be really important in taking the best regimen. They include potency. The customer posted the molecule is, these are combined to a triple combination of. They include maximal efficacy, obviously, and we showed you the 659 as an example of how is greater maximal efficacy. But they also include things like PK properties, tissue penetration, drug interactions, all of those things. And so when you think about this portfolio, think about it, not only in terms of mechanism of fashion and, not only in terms of efficacy and potency, but think about it as how do we create the best triple regimen with one or more of these molecules going forward. Does that makes sense to you in terms of how we thinking about it?"
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, that is helpful.",4,"Yes, that is helpful."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And then repeat your first question for me.Just on the strategy het min first.",15,"And then repeat your first question for me.
Just on the strategy het min first."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. So just to be clear about what we're doing here. First of all, het min, obviously, is the big group of patients with the largest unmet need. And so as we think about taking these molecules forward, that's the patient operation that we're most focused",218,"Yes. So just to be clear about what we're doing here. First of all, het min, obviously, is the big group of patients with the largest unmet need. And so as we think about taking these molecules forward, that's the patient operation that we're most focused on. But I do want to be clear that we're essentially doing these things in parallel, and so you will have results, both in the administration population and the Homozygous Population essentially at the same time and with very little delay. And that's going to let us we designed the best Phase III study, I think, here. One of the things I've really been pleased with over the last 4 or 5 years is as we develop these molecules, we've learned an awful lot about how to take the development forward most quickly, most efficiently and then how to start to think about these trials Phase III trials perhaps a little differently. And so I do think you're seeing the results of that here as we sort of streamline these Phase II trials, do them in parallel as opposed to in theories as recess we've done them in the past. And then, hopefully, based on the results, of course, launch into Phase III in a much broader fashion than we've done previously."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the subway go off JMP Securities.",11,"Our next question comes from the subway go off JMP Securities."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And just to clarify, this well-intention to formulate maybe a quad or something you wouldn't add in some of your next-generation correctors together? And, I guess, why not would be the question.",32,"And just to clarify, this well-intention to formulate maybe a quad or something you wouldn't add in some of your next-generation correctors together? And, I guess, why not would be the question."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, as a theoretical question, Lisa, of course, we will talk about quad. And as you know, we're also looking at some other of fashion things like inhibitors that can be combined. So there's nothing that we wouldn't look for in drug combinations. Obviousl",106,"Yes, as a theoretical question, Lisa, of course, we will talk about quad. And as you know, we're also looking at some other of fashion things like inhibitors that can be combined. So there's nothing that we wouldn't look for in drug combinations. Obviously, the ENaC inhibitor is inhaled, so it wouldn't be formulated. But I do think there's one difference here that's worth mentioning. I think it would be unlikely that, for instance, that we put 152 and 440 together because they do appear to have the same mechanism of action, so adding them together would be not expected to produce a lot more [indiscernible]"
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And then can you maybe talk about where you're going to be enrolling patients for some of these pulmonary phase for the next generation? Is it going to be North America, ex-U.S.?",33,"Okay. And then can you maybe talk about where you're going to be enrolling patients for some of these pulmonary phase for the next generation? Is it going to be North America, ex-U.S.?"
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Chodakewitz. We're actually going to be doing studies in size both in the U.S. and in Europe.",20,"It's Jeff Chodakewitz. We're actually going to be doing studies in size both in the U.S. and in Europe."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. Great. And then just wanted to get a little bit more clarity on the hormonal component. I think you maybe talked about this earlier before VX-440 and what you've seen there in your preclinical stuff. And then what that would just mean we do just go",48,"Okay. Great. And then just wanted to get a little bit more clarity on the hormonal component. I think you maybe talked about this earlier before VX-440 and what you've seen there in your preclinical stuff. And then what that would just mean we do just go forward."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. This is Jeff Chodakewitz again. So just to clarify perhaps. We've already talked about the rapid toxicity and why we're putting the contraceptive language in place. The hormonal word actually come from 3 critical studies. With the X440 higher doses,",82,"Sure. This is Jeff Chodakewitz again. So just to clarify perhaps. We've already talked about the rapid toxicity and why we're putting the contraceptive language in place. The hormonal word actually come from 3 critical studies. With the X440 higher doses, there was some evidence of liver enzyme production, and that can actually somewhat lower the exposure to the hormones in the contraceptives. And so, therefore, again to ensure that we're using reliable contraception, we're excluding that as being the primary method."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Tony Butler of Guggenheim Partners.",10,"Our next question comes from Tony Butler of Guggenheim Partners."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","2 questions previously  in Cohort 1a, can you help me understand the notion of using the low-dose first before you move forward. While it may be intuitive, you don't do that for 152. And then the second question is really around 152. To me, you'd outlined",74,"2 questions previously  in Cohort 1a, can you help me understand the notion of using the low-dose first before you move forward. While it may be intuitive, you don't do that for 152. And then the second question is really around 152. To me, you'd outlined very well the portfolio strategy why certainly moving forward with 440 and 659, but is the only reason for 152  the fact that it does not have the"
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Tony, it's Jeff Chodakewitz. So 2 comments. One, the 1A, as we go back to sort of the prior conversations, the intent of 1A is to go make the transition from healthy volunteers to patients and be sure the exposure is similar in the 2 groups. And since it",179,"Tony, it's Jeff Chodakewitz. So 2 comments. One, the 1A, as we go back to sort of the prior conversations, the intent of 1A is to go make the transition from healthy volunteers to patients and be sure the exposure is similar in the 2 groups. And since it could potentially go up or down, although we don't expect it to do either, that's why you wouldn't want to go in at a high dose and then have the exposure actually end up higher. That's why we always would start in that kind of situation with the low-dose and then expand, which is the intent. In terms of your broader question about VX-152 and VX-440, I think it goes back to Jeff Leiden's comment, but we think both molecules will have the potential to be well-tolerated at doses that can deliver benefit to patients, including excitingly, both homozygous patients and het min mutation that don't have a treatment option. And that's why we're taking both forward and will continues to learn as we add other molecules to our portfolio."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Michael Partridge. We have time for one more question.",11,"This is Michael Partridge. We have time for one more question."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And that question comes from the Alan Carr of Needham & Company.",11,"And that question comes from the Alan Carr of Needham & Company."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I wanted to clarify a bit some of the timing around 152 440 and the results from those and the results from your 659 Phase II. Are you trying to -- are you able to position these 3 data from 3 Phase II trials at the same time in order to decide which one",61,"I wanted to clarify a bit some of the timing around 152 440 and the results from those and the results from your 659 Phase II. Are you trying to -- are you able to position these 3 data from 3 Phase II trials at the same time in order to decide which one or 2 to bring into Phase III?"
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Allen, it's Jeff Chodakewitz. Let me just review how that winds up. Of course, in the end, all the timelines, particularly the Phase II studies, are going to be dependent on the rate of [indiscernible]. But what we expect would be that for both VX-152",121,"So Allen, it's Jeff Chodakewitz. Let me just review how that winds up. Of course, in the end, all the timelines, particularly the Phase II studies, are going to be dependent on the rate of [indiscernible]. But what we expect would be that for both VX-152 and VX-440 is that we will be getting results, as we said, in the second half of '17. At that point, we will also have the Phase I results from VX-659 as we've talked about. That's given everything we've learned about the relationship from preclinical to exposure to benefit to patients. We think that we will be able to understand a lot all 3 compounds as we're looking forward to make decisions at that point."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff Leiden. I just want to be clear that we don't think about 65  as being can exactly at the same time frame as  152 and 440. And as Jeff said, it's a little early to give you precision because it depends on how patients enrolled 659 and we'll o",132,"This is Jeff Leiden. I just want to be clear that we don't think about 65  as being can exactly at the same time frame as  152 and 440. And as Jeff said, it's a little early to give you precision because it depends on how patients enrolled 659 and we'll only have a small cohort of patients into Phase I, and so let's see what we learn from that. But if you would ask me just to put a sort of marker on the table, I think that 659 myself is about 6 months behind 152 and 440. So we're not going to be waiting, obviously, if we see positive results with both 152 and 440 before taking those into Phase III to wait for 659, if that's really the question."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, Okay. That helps. And then one other one. I guess can you give us an update on 371? Where do you think it stand with your CF program and ancillary there?",32,"Yes, Okay. That helps. And then one other one. I guess can you give us an update on 371? Where do you think it stand with your CF program and ancillary there?"
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So it's Jeff Chodakewitz. Both of our studies, both the study in CF where we're looking at the ENaC inhibitor on top of ORKAMBI and in piece for homozygous for F508del and the study in patients with PCD, both are actively enrolled.",43,"So it's Jeff Chodakewitz. Both of our studies, both the study in CF where we're looking at the ENaC inhibitor on top of ORKAMBI and in piece for homozygous for F508del and the study in patients with PCD, both are actively enrolled."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And timing for results, what's the latest on that?",9,"And timing for results, what's the latest on that?"
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's always going to be -- of course, until we end up getting the study fully enrolled, it's just too hard to give you any precision on point.",29,"It's always going to be -- of course, until we end up getting the study fully enrolled, it's just too hard to give you any precision on point."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay. Everybody, thanks for joining us tonight. For those of you who are going to the North American CF Conference, we look forward to seeing you there on first tonight this week. We will also be webcast our presentation there starting at 6:30 p.m. Easter",66,"Okay. Everybody, thanks for joining us tonight. For those of you who are going to the North American CF Conference, we look forward to seeing you there on first tonight this week. We will also be webcast our presentation there starting at 6:30 p.m. Eastern Time on Thursday. Tonight, the Investor Relations team will remain at the office if you have any additional questions. Thank you."
36235,404123072,1060693,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, that does conclude your call. You may disconnect at this time. Have a great day.",18,"Ladies and gentlemen, that does conclude your call. You may disconnect at this time. Have a great day."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening. This is Michael Partridge, Vice President of Investor Relations. Welcome to our Third Quarter 2016 Financial Results Conference Call. [Operator Instructions] This conference call is recorded, and there will be a replay available later tonigh",182,"Good evening. This is Michael Partridge, Vice President of Investor Relations. Welcome to our Third Quarter 2016 Financial Results Conference Call. [Operator Instructions] This conference call is recorded, and there will be a replay available later tonight. You can access the webcast live by going to our website. Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; Dr. Jeff Chodakewitz, Chief Medical Officer; and Ian Smith, Chief Financial Officer, will provide prepared remarks on this call. They will be joined by Dr. David Altshuler, Chief Scientific Officer, for the Q&A portion of the call. 
We will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the SEC. These statements, including without limitation, those regarding the ongoing development and potential commercialization of our drug candidates, our expectations regarding our approved medicines and Vertex' future financial performance are based on management's current assumptions. Actual outcomes and events 
[Audio Gap]
I will now turn the call over to Dr. Jeff Leiden."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. Vertex' strategy in cystic fibrosis is to treat as many people with CF as possible and to continue to enhance the clinical benefits for those treated by our medicines. Our long-term goal is to reduce the progressiv",556,"Thanks, Michael. Good evening, everyone. Vertex' strategy in cystic fibrosis is to treat as many people with CF as possible and to continue to enhance the clinical benefits for those treated by our medicines. Our long-term goal is to reduce the progressive and irreversible effects of CF by treating underlying cause of the disease. 
There are 3 key components to our strategy. First, to increase the number of eligible patients being treated with our approved medicines, mainly by obtaining reimbursement for ORKAMBI for more patients outside the U.S.; second, to further expand the labels for KALYDECO and ORKAMBI around the world; and third, to develop new combination regimens of CFTR modulators designed to enhance benefit for all patients. 
This evening, I'm pleased to report that we continue to make excellent progress on all of these fronts. Last month, the FDA approved ORKAMBI for the treatment of children with CF, ages 6 through 11, who have 2 copies of the F508del mutation. With this approval, approximately 29,000 patients worldwide are now eligible for our medicines. 
Today, we are treating approximately 9,000 of these 29,000 eligible patients. Moving forward, we remain focused on expanding access to ORKAMBI and KALYDECO for the many eligible patients who are still awaiting treatment, largely through obtaining reimbursement for ORKAMBI in Europe, Canada and Australia.
We are also continuing to make progress in our efforts to expand the labels for KALYDECO and ORKAMBI. In the U.S., we are focused on obtaining approval for KALYDECO in patients with residual function mutations. And in the EU, we expect data this quarter from our Phase III trial of ORKAMBI in children ages 6 through 11 who are homozygous for the F508del mutation. If successful, these would represent approximately 5,000 additional patients who may benefit from our approved medicines.
Beyond this important progress, our long-term goal is to treat all people with CF. During the last year, we have significantly advanced our CF pipeline, which now spans all phases of research and development. Today, we announced the planned initiation of 2 separate Phase II studies of our next-generation correctors, VX-440 and VX-152 in people with CF. And also a Phase I study of a third next-generation corrector, VX-659 as part of a triple combination.
These studies represent significant milestones in our efforts to treat as many people with CF as possible, and we'll provide the first safety and clinical efficacy data in patients, including het min patients for a triple combination regimen that includes a next-generation corrector. 
We expect to have data from the Phase II studies in the second half of 2017. Additionally, we look forward to obtaining Phase III data for the combination regimen of VX-661, which now carries the generic name tezacaftor and ivacaftor in the first half of 2017. 
As we entered the fourth quarter of 2016, Vertex is a global biotech company that has discovered and developed 2 breakthrough medicines for people with CF, while broadening our pipeline of future medicines. Our [ph] significant revenue growth and return to profitability over the past year, our metrics of the kind of company that we are becoming, a company that consistently creates transformative medicines for patients and deliver significant and sustained revenue and earnings growth for our shareholders.
With that, I'll hand the call over to Stuart to discuss the performance of our medicines."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. Tonight, I will review the performance of ORKAMBI, our ongoing efforts to obtain reimbursement in Europe, the label expansion for children ages 6 through 11 in the United States and the outlook for KALYDECO. In the thi",726,"Thanks, Jeff, and hello, everyone. Tonight, I will review the performance of ORKAMBI, our ongoing efforts to obtain reimbursement in Europe, the label expansion for children ages 6 through 11 in the United States and the outlook for KALYDECO. 
In the third quarter, global sales of ORKAMBI were $234 million, comprised of U.S. sales of $211 million and ex U.S. sales of $23 million.
This quarter, sales in the U.S. declined compared to the second quarter of this year, largely due to a slowing in refills during the summer months of July and August. We have now seen the vast majority of these patients refill their prescriptions. The overall compliance and persistence rates we are observing remain as we outlined earlier in the year. 
During the quarter, patients in the U.S. continue to initiate treatment at a slower rate as we approach peak penetration in the U.S. for patients age 12 and over. As of the end of September, approximately 6,400 patients in the U.S. have initiated therapy on ORKAMBI.
Last month, we revised our 2016 ORKAMBI revenue guidance to be between $950 million and $990 million for the full year, and we are reiterating that guidance today. U.S. treatment trends were one reason for the revised guidance. And the other main driver was the ongoing launch in Germany, which has been slower than expected. 
As of September 30, approximately 500 of the 2,500 eligible patients have initiated treatment in Germany. We remain confident that we will treat the vast majority of eligible patients over time in Germany, but it will take longer than we had originally anticipated to reach that goal.
In contrast to Germany, we continue to see strong demand in France, where approximately 900 of the 1,500 eligible patients have initiated therapy through early access programs as of the end of September. I would note that we are not recognizing revenue for these patients in France until we achieve a formal reimbursement agreement.
Throughout Europe, reimbursement is progressing as anticipated. While there are unique aspects to each process, reimbursement typically falls into 3 phases: A clinical benefit assessment and economic evaluation and price negotiations. In several countries, benefit assessments and economic evaluations are complete. We are pleased that government payers across Europe recognize the severity of this disease and the broad clinical benefits of ORKAMBI. We have now entered the third phase of the reimbursement process, which includes price negotiations in many key countries. While the process takes time to complete, we believe that we will achieve broad reimbursement from key European and other government payers. We expect our first pricing agreement in a major European market to come in Germany this December. 
Pricing and reimbursement approvals for patients eligible for ORKAMBI outside of the U.S. are expected to drive significant revenue growth in 2017.
I will now turn to our recent sNDA approval for ORKAMBI announced last month. We were delighted the FDA approved ORKAMBI for the treatment of children ages 6 to 11 who have 2 copies of the F508del mutation. And since then, we have been working to get the medicine to the approximately 2,400 eligible patients as rapidly as possible. 
Interest in ORKAMBI for this age group has been very high, and our interactions with public and private payers have been productive. We expect broad coverage of ORKAMBI for this patient population as payers have already evaluated the product after approval last year in patients 12 years and older. Thanks to the commitment of health care providers at CF centers across the country. I am pleased to report the first children, ages 6 through 11, are already receiving ORKAMBI. We expect the launch to drive revenue growth in the fourth quarter of 2016 and in 2017. 
Turning to KALYDECO. Net revenues for the product were $176 million in the third quarter. We are now treating the vast majority of currently eligible patients and, therefore, we expect this level of quarterly revenues to be maintained in the near term unless KALYDECO is approved in CF patients with residual function mutations. Today, there are approximately 29,000 people eligible for ORKAMBI or KALYDECO globally, yet we are only treating approximately 1/3 of these patients. Therefore, expanding access to both of our medicines for eligible patients around the world is our top priority. 
With that, I'll turn the call over to Jeff Chodakewitz."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart. Tonight, I'll review the significant progress we are making with our CF pipeline, and I'll start with the Phase III program of tezacaftor. We believe the investigation or combination of tezacaftor and ivacaftor could play an important role",973,"Thanks, Stuart. Tonight, I'll review the significant progress we are making with our CF pipeline, and I'll start with the Phase III program of tezacaftor. We believe the investigation or combination of tezacaftor and ivacaftor could play an important role in the treatment of people with CF. Enrollment is now complete in the Phase III study in F508del homozygous patients, and also in the study in people who have residual function mutations. 
Data from both studies are expected in the first half of 2017. The Phase III study in people with gating mutations is expected to complete enrollment in early 2017. Pending data from the Phase III program, we plan to submit an NDA in the U.S. for tezacaftor and ivacaftor in the second half of 2017. 
I'd like to turn now to the progression of our next-generation correctors and triple combination regimens. Our research and development strategy is to advance multiple compounds into development on the basis of our predictive preclinical assays and on Phase I safety studies, so we can choose the best combinations to evaluate in Phase III development. The advancement of VX-440 and VX-152 into Phase II and the selection of VX-659 for clinical development reflect this strategy. VX-440 and VX-152 will evaluate triple combination dosing for 4 weeks and 2 weeks, respectively, and we'll evaluate both het min and F508del homozygous patients. 
Data from both of these studies are expected in the second half of 2017. The Phase II study of VX-440 includes 3 parts. Each has a different strategic objective, but shares the same primary endpoint of safety and efficacy as measured by absolute change among function.
Slide 8 of the webcast outlines some of the studies' key features. Part A is focused on het min patients and Part B will enroll F508del homozygous patients. Parts A and B of the study will evaluate triple combination dosing for 4 weeks, and we expect to have the data in the second half of 2017. The potential initiation of Phase III development will depend on these data and discussions with regulatory agencies. 
Part C is designed to generate 12 weeks safety and efficacy data for triple combination dosing in het min patients and will run largely in parallel with potential Phase III development and will evaluate the contribution of the individual components to the overall triple combination regimen.
Slide 9 of our webcast outlines the Phase II study of VX-152. This study includes 2 parts. The primary endpoint of safety and tolerability, but a key focus will also be looking at measures of efficacy, including absolute change in lung function and change in sweat chloride among others. Part A will enroll het min patients and Part B will enroll F508del homozygous patients. 
The VX-152 study will evaluate triple combination dosing for 2 weeks, and data are also expected in the second half of 2017 and are intended to support the potential initiation of a longer duration Phase IIb or registration program, pending data and discussions with regulatory agencies. 
Our Phase I studies in healthy volunteers and other preclinical studies provide support for advancing both VX-440 and VX-152 into Phase II development and have informed the designs of the Phase II studies we're announcing today. 
Based on Phase I learnings, we believe VX-440 may have a wider therapeutic window, and this is the reason that the VX-440 study will evaluate 4-week dosing from the outset. We also noted in our press release today a specific contraception requirement for females of childbearing potential seeking to enroll in the VX-440 study. This enrollment criterion was based on recent results from preclinical development toxicology studies. Based on laboratory findings from our Phase I study of VX-152, we're also excluding patients with G6PD deficiency from the Phase II studies of VX-152 and also VX-440.
G6PD deficiency and CF prevalence have limit geographic overlap and, therefore, the incidence of G6PD in the CF population is very low. We estimate this impacts less than 1% of all CF patients overall. 
I will just make a few comments on the in-vitro profile for VX-659, highlighted here on Slide 10. In our HBE assays, the use of a triple combination that contains VX-659 with tezacaftor and ivacaftor resulted in maximal efficacy that was greater than that seen with VX-440 or VX-152 in triple combination. Additionally, VX-659 is highly potent in-vitro, which makes it favorable for a combination with other molecules.
The Phase I study of VX-659 will be very similar to those we conducted for VX-440 and VX-152. Pending data from healthy volunteers, we plan to conduct the first evaluation of VX-659 in CF patients as part of the initial Phase I study. We expect to initiate Phase II development for VX-659 in the second half of 2017, pending data from the Phase I study. 
Stepping back from the trial designs, we believe we are in a strong position to define the clinical activity of 3 different next-generation correctors in patients and have data in 2017 that enhance the probability of success for our next-generation corrector program.
The studies we are conducting with VX-440 and VX-152 could provide data sufficient to move to pivotal development, accelerating our ability to deliver significant clinical benefits to even more patients than we treat today. I look forward to providing updates on our triple combination regimens as they progress. 
Before I hand the call over to Ian, I did want to mention one additional clinical milestone we expect to achieve before the end of this year. Data from a Phase III efficacy study to support approval for ORKAMBI in children ages 6 to 11 in Europe is expected in the fourth quarter. Pending data from this study, we plan to submit an MAA variation in the EU in the first half of 2017.
With that, I'll hand the call over to Ian."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff. Good evening to everyone. As you've heard tonight, we continue to make significant progress across our business. In my remarks today, I'll review our third quarter financial results, review our 2016 financial guidance and discuss our antic",551,"Thanks, Jeff. Good evening to everyone. As you've heard tonight, we continue to make significant progress across our business. 
In my remarks today, I'll review our third quarter financial results, review our 2016 financial guidance and discuss our anticipated financial trajectory into 2017 and longer term.
Financial results first. In the third quarter of 2016, we reported total net CF product revenues of approximately $410 million, growing 38% compared to the third quarter of last year as the number of patients being treated with our medicines significantly increased with the launch of ORKAMBI in July 2015.
Our third quarter non-GAAP operating expenses were $298 million, including R&D expense of $214 million and SG&A expense of $84 million. The increased expenses for the third quarter of 2016 compared to 2015 were primarily the result of increased costs related to the progression of our CF pipeline and increased investment in global commercial support for the launch of ORKAMBI. 
This quarter, we recorded a non-GAAP net profit of $40 million or $0.16 per diluted share compared to a non-GAAP net loss of $32 million or $0.13 per share for the third quarter 2015. This turnaround to profit was driven by a significant increase in revenues compared to the prior year, which outpaced a smaller increase in non-GAAP operating expenses.
From a balance sheet perspective, we ended the third quarter with a strong cash position of $1.1 billion. Additionally, earlier this month, we replaced our $300 million term loan with a credit agreement that will significantly lower our interest expense and increase our available credit up to $800 million pending certain conditions. We will continue to build upon our strong financial position going forward.
Now let's turn to 2016 financial guidance. We are reiterating our 2016 ORKAMBI revenue guidance of $950 million to $990 million. And within this guidance, we expect ORKAMBI revenues to grow from the third quarter to the fourth quarter of 2016 as children's ages 6 through 11 initiate treatment in the U.S. As Stuart mentioned earlier, the initial signs of these patients initiating therapy are encouraging. And as we look into 2017, we see continued growth for ORKAMBI, primarily driven by gaining reimbursement approvals throughout Europe and continuing pediatric launch in the U.S. 
We continue to anticipate 2016 KALYDECO net revenues to be between $685 million and $705 million. As we look forward into 2017, we do not expect significant revenue growth for KALYDECO. If KALYDECO were to be approved in residual function patients, that would be the only significant driver of growth for KALYDECO in 2017.
For our operating expenses, we continue to expect our combined non-GAAP R&D and SG&A expenses to be between $1.18 billion and $1.23 billion for the full year. As we look forward to 2017, we anticipate modest growth in operating expenses to support the progression of our CF pipeline and the launch of ORKAMBI in new geographies.
As we continue to increase the number of patients that we treat, we expect our revenues to grow significantly in the coming years, while operating expenses will only increase modestly. We are well on track to deliver financial profile that is similar to many of our large-cap biotech peers, which includes high operating margins, sustainable earnings growth and significant cash generation.
I'll now open the line to questions."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question comes from the line of Michael Yee of RBC Capital Markets.",16,"[Operator Instructions] Our first question comes from the line of Michael Yee of RBC Capital Markets."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess my question on the next-generation compound is, can you talk a little bit about what you mean by therapeutic window for 440 for 152? Talk a little bit about safety and tolerability, what you saw in U.K. Just give a little more color there that wou",121,"I guess my question on the next-generation compound is, can you talk a little bit about what you mean by therapeutic window for 440 for 152? Talk a little bit about safety and tolerability, what you saw in U.K. Just give a little more color there that would be helpful and between the 2 programs. And then just a commercial question for you is in your guidance that you've given for the year on ORKAMBI, obviously, your launching the 6 to 11-year-olds. What type of cadence or ramp do you expect there? What's in your guidance? Is it a similar ramp to [indiscernible] and up, given that these are healthier patients? So just want to understand what you're expecting there."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mike, this is Jeff Chodakewitz. Maybe I'll start and talk about the next-gen program. We are excited, as you say, to have both molecules progressing into Phase II. We think that based on our Phase I result, and you know that given our ability to use our p",187,"Mike, this is Jeff Chodakewitz. Maybe I'll start and talk about the next-gen program. We are excited, as you say, to have both molecules progressing into Phase II. We think that based on our Phase I result, and you know that given our ability to use our preclinical assays, we can look at the exposure and have a sense of where we're going to get to in the clinic. We think that both compounds are going to go into their Phase II studies with doses that are both going to be well tolerated and efficacious, and I think that's very exciting. Maybe just to hone in a little bit on your question about therapeutic window. That really comes from both compounds being generally well tolerated. In VX-152, we did see some GI symptoms, mostly nausea and vomiting, and, therefore, that's the basis for that comment. So for VX-440, we're going right to 4-week studies and with the potential, therefore, to accelerate quickly into a Phase III. And then for 152, because of that, we are starting with Phase II studies and then can extend dosing from there."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Mike, just to address your question on the 6 through 11 launch, obviously, it's early days. We got the approval on the 28th of September, so we're less than a month then. But certainly, the early signs are encouraging, and you might expect interest is",127,"And Mike, just to address your question on the 6 through 11 launch, obviously, it's early days. We got the approval on the 28th of September, so we're less than a month then. But certainly, the early signs are encouraging, and you might expect interest is high in using ORKAMBI in this younger patient population. We're making good progress with both public and commercial payers in terms of securing access and already have approval for about 50% of covered lives, which is, obviously, an important prerequisite to getting access to these younger patients. And so as a result of all that, we are expecting a similarly robust update for that, which we saw with ORKAMBI in the 12-plus population. And that's what's incorporates into our overall guidance."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Geoff Meacham of Barclays.",9,"Our next question comes from Geoff Meacham of Barclays."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just had a couple on that for either 440 or 152. Can you talk a little bit about what you're looking for FEV1 bias just from a powering perspective? And then in either Phase II, is there a washout period for homozygous patients who have had prior exposu",57,"I just had a couple on that for either 440 or 152. Can you talk a little bit about what you're looking for FEV1 bias just from a powering perspective? And then in either Phase II, is there a washout period for homozygous patients who have had prior exposure to ORKAMBI? And I have one follow up."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, it's Jeff Chodakewitz. So again, I think that as you saw from our Phase II designs, we're really going to be getting a pretty robust look at how both molecules are going to perform. We're really being able to look at both het min patients and homoz",181,"Geoff, it's Jeff Chodakewitz. So again, I think that as you saw from our Phase II designs, we're really going to be getting a pretty robust look at how both molecules are going to perform. We're really being able to look at both het min patients and homozygous patients, which is, I think, very important. And the fact that we think that the doses we're going to be taking into Phase II can deliver benefit for both populations. That's really critical. The -- our Phase II studies are really not so much powered on any individual number. They're really giving us a good handle on being able to understand what the drugs are capable of doing. And to your point, we are going to actually leverage a washout from ORKAMBI so that people can participate. And we're going to importantly look after the end of dosing and -- because we think that, that follow-up period coming off that treatment actually has been -- can be very informative in terms of having competence in the results. So that gives you a sense."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Got you. Okay. And just real quick. In the past, you guys have talked about between 661 and 809, things like tissue penetration differences, half life  differences. Any way to generally characterize what you would say, or differences between 659, 440 and",54,"Got you. Okay. And just real quick. In the past, you guys have talked about between 661 and 809, things like tissue penetration differences, half life  differences. Any way to generally characterize what you would say, or differences between 659, 440 and 152, just from a -- from maybe a PK or chemistry perspective?"
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Geoff, maybe I'll just quickly take that because this question is just frequently asked. There are small differences between compounds. I think the major difference is that they are structurally different.",32,"So Geoff, maybe I'll just quickly take that because this question is just frequently asked. There are small differences between compounds. I think the major difference is that they are structurally different."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Terence Flynn of Goldman Sachs.",10,"Our next question comes from Terence Flynn of Goldman Sachs."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe 2 for me. Just on the second gen correctors. Can you give us any insight in terms of the dose limiting tox in the animal models? Was the GI seen there? And then on 440, just wondering some more details on the design of Part C of that trial. Was wond",72,"Maybe 2 for me. Just on the second gen correctors. Can you give us any insight in terms of the dose limiting tox in the animal models? Was the GI seen there? And then on 440, just wondering some more details on the design of Part C of that trial. Was wondering if you have regulatory sign off to run that as part of Phase II rather than include in Phase III."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So I think in terms of our Phase I, I think I've given you actually quite a flavor on what we've seen with the -- in the healthy volunteers, good tolerability, overall. I mentioned the nausea and vomiting. I should clarify that, that was at doses -- that",109,"So I think in terms of our Phase I, I think I've given you actually quite a flavor on what we've seen with the -- in the healthy volunteers, good tolerability, overall. I mentioned the nausea and vomiting. I should clarify that, that was at doses -- that was observed at doses higher than the doses that we're going to be taking into Phase II. That's how we think about being sure that we have a therapeutic window. In terms of the preclinical data, I really can't comment on that level of detail. And, of course, everything we do as we go forward, we'll be conferring with regulatory agencies."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And then on the 440 Part C?.",8,"Okay. And then on the 440 Part C?."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","I'm sorry. I guess I was -- as far as [indiscernible], going to that part of your question. We can't comment on the individual discussions we're having with regulatory agencies. I think to your -- as we talked about that, that is going to accomplish sever",95,"I'm sorry. I guess I was -- as far as [indiscernible], going to that part of your question. We can't comment on the individual discussions we're having with regulatory agencies. I think to your -- as we talked about that, that is going to accomplish several things. It's going to help us understand the performance of the triple. It's importantly going to give us data on 12 weeks of dosing. And depending on the results that we're seeing, as we said, this data actually could be done basically in parallel with Phase III study."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. Is that the triple versus each of the subcomponent? each -- versus mono of each of the 3 drugs, or is it versus a doublet?",26,"Okay. Is that the triple versus each of the subcomponent? each -- versus mono of each of the 3 drugs, or is it versus a doublet?"
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","No. It's really primarily about triple versus doublet.",8,"No. It's really primarily about triple versus doublet."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Yin Huang of Bank of America.",11,"Our next question comes from Yin Huang of Bank of America."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","It's great to hear the Phase II advancing for the new EASL correctors. So maybe for Stu, you mentioned that 6,400 patients now have started treatment in U.S. for ORKAMBI. That leaves about another 2,000 patients. Is there a reason we should think of why t",123,"It's great to hear the Phase II advancing for the new EASL correctors. So maybe for Stu, you mentioned that 6,400 patients now have started treatment in U.S. for ORKAMBI. That leaves about another 2,000 patients. Is there a reason we should think of why those 2,000 patients will not initiate therapy, if that's possible? And then secondly, I have a question on maybe Jeff on the Phase II protocols for these 2 molecules. Do you think, as what we have seen with the KALYDECO in G551D patients and also ORKAMBI in homozygous 508 deletion patients, 2 weeks or even 4 weeks should be long enough to see a significant improvement in lung function, given that these patients have -- has mutation?"
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yin, so thanks for the question. Yes, over 6,400 patients have initiated therapy on ORKAMBI and we're obviously delighted with that. It's over 70% of the eligible patients. But as you said, that means that 2,000 are yet to be initiated. Obviously, the ind",121,"Yin, so thanks for the question. Yes, over 6,400 patients have initiated therapy on ORKAMBI and we're obviously delighted with that. It's over 70% of the eligible patients. But as you said, that means that 2,000 are yet to be initiated. Obviously, the individual decision about whether a physician and patient want to initiate therapy is one that they have to come to themselves, but we're certainly continuing to see new patients being initiated as we deliver and develop more evidence about the long-term benefits of ORKAMBI. I think that's giving physicians and patients even more reasons to think about whether they would want to be initiated on ORKAMBI. And on the Phase II questions, I'll hand it over to Jeff."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart. I mean, yes, as you know, we obviously don't have data yet for the triple. But everything that we've seen across our portfolio, it's modulating CFTR, really suggest that both the 2-week and the 4-week studies are going to be able to give u",55,"Thanks, Stuart. I mean, yes, as you know, we obviously don't have data yet for the triple. But everything that we've seen across our portfolio, it's modulating CFTR, really suggest that both the 2-week and the 4-week studies are going to be able to give us valuable insights into the potential efficacy of the regiment."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Alethia Young of Crdit Suisse.",10,"Our next question comes from Alethia Young of Crdit Suisse."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congrats on the progress in Phase II. On the corrector front, with some of these new correctors, I guess, how do you think broadly about positioning these assets? And like, with the 440 and 152 compounds, would you think about moving both into Phase III?",53,"Congrats on the progress in Phase II. On the corrector front, with some of these new correctors, I guess, how do you think broadly about positioning these assets? And like, with the 440 and 152 compounds, would you think about moving both into Phase III? And then I have one question about Europe."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Leiden. That's more of a strategy question, so maybe I'll take that. And first, I'll just remind you that our strategy all along has been to develop a portfolio of next-generation correctors, really, for 2 reasons: one, they do have different pr",249,"It's Jeff Leiden. That's more of a strategy question, so maybe I'll take that. And first, I'll just remind you that our strategy all along has been to develop a portfolio of next-generation correctors, really, for 2 reasons: one, they do have different properties. They come in different flavors and we really want to see those different flavors in people in understand how they perform; and two, there's a probability of success issue here, right. By bringing 3 or 4 of these different correctors into Phase I and now in this case, Phase II studies, it increases the probability of success that will come up with the best regiments for each of the patient population. And while we can predict an awful lot from our preclinical study of cellular- assays, particularly quite well on the efficacy front. As a couple of folks noted before, there can be differences in potency and maximal efficacy and drug-like properties, and those are best seen, really, from these Phase I and Phase II trials, and we're learning a lot as we go about these different molecules. Would we ever take 2 molecules into Phase III development? It's absolutely possible just as you've seen with lumacaftor and 661, 2 first generation correctors because they may also have different protocols so -- profiles. It's just going to depend on the data that we see from these Phase II studies. But I think the important thing is the strategy we're taking is this portfolio strategy."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Great. And then on Europe, for Stuart perhaps. Maybe with some of the reimbursement conversations, do you find them kind of, of different flavor as you go through each country? Is there kind of similar themes on what kind of payers are concerned about for",46,"Great. And then on Europe, for Stuart perhaps. Maybe with some of the reimbursement conversations, do you find them kind of, of different flavor as you go through each country? Is there kind of similar themes on what kind of payers are concerned about for ORKAMBI?"
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, I'd say the concerns and questions that we get, Alethia, are very consistent. As we've said a number of times, whilst each process is different, they tend to kind of orbit themselves around 3 phases. One is the discussion of the clinical benefits of",143,"Yes, I'd say the concerns and questions that we get, Alethia, are very consistent. As we've said a number of times, whilst each process is different, they tend to kind of orbit themselves around 3 phases. One is the discussion of the clinical benefits of ORKAMBI. In general, we've been very pleased that payers across Europe have recognized the broad clinical benefits of ORKAMBI. Then there is an economic evaluation. And after that phase, you enter into the price negotiation. And so whilst each process is different in each different country, they tend to follow that same pattern and they are kind of proceeding as we anticipated. And I'd say the last thing is that, in addition to evaluating the clinical benefits from an economic perspective, they are concerned about the overall budget impact it might have for them in their individual country."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Brian Abrahams of Jefferies.",9,"Our next question comes from Brian Abrahams of Jefferies."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","My congrats as well on the progress of the next-gen correctors. Two questions. First, I was wondering if you might be able to expand upon the comments you made regarding preclinical toxic studies that led you to include contraception and exclude the G6PD",103,"My congrats as well on the progress of the next-gen correctors. Two questions. First, I was wondering if you might be able to expand upon the comments you made regarding preclinical toxic studies that led you to include contraception and exclude the G6PD deficiency patients for the 440 study? Was that something just related to a hormonal interaction? And then on the commercial side, I realize it's very early days, but just wondering if you had any sense of compliance and persistence -- or at least compliance in the 6 to 11-year-old patients relative to what you've seen in adults thus far?"
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Brian, it's Jeff Chodakewitz. I'll start and then turn it over. I just want to be sure I understand your question. For the preclinical data for 440 and contraception, there are a set of standard studies that are done actually in rabbits and there, we test",120,"Brian, it's Jeff Chodakewitz. I'll start and then turn it over. I just want to be sure I understand your question. For the preclinical data for 440 and contraception, there are a set of standard studies that are done actually in rabbits and there, we test the developmental toxicity, the effects of the drug. And we did find for the X-440 that there were some abnormalities suggesting a potential deleterious effect on the fetus. We don't know whether that actually translates to people, but the prudent thing to do, clearly, is to ensure that women in this study are using highly effective contraception and that's what we flagged them, we'll be doing that in our Phase II study with X-440."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And on your compliance question. As you say, it's very early days yet. We're just 1 month into the launch in the 6 to 11-year-old children. However, I think there are some reasons to be optimistic that the compliance rate there could be higher than we see",101,"And on your compliance question. As you say, it's very early days yet. We're just 1 month into the launch in the 6 to 11-year-old children. However, I think there are some reasons to be optimistic that the compliance rate there could be higher than we see in teenagers and in young adults. Certainly, that's what we've seen with KALYDECO, and that's not atypical for what you see in other chronic diseases where, clearly, these young kids are largely or exclusively under the supervision of their parents and therefore, compliance rates tend to be at the higher end of the spectrum."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have two things that I just wanted to ask. So, I guess, both on next-generation correctors. One, can you just compare and contrast what you would expect to learn from 2 weeks of dosing versus 4 weeks of dosing, and how you would correlate whatever signa",85,"I have two things that I just wanted to ask. So, I guess, both on next-generation correctors. One, can you just compare and contrast what you would expect to learn from 2 weeks of dosing versus 4 weeks of dosing, and how you would correlate whatever signals you're going to get out of that to how you might move those compounds ahead? And then second, can you just tell us the dose levels of 152 and 440 that you're using in these Phase II studies?"
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Matthew, Jeff Chodakewitz. So let me talk about the 2 and the 4 weeks because we're actually going to have very similar end point in both. And as we spoke about earlier, actually, we think that both 2 and 4 weeks are going to be able to give us meaningful",224,"Matthew, Jeff Chodakewitz. So let me talk about the 2 and the 4 weeks because we're actually going to have very similar end point in both. And as we spoke about earlier, actually, we think that both 2 and 4 weeks are going to be able to give us meaningful information. We're also going to have sweat chloride being evaluated in both drugs, which will also be valuable. Ultimately, what we're going to do is use all the information. We actually also have a lot of work being done to actually understand from a modeling perspective, so that we can get the absolute most information out of our clinical trial. And so we're going to use all that information across both to make the best decisions, and we think that, that will contribute to both. I think in terms of the specifics of the doses, as you may see in the design, we're going to go into patients with a small cohort. That's really just to confirm that, that exposure is the same in patients as it is in healthy volunteers. We don't have any reason to think that it will be different, but we're going to do that just to be sure we're taking the right approach. And then we'll choose our doses from there to confirm for the rest of the trial."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Geoffrey Porges of Leerink Partners.",10,"Our next question comes from Geoffrey Porges of Leerink Partners."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congratulations on advancing some more CF compound. First, just wondering if on Slide 10, you could tell us where 152, David, compared to 440 in tezacaftor in that assay? And then a couple of commercial questions. Ian, you've been fairly clear about what",171,"Congratulations on advancing some more CF compound. First, just wondering if on Slide 10, you could tell us where 152, David, compared to 440 in tezacaftor in that assay? And then a couple of commercial questions. Ian, you've been fairly clear about what we should be expecting for KALYDECO in 2017 and there's certainly been some ups and downs in both consensus and in guidance this year for ORKAMBI. So wondering where you would suggest that we sort of should be bracketing for next year for ORKAMBI. There are certainly a lot of variables with Europe with the pediatric indication coming online in the U.S. So that would be helpful. And then Stuart, lastly, as you're negotiating price in Europe, could you give us a sense of how you're thinking about having a portfolio of CF combination? Are you expecting to have them at different price points? Or should we be thinking that over time, they gravitate towards a band, regardless of whether it's 2 or 3 drugs in the combination?"
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is David Altshuler. I'll take the first part. As we showed last year in the het min cells and also homozygous cells, 152 and 440 have very similar levels of max efficacy.",33,"This is David Altshuler. I'll take the first part. As we showed last year in the het min cells and also homozygous cells, 152 and 440 have very similar levels of max efficacy."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Geoff, to your question on guidance. I hoped I was very clear on KALYDECO in my prepared remarks where KALYDECO is treating approximately 90% of eligible patients that -- and has a very good persistence rate and compliance rate, and we'd anticipate th",315,"And Geoff, to your question on guidance. I hoped I was very clear on KALYDECO in my prepared remarks where KALYDECO is treating approximately 90% of eligible patients that -- and has a very good persistence rate and compliance rate, and we'd anticipate that continuing on into next year. So as you see, the current quarterly run rate for KALYDECO, we see that continuing on in 2017, the mark of potentially increasing would be if we were able to gather residual function approval. And as Jeff Chodakewitz explained, we are currently in discussions with the regulatory authorities in the U.S. regarding that approval and that continues that discussion. Regarding ORKAMBI, it's a little too early to say. We're very comfortable with the guidance we've provided through the end of this year of $950 million to $990 million, and that does include the recent pediatric approval. As we look to 2017, we'll probably be thinking about how we give guidance around the U.S. market and maybe Germany as well because we do have visibility and knowledge to those markets. In terms of the other international markets, of how quickly and the time that they come on, we just need to give that some thought over the next few months of whether we actually try to provide a bracket around that guidance. There is a certain unknown element, but I'm sure you can only appreciate with these discussions. And sometimes the discussions push out because you are actually holding out for a price that you believe is appropriate for the medicine. And so it's about us getting to the right spot and rather than putting guidance around and be forced around guidance, we'll give it some consideration of how we put a bracket around that and we'll be back to you early in early 2017. And then to your third question, I'll pass it over to Stuart."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, in terms of pricing principles, obviously, we can't comment on the pricing of future products, but I'll talk to our pricing principles overall which have been very consistent for how we price KALYDECO and ORKAMBI, and the 2 primary drivers are real",168,"Geoff, in terms of pricing principles, obviously, we can't comment on the pricing of future products, but I'll talk to our pricing principles overall which have been very consistent for how we price KALYDECO and ORKAMBI, and the 2 primary drivers are really the number of patients that were able to benefit with our medicines and then the level of clinical benefit or value that we're able to bring. I think you've seen that we've adhered to those principles with ORKAMBI. And whilst we don't have formal pricing agreements in place across Europe yet, you have seen with the list prices of ORKAMBI where they are lower than they are for KALYDECO, which reflects the fact that, clearly, ORKAMBI is -- has a much wider eligible patient population despite the fact that, that medicine has two different components within it. So I think you can expect that we'll be adhering to those pricing principles as we bring next-gen correctors and other medicines to market for eligible CF patients."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from John Scotti of Evercore ISI.",10,"Our next question comes from John Scotti of Evercore ISI."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just want to ask on VX-659. If you were to compare the preclinical toxicity profile of that aspect to 440 with regard to potential teratogenicity, et cetera, and then 152 with the nausea. Are you confident that the chemical structure of 659 is different",119,"I just want to ask on VX-659. If you were to compare the preclinical toxicity profile of that aspect to 440 with regard to potential teratogenicity, et cetera, and then 152 with the nausea. Are you confident that the chemical structure of 659 is different enough where we won't see those issues in humans in the clinic with regard to what we see with 440 and 152? And then I guess, just quickly on timing. Given the trials are small and if we assume they enroll quickly, is it unreasonable to assume that we could see data more towards mid-next year rather than towards the end of the year? I know you got it in the second half."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So John, first of all, I just want to pass on the team's best wishes to Mark and we look forward to [indiscernible] from Mark at some point and I'm sure I share everybody else's thoughts that are on the phone. In terms of the question, I'm just going to a",99,"So John, first of all, I just want to pass on the team's best wishes to Mark and we look forward to [indiscernible] from Mark at some point and I'm sure I share everybody else's thoughts that are on the phone. In terms of the question, I'm just going to ask Jeff Leiden to answer it because there is a whole portfolio approach here that we have, starting from 659. And the methodology of how we probably pick our molecules and what with that basis is. And you should anticipate that there will be more modules coming. So Jeff."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for the question, John. Maybe just to go back one step and remind you of how we look at these molecules and select them. The first real assay test for these molecules is our human HPE cells, both het min cells and homozygous cells from multipl",371,"Yes, thanks for the question, John. Maybe just to go back one step and remind you of how we look at these molecules and select them. The first real assay test for these molecules is our human HPE cells, both het min cells and homozygous cells from multiple donors. And as we showed you, I think in one of the slides today, 659 actually has efficacy as measured by chloride transport, which is maximal efficacy that's significantly higher than what we were seeing in 440 and 152, which were also quite high by themselves, by the way. We've also measured a number of other things in that assay like cilia beat frequency and others, and we see the same kind of difference between 659 and 440. We've entered the molecules through a pretty rigorous screen with respect to PK, tox, coformulability, really making sure that we're bringing drugs in the clinic as opposed to molecules. And we're done with most but not all of that for 659. We're certainly done with them now so we feel very comfortable that we have a tox profile and a PK profile that we're confident in taking into Phase I studies, both in normals and in patients this time as well. We have not done yet with the developmental studies in rabbits, and we don't have that data yet. And obviously, we don't have any human data, which is the final test of PK and safety and we'll only see that in the Phase I study. In addition, just as Ian mentioned, just -- we need to be clear with our expectations, we have a number of other next-gen correctors in our late preclinical pipeline. We expect to bring at least one of those forward into the clinic in the first half of next year and maybe more. And the reason for that, again, is that these molecules come in a number of different flavors, different potencies, different properties, and we want to bring multiple of them into humans as part of triple combinations to understand how they interact. I hope that gives you a flavor of where 659 fits and what we know and some things we don't yet know, but we'll know soon."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Brian Skorney of Robert W. Baird.",14,"Our next question comes from the line of Brian Skorney of Robert W. Baird."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have two questions. I guess, why both -- why start both programs in het min? It seems like you'd potentially get more information out of adding this on top of 661 ivacaftor, in patients with 2 F508del alleles. and Also, when we look at the relative diff",81,"I have two questions. I guess, why both -- why start both programs in het min? It seems like you'd potentially get more information out of adding this on top of 661 ivacaftor, in patients with 2 F508del alleles. and Also, when we look at the relative differences of the 4 generations, is that reasonable to assume that 2 correctors within the same generations still are redundant? And is there any obvious redundancy to cross combining correctors of these different generations?"
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Brian, it's Jeff again. Let me answer both really good questions. Maybe I'll answer your second question first. Really, the portfolio approach is based upon the fact that while the molecules may bind to the same site, it may even have the same mechanism o",186,"Brian, it's Jeff again. Let me answer both really good questions. Maybe I'll answer your second question first. Really, the portfolio approach is based upon the fact that while the molecules may bind to the same site, it may even have the same mechanism of action, there are obviously a number of other properties that are going to be really important in picking the best regimen. They include potency, because the more potent the molecule is, the easier it is to combine and to triple combination formulate. They include maximal efficacy, obviously, and we showed you the 659 as an example of its greater maximal efficacy. But they also include things like PK properties, tissue penetration, drug-drug interactions, all of those things. And so when you think about this portfolio, think about it not only in terms of mechanism of action and not only in terms of efficacy and potency, but think about it as how do we create the best triple regimen with one or more of these molecules going forward. Does that makes sense to you in terms of how we're thinking about it?"
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, that is helpful.",4,"Yes, that is helpful."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And then repeat your first question for me.",8,"And then repeat your first question for me."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Just on the strategy of [indiscernible] first.",7,"Just on the strategy of [indiscernible] first."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. So just to be clear about what we're doing here. First of all, het min, obviously, is the big group of patients with the largest unmet need. And so as we think about taking these molecules forward, that's the patient population that we're most focuse",221,"Yes. So just to be clear about what we're doing here. First of all, het min, obviously, is the big group of patients with the largest unmet need. And so as we think about taking these molecules forward, that's the patient population that we're most focused on. But I do want to be clear that we're essentially doing these things in parallel, and so we will have results both in the het min administration population and the homozygous population essentially at the same time and with very little delay. And that's going to let us really design the best Phase III study, I think, here. One of the things that I'm really been pleased with over the last 4 or 5 years is as we develop these molecules, we've learned an awful lot about how to take the development forward most quickly, most efficiently and then how to start to think about phase trials -- Phase III trials perhaps a little differently. And so I do think you're seeing the results of that here as we sort of streamline these Phase II trials, do them in parallel as opposed to in theories as we've done them in the past. And then hopefully, based on the results, of course, launch into Phase III in a much broader fashion than we've done previously."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Liisa Bayko of JMP Securities.",10,"Our next question comes from Liisa Bayko of JMP Securities."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And just to clarify, there's no intention to formulate maybe a quad or something? You wouldn't add some of your next-generation correctors together? And I guess, why not would be the question.",32,"And just to clarify, there's no intention to formulate maybe a quad or something? You wouldn't add some of your next-generation correctors together? And I guess, why not would be the question."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, so as a theoretical question, Liisa, of course, we would think about quad. And as you know, we're also looking at some other mechanisms of action, things like ENaC inhibitors that could be combined. So there's nothing of priority that we wouldn't loo",113,"Yes, so as a theoretical question, Liisa, of course, we would think about quad. And as you know, we're also looking at some other mechanisms of action, things like ENaC inhibitors that could be combined. So there's nothing of priority that we wouldn't look for in drug combinations. Obviously, an ENaC inhibitor's inhaled, so it wouldn't be co-formulated. But I do think there's one difference here that's worth mentioning. I think it would be unlikely that, for instance, that will we put 152 and 440 together because they do appear to have the same mechanism of action, and so adding them together, would be not expect it to produce a lot more benefit."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And then can you maybe talk about where you're going to be enrolling patients for some of these preliminary space for the next generation? Is it going to be North America, ex U.S.?",34,"Okay. And then can you maybe talk about where you're going to be enrolling patients for some of these preliminary space for the next generation? Is it going to be North America, ex U.S.?"
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This Jeff Chodakewitz. We're actually going to be doing studies in sites both in the U.S. and in Europe.",19,"This Jeff Chodakewitz. We're actually going to be doing studies in sites both in the U.S. and in Europe."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, great. And then just wanted to get a little bit more clarity on the hormonal component. I think you maybe talked about this earlier before VX-440 and what you've seen there in your preclinical stuff. And then what that would just mean if you were to",50,"Okay, great. And then just wanted to get a little bit more clarity on the hormonal component. I think you maybe talked about this earlier before VX-440 and what you've seen there in your preclinical stuff. And then what that would just mean if you were to take it forward."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure. This is Jeff Chodakewitz again. So just to clarify perhaps. We've already talked about the rapid toxicity and why we're putting the contraceptive language in place. The hormonal wording doesn't actually come from preclinical studies. With the X440 a",84,"Sure. This is Jeff Chodakewitz again. So just to clarify perhaps. We've already talked about the rapid toxicity and why we're putting the contraceptive language in place. The hormonal wording doesn't actually come from preclinical studies. With the X440 at higher doses, there was some evidence of liver enzyme induction, and that can actually somewhat lower the exposure to the hormones in the contraceptives. And so therefore, again, to ensure that we're using highly reliable contraception, we're excluding that as being the primary method."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Tony Butler of Guggenheim Partners.",10,"Our next question comes from Tony Butler of Guggenheim Partners."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two questions briefly. In Cohort 1a, can you help me understand the notion of using the low-dose first before you move forward. While it may be intuitive, you don't do that for 152. And then the second question is really around 152. To me, you've outlined",75,"Two questions briefly. In Cohort 1a, can you help me understand the notion of using the low-dose first before you move forward. While it may be intuitive, you don't do that for 152. And then the second question is really around 152. To me, you've outlined very well the portfolio strategy, why certainly you're moving forward with 440 and 659, but is the only reason for 152 the fact that it does not have teratogenicity?"
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Tony, it's Jeff Chodakewitz. So two comments. One, the 1a, as we go back to sort of the prior conversations, the intent of 1a is to go make the transition from healthy volunteers to patients. And be sure -- basically, the exposure is similar in the two gr",182,"Tony, it's Jeff Chodakewitz. So two comments. One, the 1a, as we go back to sort of the prior conversations, the intent of 1a is to go make the transition from healthy volunteers to patients. And be sure -- basically, the exposure is similar in the two groups. And since it could potentially go up or down, although we don't expect it to do either, that's why you wouldn't want to go in at a high dose and then have the exposure actually end up higher. That's why we always would start in that kind of situation with the low dose and then expand, which is the intent. In terms of your broader question about VX-152 and VX-440, I think it goes back to Jeff Leiden's comments, that we think both molecules will have the potential to be well-tolerated at doses that can deliver benefit to patients, including, excitingly, both homozygous patients and het min patients that don't have a treatment option. And that's why we're taking both forward and we'll continue to learn as we add other molecules to our portfolio."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Operator, it's Michael Partridge. We have time for one more question.",11,"Operator, it's Michael Partridge. We have time for one more question."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And that question comes from the line of Alan Carr of Needham & Company.",13,"And that question comes from the line of Alan Carr of Needham & Company."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Wondering if you can clarify that some of the timing around 152, 440 and the results from those and the results from your 659 Phase II. Are you trying to -- are you able to position these 3 data from 3 Phase II trials at the same time in order to decide w",61,"Wondering if you can clarify that some of the timing around 152, 440 and the results from those and the results from your 659 Phase II. Are you trying to -- are you able to position these 3 data from 3 Phase II trials at the same time in order to decide which one or 2 to bring into Phase III?"
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Alan, it's Jeff Chodakewitz. I mean, just review how that winds up. Of course, in the end, all the time lines, particularly the Phase II studies, are going to be dependent on the rate of enrollment. But what we expect would be that for both VX-152 and",123,"So Alan, it's Jeff Chodakewitz. I mean, just review how that winds up. Of course, in the end, all the time lines, particularly the Phase II studies, are going to be dependent on the rate of enrollment. But what we expect would be that for both VX-152 and VX-440, that we will be getting results, as we said, in the second half of '17. At that point, we will also have the Phase I results from VX-659. And as we've talked about that, given everything we've learned about the relationship from preclinical to exposure to benefit of patients, we think that we will be able to understand a lot about all 3  compounds as we're looking forward to make decisions at that point."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff Leiden. I just want to be clear that we don't think about 659 as being on exactly the same time frame as 152 and 440. And as Jeff said, it's a little difficult to give you precision because it depends on how users enrolled. 659 will only have",132,"This is Jeff Leiden. I just want to be clear that we don't think about 659 as being on exactly the same time frame as 152 and 440. And as Jeff said, it's a little difficult to give you precision because it depends on how users enrolled. 659 will only have a small cohort of patients from the Phase I, and so we'll have to see what we learn from that. But if you would ask me just to put a sort of marker on the table, I think that 659 myself is about 6 months behind 152 and 440. So we're not going to be waiting, obviously, if we see positive results with 152 and 440 before taking those into Phase III to wait for 659, if that's really the question."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes. Okay, that helps. And then one other one. I guess, can you give us an update on 371? Where things stand with your CF program and ciliary dyskinesia there?",30,"Yes. Okay, that helps. And then one other one. I guess, can you give us an update on 371? Where things stand with your CF program and ciliary dyskinesia there?"
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So it's Jeff Chodakewitz. Both of our studies, both the study in CF where we're looking at the ENaC inhibitor on top of ORKAMBI and in piece for homozygous for F508del and the study in patients with PCD, both are actively enrolling.",43,"So it's Jeff Chodakewitz. Both of our studies, both the study in CF where we're looking at the ENaC inhibitor on top of ORKAMBI and in piece for homozygous for F508del and the study in patients with PCD, both are actively enrolling."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And timing for results, what's the latest on that?",9,"And timing for results, what's the latest on that?"
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's always going to be -- of course, until we end up getting the study fully enrolled, it's just too hard to give you any precision on the time.",30,"It's always going to be -- of course, until we end up getting the study fully enrolled, it's just too hard to give you any precision on the time."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay. Everybody, thanks for joining us tonight. For those of you who are going to the North American CF Conference, we look forward to seeing you there on Thursday night this week. We will also be webcasting our presentation there starting at 6:30 p.m. Ea",66,"Okay. Everybody, thanks for joining us tonight. For those of you who are going to the North American CF Conference, we look forward to seeing you there on Thursday night this week. We will also be webcasting our presentation there starting at 6:30 p.m. Eastern Time on Thursday. Tonight, the Investor Relations team will remain in the office if you have any additional questions. Thank you."
36235,404123072,1060892,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, that does conclude your call. You may disconnect at this time. Have a great day.",18,"Ladies and gentlemen, that does conclude your call. You may disconnect at this time. Have a great day."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening. This is Michael Partridge, Vice President of Investor Relations. Welcome to our Third Quarter 2016 Financial Results Conference Call. [Operator Instructions] This conference call is recorded, and there will be a replay available later tonigh",182,"Good evening. This is Michael Partridge, Vice President of Investor Relations. Welcome to our Third Quarter 2016 Financial Results Conference Call. [Operator Instructions] This conference call is recorded, and there will be a replay available later tonight. You can access the webcast live by going to our website. Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; Dr. Jeff Chodakewitz, Chief Medical Officer; and Ian Smith, Chief Financial Officer, will provide prepared remarks on this call. They will be joined by Dr. David Altshuler, Chief Scientific Officer, for the Q&A portion of the call. 
We will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the SEC. These statements, including without limitation, those regarding the ongoing development and potential commercialization of our drug candidates, our expectations regarding our approved medicines and Vertex' future financial performance are based on management's current assumptions. Actual outcomes and events 
[Audio Gap]
I will now turn the call over to Dr. Jeff Leiden."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. Vertex' strategy in cystic fibrosis is to treat as many people with CF as possible and to continue to enhance the clinical benefits for those treated by our medicines. Our long-term goal is to reduce the progressiv",555,"Thanks, Michael. Good evening, everyone. Vertex' strategy in cystic fibrosis is to treat as many people with CF as possible and to continue to enhance the clinical benefits for those treated by our medicines. Our long-term goal is to reduce the progressive and irreversible effects of CF by treating underlying cause of the disease. 
There are 3 key components to our strategy. First, to increase the number of eligible patients being treated with our approved medicines, mainly by obtaining reimbursement for ORKAMBI for more patients outside the U.S.; second, to further expand the labels for KALYDECO and ORKAMBI around the world; and third, to develop new combination regimens of CFTR modulators designed to enhance benefit for all patients. 
This evening, I'm pleased to report that we continue to make excellent progress on all of these fronts. Last month, the FDA approved ORKAMBI for the treatment of children with CF, ages 6 through 11, who have 2 copies of the F508del mutation. With this approval, approximately 29,000 patients worldwide are now eligible for our medicines. 
Today, we are treating approximately 9,000 of these 29,000 eligible patients. Moving forward, we remain focused on expanding access to ORKAMBI and KALYDECO for the many eligible patients who are still awaiting treatment, largely through obtaining reimbursement for ORKAMBI in Europe, Canada and Australia.
We are also continuing to make progress in our efforts to expand the labels for KALYDECO and ORKAMBI. In the U.S., we are focused on obtaining approval for KALYDECO in patients with residual function mutations. And in the EU, we expect data this quarter from our Phase III trial of ORKAMBI in children ages 6 through 11 who are homozygous for the F508del mutation. If successful, these would represent approximately 5,000 additional patients who may benefit from our approved medicines.
Beyond this important progress, our long-term goal is to treat all people with CF. During the last year, we have significantly advanced our CF pipeline, which now spans all phases of research and development. Today, we announced the planned initiation of 2 separate Phase II studies of our next-generation correctors, VX-440 and VX-152 in people with CF. And also a Phase I study of a third next-generation corrector, VX-659 as part of a triple combination.
These studies represent significant milestones in our efforts to treat as many people with CF as possible, and we'll provide the first safety and clinical efficacy data in patients, including het min patients for a triple combination regimen that includes a next-generation corrector. 
We expect to have data from the Phase II studies in the second half of 2017. Additionally, we look forward to obtaining Phase III data for the combination regimen of VX-661, which now carries the generic name tezacaftor and ivacaftor in the first half of 2017. 
As we enter the fourth quarter of 2016, Vertex is a global biotech company that has discovered and developed 2 breakthrough medicines for people with CF, while broadening our pipeline of future medicines. Our significant revenue growth and return to profitability over the past year, our metrics of the kind of company that we are becoming, a company that consistently creates transformative medicines for patients and deliver significant and sustained revenue and earnings growth for our shareholders.
With that, I'll hand the call over to Stuart to discuss the performance of our medicines."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. Tonight, I will review the performance of ORKAMBI, our ongoing efforts to obtain reimbursement in Europe, the label expansion for children ages 6 through 11 in the United States and the outlook for KALYDECO. In the thi",726,"Thanks, Jeff, and hello, everyone. Tonight, I will review the performance of ORKAMBI, our ongoing efforts to obtain reimbursement in Europe, the label expansion for children ages 6 through 11 in the United States and the outlook for KALYDECO. 
In the third quarter, global sales of ORKAMBI were $234 million, comprised of U.S. sales of $211 million and ex U.S. sales of $23 million.
This quarter, sales in the U.S. declined compared to the second quarter of this year, largely due to a slowing in refills during the summer months of July and August. We have now seen the vast majority of these patients refill their prescriptions. The overall compliance and persistence rates we are observing remain as we outlined earlier in the year. 
During the quarter, patients in the U.S. continue to initiate treatment at a slower rate as we approach peak penetration in the U.S. for patients age 12 and over. As of the end of September, approximately 6,400 patients in the U.S. have initiated therapy on ORKAMBI.
Last month, we revised our 2016 ORKAMBI revenue guidance to be between $950 million and $990 million for the full year, and we are reiterating that guidance today. U.S. treatment trends were one reason for the revised guidance. And the other main driver was the ongoing launch in Germany, which has been slower than expected. 
As of September 30, approximately 500 of the 2,500 eligible patients have initiated treatment in Germany. We remain confident that we will treat the vast majority of eligible patients over time in Germany, but it will take longer than we had originally anticipated to reach that goal.
In contrast to Germany, we continue to see strong demand in France, where approximately 900 of the 1,500 eligible patients have initiated therapy through early access programs as of the end of September. I would note that we are not recognizing revenue for these patients in France until we achieve a formal reimbursement agreement.
Throughout Europe, reimbursement is progressing as anticipated. While there are unique aspects to each process, reimbursement typically falls into 3 phases: A clinical benefit assessment and economic evaluation and price negotiations. In several countries, benefit assessments and economic evaluations are complete. We are pleased that government payers across Europe recognize the severity of this disease and the broad clinical benefits of ORKAMBI. We have now entered the third phase of the reimbursement process, which includes price negotiations in many key countries. While the process takes time to complete, we believe that we will achieve broad reimbursement from key European and other government payers. We expect our first pricing agreement in a major European market to come in Germany this December. 
Pricing and reimbursement approvals for patients eligible for ORKAMBI outside of the U.S. are expected to drive significant revenue growth in 2017.
I will now turn to our recent sNDA approval for ORKAMBI announced last month. We were delighted the FDA approved ORKAMBI for the treatment of children ages 6 to 11 who have 2 copies of the F508del mutation. And since then, we have been working to get the medicine to the approximately 2,400 eligible patients as rapidly as possible. 
Interest in ORKAMBI for this age group has been very high, and our interactions with public and private payers have been productive. We expect broad coverage of ORKAMBI for this patient population as payers have already evaluated the product after approval last year in patients 12 years and older. Thanks to the commitment of health care providers at CF centers across the country. I am pleased to report the first children, ages 6 through 11, are already receiving ORKAMBI. We expect the launch to drive revenue growth in the fourth quarter of 2016 and in 2017. 
Turning to KALYDECO. Net revenues for the product were $176 million in the third quarter. We are now treating the vast majority of currently eligible patients and, therefore, we expect this level of quarterly revenues to be maintained in the near term unless KALYDECO is approved in CF patients with residual function mutations. Today, there are approximately 29,000 people eligible for ORKAMBI or KALYDECO globally, yet we are only treating approximately 1/3 of these patients. Therefore, expanding access to both of our medicines for eligible patients around the world is our top priority. 
With that, I'll turn the call over to Jeff Chodakewitz."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart. Tonight, I'll review the significant progress we are making with our CF pipeline, and I'll start with the Phase III program of tezacaftor. We believe the investigational combination of tezacaftor and ivacaftor could play an important role",972,"Thanks, Stuart. Tonight, I'll review the significant progress we are making with our CF pipeline, and I'll start with the Phase III program of tezacaftor. We believe the investigational combination of tezacaftor and ivacaftor could play an important role in the treatment of people with CF. Enrollment is now complete in the Phase III study in F508del homozygous patients, and also in the study in people who have residual function mutations. 
Data from both studies are expected in the first half of 2017. The Phase III study in people with gating mutations is expected to complete enrollment in early 2017. Pending data from the Phase III program, we plan to submit an NDA in the U.S. for tezacaftor and ivacaftor in the second half of 2017. 
I'd like to turn now to the progression of our next-generation correctors and triple combination regimens. Our research and development strategy is to advance multiple compounds into development on the basis of our predictive preclinical assays and on Phase I safety studies, so we can choose the best combinations to evaluate in Phase III development. The advancement of VX-440 and VX-152 into Phase II and the selection of VX-659 for clinical development reflect this strategy. VX-440 and VX-152 will evaluate triple combination dosing for 4 weeks and 2 weeks, respectively, and we'll evaluate both het min and F508del homozygous patients. 
Data from both of these studies are expected in the second half of 2017. The Phase II study of VX-440 includes 3 parts. Each has a different strategic objective, but shares the same primary endpoints of safety and efficacy as measured by absolute change among function.
Slide 8 of the webcast outlines some of the studies' key features. Part A is focused on het min patients, and Part B will enroll F508del homozygous patients. Parts A and B of the study will evaluate triple combination dosing for 4 weeks, and we expect to have the data in the second half of 2017. The potential initiation of Phase III development will depend on these data and discussions with regulatory agencies. 
Part C is designed to generate 12 weeks safety and efficacy data for triple combination dosing in het min patients and will run largely in parallel with potential Phase III development and will evaluate the contribution of the individual components to the overall triple combination regimen.
Slide 9 of our webcast outlines the Phase II study of VX-152. This study includes 2 parts. The primary endpoint of safety and tolerability, but a key focus will also be looking at measures of efficacy, including absolute change in lung function and change in sweat chloride among others. Part A will enroll het min patients, and Part B will enroll F508del homozygous patients. 
The VX-152 study will evaluate triple combination dosing for 2 weeks, and data are also expected in the second half of 2017 and are intended to support the potential initiation of a longer duration Phase IIb or registration program, pending data and discussions with regulatory agencies. 
Our Phase I studies in healthy volunteers and other preclinical studies provide support for advancing both VX-440 and VX-152 into Phase II development and have informed the designs of the Phase II studies we're announcing today. 
Based on Phase I learnings, we believe VX-440 may have a wider therapeutic window, and this is the reason that the VX-440 study will evaluate 4-week dosing from the outset. We also noted in our press release today a specific contraception requirement for females of childbearing potential seeking to enroll in the VX-440 study. This enrollment criterion was based on recent results from preclinical development toxicology studies. Based on laboratory findings from our Phase I study of VX-152, we're also excluding patients with G6PD deficiency from the Phase II studies of VX-152 and also VX-440.
G6PD deficiency and CF prevalence have limit geographic overlap and, therefore, the incidence of G6PD in the CF population is very low. We estimate this impacts less than 1% of all CF patients overall. 
I will just make a few comments on the in-vitro profile for VX-659, highlighted here on Slide 10. In our HBE assays, the use of a triple combination that contains VX-659 with tezacaftor and ivacaftor resulted in maximal efficacy that was greater than that seen with VX-440 or VX-152 in triple combination. Additionally, VX-659 is highly potent in-vitro, which makes it favorable for a combination with other molecules.
The Phase I study of VX-659 will be very similar to those we conducted for VX-440 and VX-152. Pending data from healthy volunteers, we plan to conduct the first evaluation of VX-659 in CF patients as part of the initial Phase I study. We expect to initiate Phase II development for VX-659 in the second half of 2017, pending data from the Phase I study. 
Stepping back from the trial designs, we believe we are in a strong position to define the clinical activity of 3 different next-generation correctors in patients and have data in 2017 that enhance the probability of success for our next-generation corrector program.
The studies we are conducting with VX-440 and VX-152 could provide data sufficient to move to pivotal development, accelerating our ability to deliver significant clinical benefits to even more patients than we treat today. I look forward to providing updates on our triple combination regimens as they progress. 
Before I hand the call over to Ian, I did want to mention one additional clinical milestone we expect to achieve before the end of this year. Data from a Phase III efficacy study to support approval for ORKAMBI in children ages 6 to 11 in Europe is expected in the fourth quarter. Pending data from this study, we plan to submit an MAA variation in the EU in the first half of 2017.
With that, I'll hand the call over to Ian."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff. Good evening to everyone. As you've heard tonight, we continue to make significant progress across our business. In my remarks today, I'll review our third quarter financial results, review our 2016 financial guidance and discuss our antic",552,"Thanks, Jeff. Good evening to everyone. As you've heard tonight, we continue to make significant progress across our business. 
In my remarks today, I'll review our third quarter financial results, review our 2016 financial guidance and discuss our anticipated financial trajectory into 2017 and longer term.
Financial results first. In the third quarter of 2016, we reported total net CF product revenues of approximately $410 million, growing 38% compared to the third quarter of last year as the number of patients being treated with our medicines significantly increased with the launch of ORKAMBI in July 2015.
Our third quarter non-GAAP operating expenses were $298 million, including R&D expense of $214 million and SG&A expense of $84 million. The increased expenses for the third quarter of 2016 compared to 2015 were primarily the result of increased costs related to the progression of our CF pipeline and increased investment in global commercial support for the launch of ORKAMBI. 
This quarter, we recorded a non-GAAP net profit of $40 million or $0.16 per diluted share compared to a non-GAAP net loss of $32 million or $0.13 per share for the third quarter 2015. This turnaround to profit was driven by a significant increase in revenues compared to the prior year, which outpaced a smaller increase in non-GAAP operating expenses.
From a balance sheet perspective, we ended the third quarter with a strong cash position of $1.1 billion. Additionally, earlier this month, we replaced our $300 million term loan with a credit agreement that will significantly lower our interest expense and increase our available credit up to $800 million pending certain conditions. We will continue to build upon our strong financial position going forward.
Now let's turn to 2016 financial guidance. We are reiterating our 2016 ORKAMBI revenue guidance of $950 million to $990 million. And within this guidance, we expect ORKAMBI revenues to grow from the third quarter to the fourth quarter of 2016 as children's ages 6 through 11 initiate treatment in the U.S. As Stuart mentioned earlier, the initial signs of these patients initiating therapy are encouraging. And as we look into 2017, we see continued growth for ORKAMBI, primarily driven by gaining reimbursement approvals throughout Europe and continuing pediatric launch in the U.S. 
We continue to anticipate 2016 KALYDECO net revenues to be between $685 million and $705 million. As we look forward into 2017, we do not expect significant revenue growth for KALYDECO. If KALYDECO were to be approved in residual function patients, that would be the only significant driver of growth for KALYDECO in 2017.
For our operating expenses, we continue to expect our combined non-GAAP R&D and SG&A expenses to be between $1.18 billion and $1.23 billion for the full year. As we look forward to 2017, we anticipate modest growth in operating expenses to support the progression of our CF pipeline and the launch of ORKAMBI in new geographies.
As we continue to increase the number of patients that we treat, we expect our revenues to grow significantly in the coming years, while operating expenses will only increase modestly. We are well on track to deliver a financial profile that is similar to many of our large-cap biotech peers, which includes high operating margins, sustainable earnings growth and significant cash generation.
I'll now open the line to questions."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question comes from the line of Michael Yee of RBC Capital Markets.",16,"[Operator Instructions] Our first question comes from the line of Michael Yee of RBC Capital Markets."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess my question on the next-generation compound is, can you talk a little bit about what you mean by therapeutic window for 440 for 152? Talk a little bit about safety and tolerability, what you saw in U.K. Just give a little more color there that wou",122,"I guess my question on the next-generation compound is, can you talk a little bit about what you mean by therapeutic window for 440 for 152? Talk a little bit about safety and tolerability, what you saw in U.K. Just give a little more color there that would be helpful and between the 2 programs. And then just a commercial question for you is in your guidance that you've given for the year on ORKAMBI, obviously, you're launching the 6 to 11-year-olds. What type of cadence or ramp do you expect there? What's in your guidance? Is it a similar ramp to the 12 and up, given that these are healthier patients? So just want to understand what you're expecting there."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mike, this is Jeff Chodakewitz. Maybe I'll start and talk about the next-gen program. We are excited, as you say, to have both molecules progressing into Phase II. We think that based on our Phase I result, and you know that given our ability to use our p",187,"Mike, this is Jeff Chodakewitz. Maybe I'll start and talk about the next-gen program. We are excited, as you say, to have both molecules progressing into Phase II. We think that based on our Phase I result, and you know that given our ability to use our preclinical assays, we can look at the exposure and have a sense of where we're going to get to in the clinic. We think that both compounds are going to go into their Phase II studies with doses that are both going to be well tolerated and efficacious, and I think that's very exciting. Maybe just to hone in a little bit on your question about therapeutic window. That really comes from both compounds being generally well tolerated. In VX-152, we did see some GI symptoms, mostly nausea and vomiting, and, therefore, that's the basis for that comment. So for VX-440, we're going right to 4-week studies and with the potential, therefore, to accelerate quickly into a Phase III. And then for 152, because of that, we are starting with Phase II studies and then can extend dosing from there."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Mike, just to address your question on the 6 through 11 launch, obviously, it's early days. We got the approval on the 28th of September, so we're less than a month in. But certainly, the early signs are encouraging, and you might expect interest is h",127,"And Mike, just to address your question on the 6 through 11 launch, obviously, it's early days. We got the approval on the 28th of September, so we're less than a month in. But certainly, the early signs are encouraging, and you might expect interest is high in using ORKAMBI in this younger patient population. We're making good progress with both public and commercial payers in terms of securing access and already have approval for about 50% of covered lives, which is, obviously, an important prerequisite to getting access to these younger patients. And so as a result of all that, we are expecting a similarly robust uptake for that, which we saw with ORKAMBI in the 12-plus population. And that's what's incorporates into our overall guidance."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Geoff Meacham of Barclays.",9,"Our next question comes from Geoff Meacham of Barclays."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just had a couple on that for either 440 or 152. Can you talk a little bit about what you're looking for FEV1 bias, just from a powering perspective? And then in either Phase II, is there a washout period for homozygous patients who have had prior expos",57,"I just had a couple on that for either 440 or 152. Can you talk a little bit about what you're looking for FEV1 bias, just from a powering perspective? And then in either Phase II, is there a washout period for homozygous patients who have had prior exposure to ORKAMBI? And I have one follow up."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, it's Jeff Chodakewitz. So again, I think that as you saw from our Phase II designs, we're really going to be getting a pretty robust look at how both molecules are going to perform. We're really being able to look at both het min patients and homoz",181,"Geoff, it's Jeff Chodakewitz. So again, I think that as you saw from our Phase II designs, we're really going to be getting a pretty robust look at how both molecules are going to perform. We're really being able to look at both het min patients and homozygous patients, which is, I think, very important. And the fact that we think that the doses we're going to be taking into Phase II can deliver benefit for both populations. That's really critical. The -- our Phase II studies are really not so much powered on any individual number. They're really giving us a good handle on being able to understand what the drugs are capable of doing. And to your point, we are going to actually leverage a washout from ORKAMBI so that people can participate. And we're going to importantly look after the end of dosing and -- because we think that, that follow-up period coming off that treatment actually has been -- can be very informative in terms of having competence in the results. So that gives you a sense."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Got you. Okay. And just real quick. In the past, you guys have talked about between 661 and 809, things like tissue penetration differences, half life  differences. Any way to generally characterize what you would say, or differences between 659, 440 and",54,"Got you. Okay. And just real quick. In the past, you guys have talked about between 661 and 809, things like tissue penetration differences, half life  differences. Any way to generally characterize what you would say, or differences between 659, 440 and 152, just from a -- from maybe a PK or chemistry perspective?"
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Geoff, maybe I'll just quickly take that because this question is just frequently asked. There are small differences between compounds. And I think the major difference is that they are structurally different.",33,"So Geoff, maybe I'll just quickly take that because this question is just frequently asked. There are small differences between compounds. And I think the major difference is that they are structurally different."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Terence Flynn of Goldman Sachs.",10,"Our next question comes from Terence Flynn of Goldman Sachs."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe 2 for me. Just on the second gen correctors. Can you give us any insight in terms of the dose limiting tox in the animal models? Was the GI seen there? And then on 440, just wondering some more details on the design of Part C of that trial. Was wond",72,"Maybe 2 for me. Just on the second gen correctors. Can you give us any insight in terms of the dose limiting tox in the animal models? Was the GI seen there? And then on 440, just wondering some more details on the design of Part C of that trial. Was wondering if you have regulatory sign off to run that as part of Phase II rather than include in Phase III."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So I think in terms of our Phase I, I think I've given you actually quite a flavor on what we've seen with the -- in the healthy volunteers, good tolerability, overall. I mentioned the nausea and vomiting. I should clarify that, that was at doses -- that",109,"So I think in terms of our Phase I, I think I've given you actually quite a flavor on what we've seen with the -- in the healthy volunteers, good tolerability, overall. I mentioned the nausea and vomiting. I should clarify that, that was at doses -- that was observed at doses higher than the doses that we're going to be taking into Phase II. That's how we think about being sure that we have a therapeutic window. In terms of the preclinical data, I really can't comment on that level of detail. And, of course, everything we do as we go forward, we'll be conferring with regulatory agencies."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And then on the 440 Part C?",8,"Okay. And then on the 440 Part C?"
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Oh, I'm sorry. I guess I was -- as far as [indiscernible], going to that part of your question. We can't comment on the individual discussions we're having with regulatory agencies. I think to your -- as we talked about that, that is going to accomplish s",95,"Oh, I'm sorry. I guess I was -- as far as [indiscernible], going to that part of your question. We can't comment on the individual discussions we're having with regulatory agencies. I think to your -- as we talked about that, that is going to accomplish several things. It's going to help us understand the performance of the triple. It's importantly going to give us data on 12 weeks of dosing. And depending on the results that we're seeing, as we said, this data actually could be done basically in parallel with Phase III study."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And is that the triple versus each of the subcomponent? Each -- versus mono of each of the 3 drugs, or is it versus a doublet?",27,"Okay. And is that the triple versus each of the subcomponent? Each -- versus mono of each of the 3 drugs, or is it versus a doublet?"
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","No. It's really primarily about triple versus doublet.",8,"No. It's really primarily about triple versus doublet."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Yin Huang of Bank of America.",11,"Our next question comes from Yin Huang of Bank of America."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","It's great to hear the Phase II advancing for the new EASL correctors. So maybe for Stu, you mentioned that 6,400 patients now have started treatment in U.S. for ORKAMBI. That leaves about another 2,000 patients. Is there a reason we should think of why t",123,"It's great to hear the Phase II advancing for the new EASL correctors. So maybe for Stu, you mentioned that 6,400 patients now have started treatment in U.S. for ORKAMBI. That leaves about another 2,000 patients. Is there a reason we should think of why those 2,000 patients will not initiate therapy, if that's possible? And then secondly, I have a question on maybe Jeff on the Phase II protocols for these 2 molecules. Do you think, as what we have seen with the KALYDECO in G551D patients and also ORKAMBI in homozygous 508 deletion patients, 2 weeks or even 4 weeks should be long enough to see a significant improvement in lung function, given that these patients have -- has mutation?"
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Ying, so thanks for the question. Yes, over 6,400 patients have initiated therapy on ORKAMBI and we're obviously delighted with that. That's over 70% of the eligible patients. But as you said, that means that 2,000 are yet to be initiated. Obviously, the",121,"Ying, so thanks for the question. Yes, over 6,400 patients have initiated therapy on ORKAMBI and we're obviously delighted with that. That's over 70% of the eligible patients. But as you said, that means that 2,000 are yet to be initiated. Obviously, the individual decision about whether a physician and patient want to initiate therapy is one that they have to come to themselves, but we're certainly continuing to see new patients being initiated as we deliver and develop more evidence about the long-term benefits of ORKAMBI. I think that's giving physicians and patients even more reasons to think about whether they would want to be initiated on ORKAMBI. And on the Phase II questions, I'll hand it over to Jeff."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart. I mean, yes, as you know, we obviously don't have data yet for the triple. But everything that we've seen across our portfolio, it's modulating CFTR, really suggest that both the 2-week and the 4-week studies are going to be able to give u",55,"Thanks, Stuart. I mean, yes, as you know, we obviously don't have data yet for the triple. But everything that we've seen across our portfolio, it's modulating CFTR, really suggest that both the 2-week and the 4-week studies are going to be able to give us valuable insights into the potential efficacy of the regimen."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Alethia Young of Crdit Suisse.",10,"Our next question comes from Alethia Young of Crdit Suisse."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congrats on the progress in Phase II. On the corrector front, with some of these new correctors, I guess, how do you think broadly about positioning these assets? And like, with the 440 and 152 compounds, would you think about moving both into Phase III?",53,"Congrats on the progress in Phase II. On the corrector front, with some of these new correctors, I guess, how do you think broadly about positioning these assets? And like, with the 440 and 152 compounds, would you think about moving both into Phase III? And then I have one question about Europe."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Leiden. That's more of a strategy question, so maybe I'll take that. And first, I'll just remind you that our strategy all along has been to develop a portfolio of next-generation correctors, really, for 2 reasons: one, they do have different pr",249,"It's Jeff Leiden. That's more of a strategy question, so maybe I'll take that. And first, I'll just remind you that our strategy all along has been to develop a portfolio of next-generation correctors, really, for 2 reasons: one, they do have different properties. They come in different flavors and we really want to see those different flavors in people in understand how they perform; and two, there's a probability of success issue here, right? By bringing 3 or 4 of these different correctors into Phase I and now in this case, Phase II studies, it increases the probability of success that will come up with the best regimens for each of the patient population. And while we can predict an awful lot from our preclinical study of cellular- assays, particularly quite well on the efficacy front. As a couple of folks noted before, there can be differences in potency and maximal efficacy and drug-like properties, and those are best seen, really, from these Phase I and Phase II trials, and we're learning a lot as we go about these different molecules. Would we ever take 2 molecules into Phase III development? It's absolutely possible just as you've seen with lumacaftor and 661, 2 first generation correctors because they may also have different protocols so -- profiles. It's just going to depend on the data that we see from these Phase II studies. But I think the important thing is the strategy we're taking is this portfolio strategy."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Great. And then on Europe, for Stuart perhaps. Maybe with some of the reimbursement conversations, do you find them kind of, of different flavor as you go through each country? Or is there kind of similar themes on what kind of payers are concerned about",47,"Great. And then on Europe, for Stuart perhaps. Maybe with some of the reimbursement conversations, do you find them kind of, of different flavor as you go through each country? Or is there kind of similar themes on what kind of payers are concerned about for ORKAMBI?"
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, I'd say the concerns and questions that we get, Alethia, are very consistent. As we've said a number of times, whilst each process is different, they tend to kind of orient themselves around 3 phases. One is the discussion of the clinical benefits of",143,"Yes, I'd say the concerns and questions that we get, Alethia, are very consistent. As we've said a number of times, whilst each process is different, they tend to kind of orient themselves around 3 phases. One is the discussion of the clinical benefits of ORKAMBI. In general, we've been very pleased that payers across Europe have recognized the broad clinical benefits of ORKAMBI. Then there is an economic evaluation. And after that phase, you enter into the price negotiation. And so whilst each process is different in each different country, they tend to follow that same pattern and they are kind of proceeding as we anticipated. And I'd say the last thing is that, in addition to evaluating the clinical benefits from an economic perspective, they are concerned about the overall budget impact it might have for them in their individual country."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Brian Abrahams of Jefferies.",9,"Our next question comes from Brian Abrahams of Jefferies."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","My congrats as well on the progress of the next-gen correctors. Two questions. First, I was wondering if you might be able to expand upon the comments you made regarding preclinical toxic studies that led you to include contraception and exclude the G6PD",103,"My congrats as well on the progress of the next-gen correctors. Two questions. First, I was wondering if you might be able to expand upon the comments you made regarding preclinical toxic studies that led you to include contraception and exclude the G6PD deficiency patients for the 440 study? Was that something just related to a hormonal interaction? And then on the commercial side, I realize it's very early days, but just wondering if you had any sense of compliance and persistence -- or at least compliance in the 6 to 11-year-old patients relative to what you've seen in adults thus far?"
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Brian, it's Jeff Chodakewitz. I'll start and then turn it over. I just want to be sure I understand your question. For the preclinical data for 440 and contraception, there are a set of standard studies that are done actually in rabbits and there, we t",121,"So Brian, it's Jeff Chodakewitz. I'll start and then turn it over. I just want to be sure I understand your question. For the preclinical data for 440 and contraception, there are a set of standard studies that are done actually in rabbits and there, we test the developmental toxicity, the effects of the drug. And we did find for the X-440 that there were some abnormalities suggesting a potential deleterious effect on the fetus. We don't know whether that actually translates to people, but the prudent thing to do, clearly, is to ensure that women in this study are using highly effective contraception and that's what we flagged them, we'll be doing that in our Phase II study with X-440."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And on your compliance question. As you say, it's very early days yet. We're just 1 month into the launch in the 6 to 11-year-old children. However, I think there are some reasons to be optimistic that the compliance rate there could be higher than we see",101,"And on your compliance question. As you say, it's very early days yet. We're just 1 month into the launch in the 6 to 11-year-old children. However, I think there are some reasons to be optimistic that the compliance rate there could be higher than we see in teenagers and in young adults. Certainly, that's what we've seen with KALYDECO, and that's not atypical for what you see in other chronic diseases where, clearly, these young kids are largely or exclusively under the supervision of their parents and therefore, compliance rates tend to be at the higher end of the spectrum."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have two things that I just wanted to ask. So, I guess, both on next-generation correctors. One, can you just compare and contrast what you would expect to learn from 2 weeks of dosing versus 4 weeks of dosing, and how you would correlate whatever signa",85,"I have two things that I just wanted to ask. So, I guess, both on next-generation correctors. One, can you just compare and contrast what you would expect to learn from 2 weeks of dosing versus 4 weeks of dosing, and how you would correlate whatever signals you're going to get out of that to how you might move those compounds ahead? And then second, can you just tell us the dose levels of 152 and 440 that you're using in these Phase II studies?"
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Matthew, Jeff Chodakewitz. So let me talk about the 2 and the 4 weeks because we're actually going to have very similar end point in both. And as we spoke about earlier, actually, we think that both 2 and 4 weeks are going to be able to give us meaningful",224,"Matthew, Jeff Chodakewitz. So let me talk about the 2 and the 4 weeks because we're actually going to have very similar end point in both. And as we spoke about earlier, actually, we think that both 2 and 4 weeks are going to be able to give us meaningful information. We're also going to have sweat chloride being evaluated in both drugs, which will also be valuable. Ultimately, what we're going to do is use all the information. We actually also have a lot of work being done to actually understand from a modeling perspective, so that we can get the absolute most information out of our clinical trial. And so we're going to use all that information across both to make the best decisions, and we think that, that will contribute to both. I think in terms of the specifics of the doses, as you may see in the design, we're going to go into patients with a small cohort. That's really just to confirm that, that exposure is the same in patients as it is in healthy volunteers. We don't have any reason to think that it will be different, but we're going to do that just to be sure we're taking the right approach. And then we'll choose our doses from there to confirm for the rest of the trial."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Geoffrey Porges of Leerink Partners.",10,"Our next question comes from Geoffrey Porges of Leerink Partners."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congratulations on advancing some more CF compound. First, just wondering if on Slide 10, you could tell us where 152, David, compared to 440 in tezacaftor in that assay? And then a couple of commercial questions. Ian, you've been fairly clear about what",171,"Congratulations on advancing some more CF compound. First, just wondering if on Slide 10, you could tell us where 152, David, compared to 440 in tezacaftor in that assay? And then a couple of commercial questions. Ian, you've been fairly clear about what we should be expecting for KALYDECO in 2017 and there's certainly been some ups and downs in both consensus and in guidance this year for ORKAMBI. So wondering where you would suggest that we sort of should be bracketing for next year for ORKAMBI. There are certainly a lot of variables with Europe with the pediatric indication coming online in the U.S. So that would be helpful. And then Stuart, lastly, as you're negotiating price in Europe, could you give us a sense of how you're thinking about having a portfolio of CF combination? Are you expecting to have them at different price points? Or should we be thinking that over time, they gravitate towards a band, regardless of whether it's 2 or 3 drugs in the combination?"
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is David Altshuler. I'll take the first part. As we showed last year in the het min cells and also homozygous cells, 152 and 440 have very similar levels of max efficacy.",33,"This is David Altshuler. I'll take the first part. As we showed last year in the het min cells and also homozygous cells, 152 and 440 have very similar levels of max efficacy."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Geoff, to your question on guidance. I hoped I was very clear on KALYDECO, in my prepared remarks, where KALYDECO is treating approximately 90% of eligible patients that -- and it has a very good persistence rate and compliance rate, and we'd anticipa",317,"And Geoff, to your question on guidance. I hoped I was very clear on KALYDECO, in my prepared remarks, where KALYDECO is treating approximately 90% of eligible patients that -- and it has a very good persistence rate and compliance rate, and we'd anticipate that continuing on into next year. So as you see, the current quarterly run rate for KALYDECO, we see that continuing on in 2017, the mark of that potentially increasing would be if we were able to gather residual function approval. And as Jeff Chodakewitz explained, we are currently in discussions with the regulatory authorities in the U.S. regarding that approval and that continues that discussion. Regarding ORKAMBI, it's a little too early to say. We're very comfortable with the guidance we've provided through the end of this year of $950 million to $990 million, and that does include the recent pediatric approval. As we look to 2017, we'll probably be thinking about how we give guidance around the U.S. market and maybe Germany as well because we do have visibility and knowledge to those markets. In terms of the other international markets, of how quickly and the time that they come on, we just need to give that some thought over the next few months of whether we actually try to provide a bracket around that guidance. There is a certain unknown element, but I'm sure you can only appreciate with these discussions. And sometimes the discussions push out because you are actually holding out for a price that you believe is appropriate for the medicine. And so it's about us getting to the right spot and rather than putting guidance around it and be forced around guidance, we'll give it some consideration of how we put a bracket around that and we'll be back to you early in 2017. And then to your third question, I'll pass it over to Stuart."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, in terms of pricing principles, obviously, we can't comment on the pricing of future products, but I'll talk to our pricing principles overall which have been very consistent for how we price KALYDECO and ORKAMBI, and the 2 primary drivers are real",168,"Geoff, in terms of pricing principles, obviously, we can't comment on the pricing of future products, but I'll talk to our pricing principles overall which have been very consistent for how we price KALYDECO and ORKAMBI, and the 2 primary drivers are really the number of patients that were able to benefit with our medicines and then the level of clinical benefit or value that we're able to bring. I think you've seen that we've adhered to those principles with ORKAMBI. And whilst we don't have formal pricing agreements in place across Europe yet, you have seen with the list prices of ORKAMBI that they are lower than they are for KALYDECO, which reflects the fact that, clearly, ORKAMBI is -- has a much wider eligible patient population despite the fact that, that medicine has two different components within it. So I think you can expect that we'll be adhering to those pricing principles as we bring next-gen correctors and other medicines to market for eligible CF patients."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from John Scotti of Evercore ISI.",10,"Our next question comes from John Scotti of Evercore ISI."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just want to ask on VX-659. If you were to compare the preclinical toxicity profile of that aspect to 440 with regard to potential teratogenicity, et cetera, and then 152 with the nausea. Are you confident that the chemical structure of 659 is different",119,"I just want to ask on VX-659. If you were to compare the preclinical toxicity profile of that aspect to 440 with regard to potential teratogenicity, et cetera, and then 152 with the nausea. Are you confident that the chemical structure of 659 is different enough where we won't see those issues in humans in the clinic with regard to what we see with 440 and 152? And then I guess, just quickly on timing. Given the trials are small and if we assume they enroll quickly, is it unreasonable to assume that we could see data more towards mid-next year rather than towards the end of the year? I know you got it in the second half."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So John, first of all, I just want to pass on the team's best wishes to Mark and we look forward to [indiscernible] from Mark at some point and I'm sure I share everybody else's thoughts that are on the phone. In terms of the question, I'm actually going",99,"So John, first of all, I just want to pass on the team's best wishes to Mark and we look forward to [indiscernible] from Mark at some point and I'm sure I share everybody else's thoughts that are on the phone. In terms of the question, I'm actually going to ask Jeff Leiden to answer it because there is a whole portfolio approach here that we have, starting from 659. And the methodology of how we probably pick our molecules and what with that basis is. And you should anticipate that there will be more modules coming. So Jeff."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for the question, John. Maybe just to go back one step and remind you of how we look at these molecules and select them. The first real acid test for these molecules is our human HBE cells, both het min cells and homozygous cells from multiple",371,"Yes, thanks for the question, John. Maybe just to go back one step and remind you of how we look at these molecules and select them. The first real acid test for these molecules is our human HBE cells, both het min cells and homozygous cells from multiple donors. And as we showed you, I think in one of the slides today, 659 actually has efficacy as measured by chloride transport, which is maximal efficacy that's significantly higher than what we were seeing in 440 and 152, which were also quite high by themselves, by the way. We've also measured a number of other things in that assay like cilia beat frequency and others, and we see the same kind of difference between 659 and 440. We've entered the molecules through a pretty rigorous screen with respect to PK, tox, coformulability, really making sure that we're bringing drugs in the clinic as opposed to molecules. And we're done with most but not all of that for 659. We're certainly done with them now so we feel very comfortable that we have a tox profile and a PK profile that we're confident in taking into Phase I studies, both in normals and in patients this time as well. We have not done yet with the developmental studies in rabbits, and we don't have that data yet. And obviously, we don't have any human data, which is the final test of PK and safety and we'll only see that in the Phase I study. In addition, just as Ian mentioned, just -- we need to be clear with our expectations, we have a number of other next-gen correctors in our late preclinical pipeline. We expect to bring at least one of those forward into the clinic in the first half of next year and maybe more. And the reason for that, again, is that these molecules come in a number of different flavors, different potencies, different properties, and we want to bring multiple of them into humans as part of triple combinations to understand how they interact. I hope that gives you a flavor of where 659 fits and what we know and some things we don't yet know, but we'll know soon."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Brian Skorney of Robert W. Baird.",14,"Our next question comes from the line of Brian Skorney of Robert W. Baird."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have two questions. I guess, why both -- why start both programs in het min? It seems like you'd potentially get more information out of adding this on top of 661 ivacaftor, in patients with 2 F508del alleles. and Also, when we look at the relative diff",81,"I have two questions. I guess, why both -- why start both programs in het min? It seems like you'd potentially get more information out of adding this on top of 661 ivacaftor, in patients with 2 F508del alleles. and Also, when we look at the relative differences of the 4 generations, is that reasonable to assume that 2 correctors within the same generations still are redundant? And is there any obvious redundancy to cross combining correctors of these different generations?"
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Brian, it's Jeff again. Let me answer both. Both are really good questions. Maybe I'll answer your second question first. Really, the portfolio approach is based upon the fact that while the molecules may bind to the same site, it may even have the s",188,"Yes. Brian, it's Jeff again. Let me answer both. Both are really good questions. Maybe I'll answer your second question first. Really, the portfolio approach is based upon the fact that while the molecules may bind to the same site, it may even have the same mechanism of action, there are obviously a number of other properties that are going to be really important in picking the best regimen. They include potency, because the more potent the molecule is, the easier it is to combine into triple combination formulate. They include maximal efficacy, obviously, and we showed you the 659 as an example of its greater maximal efficacy. But they also include things like PK properties, tissue penetration, drug-drug interactions, all of those things. And so when you think about this portfolio, think about it not only in terms of mechanism of action and not only in terms of efficacy and potency, but think about it as how do we create the best triple regimen with one or more of these molecules going forward. Does that makes sense to you in terms of how we're thinking about it?"
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, it does. That is helpful.",6,"Yes, it does. That is helpful."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And then repeat your first question for me.",8,"And then repeat your first question for me."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Oh, just on the strategy of going in het mins first.",11,"Oh, just on the strategy of going in het mins first."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. So just to be clear about what we're doing here. First of all, het mins, obviously, is the big group of patients with the largest unmet need. And so as we think about taking these molecules forward, that's the patient population that we're most focus",220,"Yes. So just to be clear about what we're doing here. First of all, het mins, obviously, is the big group of patients with the largest unmet need. And so as we think about taking these molecules forward, that's the patient population that we're most focused on. But I do want to be clear that we're essentially doing these things in parallel, and so we will have results both in the het min population and the homozygous population essentially at the same time or with very little delay. And that's going to let us really design the best Phase III study, I think, here. One of the things that I'm really been pleased with over the last 4 or 5 years is as we develop these molecules, we've learned an awful lot about how to take the development forward most quickly, most efficiently and then how to start to think about phase trials -- Phase III trials perhaps a little differently. And so I do think you're seeing the results of that here as we sort of streamline these Phase II trials, do them in parallel as opposed to in theories as we've done them in the past. And then hopefully, based on the results, of course, launch into Phase III in a much broader fashion than we've done previously."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Liisa Bayko of JMP Securities.",10,"Our next question comes from Liisa Bayko of JMP Securities."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And just to clarify, there's no intention to formulate maybe a quad or something? You wouldn't add some of your next-generation correctors together? And I guess, why not would be the question?",32,"And just to clarify, there's no intention to formulate maybe a quad or something? You wouldn't add some of your next-generation correctors together? And I guess, why not would be the question?"
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, so as a theoretical question, Liisa, of course, we would think about quads. And as you know, we're also looking at some other mechanisms of action, things like ENaC inhibitors that could be combined. So there's nothing a priori that we wouldn't look",111,"Yes, so as a theoretical question, Liisa, of course, we would think about quads. And as you know, we're also looking at some other mechanisms of action, things like ENaC inhibitors that could be combined. So there's nothing a priori that we wouldn't look at 4-drug combinations. Obviously, an ENaC inhibitor's inhaled, so it wouldn't be co-formulated. But I do think there's one difference here that's worth mentioning. I think it would be unlikely that, for instance, that will we put 152 and 440 together because they do appear to have the same mechanism of action, and so adding them together, would be not expected to produce a lot more benefit."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And then can you maybe talk about where you're going to be enrolling patients for some of these preliminary studies for the next generation? Is it going to be North America, ex U.S.?",34,"Okay. And then can you maybe talk about where you're going to be enrolling patients for some of these preliminary studies for the next generation? Is it going to be North America, ex U.S.?"
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This Jeff Chodakewitz. We're actually going to be doing studies in sites both in the U.S. and in Europe.",19,"This Jeff Chodakewitz. We're actually going to be doing studies in sites both in the U.S. and in Europe."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, great. And then just wanted to get a little bit more clarity on the hormonal component. I think you maybe talked about this earlier before VX-440 and what you've seen there in your preclinical stuff. And then what that would just mean if you were to",50,"Okay, great. And then just wanted to get a little bit more clarity on the hormonal component. I think you maybe talked about this earlier before VX-440 and what you've seen there in your preclinical stuff. And then what that would just mean if you were to take it forward."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure, Liisa. This is Jeff Chodakewitz again. So just to clarify, perhaps. We've already talked about the rapid toxicity and why we're putting the contraceptive language in place. The hormonal wording doesn't actually come from preclinical studies. With th",84,"Sure, Liisa. This is Jeff Chodakewitz again. So just to clarify, perhaps. We've already talked about the rapid toxicity and why we're putting the contraceptive language in place. The hormonal wording doesn't actually come from preclinical studies. With the X440 at higher doses, there was some evidence of liver enzyme induction, and that can actually somewhat lower the exposure to the hormones in contraceptives. And so therefore, again, to ensure that we're using highly reliable contraception, we're excluding that as being the primary method."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Tony Butler of Guggenheim Partners.",10,"Our next question comes from Tony Butler of Guggenheim Partners."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two questions briefly. In Cohort 1a, can you help me understand the notion of using the low-dose first before you move forward? While it may be intuitive, you don't do that for 152. And then the second question is really around 152. To me, you've outlined",75,"Two questions briefly. In Cohort 1a, can you help me understand the notion of using the low-dose first before you move forward? While it may be intuitive, you don't do that for 152. And then the second question is really around 152. To me, you've outlined very well the portfolio strategy, why certainly you're moving forward with 440 and 659, but is the only reason for 152 the fact that it does not have teratogenicity?"
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Tony, it's Jeff Chodakewitz. So two comments. One, the 1a, as we go back to sort of a prior conversation, the intent of 1a is to go make the transition from healthy volunteers to patients. And be sure -- basically, the exposure is similar in the two group",182,"Tony, it's Jeff Chodakewitz. So two comments. One, the 1a, as we go back to sort of a prior conversation, the intent of 1a is to go make the transition from healthy volunteers to patients. And be sure -- basically, the exposure is similar in the two groups. And since it could potentially go up or down, although we don't expect it to do either, that's why you wouldn't want to go in at a high dose and then have the exposure actually end up higher. That's why we always would start in that kind of situation with the low dose and then expand, which is the intent. In terms of your broader question about VX-152 and VX-440, I think it goes back to Jeff Leiden's comments, that we think both molecules will have the potential to be well-tolerated at doses that can deliver benefit to patients, including, excitingly, both homozygous patients and het min patients who don't have a treatment option. And that's why we're taking both forward and we'll continue to learn as we add other molecules to our portfolio."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Operator, it's Michael Partridge. We have time for one more question.",11,"Operator, it's Michael Partridge. We have time for one more question."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And that question comes from the line of Alan Carr of Needham & Company.",13,"And that question comes from the line of Alan Carr of Needham & Company."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Wondering if you can clarify that some of the timing around 152, 440 and the results from those and the results from your 659 Phase II. Are you trying to -- are you able to position these 3 data from 3 Phase II trials at the same time in order to decide w",61,"Wondering if you can clarify that some of the timing around 152, 440 and the results from those and the results from your 659 Phase II. Are you trying to -- are you able to position these 3 data from 3 Phase II trials at the same time in order to decide which one or 2 to bring into Phase III?"
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Alan, it's Jeff Chodakewitz. Let me just review how that winds up. Of course, in the end, all the time lines, particularly the Phase II studies, are going to be dependent on the rate of enrollment. But what we expect would be that for both VX-152 and V",123,"So Alan, it's Jeff Chodakewitz. Let me just review how that winds up. Of course, in the end, all the time lines, particularly the Phase II studies, are going to be dependent on the rate of enrollment. But what we expect would be that for both VX-152 and VX-440, that we will be getting results, as we said, in the second half of '17. At that point, we will also have the Phase I results from VX-659. And as we've talked about that, given everything we've learned about the relationship from preclinical to exposure to benefit of patients, we think that we will be able to understand a lot about all 3 compounds as we're looking forward to make decisions at that point."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff Leiden. I just want to be clear that we don't think about 659 as being on exactly the same time frame as 152 and 440. And as Jeff said, it's a little difficult to give you precision because it depends on how users enrolled. 659 will only have",132,"This is Jeff Leiden. I just want to be clear that we don't think about 659 as being on exactly the same time frame as 152 and 440. And as Jeff said, it's a little difficult to give you precision because it depends on how users enrolled. 659 will only have a small cohort of patients from the Phase I, and so we'll have to see what we learn from that. But if you would ask me just to put a sort of marker on the table, I think that 659 myself is about 6 months behind 152 and 440. So we're not going to be waiting, obviously, if we see positive results with 152 and 440 before taking those into Phase III to wait for 659, if that's really the question."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes. Okay, that helps. And then one other one. I guess, can you give us an update on 371? Where things stand with your CF program and ciliary dyskinesia there?",30,"Yes. Okay, that helps. And then one other one. I guess, can you give us an update on 371? Where things stand with your CF program and ciliary dyskinesia there?"
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So it's Jeff Chodakewitz. Both of our studies, both the study in CF where we're looking at the ENaC inhibitor on top of ORKAMBI and in piece for homozygous for F508del and the study in patients with PCD, both are actively enrolling.",43,"So it's Jeff Chodakewitz. Both of our studies, both the study in CF where we're looking at the ENaC inhibitor on top of ORKAMBI and in piece for homozygous for F508del and the study in patients with PCD, both are actively enrolling."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And timing for results, what's the latest on that?",9,"And timing for results, what's the latest on that?"
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's always going to be -- of course, until we end up getting the study fully enrolled, it's just too hard to give you any precision on the time.",30,"It's always going to be -- of course, until we end up getting the study fully enrolled, it's just too hard to give you any precision on the time."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay. Everybody, thanks for joining us tonight. For those of you who are going to the North American CF Conference, we look forward to seeing you there on Thursday night this week. We will also be webcasting our presentation there starting at 6:30 p.m. Ea",66,"Okay. Everybody, thanks for joining us tonight. For those of you who are going to the North American CF Conference, we look forward to seeing you there on Thursday night this week. We will also be webcasting our presentation there starting at 6:30 p.m. Eastern Time on Thursday. Tonight, the Investor Relations team will remain in the office if you have any additional questions. Thank you."
36235,404123072,1060935,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, that does conclude your call. You may disconnect at this time. Have a great day.",18,"Ladies and gentlemen, that does conclude your call. You may disconnect at this time. Have a great day."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Good evening. This is Michael Partridge, Vice President of Investor Relations. Welcome to our Third Quarter 2016 Financial Results Conference Call. [Operator Instructions] This conference call is recorded, and there will be a replay available later tonigh",182,"Good evening. This is Michael Partridge, Vice President of Investor Relations. Welcome to our Third Quarter 2016 Financial Results Conference Call. [Operator Instructions] This conference call is recorded, and there will be a replay available later tonight. You can access the webcast live by going to our website. Dr. Jeff Leiden, Chairman and CEO; Stuart Arbuckle, Chief Commercial Officer; Dr. Jeff Chodakewitz, Chief Medical Officer; and Ian Smith, Chief Financial Officer, will provide prepared remarks on this call. They will be joined by Dr. David Altshuler, Chief Scientific Officer, for the Q&A portion of the call. 
We will make forward-looking statements on this conference call. These statements are subject to the risks and uncertainties discussed in detail in today's press release and our 10-K, which has been filed with the SEC. These statements, including without limitation, those regarding the ongoing development and potential commercialization of our drug candidates, our expectations regarding our approved medicines and Vertex' future financial performance are based on management's current assumptions. Actual outcomes and events 
[Audio Gap]
I will now turn the call over to Dr. Jeff Leiden."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Michael. Good evening, everyone. Vertex' strategy in cystic fibrosis is to treat as many people with CF as possible and to continue to enhance the clinical benefits for those treated by our medicines. Our long-term goal is to reduce the progressiv",555,"Thanks, Michael. Good evening, everyone. Vertex' strategy in cystic fibrosis is to treat as many people with CF as possible and to continue to enhance the clinical benefits for those treated by our medicines. Our long-term goal is to reduce the progressive and irreversible effects of CF by treating underlying cause of the disease. 
There are 3 key components to our strategy. First, to increase the number of eligible patients being treated with our approved medicines, mainly by obtaining reimbursement for ORKAMBI for more patients outside the U.S.; second, to further expand the labels for KALYDECO and ORKAMBI around the world; and third, to develop new combination regimens of CFTR modulators designed to enhance benefit for all patients. 
This evening, I'm pleased to report that we continue to make excellent progress on all of these fronts. Last month, the FDA approved ORKAMBI for the treatment of children with CF, ages 6 through 11, who have 2 copies of the F508del mutation. With this approval, approximately 29,000 patients worldwide are now eligible for our medicines. 
Today, we are treating approximately 9,000 of these 29,000 eligible patients. Moving forward, we remain focused on expanding access to ORKAMBI and KALYDECO for the many eligible patients who are still awaiting treatment, largely through obtaining reimbursement for ORKAMBI in Europe, Canada and Australia.
We are also continuing to make progress in our efforts to expand the labels for KALYDECO and ORKAMBI. In the U.S., we are focused on obtaining approval for KALYDECO in patients with residual function mutations. And in the EU, we expect data this quarter from our Phase III trial of ORKAMBI in children ages 6 through 11 who are homozygous for the F508del mutation. If successful, these would represent approximately 5,000 additional patients who may benefit from our approved medicines.
Beyond this important progress, our long-term goal is to treat all people with CF. During the last year, we have significantly advanced our CF pipeline, which now spans all phases of research and development. Today, we announced the planned initiation of 2 separate Phase II studies of our next-generation correctors, VX-440 and VX-152 in people with CF. And also a Phase I study of a third next-generation corrector, VX-659 as part of a triple combination.
These studies represent significant milestones in our efforts to treat as many people with CF as possible, and we'll provide the first safety and clinical efficacy data in patients, including het min patients for a triple combination regimen that includes a next-generation corrector. 
We expect to have data from the Phase II studies in the second half of 2017. Additionally, we look forward to obtaining Phase III data for the combination regimen of VX-661, which now carries the generic name tezacaftor and ivacaftor in the first half of 2017. 
As we enter the fourth quarter of 2016, Vertex is a global biotech company that has discovered and developed 2 breakthrough medicines for people with CF, while broadening our pipeline of future medicines. Our significant revenue growth and return to profitability over the past year, our metrics of the kind of company that we are becoming, a company that consistently creates transformative medicines for patients and deliver significant and sustained revenue and earnings growth for our shareholders.
With that, I'll hand the call over to Stuart to discuss the performance of our medicines."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff, and hello, everyone. Tonight, I will review the performance of ORKAMBI, our ongoing efforts to obtain reimbursement in Europe, the label expansion for children ages 6 through 11 in the United States and the outlook for KALYDECO. In the thi",726,"Thanks, Jeff, and hello, everyone. Tonight, I will review the performance of ORKAMBI, our ongoing efforts to obtain reimbursement in Europe, the label expansion for children ages 6 through 11 in the United States and the outlook for KALYDECO. 
In the third quarter, global sales of ORKAMBI were $234 million, comprised of U.S. sales of $211 million and ex U.S. sales of $23 million.
This quarter, sales in the U.S. declined compared to the second quarter of this year, largely due to a slowing in refills during the summer months of July and August. We have now seen the vast majority of these patients refill their prescriptions. The overall compliance and persistence rates we are observing remain as we outlined earlier in the year. 
During the quarter, patients in the U.S. continue to initiate treatment at a slower rate as we approach peak penetration in the U.S. for patients age 12 and over. As of the end of September, approximately 6,400 patients in the U.S. have initiated therapy on ORKAMBI.
Last month, we revised our 2016 ORKAMBI revenue guidance to be between $950 million and $990 million for the full year, and we are reiterating that guidance today. U.S. treatment trends were one reason for the revised guidance. And the other main driver was the ongoing launch in Germany, which has been slower than expected. 
As of September 30, approximately 500 of the 2,500 eligible patients have initiated treatment in Germany. We remain confident that we will treat the vast majority of eligible patients over time in Germany, but it will take longer than we had originally anticipated to reach that goal.
In contrast to Germany, we continue to see strong demand in France, where approximately 900 of the 1,500 eligible patients have initiated therapy through early access programs as of the end of September. I would note that we are not recognizing revenue for these patients in France until we achieve a formal reimbursement agreement.
Throughout Europe, reimbursement is progressing as anticipated. While there are unique aspects to each process, reimbursement typically falls into 3 phases: A clinical benefit assessment and economic evaluation and price negotiations. In several countries, benefit assessments and economic evaluations are complete. We are pleased that government payers across Europe recognize the severity of this disease and the broad clinical benefits of ORKAMBI. We have now entered the third phase of the reimbursement process, which includes price negotiations in many key countries. While the process takes time to complete, we believe that we will achieve broad reimbursement from key European and other government payers. We expect our first pricing agreement in a major European market to come in Germany this December. 
Pricing and reimbursement approvals for patients eligible for ORKAMBI outside of the U.S. are expected to drive significant revenue growth in 2017.
I will now turn to our recent sNDA approval for ORKAMBI announced last month. We were delighted the FDA approved ORKAMBI for the treatment of children ages 6 to 11 who have 2 copies of the F508del mutation. And since then, we have been working to get the medicine to the approximately 2,400 eligible patients as rapidly as possible. 
Interest in ORKAMBI for this age group has been very high, and our interactions with public and private payers have been productive. We expect broad coverage of ORKAMBI for this patient population as payers have already evaluated the product after approval last year in patients 12 years and older. Thanks to the commitment of health care providers at CF centers across the country. I am pleased to report the first children, ages 6 through 11, are already receiving ORKAMBI. We expect the launch to drive revenue growth in the fourth quarter of 2016 and in 2017. 
Turning to KALYDECO. Net revenues for the product were $176 million in the third quarter. We are now treating the vast majority of currently eligible patients and, therefore, we expect this level of quarterly revenues to be maintained in the near term unless KALYDECO is approved in CF patients with residual function mutations. Today, there are approximately 29,000 people eligible for ORKAMBI or KALYDECO globally, yet we are only treating approximately 1/3 of these patients. Therefore, expanding access to both of our medicines for eligible patients around the world is our top priority. 
With that, I'll turn the call over to Jeff Chodakewitz."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart. Tonight, I'll review the significant progress we are making with our CF pipeline, and I'll start with the Phase III program of tezacaftor. We believe the investigational combination of tezacaftor and ivacaftor could play an important role",972,"Thanks, Stuart. Tonight, I'll review the significant progress we are making with our CF pipeline, and I'll start with the Phase III program of tezacaftor. We believe the investigational combination of tezacaftor and ivacaftor could play an important role in the treatment of people with CF. Enrollment is now complete in the Phase III study in F508del homozygous patients, and also in the study in people who have residual function mutations. 
Data from both studies are expected in the first half of 2017. The Phase III study in people with gating mutations is expected to complete enrollment in early 2017. Pending data from the Phase III program, we plan to submit an NDA in the U.S. for tezacaftor and ivacaftor in the second half of 2017. 
I'd like to turn now to the progression of our next-generation correctors and triple combination regimens. Our research and development strategy is to advance multiple compounds into development on the basis of our predictive preclinical assays and on Phase I safety studies, so we can choose the best combinations to evaluate in Phase III development. The advancement of VX-440 and VX-152 into Phase II and the selection of VX-659 for clinical development reflect this strategy. VX-440 and VX-152 will evaluate triple combination dosing for 4 weeks and 2 weeks, respectively, and we'll evaluate both het min and F508del homozygous patients. 
Data from both of these studies are expected in the second half of 2017. The Phase II study of VX-440 includes 3 parts. Each has a different strategic objective, but shares the same primary endpoints of safety and efficacy as measured by absolute change among function.
Slide 8 of the webcast outlines some of the studies' key features. Part A is focused on het min patients, and Part B will enroll F508del homozygous patients. Parts A and B of the study will evaluate triple combination dosing for 4 weeks, and we expect to have the data in the second half of 2017. The potential initiation of Phase III development will depend on these data and discussions with regulatory agencies. 
Part C is designed to generate 12 weeks safety and efficacy data for triple combination dosing in het min patients and will run largely in parallel with potential Phase III development and will evaluate the contribution of the individual components to the overall triple combination regimen.
Slide 9 of our webcast outlines the Phase II study of VX-152. This study includes 2 parts. The primary endpoint of safety and tolerability, but a key focus will also be looking at measures of efficacy, including absolute change in lung function and change in sweat chloride among others. Part A will enroll het min patients, and Part B will enroll F508del homozygous patients. 
The VX-152 study will evaluate triple combination dosing for 2 weeks, and data are also expected in the second half of 2017 and are intended to support the potential initiation of a longer duration Phase IIb or registration program, pending data and discussions with regulatory agencies. 
Our Phase I studies in healthy volunteers and other preclinical studies provide support for advancing both VX-440 and VX-152 into Phase II development and have informed the designs of the Phase II studies we're announcing today. 
Based on Phase I learnings, we believe VX-440 may have a wider therapeutic window, and this is the reason that the VX-440 study will evaluate 4-week dosing from the outset. We also noted in our press release today a specific contraception requirement for females of childbearing potential seeking to enroll in the VX-440 study. This enrollment criterion was based on recent results from preclinical development toxicology studies. Based on laboratory findings from our Phase I study of VX-152, we're also excluding patients with G6PD deficiency from the Phase II studies of VX-152 and also VX-440.
G6PD deficiency and CF prevalence have limit geographic overlap and, therefore, the incidence of G6PD in the CF population is very low. We estimate this impacts less than 1% of all CF patients overall. 
I will just make a few comments on the in-vitro profile for VX-659, highlighted here on Slide 10. In our HBE assays, the use of a triple combination that contains VX-659 with tezacaftor and ivacaftor resulted in maximal efficacy that was greater than that seen with VX-440 or VX-152 in triple combination. Additionally, VX-659 is highly potent in-vitro, which makes it favorable for a combination with other molecules.
The Phase I study of VX-659 will be very similar to those we conducted for VX-440 and VX-152. Pending data from healthy volunteers, we plan to conduct the first evaluation of VX-659 in CF patients as part of the initial Phase I study. We expect to initiate Phase II development for VX-659 in the second half of 2017, pending data from the Phase I study. 
Stepping back from the trial designs, we believe we are in a strong position to define the clinical activity of 3 different next-generation correctors in patients and have data in 2017 that enhance the probability of success for our next-generation corrector program.
The studies we are conducting with VX-440 and VX-152 could provide data sufficient to move to pivotal development, accelerating our ability to deliver significant clinical benefits to even more patients than we treat today. I look forward to providing updates on our triple combination regimens as they progress. 
Before I hand the call over to Ian, I did want to mention one additional clinical milestone we expect to achieve before the end of this year. Data from a Phase III efficacy study to support approval for ORKAMBI in children ages 6 to 11 in Europe is expected in the fourth quarter. Pending data from this study, we plan to submit an MAA variation in the EU in the first half of 2017.
With that, I'll hand the call over to Ian."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Jeff. Good evening to everyone. As you've heard tonight, we continue to make significant progress across our business. In my remarks today, I'll review our third quarter financial results, review our 2016 financial guidance and discuss our antic",552,"Thanks, Jeff. Good evening to everyone. As you've heard tonight, we continue to make significant progress across our business. 
In my remarks today, I'll review our third quarter financial results, review our 2016 financial guidance and discuss our anticipated financial trajectory into 2017 and longer term.
Financial results first. In the third quarter of 2016, we reported total net CF product revenues of approximately $410 million, growing 38% compared to the third quarter of last year as the number of patients being treated with our medicines significantly increased with the launch of ORKAMBI in July 2015.
Our third quarter non-GAAP operating expenses were $298 million, including R&D expense of $214 million and SG&A expense of $84 million. The increased expenses for the third quarter of 2016 compared to 2015 were primarily the result of increased costs related to the progression of our CF pipeline and increased investment in global commercial support for the launch of ORKAMBI. 
This quarter, we recorded a non-GAAP net profit of $40 million or $0.16 per diluted share compared to a non-GAAP net loss of $32 million or $0.13 per share for the third quarter 2015. This turnaround to profit was driven by a significant increase in revenues compared to the prior year, which outpaced a smaller increase in non-GAAP operating expenses.
From a balance sheet perspective, we ended the third quarter with a strong cash position of $1.1 billion. Additionally, earlier this month, we replaced our $300 million term loan with a credit agreement that will significantly lower our interest expense and increase our available credit up to $800 million pending certain conditions. We will continue to build upon our strong financial position going forward.
Now let's turn to 2016 financial guidance. We are reiterating our 2016 ORKAMBI revenue guidance of $950 million to $990 million. And within this guidance, we expect ORKAMBI revenues to grow from the third quarter to the fourth quarter of 2016 as children's ages 6 through 11 initiate treatment in the U.S. As Stuart mentioned earlier, the initial signs of these patients initiating therapy are encouraging. And as we look into 2017, we see continued growth for ORKAMBI, primarily driven by gaining reimbursement approvals throughout Europe and continuing pediatric launch in the U.S. 
We continue to anticipate 2016 KALYDECO net revenues to be between $685 million and $705 million. As we look forward into 2017, we do not expect significant revenue growth for KALYDECO. If KALYDECO were to be approved in residual function patients, that would be the only significant driver of growth for KALYDECO in 2017.
For our operating expenses, we continue to expect our combined non-GAAP R&D and SG&A expenses to be between $1.18 billion and $1.23 billion for the full year. As we look forward to 2017, we anticipate modest growth in operating expenses to support the progression of our CF pipeline and the launch of ORKAMBI in new geographies.
As we continue to increase the number of patients that we treat, we expect our revenues to grow significantly in the coming years, while operating expenses will only increase modestly. We are well on track to deliver a financial profile that is similar to many of our large-cap biotech peers, which includes high operating margins, sustainable earnings growth and significant cash generation.
I'll now open the line to questions."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","[Operator Instructions] Our first question comes from the line of Michael Yee of RBC Capital Markets.",16,"[Operator Instructions] Our first question comes from the line of Michael Yee of RBC Capital Markets."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I guess my question on the next-generation compound is, can you talk a little bit about what you mean by therapeutic window for 440 for 152? Talk a little bit about safety and tolerability, what you saw in U.K. Just give a little more color there that wou",122,"I guess my question on the next-generation compound is, can you talk a little bit about what you mean by therapeutic window for 440 for 152? Talk a little bit about safety and tolerability, what you saw in U.K. Just give a little more color there that would be helpful and between the 2 programs. And then just a commercial question for you is in your guidance that you've given for the year on ORKAMBI, obviously, you're launching the 6 to 11-year-olds. What type of cadence or ramp do you expect there? What's in your guidance? Is it a similar ramp to the 12 and up, given that these are healthier patients? So just want to understand what you're expecting there."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Mike, this is Jeff Chodakewitz. Maybe I'll start and talk about the next-gen program. We are excited, as you say, to have both molecules progressing into Phase II. We think that based on our Phase I result, and you know that given our ability to use our p",187,"Mike, this is Jeff Chodakewitz. Maybe I'll start and talk about the next-gen program. We are excited, as you say, to have both molecules progressing into Phase II. We think that based on our Phase I result, and you know that given our ability to use our preclinical assays, we can look at the exposure and have a sense of where we're going to get to in the clinic. We think that both compounds are going to go into their Phase II studies with doses that are both going to be well tolerated and efficacious, and I think that's very exciting. Maybe just to hone in a little bit on your question about therapeutic window. That really comes from both compounds being generally well tolerated. In VX-152, we did see some GI symptoms, mostly nausea and vomiting, and, therefore, that's the basis for that comment. So for VX-440, we're going right to 4-week studies and with the potential, therefore, to accelerate quickly into a Phase III. And then for 152, because of that, we are starting with Phase II studies and then can extend dosing from there."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Mike, just to address your question on the 6 through 11 launch, obviously, it's early days. We got the approval on the 28th of September, so we're less than a month in. But certainly, the early signs are encouraging, and you might expect interest is h",127,"And Mike, just to address your question on the 6 through 11 launch, obviously, it's early days. We got the approval on the 28th of September, so we're less than a month in. But certainly, the early signs are encouraging, and you might expect interest is high in using ORKAMBI in this younger patient population. We're making good progress with both public and commercial payers in terms of securing access and already have approval for about 50% of covered lives, which is, obviously, an important prerequisite to getting access to these younger patients. And so as a result of all that, we are expecting a similarly robust uptake for that, which we saw with ORKAMBI in the 12-plus population. And that's what's incorporates into our overall guidance."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Geoff Meacham of Barclays.",9,"Our next question comes from Geoff Meacham of Barclays."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just had a couple on that for either 440 or 152. Can you talk a little bit about what you're looking for FEV1 bias, just from a powering perspective? And then in either Phase II, is there a washout period for homozygous patients who have had prior expos",57,"I just had a couple on that for either 440 or 152. Can you talk a little bit about what you're looking for FEV1 bias, just from a powering perspective? And then in either Phase II, is there a washout period for homozygous patients who have had prior exposure to ORKAMBI? And I have one follow up."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, it's Jeff Chodakewitz. So again, I think that as you saw from our Phase II designs, we're really going to be getting a pretty robust look at how both molecules are going to perform. We're really being able to look at both het min patients and homoz",181,"Geoff, it's Jeff Chodakewitz. So again, I think that as you saw from our Phase II designs, we're really going to be getting a pretty robust look at how both molecules are going to perform. We're really being able to look at both het min patients and homozygous patients, which is, I think, very important. And the fact that we think that the doses we're going to be taking into Phase II can deliver benefit for both populations. That's really critical. The -- our Phase II studies are really not so much powered on any individual number. They're really giving us a good handle on being able to understand what the drugs are capable of doing. And to your point, we are going to actually leverage a washout from ORKAMBI so that people can participate. And we're going to importantly look after the end of dosing and -- because we think that, that follow-up period coming off that treatment actually has been -- can be very informative in terms of having competence in the results. So that gives you a sense."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Got you. Okay. And just real quick. In the past, you guys have talked about between 661 and 809, things like tissue penetration differences, half life  differences. Any way to generally characterize what you would say, or differences between 659, 440 and",54,"Got you. Okay. And just real quick. In the past, you guys have talked about between 661 and 809, things like tissue penetration differences, half life  differences. Any way to generally characterize what you would say, or differences between 659, 440 and 152, just from a -- from maybe a PK or chemistry perspective?"
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Geoff, maybe I'll just quickly take that because this question is just frequently asked. There are small differences between compounds. And I think the major difference is that they are structurally different.",33,"So Geoff, maybe I'll just quickly take that because this question is just frequently asked. There are small differences between compounds. And I think the major difference is that they are structurally different."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Terence Flynn of Goldman Sachs.",10,"Our next question comes from Terence Flynn of Goldman Sachs."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Maybe 2 for me. Just on the second gen correctors. Can you give us any insight in terms of the dose limiting tox in the animal models? Was the GI seen there? And then on 440, just wondering some more details on the design of Part C of that trial. Was wond",72,"Maybe 2 for me. Just on the second gen correctors. Can you give us any insight in terms of the dose limiting tox in the animal models? Was the GI seen there? And then on 440, just wondering some more details on the design of Part C of that trial. Was wondering if you have regulatory sign off to run that as part of Phase II rather than include in Phase III."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So I think in terms of our Phase I, I think I've given you actually quite a flavor on what we've seen with the -- in the healthy volunteers, good tolerability, overall. I mentioned the nausea and vomiting. I should clarify that, that was at doses -- that",109,"So I think in terms of our Phase I, I think I've given you actually quite a flavor on what we've seen with the -- in the healthy volunteers, good tolerability, overall. I mentioned the nausea and vomiting. I should clarify that, that was at doses -- that was observed at doses higher than the doses that we're going to be taking into Phase II. That's how we think about being sure that we have a therapeutic window. In terms of the preclinical data, I really can't comment on that level of detail. And, of course, everything we do as we go forward, we'll be conferring with regulatory agencies."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And then on the 440 Part C?",8,"Okay. And then on the 440 Part C?"
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Oh, I'm sorry. I guess I was -- as far as [indiscernible], going to that part of your question. We can't comment on the individual discussions we're having with regulatory agencies. I think to your -- as we talked about that, that is going to accomplish s",95,"Oh, I'm sorry. I guess I was -- as far as [indiscernible], going to that part of your question. We can't comment on the individual discussions we're having with regulatory agencies. I think to your -- as we talked about that, that is going to accomplish several things. It's going to help us understand the performance of the triple. It's importantly going to give us data on 12 weeks of dosing. And depending on the results that we're seeing, as we said, this data actually could be done basically in parallel with Phase III study."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And is that the triple versus each of the subcomponent? Each -- versus mono of each of the 3 drugs, or is it versus a doublet?",27,"Okay. And is that the triple versus each of the subcomponent? Each -- versus mono of each of the 3 drugs, or is it versus a doublet?"
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","No. It's really primarily about triple versus doublet.",8,"No. It's really primarily about triple versus doublet."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Yin Huang of Bank of America.",11,"Our next question comes from Yin Huang of Bank of America."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","It's great to hear the Phase II advancing for the new EASL correctors. So maybe for Stu, you mentioned that 6,400 patients now have started treatment in U.S. for ORKAMBI. That leaves about another 2,000 patients. Is there a reason we should think of why t",123,"It's great to hear the Phase II advancing for the new EASL correctors. So maybe for Stu, you mentioned that 6,400 patients now have started treatment in U.S. for ORKAMBI. That leaves about another 2,000 patients. Is there a reason we should think of why those 2,000 patients will not initiate therapy, if that's possible? And then secondly, I have a question on maybe Jeff on the Phase II protocols for these 2 molecules. Do you think, as what we have seen with the KALYDECO in G551D patients and also ORKAMBI in homozygous 508 deletion patients, 2 weeks or even 4 weeks should be long enough to see a significant improvement in lung function, given that these patients have -- has mutation?"
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Ying, so thanks for the question. Yes, over 6,400 patients have initiated therapy on ORKAMBI and we're obviously delighted with that. That's over 70% of the eligible patients. But as you said, that means that 2,000 are yet to be initiated. Obviously, the",121,"Ying, so thanks for the question. Yes, over 6,400 patients have initiated therapy on ORKAMBI and we're obviously delighted with that. That's over 70% of the eligible patients. But as you said, that means that 2,000 are yet to be initiated. Obviously, the individual decision about whether a physician and patient want to initiate therapy is one that they have to come to themselves, but we're certainly continuing to see new patients being initiated as we deliver and develop more evidence about the long-term benefits of ORKAMBI. I think that's giving physicians and patients even more reasons to think about whether they would want to be initiated on ORKAMBI. And on the Phase II questions, I'll hand it over to Jeff."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Thanks, Stuart. I mean, yes, as you know, we obviously don't have data yet for the triple. But everything that we've seen across our portfolio, it's modulating CFTR, really suggest that both the 2-week and the 4-week studies are going to be able to give u",55,"Thanks, Stuart. I mean, yes, as you know, we obviously don't have data yet for the triple. But everything that we've seen across our portfolio, it's modulating CFTR, really suggest that both the 2-week and the 4-week studies are going to be able to give us valuable insights into the potential efficacy of the regimen."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Alethia Young of Crdit Suisse.",10,"Our next question comes from Alethia Young of Crdit Suisse."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congrats on the progress in Phase II. On the corrector front, with some of these new correctors, I guess, how do you think broadly about positioning these assets? And like, with the 440 and 152 compounds, would you think about moving both into Phase III?",53,"Congrats on the progress in Phase II. On the corrector front, with some of these new correctors, I guess, how do you think broadly about positioning these assets? And like, with the 440 and 152 compounds, would you think about moving both into Phase III? And then I have one question about Europe."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's Jeff Leiden. That's more of a strategy question, so maybe I'll take that. And first, I'll just remind you that our strategy all along has been to develop a portfolio of next-generation correctors, really, for 2 reasons: one, they do have different pr",249,"It's Jeff Leiden. That's more of a strategy question, so maybe I'll take that. And first, I'll just remind you that our strategy all along has been to develop a portfolio of next-generation correctors, really, for 2 reasons: one, they do have different properties. They come in different flavors and we really want to see those different flavors in people in understand how they perform; and two, there's a probability of success issue here, right? By bringing 3 or 4 of these different correctors into Phase I and now in this case, Phase II studies, it increases the probability of success that will come up with the best regimens for each of the patient population. And while we can predict an awful lot from our preclinical study of cellular- assays, particularly quite well on the efficacy front. As a couple of folks noted before, there can be differences in potency and maximal efficacy and drug-like properties, and those are best seen, really, from these Phase I and Phase II trials, and we're learning a lot as we go about these different molecules. Would we ever take 2 molecules into Phase III development? It's absolutely possible just as you've seen with lumacaftor and 661, 2 first generation correctors because they may also have different protocols so -- profiles. It's just going to depend on the data that we see from these Phase II studies. But I think the important thing is the strategy we're taking is this portfolio strategy."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Great. And then on Europe, for Stuart perhaps. Maybe with some of the reimbursement conversations, do you find them kind of, of different flavor as you go through each country? Or is there kind of similar themes on what kind of payers are concerned about",47,"Great. And then on Europe, for Stuart perhaps. Maybe with some of the reimbursement conversations, do you find them kind of, of different flavor as you go through each country? Or is there kind of similar themes on what kind of payers are concerned about for ORKAMBI?"
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, I'd say the concerns and questions that we get, Alethia, are very consistent. As we've said a number of times, whilst each process is different, they tend to kind of orient themselves around 3 phases. One is the discussion of the clinical benefits of",143,"Yes, I'd say the concerns and questions that we get, Alethia, are very consistent. As we've said a number of times, whilst each process is different, they tend to kind of orient themselves around 3 phases. One is the discussion of the clinical benefits of ORKAMBI. In general, we've been very pleased that payers across Europe have recognized the broad clinical benefits of ORKAMBI. Then there is an economic evaluation. And after that phase, you enter into the price negotiation. And so whilst each process is different in each different country, they tend to follow that same pattern and they are kind of proceeding as we anticipated. And I'd say the last thing is that, in addition to evaluating the clinical benefits from an economic perspective, they are concerned about the overall budget impact it might have for them in their individual country."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Brian Abrahams of Jefferies.",9,"Our next question comes from Brian Abrahams of Jefferies."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","My congrats as well on the progress of the next-gen correctors. Two questions. First, I was wondering if you might be able to expand upon the comments you made regarding preclinical toxic studies that led you to include contraception and exclude the G6PD",103,"My congrats as well on the progress of the next-gen correctors. Two questions. First, I was wondering if you might be able to expand upon the comments you made regarding preclinical toxic studies that led you to include contraception and exclude the G6PD deficiency patients for the 440 study? Was that something just related to a hormonal interaction? And then on the commercial side, I realize it's very early days, but just wondering if you had any sense of compliance and persistence -- or at least compliance in the 6 to 11-year-old patients relative to what you've seen in adults thus far?"
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Brian, it's Jeff Chodakewitz. I'll start and then turn it over. I just want to be sure I understand your question. For the preclinical data for 440 and contraception, there are a set of standard studies that are done actually in rabbits and there, we t",121,"So Brian, it's Jeff Chodakewitz. I'll start and then turn it over. I just want to be sure I understand your question. For the preclinical data for 440 and contraception, there are a set of standard studies that are done actually in rabbits and there, we test the developmental toxicity, the effects of the drug. And we did find for the X-440 that there were some abnormalities suggesting a potential deleterious effect on the fetus. We don't know whether that actually translates to people, but the prudent thing to do, clearly, is to ensure that women in this study are using highly effective contraception and that's what we flagged them, we'll be doing that in our Phase II study with X-440."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And on your compliance question. As you say, it's very early days yet. We're just 1 month into the launch in the 6 to 11-year-old children. However, I think there are some reasons to be optimistic that the compliance rate there could be higher than we see",101,"And on your compliance question. As you say, it's very early days yet. We're just 1 month into the launch in the 6 to 11-year-old children. However, I think there are some reasons to be optimistic that the compliance rate there could be higher than we see in teenagers and in young adults. Certainly, that's what we've seen with KALYDECO, and that's not atypical for what you see in other chronic diseases where, clearly, these young kids are largely or exclusively under the supervision of their parents and therefore, compliance rates tend to be at the higher end of the spectrum."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And our next question comes from Matthew Harrison of Morgan Stanley.",11,"And our next question comes from Matthew Harrison of Morgan Stanley."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have two things that I just wanted to ask. So, I guess, both on next-generation correctors. One, can you just compare and contrast what you would expect to learn from 2 weeks of dosing versus 4 weeks of dosing, and how you would correlate whatever signa",85,"I have two things that I just wanted to ask. So, I guess, both on next-generation correctors. One, can you just compare and contrast what you would expect to learn from 2 weeks of dosing versus 4 weeks of dosing, and how you would correlate whatever signals you're going to get out of that to how you might move those compounds ahead? And then second, can you just tell us the dose levels of 152 and 440 that you're using in these Phase II studies?"
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Matthew, Jeff Chodakewitz. So let me talk about the 2 and the 4 weeks because we're actually going to have very similar end point in both. And as we spoke about earlier, actually, we think that both 2 and 4 weeks are going to be able to give us meaningful",224,"Matthew, Jeff Chodakewitz. So let me talk about the 2 and the 4 weeks because we're actually going to have very similar end point in both. And as we spoke about earlier, actually, we think that both 2 and 4 weeks are going to be able to give us meaningful information. We're also going to have sweat chloride being evaluated in both drugs, which will also be valuable. Ultimately, what we're going to do is use all the information. We actually also have a lot of work being done to actually understand from a modeling perspective, so that we can get the absolute most information out of our clinical trial. And so we're going to use all that information across both to make the best decisions, and we think that, that will contribute to both. I think in terms of the specifics of the doses, as you may see in the design, we're going to go into patients with a small cohort. That's really just to confirm that, that exposure is the same in patients as it is in healthy volunteers. We don't have any reason to think that it will be different, but we're going to do that just to be sure we're taking the right approach. And then we'll choose our doses from there to confirm for the rest of the trial."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Geoffrey Porges of Leerink Partners.",10,"Our next question comes from Geoffrey Porges of Leerink Partners."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Congratulations on advancing some more CF compound. First, just wondering if on Slide 10, you could tell us where 152, David, compared to 440 in tezacaftor in that assay? And then a couple of commercial questions. Ian, you've been fairly clear about what",171,"Congratulations on advancing some more CF compound. First, just wondering if on Slide 10, you could tell us where 152, David, compared to 440 in tezacaftor in that assay? And then a couple of commercial questions. Ian, you've been fairly clear about what we should be expecting for KALYDECO in 2017 and there's certainly been some ups and downs in both consensus and in guidance this year for ORKAMBI. So wondering where you would suggest that we sort of should be bracketing for next year for ORKAMBI. There are certainly a lot of variables with Europe with the pediatric indication coming online in the U.S. So that would be helpful. And then Stuart, lastly, as you're negotiating price in Europe, could you give us a sense of how you're thinking about having a portfolio of CF combination? Are you expecting to have them at different price points? Or should we be thinking that over time, they gravitate towards a band, regardless of whether it's 2 or 3 drugs in the combination?"
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is David Altshuler. I'll take the first part. As we showed last year in the het min cells and also homozygous cells, 152 and 440 have very similar levels of max efficacy.",33,"This is David Altshuler. I'll take the first part. As we showed last year in the het min cells and also homozygous cells, 152 and 440 have very similar levels of max efficacy."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And Geoff, to your question on guidance. I hoped I was very clear on KALYDECO, in my prepared remarks, where KALYDECO is treating approximately 90% of eligible patients that -- and it has a very good persistence rate and compliance rate, and we'd anticipa",317,"And Geoff, to your question on guidance. I hoped I was very clear on KALYDECO, in my prepared remarks, where KALYDECO is treating approximately 90% of eligible patients that -- and it has a very good persistence rate and compliance rate, and we'd anticipate that continuing on into next year. So as you see, the current quarterly run rate for KALYDECO, we see that continuing on in 2017, the mark of that potentially increasing would be if we were able to gather residual function approval. And as Jeff Chodakewitz explained, we are currently in discussions with the regulatory authorities in the U.S. regarding that approval and that continues that discussion. Regarding ORKAMBI, it's a little too early to say. We're very comfortable with the guidance we've provided through the end of this year of $950 million to $990 million, and that does include the recent pediatric approval. As we look to 2017, we'll probably be thinking about how we give guidance around the U.S. market and maybe Germany as well because we do have visibility and knowledge to those markets. In terms of the other international markets, of how quickly and the time that they come on, we just need to give that some thought over the next few months of whether we actually try to provide a bracket around that guidance. There is a certain unknown element, but I'm sure you can only appreciate with these discussions. And sometimes the discussions push out because you are actually holding out for a price that you believe is appropriate for the medicine. And so it's about us getting to the right spot and rather than putting guidance around it and be forced around guidance, we'll give it some consideration of how we put a bracket around that and we'll be back to you early in 2017. And then to your third question, I'll pass it over to Stuart."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Geoff, in terms of pricing principles, obviously, we can't comment on the pricing of future products, but I'll talk to our pricing principles overall which have been very consistent for how we price KALYDECO and ORKAMBI, and the 2 primary drivers are real",168,"Geoff, in terms of pricing principles, obviously, we can't comment on the pricing of future products, but I'll talk to our pricing principles overall which have been very consistent for how we price KALYDECO and ORKAMBI, and the 2 primary drivers are really the number of patients that were able to benefit with our medicines and then the level of clinical benefit or value that we're able to bring. I think you've seen that we've adhered to those principles with ORKAMBI. And whilst we don't have formal pricing agreements in place across Europe yet, you have seen with the list prices of ORKAMBI that they are lower than they are for KALYDECO, which reflects the fact that, clearly, ORKAMBI is -- has a much wider eligible patient population despite the fact that, that medicine has two different components within it. So I think you can expect that we'll be adhering to those pricing principles as we bring next-gen correctors and other medicines to market for eligible CF patients."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from John Scotti of Evercore ISI.",10,"Our next question comes from John Scotti of Evercore ISI."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I just want to ask on VX-659. If you were to compare the preclinical toxicity profile of that aspect to 440 with regard to potential teratogenicity, et cetera, and then 152 with the nausea. Are you confident that the chemical structure of 659 is different",119,"I just want to ask on VX-659. If you were to compare the preclinical toxicity profile of that aspect to 440 with regard to potential teratogenicity, et cetera, and then 152 with the nausea. Are you confident that the chemical structure of 659 is different enough where we won't see those issues in humans in the clinic with regard to what we see with 440 and 152? And then I guess, just quickly on timing. Given the trials are small and if we assume they enroll quickly, is it unreasonable to assume that we could see data more towards mid-next year rather than towards the end of the year? I know you got it in the second half."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So John, first of all, I just want to pass on the team's best wishes to Mark and we look forward to [indiscernible] from Mark at some point and I'm sure I share everybody else's thoughts that are on the phone. In terms of the question, I'm actually going",99,"So John, first of all, I just want to pass on the team's best wishes to Mark and we look forward to [indiscernible] from Mark at some point and I'm sure I share everybody else's thoughts that are on the phone. In terms of the question, I'm actually going to ask Jeff Leiden to answer it because there is a whole portfolio approach here that we have, starting from 659. And the methodology of how we probably pick our molecules and what with that basis is. And you should anticipate that there will be more modules coming. So Jeff."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, thanks for the question, John. Maybe just to go back one step and remind you of how we look at these molecules and select them. The first real acid test for these molecules is our human HBE cells, both het min cells and homozygous cells from multiple",371,"Yes, thanks for the question, John. Maybe just to go back one step and remind you of how we look at these molecules and select them. The first real acid test for these molecules is our human HBE cells, both het min cells and homozygous cells from multiple donors. And as we showed you, I think in one of the slides today, 659 actually has efficacy as measured by chloride transport, which is maximal efficacy that's significantly higher than what we were seeing in 440 and 152, which were also quite high by themselves, by the way. We've also measured a number of other things in that assay like cilia beat frequency and others, and we see the same kind of difference between 659 and 440. We've entered the molecules through a pretty rigorous screen with respect to PK, tox, coformulability, really making sure that we're bringing drugs in the clinic as opposed to molecules. And we're done with most but not all of that for 659. We're certainly done with them now so we feel very comfortable that we have a tox profile and a PK profile that we're confident in taking into Phase I studies, both in normals and in patients this time as well. We have not done yet with the developmental studies in rabbits, and we don't have that data yet. And obviously, we don't have any human data, which is the final test of PK and safety and we'll only see that in the Phase I study. In addition, just as Ian mentioned, just -- we need to be clear with our expectations, we have a number of other next-gen correctors in our late preclinical pipeline. We expect to bring at least one of those forward into the clinic in the first half of next year and maybe more. And the reason for that, again, is that these molecules come in a number of different flavors, different potencies, different properties, and we want to bring multiple of them into humans as part of triple combinations to understand how they interact. I hope that gives you a flavor of where 659 fits and what we know and some things we don't yet know, but we'll know soon."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from the line of Brian Skorney of Robert W. Baird.",14,"Our next question comes from the line of Brian Skorney of Robert W. Baird."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","I have two questions. I guess, why both -- why start both programs in het min? It seems like you'd potentially get more information out of adding this on top of 661 ivacaftor, in patients with 2 F508del alleles. and Also, when we look at the relative diff",81,"I have two questions. I guess, why both -- why start both programs in het min? It seems like you'd potentially get more information out of adding this on top of 661 ivacaftor, in patients with 2 F508del alleles. and Also, when we look at the relative differences of the 4 generations, is that reasonable to assume that 2 correctors within the same generations still are redundant? And is there any obvious redundancy to cross combining correctors of these different generations?"
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. Brian, it's Jeff again. Let me answer both. Both are really good questions. Maybe I'll answer your second question first. Really, the portfolio approach is based upon the fact that while the molecules may bind to the same site, it may even have the s",188,"Yes. Brian, it's Jeff again. Let me answer both. Both are really good questions. Maybe I'll answer your second question first. Really, the portfolio approach is based upon the fact that while the molecules may bind to the same site, it may even have the same mechanism of action, there are obviously a number of other properties that are going to be really important in picking the best regimen. They include potency, because the more potent the molecule is, the easier it is to combine into triple combination formulate. They include maximal efficacy, obviously, and we showed you the 659 as an example of its greater maximal efficacy. But they also include things like PK properties, tissue penetration, drug-drug interactions, all of those things. And so when you think about this portfolio, think about it not only in terms of mechanism of action and not only in terms of efficacy and potency, but think about it as how do we create the best triple regimen with one or more of these molecules going forward. Does that makes sense to you in terms of how we're thinking about it?"
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes, it does. That is helpful.",6,"Yes, it does. That is helpful."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","And then repeat your first question for me.",8,"And then repeat your first question for me."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Oh, just on the strategy of going in het mins first.",11,"Oh, just on the strategy of going in het mins first."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes. So just to be clear about what we're doing here. First of all, het mins, obviously, is the big group of patients with the largest unmet need. And so as we think about taking these molecules forward, that's the patient population that we're most focus",220,"Yes. So just to be clear about what we're doing here. First of all, het mins, obviously, is the big group of patients with the largest unmet need. And so as we think about taking these molecules forward, that's the patient population that we're most focused on. But I do want to be clear that we're essentially doing these things in parallel, and so we will have results both in the het min population and the homozygous population essentially at the same time or with very little delay. And that's going to let us really design the best Phase III study, I think, here. One of the things that I'm really been pleased with over the last 4 or 5 years is as we develop these molecules, we've learned an awful lot about how to take the development forward most quickly, most efficiently and then how to start to think about phase trials -- Phase III trials perhaps a little differently. And so I do think you're seeing the results of that here as we sort of streamline these Phase II trials, do them in parallel as opposed to in theories as we've done them in the past. And then hopefully, based on the results, of course, launch into Phase III in a much broader fashion than we've done previously."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Liisa Bayko of JMP Securities.",10,"Our next question comes from Liisa Bayko of JMP Securities."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And just to clarify, there's no intention to formulate maybe a quad or something? You wouldn't add some of your next-generation correctors together? And I guess, why not would be the question?",32,"And just to clarify, there's no intention to formulate maybe a quad or something? You wouldn't add some of your next-generation correctors together? And I guess, why not would be the question?"
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Yes, so as a theoretical question, Liisa, of course, we would think about quads. And as you know, we're also looking at some other mechanisms of action, things like ENaC inhibitors that could be combined. So there's nothing a priori that we wouldn't look",111,"Yes, so as a theoretical question, Liisa, of course, we would think about quads. And as you know, we're also looking at some other mechanisms of action, things like ENaC inhibitors that could be combined. So there's nothing a priori that we wouldn't look at 4-drug combinations. Obviously, an ENaC inhibitor's inhaled, so it wouldn't be co-formulated. But I do think there's one difference here that's worth mentioning. I think it would be unlikely that, for instance, that will we put 152 and 440 together because they do appear to have the same mechanism of action, and so adding them together, would be not expected to produce a lot more benefit."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay. And then can you maybe talk about where you're going to be enrolling patients for some of these preliminary studies for the next generation? Is it going to be North America, ex U.S.?",34,"Okay. And then can you maybe talk about where you're going to be enrolling patients for some of these preliminary studies for the next generation? Is it going to be North America, ex U.S.?"
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This Jeff Chodakewitz. We're actually going to be doing studies in sites both in the U.S. and in Europe.",19,"This Jeff Chodakewitz. We're actually going to be doing studies in sites both in the U.S. and in Europe."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Okay, great. And then just wanted to get a little bit more clarity on the hormonal component. I think you maybe talked about this earlier before VX-440 and what you've seen there in your preclinical stuff. And then what that would just mean if you were to",50,"Okay, great. And then just wanted to get a little bit more clarity on the hormonal component. I think you maybe talked about this earlier before VX-440 and what you've seen there in your preclinical stuff. And then what that would just mean if you were to take it forward."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Sure, Liisa. This is Jeff Chodakewitz again. So just to clarify, perhaps. We've already talked about the rapid toxicity and why we're putting the contraceptive language in place. The hormonal wording doesn't actually come from preclinical studies. With th",84,"Sure, Liisa. This is Jeff Chodakewitz again. So just to clarify, perhaps. We've already talked about the rapid toxicity and why we're putting the contraceptive language in place. The hormonal wording doesn't actually come from preclinical studies. With the X440 at higher doses, there was some evidence of liver enzyme induction, and that can actually somewhat lower the exposure to the hormones in contraceptives. And so therefore, again, to ensure that we're using highly reliable contraception, we're excluding that as being the primary method."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Our next question comes from Tony Butler of Guggenheim Partners.",10,"Our next question comes from Tony Butler of Guggenheim Partners."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Two questions briefly. In Cohort 1a, can you help me understand the notion of using the low-dose first before you move forward? While it may be intuitive, you don't do that for 152. And then the second question is really around 152. To me, you've outlined",75,"Two questions briefly. In Cohort 1a, can you help me understand the notion of using the low-dose first before you move forward? While it may be intuitive, you don't do that for 152. And then the second question is really around 152. To me, you've outlined very well the portfolio strategy, why certainly you're moving forward with 440 and 659, but is the only reason for 152 the fact that it does not have teratogenicity?"
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Tony, it's Jeff Chodakewitz. So two comments. One, the 1a, as we go back to sort of a prior conversation, the intent of 1a is to go make the transition from healthy volunteers to patients. And be sure -- basically, the exposure is similar in the two group",182,"Tony, it's Jeff Chodakewitz. So two comments. One, the 1a, as we go back to sort of a prior conversation, the intent of 1a is to go make the transition from healthy volunteers to patients. And be sure -- basically, the exposure is similar in the two groups. And since it could potentially go up or down, although we don't expect it to do either, that's why you wouldn't want to go in at a high dose and then have the exposure actually end up higher. That's why we always would start in that kind of situation with the low dose and then expand, which is the intent. In terms of your broader question about VX-152 and VX-440, I think it goes back to Jeff Leiden's comments, that we think both molecules will have the potential to be well-tolerated at doses that can deliver benefit to patients, including, excitingly, both homozygous patients and het min patients who don't have a treatment option. And that's why we're taking both forward and we'll continue to learn as we add other molecules to our portfolio."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Operator, it's Michael Partridge. We have time for one more question.",11,"Operator, it's Michael Partridge. We have time for one more question."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","And that question comes from the line of Alan Carr of Needham & Company.",13,"And that question comes from the line of Alan Carr of Needham & Company."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Wondering if you can clarify that some of the timing around 152, 440 and the results from those and the results from your 659 Phase II. Are you trying to -- are you able to position these 3 data from 3 Phase II trials at the same time in order to decide w",61,"Wondering if you can clarify that some of the timing around 152, 440 and the results from those and the results from your 659 Phase II. Are you trying to -- are you able to position these 3 data from 3 Phase II trials at the same time in order to decide which one or 2 to bring into Phase III?"
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So Alan, it's Jeff Chodakewitz. Let me just review how that winds up. Of course, in the end, all the time lines, particularly the Phase II studies, are going to be dependent on the rate of enrollment. But what we expect would be that for both VX-152 and V",123,"So Alan, it's Jeff Chodakewitz. Let me just review how that winds up. Of course, in the end, all the time lines, particularly the Phase II studies, are going to be dependent on the rate of enrollment. But what we expect would be that for both VX-152 and VX-440, that we will be getting results, as we said, in the second half of '17. At that point, we will also have the Phase I results from VX-659. And as we've talked about that, given everything we've learned about the relationship from preclinical to exposure to benefit of patients, we think that we will be able to understand a lot about all 3 compounds as we're looking forward to make decisions at that point."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","This is Jeff Leiden. I just want to be clear that we don't think about 659 as being on exactly the same time frame as 152 and 440. And as Jeff said, it's a little difficult to give you precision because it depends on how users enrolled. 659 will only have",132,"This is Jeff Leiden. I just want to be clear that we don't think about 659 as being on exactly the same time frame as 152 and 440. And as Jeff said, it's a little difficult to give you precision because it depends on how users enrolled. 659 will only have a small cohort of patients from the Phase I, and so we'll have to see what we learn from that. But if you would ask me just to put a sort of marker on the table, I think that 659 myself is about 6 months behind 152 and 440. So we're not going to be waiting, obviously, if we see positive results with 152 and 440 before taking those into Phase III to wait for 659, if that's really the question."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","Yes. Okay, that helps. And then one other one. I guess, can you give us an update on 371? Where things stand with your CF program and ciliary dyskinesia there?",30,"Yes. Okay, that helps. And then one other one. I guess, can you give us an update on 371? Where things stand with your CF program and ciliary dyskinesia there?"
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","So it's Jeff Chodakewitz. Both of our studies, both the study in CF where we're looking at the ENaC inhibitor on top of ORKAMBI and in piece for homozygous for F508del and the study in patients with PCD, both are actively enrolling.",43,"So it's Jeff Chodakewitz. Both of our studies, both the study in CF where we're looking at the ENaC inhibitor on top of ORKAMBI and in piece for homozygous for F508del and the study in patients with PCD, both are actively enrolling."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Analysts","And timing for results, what's the latest on that?",9,"And timing for results, what's the latest on that?"
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","It's always going to be -- of course, until we end up getting the study fully enrolled, it's just too hard to give you any precision on the time.",30,"It's always going to be -- of course, until we end up getting the study fully enrolled, it's just too hard to give you any precision on the time."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Executives","Okay. Everybody, thanks for joining us tonight. For those of you who are going to the North American CF Conference, we look forward to seeing you there on Thursday night this week. We will also be webcasting our presentation there starting at 6:30 p.m. Ea",66,"Okay. Everybody, thanks for joining us tonight. For those of you who are going to the North American CF Conference, we look forward to seeing you there on Thursday night this week. We will also be webcasting our presentation there starting at 6:30 p.m. Eastern Time on Thursday. Tonight, the Investor Relations team will remain in the office if you have any additional questions. Thank you."
36235,404123072,1061367,"Vertex Pharmaceuticals Incorporated, Q3 2016 Earnings Call, Oct 25, 2016",2016-10-25,"Earnings Calls","Vertex Pharmaceuticals Incorporated","Operator","Ladies and gentlemen, that does conclude your call. You may disconnect at this time. Have a great day.",18,"Ladies and gentlemen, that does conclude your call. You may disconnect at this time. Have a great day."
